<SEC-DOCUMENT>0001213900-25-110979.txt : 20251114
<SEC-HEADER>0001213900-25-110979.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114165040
ACCESSION NUMBER:		0001213900-25-110979
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		251487725

	BUSINESS ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(646) 677-3870

	MAIL ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ea0262047-10q_actinium.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 14 19:35:08 UTC 2025 -->
<html xmlns:atnm="http://www.actiniumpharma.com/20250930" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-8932">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="ixv-8933">&#9746;</ix:nonNumeric><b>&#160;QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended <b><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-8934">September 30,
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-8935">2025</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-8936">&#9744;</ix:nonNumeric><b>&#160;TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from __________ to __________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-57"><b>001-36374</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-63"><b>ACTINIUM PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-73"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-78"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>74-2963609</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<br/>
Incorporation or Organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-96"><b>100 Park Ave., 23<sup>rd</sup> Floor</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-8937">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-8938">NY</ix:nonNumeric> </b></p></td> <td style="vertical-align: bottom; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-103"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10017</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-8939">(646)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-8940">677-3870</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(b)
of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol</b>&#160;</span></td> <td style="width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-142"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock, par value $0.001</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-147"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATNM</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-152"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NYSE American</b></span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. &#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-8941">Yes</ix:nonNumeric> &#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). &#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-8942">Yes</ix:nonNumeric> &#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="background-color: white"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="background-color: white"> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-182"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-189"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="background-color: white"> <td>&#160;</td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-8943">&#9744;</ix:nonNumeric>&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards, provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744;&#160;Yes <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-8944">&#9746;</ix:nonNumeric>&#160;No</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate the number of shares
outstanding of each of the issuer&#8217;s classes of common stock, as of November 14, 2025: <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8945">31,195,891</ix:nonFraction></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top; width: 86%"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II &#8211; OTHER INFORMATION</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="vertical-align: bottom; text-align: center">83</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: top"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I - FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. UNAUDITED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
consolidated financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion
of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at
September 30, 2025 and December 31, 2024, and the results of operations and cash flows for the three months and nine months ended September
30, 2025 and 2024, respectively, have been made. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It
is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s
audited financial statements for the year ended December 31, 2024 in the Company&#8217;s Annual Report on Form 10-K. The results of operations
for the three months and nine months ended September 30, 2025 are not necessarily indicative of the operating results for the full year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-8946">53,391</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-8947">72,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-8948">975</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-8949">1,602</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-8950">54,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-8951">74,506</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment, net of accumulated depreciation of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-8952">1,030</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-8953">891</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-8954">226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-8955">364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Restricted cash &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-8956">332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-8957">324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-8958">1,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-8959">1,685</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance leases right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-8960">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-8961">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-8962">56,151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-8963">76,899</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; text-indent: -9pt; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-8964">6,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-8965">7,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating leases current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-8966">599</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-8967">569</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Finance leases current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-8968">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-8969">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-8970">6,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-8971">8,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8972">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8973">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8974">531</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8975">984</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Long-term finance lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8976">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8977">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-8978">42,367</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-8979">44,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-8980"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-8981">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-8982"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-8983">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-8984"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-8985"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8986"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8987">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-8988"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-8989">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-8990"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-8991">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-8992"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8993">31,195,891</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-8994"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8995">31,195,891</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-8996">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-8997">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-8998">417,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-8999">408,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-9000">403,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-9001">375,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9002">13,784</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9003">32,758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-9004">56,151</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-9005">76,899</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Three Months Ended<br/> September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Nine Months Ended<br/> September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-9006">90</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-9007">90</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-9008">90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-9009">90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9010">4,248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9011">9,774</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9012">16,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-9013">25,234</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9014">1,534</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9015">2,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9016">13,096</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-9017">9,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-9018">5,782</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-9019">12,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-9020">29,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-9021">34,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9022">5,692</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9023">12,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9024">29,833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9025">34,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest income - net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-9026">561</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-9027">1,033</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-9028">1,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-9029">3,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-9030">561</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-9031">1,033</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-9032">1,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-9033">3,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9034">5,131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9035">11,568</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9036">27,947</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9037">31,591</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-9038"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-9039">0.16</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-9040"><ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-9041">0.37</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-9042"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-9043">0.90</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-9044"><ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-9045">1.06</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-9046"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-9047">31,195,891</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-9048"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-9049">31,071,297</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-9050"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-9051">31,195,891</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-9052"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-9053">29,692,001</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2025 to September
30, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)	</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Common Stock</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Additional Paid-In</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Accumulated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Stockholders&#8217;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Equity</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance, January 1, 2025</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9054">31,195,891</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9055">31</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9056">408,553</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9057">375,826</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9058">32,758</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9059">8,874</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9060">8,874</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9061">15,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9062">15,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, March 31, 2025</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9063">31,195,891</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9064">31</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9065">417,427</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9066">391,764</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9067">25,694</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9068">197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9069">197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9070">6,878</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9071">6,878</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, June 30, 2025</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9072">31,195,891</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9073">31</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9074">417,624</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9075">398,642</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9076">19,013</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9077">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9078">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units withheld to cover tax obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9079">207</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9080">207</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9081">5,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9082">5,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, September 30, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9083">31,195,891</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9084">31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9085">417,526</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9086">403,773</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9087">13,784</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2024 to September
30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January 1, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9088">27,634,213</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9089">28</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9090">373,934</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9091">337,583</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9092">36,379</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9093">1,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9094">1,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-9095">1,752,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-9096">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-9097">14,694</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-9098">14,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-9099">10,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9100">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9101">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9102">8,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9103">8,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, March 31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9104">29,396,411</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9105">29</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9106">390,081</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9107">346,253</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9108">43,857</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9109">1,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9110">1,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-9111">1,154,191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-9112">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-9113">9,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-9114">9,957</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9115">11,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9116">11,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9117">30,550,602</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9118">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9119">401,410</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9120">357,606</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9121">43,835</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-9122">13,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9123">1,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-9124">1,337</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-9125">631,895</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-9126">4,604</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-9127">4,604</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9128">11,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9129">11,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, September 30, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-9130">31,195,891</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9131">31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9132">407,351</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-9133">369,174</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-9134">38,208</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands)</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Cash flows used in operating activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9135">27,947</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-9136">31,591</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9137">9,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9138">4,089</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Depreciation and amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-9139">615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-9140">607</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-9141">627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-9142">726</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-9143">1,343</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-9144">758</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-9145">423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-9146">394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9147">19,291</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9148">27,321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows used in investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-9149">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash used in investing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9150">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows used in/provided by financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-9151">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-9152">7</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Sales of shares of common stock, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-9153">29,256</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted stock units withheld to cover tax obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" unitRef="usd" id="ixv-9154">207</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Proceeds from the exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-9155">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash used in/provided by financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" sign="-" unitRef="usd" id="ixv-9156">214</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-9157">29,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net change in cash, cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-9158">19,505</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-9159">1,992</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9160">73,228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9161">76,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at end of period</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9162">53,723</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9163">78,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Condensed Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="ixv-2435"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:NatureOfBusinessPolicyPolicyTextBlock" id="ixv-2439"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. is a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve
outcomes for patients with advanced cancers. The Company is focused on developing highly innovative, first-in-class product candidates.
To support its objective of achieving industry leading, cost-effective product development to maximize value creation from its innovative
pipeline, the Company is working to expand the scope of its capabilities to include radioisotope production of Ac-225 via collaborations
for its Ac-225 technology and in-house manufacturing of pipeline candidates to support clinical trials. The Company is deploying its technologies,
capabilities and intellectual property with approximately 250 issued and pending patents worldwide, to develop next-generation radiotherapies
focused on solid tumors, hematology and conditioning for cellular therapies.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-2444"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-2448"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates" id="ixv-2452"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-2457"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-2462"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="ixv-2466"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at September 30, 2025 and December 31, 2024:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-9164">53,391</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-9165">72,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-9166">332</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-9167">324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9168">53,723</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-9169">73,228</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-2531"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-2535"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-2539"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers
</i>(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="ixv-2554"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i> There was no revenue from collaborative arrangements for the nine months ended September 30, 2025 and
September 30, 2024, respectively.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="ixv-2574"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>Grant
revenue for the three and nine months ended September 30, 2025 was $<ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" unitRef="usd" id="ixv-9170"><ix:nonFraction contextRef="c68" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" unitRef="usd" id="ixv-9171">0.1</ix:nonFraction></ix:nonFraction> million. There was <span style="-sec-ix-hidden: hidden-fact-55"><span style="-sec-ix-hidden: hidden-fact-56">no</span></span> grant revenue recognized for the three and
nine months ended September 30, 2024.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1" escape="true" name="atnm:LicenseRevenuePolicyTextBlock" id="ixv-2582"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no license revenue for the three and nine months ended September
30, 2025 and September 30, 2024.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-2602"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-2607"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_4" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-2626"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-9172">For the three and nine months ended
September 30, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted
stock units, vested unissued shares of common stock and warrants, have not been included in the computation of diluted net loss per share
as the result would have been anti-dilutive.</ix:nonNumeric></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-9173">162</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-9174">5,216</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-9175">300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vested unissued shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-9176">179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-9177">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-9178">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-9179">348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-9180">5,525</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-2696"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
December 2023, the Financial Accounting Standards Board, (the &#8220;FASB&#8221;), issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements
to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09
provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures.
The Company is required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount
computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required to disclose income
taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). <span style="background-color: white">The
amendments in ASU 2023-09 are effective January 1, 2025. The Company adopted this standard effective January 1, 2025 and will report on
it in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company will update all required disclosures
pursuant to ASU 2023-09 at that time.</span></span>&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, the One Big
Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension
of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable
tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025
and others expected to be implemented through 2027. The Company has evaluated the impact of the OBBBA and determined that it does not
have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1" escape="true" name="atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock" id="ixv-2709"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_2" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, the FASB
issued ASU 2025-07, <i>Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements
and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</i>, which excludes from derivative
accounting non-exchange-traded contracts with underlying terms that are based on operations or activities specific to one of the parties
to the contract. However, this scope exception does not apply to (1) variables based on a market rate, market price, or market index,
(2) variables based on the price or performance of a financial asset or financial liability of one of the parties to the contract, (3)
contracts (or features) involving the issuer&#8217;s own equity that are evaluated under the guidance in Subtopic 815-40, <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity,</i> and (4) call options and put options on debt instruments. The Company can
apply the amendments in AUS 2025-07 either (1) prospectively to new contracts entered into on or after the date of adoption or (2) on
a modified retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning
of the annual reporting period of adoption for contracts existing as of the beginning of the annual reporting period of adoption. The
amendments in ASU 2025-07 are effective January 1, 2027, for annual for annual reporting periods, including interim periods within annual
reporting periods. Early adoption is permitted. The Company is evaluating the impact of ASU 2025-07 on its financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_3" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, the FASB
issued ASU 2025-06, <i>Intangibles&#8212;Goodwill and Other&#8212; Internal-Use Software</i> (Subtopic 350-40): Targeted Improvements
to the Accounting for Internal-Use Software, which modernizes the accounting for software costs that are accounted for under Subtopic
350-40. The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages (referred to as
&#8220;project stages&#8221;) throughout Subtopic 350-40. Therefore, an entity is required to start capitalizing software costs when both
of the following occur: (a) the Company has authorized and committed to funding the software project and (b) it is probable that the project
will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition
threshold&#8221;). In evaluating the probable-to-complete recognition threshold, the Company is required to consider whether there is
significant uncertainty associated with the development activities of the software, such as determining whether (a) the software being
developed has technological innovations or novel, unique, or unproven functions or features, and the uncertainty related to those technological
innovations, functions, or features, if identified, has not been resolved through coding and testing and (b) the Company has determined
what it needs the software to do (for example, functions or features), including whether the entity has identified or continues to substantially
revise the software&#8217;s significant performance requirements. ASU 2025-06 specifies that disclosures in Subtopic 360- 10, <i>Property,
Plant, and Equipment&#8212;Overall</i>, are required for all capitalized internal-use software costs, regardless of how those costs are
presented in the financial statements and removes the requirement to disclose internal-use software information pursuant to paragraphs
350-30-50-1 through 50-3. ASU 2025-06 supersedes the website development costs guidance and incorporates the recognition requirements
for website-specific development costs from Subtopic 350-50, <i>Website Development Costs</i>, into Subtopic 350-40. The amendments in
ASU 2025-06 permit an entity to apply the new guidance using either (i) a prospective transition approach, (ii) a modified transition
approach that is based on the status of the project and whether software costs were capitalized before the date of adoption, or (iii)
a retrospective transition approach. The amendments in ASU 2025-06 are effective January 1, 2028 for annual reporting periods, including
interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The Company
is evaluating the impact of ASU 2025-06 on its financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_4" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, the FASB
issued ASU 2025-05, <i>Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets</i>, which permits a practical expedient whereby, when assessing credit losses on current accounts receivable
and current contract assets, the Company would assume that current conditions as of the balance sheet date do not change for the
remaining life of the asset and would not require the Company to consider adjustments to forecasts to also include anticipated
changes in the future to the underlying conditions as of the balance sheet date when measuring the credit losses for current
accounts receivable and current contract assets. The amendments in ASU 2025-05 are effective January 1, 2026 for annual reporting
periods, including interim periods within annual reporting periods and is required to be applied on a perspective basis. Early adoption is permitted in both interim and annual
reporting periods in which financial statements have not yet been issued or made available for issuance. The impact of ASU 2025-04
is not expected to be material to the financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_5" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2025, FASB issued ASU
2025-04, <i>Compensation&#8212;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer</i>, which revises the Master Glossary definition of the term &#8220;performance condition&#8221;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#8217;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#8217;s goods or services from the grantor&#8217;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#8217;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#8217;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2025-04 are effective January 1, 2027 for annual reporting periods,
including interim periods within annual reporting periods. The Company is evaluating the impact of ASU 2025-04 on its financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028, either on a prospective or retrospective basis. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-2766"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $<ix:nonFraction contextRef="c79" decimals="-6" format="ixt:num-dot-decimal" name="atnm:MilestonePayment" scale="6" unitRef="usd" id="ixv-9181">1</ix:nonFraction> million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of <ix:nonFraction contextRef="c79" decimals="2" format="ixt:num-dot-decimal" name="atnm:NetSalesPercentage" scale="-2" unitRef="pure" id="ixv-9182">2</ix:nonFraction>% of net sales will be due to FHCRC.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the United States District Court for the Southern District of New York. The Securities Complaint alleges that the
Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims
against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint
purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities
between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&#160; On June 24, 2025, the court in the
securities action appointed lead plaintiffs who filed an amended Securities Complaint on August 25, 2025. Defendants moved to dismiss
the amended Securities Complaint on October 24, 2025. Lead plaintiffs&#8217; opposition is due in late December 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On May 5, 2025, a derivative shareholder complaint (the &#8220;<i>Georges</i>
Complaint&#8221;) was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability
for the allegations made in the Securities Complaint.&#160; On May 13, 2025, a second derivative shareholder complaint (the &#8220;<i>Robinson
</i>Complaint&#8221; and, together with the <i>Georges </i>Complaint, the &#8220;Derivative Complaints&#8221;) was filed against the Company
and certain of the Company&#8217;s directors also alleging derivative liability for the allegations made in the Securities Complaint.
On June 24, 2025, the Court consolidated the Derivative Complaints (the &#8220;Derivative Action&#8221;). On July 29, 2025, the parties
to the Derivative Action filed a stipulation with the Court to stay the Derivative Action pending resolution of any motion to dismiss
the Securities Complaint. The Court entered the stipulation on July 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company and other Defendants intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>



</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_LeasesTextBlock-c0_cont_1" escape="true" name="atnm:LeasesTextBlock" id="ixv-2784"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="atnm_LeasesTextBlock-c0_cont_2" id="atnm_LeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At September 30, 2025, the
Company has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment.
The Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseDescription" id="ixv-9183">5 years 2 months</ix:nonNumeric>, with an
expiration date of <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1" id="ixv-9184">July 30, 2027</ix:nonNumeric> and current annual rent of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="6" unitRef="usd" id="ixv-9185">0.6</ix:nonFraction> million. The Company is also responsible for certain other costs, such
as insurance, utilities and maintenance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-2811"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-9186">173</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-9187">173</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-9188">519</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-9189">519</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-9190">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-9191">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-9192">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-9193">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-9194">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-9195">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total finance lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-9196">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-9197">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-9198">8</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-9199">9</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-9200">471</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-9201">462</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd" id="ixv-9202">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd" id="ixv-9203">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-9204">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-9205">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock-c0_cont_1" escape="true" name="atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" id="ixv-3077"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-9206">1.3</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance Leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-9207">1.8</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. <ix:continuation continuedAt="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock-c0_cont_2" id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock-c0_cont_1">Below is information on the weighted average discount rates used at the time that the leases were evaluated:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-9209">4.8</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-9210">6.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="atnm:LesseeLeaseLiabilityMaturityTableTextBlock" id="ixv-3138"><ix:continuation id="atnm_LeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding nine months ended September 30, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-9211">159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-9212">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-9213">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-9214">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-9215">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-9216">1,182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-9217">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-9218">52</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-9219">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-9220">1,130</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" unitRef="usd" id="ixv-9221">13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="atnm:OtherRevenueTextBlock" id="ixv-3218"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 - Other revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Grant revenue recognized
for the nine months ended September 30, 2025 was $<ix:nonFraction contextRef="c68" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" unitRef="usd" id="ixv-9222">0.1</ix:nonFraction> million. There was no grant revenue recognized for the nine months ended September
30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#8220;EUMENA&#8221;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $<ix:nonFraction contextRef="c82" decimals="-6" format="ixt:num-dot-decimal" name="atnm:NonRefundablePaymentReceived" scale="6" unitRef="usd" id="ixv-9223">35</ix:nonFraction> million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#8217;s contract liabilities consist of advanced payments from licensees. Long-term license revenue deferred was $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-9224"><ix:nonFraction contextRef="c3" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-9225">35</ix:nonFraction></ix:nonFraction> million at
September 30, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#8217;s regulatory approval of
Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-3230"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company entered into the Capital on Demand&#8482;
Sales Agreement with JonesTrading Institutional Services LLC, &#8220;JonesTrading&#8221;, pursuant to which the Company may sell, from
time to time, through or to JonesTrading, up to an aggregate of $<ix:nonFraction contextRef="c83" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-9226">200</ix:nonFraction> million of its common stock. On June 28, 2022, the Company entered
into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales Agreement&#8221;) with JonesTrading and
B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The A&amp;R Sales Agreement modifies the original Capital on Demand&#8482; Sales Agreement
to include B. Riley Securities as an additional sales agent thereunder. Shares of common stock are offered pursuant to a shelf registration
statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the &#8220;Prior Shelf Registration Statement&#8221;).
On August 11, 2023, the Company filed a new registration statement on Form S-3 (File No. 333-273911), which registration statement was
amended on February 2, 2024, and declared effective on February 5, 2024, to replace the Prior Shelf Registration Statement, including
a base prospectus which covers the offering, issuance and sale of up to $<ix:nonFraction contextRef="c84" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="6" unitRef="usd" id="ixv-9227">500</ix:nonFraction> million of common stock, preferred stock, warrants, units
and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum aggregate offering
price of $<ix:nonFraction contextRef="c84" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-9228">200</ix:nonFraction> million of common stock that may be issued and sold under the Amended Sales Agreement.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company did not sell any
shares of common stock during the nine months ended September 30, 2025. During the nine months ended September 30, 2024, the Company sold
<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares" id="ixv-9229">3.5</ix:nonFraction> million shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-9230">29.9</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="atnm:NetProceedFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-9231">29.3</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-3256"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-9232">5,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9233">6.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c97" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-9234">7.04</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares" id="ixv-9235">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9236">1.46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" unitRef="shares" id="ixv-9237">5,012</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9238">6.42</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-9239">161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9240">7.17</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-9241">3.40</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-9242">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, September 30, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares" id="ixv-9243">134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9244">7.87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-9245">2.31</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2025, the Company granted newly hired employees options to purchase <ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares" id="ixv-9246">36</ix:nonFraction> thousand shares of common stock with an exercise
price ranging from $<ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-9247">1.06</ix:nonFraction> to $<ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-9248">1.55</ix:nonFraction> per share, a term of <ix:nonNumeric contextRef="c87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="ixv-9249">10 years</ix:nonNumeric>, and a vesting period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-9250">4</ix:nonNumeric> years. The stock options had an aggregated
fair value of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="3" unitRef="usd" id="ixv-9251">41</ix:nonFraction> thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from <ix:nonFraction contextRef="c88" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-9252">4.0</ix:nonFraction>% to <ix:nonFraction contextRef="c89" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-9253">4.5</ix:nonFraction>% (2) expected life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-9254">6</ix:nonNumeric> years, (3) expected volatility range from <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" unitRef="pure" id="ixv-9255">90.1</ix:nonFraction>% to <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" unitRef="pure" id="ixv-9256">90.7</ix:nonFraction>%,
and (4) <span style="-sec-ix-hidden: hidden-fact-81">zero</span> expected dividends. During the nine months ended September 30, 2024, the Company granted options to purchase <ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitRef="shares" id="ixv-9257">104</ix:nonFraction> thousand
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, the Board
of Directors approved of the cancellation of stock options to purchase an aggregate of <ix:nonFraction contextRef="c90" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" unitRef="shares" id="ixv-9258">4.9</ix:nonFraction> million shares of common stock held by certain
current employees and directors that were initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated
Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options, which the Company received.
The cancellation of these stock options resulted in the recording of $<ix:nonFraction contextRef="c87" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="6" unitRef="usd" id="ixv-9259">8.8</ix:nonFraction> million in stock option compensation expense for the nine months
ended September 30, 2025. During the nine months ended September 30, 2024, the Company recorded stock option compensation expense of $<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-9260">3.6</ix:nonFraction>
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30,
2025 was $<ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" unitRef="usd" id="ixv-9261">0.1</ix:nonFraction> million related to unvested stock options, which is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c87" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-9262">2.4</ix:nonNumeric> years.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-3439"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c98" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" unitRef="shares" id="ixv-9263">300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-9264">5.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c94" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" unitRef="shares" id="ixv-9265">300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vested on August
18, 2025. The fair value of the RSUs, $<ix:nonFraction contextRef="c93" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="6" unitRef="usd" id="ixv-9266">1.8</ix:nonFraction> million, was determined based on the stock price on the dates of the grant and was recognized
over three years. During the nine months ended September 30, 2025 and 2024, the Company recorded compensation expense related to RSUs
of $<ix:nonFraction contextRef="c94" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-9267">0.4</ix:nonFraction> million and $<ix:nonFraction contextRef="c95" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-9268">0.4</ix:nonFraction> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-3519"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="3" unitRef="shares" id="ixv-9269">7</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9270">17.33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c100" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-9271">4.46</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="3" unitRef="shares" id="ixv-9272">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9273">17.33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c101" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-9274">3.70</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="3" unitRef="shares" id="ixv-9275">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-9276">17.33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c101" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" id="ixv-9277">3.70</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENT NOTICE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Quarterly Report on Form
10-Q and other reports filed by the Company from time to time with the Securities and Exchange Commission contains or may contain certain
forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company&#8217;s
management as well as estimates and assumptions made by Company&#8217;s management. Readers are cautioned not to place undue reliance
on these forward-looking statements, which are only predictions and speak only as of the date hereof. For this purpose, any statements
contained in this Quarterly Report on Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements.
&#160;Without limiting the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221;
&#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221; or comparable terminology are intended to identify forward-looking
statements. &#160;These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially
depending on a variety of factors, many of which are not within our control. &#160;These factors include but are not limited to economic
conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition
from much larger competitors; technological advances and failure to successfully develop business relationships. Although we believe that
the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance,
or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update
any of the forward-looking statements to conform these statements to actual results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium Pharmaceuticals,
Inc. is a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve outcomes for patients
with advanced cancers. We are focused on developing highly innovative, first-in-class product candidates. To support our objective of
achieving industry leading, cost-effective product development to maximize value creation from our innovative pipeline, we are working
to expand the scope of our capabilities to include radioisotope production of Ac-225 via collaborations for our Ac-225 technology and
in-house manufacturing of pipeline candidates to support clinical trials. We are deploying our technologies, capabilities and intellectual
property with approximately 250 issued and pending patents worldwide, to develop next-generation radiotherapies focused on solid tumors,
hematology and conditioning for cellular therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Targeted Radiotherapy Candidate Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are advancing
clinical stage and preclinical stage targeted radiotherapy candidates directed against validated cancer targets for indications in
solid tumors, hematology and conditioning for cell and gene therapies that we believe have high unmet needs not addressed by
currently available treatment options. Recently prioritized as our lead program, ATNM-400, is a highly innovative, first-in-class,
and pan-tumor Actinium-225 (&#8220;Ac-225&#8221;) alpha-emitter targeted radiotherapy candidate with preclinical data in prostate
cancer, non-small cell lung cancer (&#8220;NSCLC&#8221;) and breast cancer. We believe ATNM-400 has the potential to address
critical gaps across multiple treatment settings in each of these targeted indications and can therefore address large patient
populations. Actimab-A is our most advanced clinical-stage product candidate, which utilizes an antibody linked to Ac-225 to target
CD33, a cell surface protein that Actimab-A is designed to target, that is expressed ubiquitously in acute myeloid leukemia
(&#8220;AML&#8221;) and myelodysplastic syndromes (&#8220;MDS&#8221;) and on myeloid derived suppressor cells (&#8220;MDSC&#8221;).
We are evaluating Actimab-A&#8217;s potential to synergize with immune checkpoint inhibitors (&#8220;ICIs&#8221;) such as programmed
cell death 1 (&#8220;PD-1) inhibitors in solid tumors by depleting MDSC immune cells. Iomab-ACT is our next-generation targeted
conditioning agent we are developing with the intent to improve patient access to, and outcomes with, cellular therapies such as
CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease
(&#8220;SCD&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to
prioritized development efforts described above, we plan to continue to advance Actimab-A in a focused manner as a therapeutic for
select hematology indications including supporting our Cooperative Research and Development Agreement (&#8220;CRADA&#8221;) with the
National Cancer Institute (&#8220;NCI&#8221;). Actimab-A has the potential to address the significant unmet medical needs of
patients across multiple solid tumor indications and with high-risk blood cancers including AML and MDS which are highly sensitive
and susceptible to radiation. We also plan to support Iomab-ACT as a targeted conditioning agent for cell and gene therapies while
simultaneously seeking strategic development partners or collaborators for these programs. We are actively seeking a strategic
partner for Iomab-B, our CD45 targeted conditioning agent for bone marrow transplant (&#8220;BMT&#8221;) in the U.S. and we may seek
to partner, divest, spin-out, or out-license Iomab-B, Actimab-A, and Iomab-ACT individually or collectively for all non-solid tumor
indications. We believe, in the aggregate, the clinical data from these hematology and cellular therapy focused programs is
supportive of a partnering approach, which if successful, may yield greater value as the Company focuses on its solid tumor
development efforts utilizing existing resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>Recent
Pipeline Candidate Highlights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presented new data at the 2025 Prostate Cancer Foundation Scientific Retreat (&#8220;PCF&#8221;) demonstrating the potent and durable efficacy of ATNM-400 compared to enzalutamide, the active agent in Xtandi<sup>&#174;</sup> (Astellas/Pfizer), the leading androgen receptor pathway inhibitor (&#8220;ARPI&#8221;) and 177L-PSMA-617, the active agent in Pluvicto<sup>&#174;</sup> (Novartis), the first blockbuster targeted radiotherapy. Xtandi accounted for $5.9 billion of the $10.0 billion 2024 sales of all ARPI therapies and Pluvicto generated sales of $1.7 billion in the last twelve months with approximately $1.4 billion in sales in the first nine months of 2025;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presented the first ever
    ATNM-400 data in NSCLC at the Triple Targets Meeting that showed superior anti-tumor activity of ATNM-400 compared to epithelial
    growth factor receptor (&#8220;EGFR&#8221;) mutant therapies including front line therapy osimertinib (EGFR TKI
    TAGRISSO<sup>&#174;</sup>, AstraZeneca), second line therapy Dato-DXd (Trop-2 ADC DATROWAY<sup>&#174;</sup>, AstraZeneca/Daiichi
    Sankyo) and third line therapy amivantamab (EGFR-cMET bispecific RYBREVANT<sup>&#174;</sup>, Johnson &amp; Johnson). ATNM-400 also
    demonstrated synergistic activity in combination with osimertinib with complete tumor regression in 100% of tumor-bearing animals.
    The synergistic mechanism of this combination is supported by increased expression of the ATNM-400 target antigen after EGFR
    inhibition with osimertinib. In addition, previously published clinical data provide a strong rationale for combining targeted
    alpha-therapy via ATNM-400 with EGFR targeting therapies as progression free survival (PFS) with osimertinib alone of 20 months was
    increased to 32.2 months by combining osimertinib with external beam radiotherapy (EBRT). We believe ATNM-400 offers a potentially
    safer and more effective way of delivering synergistic radiation in NSCLC;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announced the continued expansion of ATNM-400&#8217;s pan-tumor potential
with preclinical data in breast cancer This data has been accepted for presentation at the San Antonio Breast Cancer Symposium (&#8220;SABCS&#8221;)
on December 11, 2025; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progressed the Iomab-ACT SCD trial at Columbia University with increased patient
recruitment and treatment that is expected to yield initial proof of concept clinical data in the first half of 2026.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>Solid
Tumor Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ATNM-400:
Differentiated, First-in-Class, Pan-Tumor Alpha-Targeted Precision Radiotherapy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 is an antibody radioconjugate (&#8220;ARC&#8221;) armed with
the potent alpha-emitter Ac-225. It is designed to deliver highly localized, potent alpha radiation to cancer cells while sparing normal
tissue. ATNM-400 targets a clinically validated antigen that is overexpressed across multiple solid tumors and is associated with disease
progression, therapeutic resistance, and poor clinical outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg" style="width: 624px; height: 232px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical data across metastatic
castrate-resistant prostate cancer (mCRPC), NSCLC, and breast cancer models demonstrate broad and durable anti-tumor efficacy with a favorable
safety profile, supporting ATNM-400 as a pan-tumor Actinium-225 pipeline with potential to overcome resistance to multiple current standard
therapies. These high-value indications total over 800,000 new cases each year in the U.S. alone. We believe ATNM-400 has the potential
to address multiple segments in these indications that exceed $20 billion in market potential.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ATNM-400 for Metastatic Castrate-Resistant Prostate Cancer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Prostate cancer is the most
commonly diagnosed cancer in men, with approximately 1.5 million new cases globally and over 313,000 expected in the U.S. in 2025. While
early-stage disease is typically managed with surgery, radiation, and ARPI therapy, up to twenty percent of cases progress to mCRPC -
a lethal stage with limited treatment options. Targeted radiotherapy is a growing field in prostate cancer, dominated by prostate specific
membrane antigen (&#8220;PSMA&#8221;) targeting agents like Pluvicto<sup>&#174;</sup>. However, approximately one-third of mCRPC patients
are ineligible for or do not respond to Pluvicto and virtually all patients will develop resistance to or progress on Pluvicto<sup>&#174;</sup>
within twelve months. While ARPI therapies such as enzalutamide (active agent in Xtandi<sup>&#174;</sup>, Pfizer/Astellas) and PSMA-targeted
radiotherapies such as lutetium Lu 177 vipivotide tetraxetan (active agent in Pluvicto<sup>&#174;</sup>, Novartis) have improved patient
outcomes, treatment resistance is common.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 targets a non-PSMA
antigen that drives tumor survival and resistance mechanisms. High expression of this target correlates with rapid disease progression,
shorter time to castration resistance, and poor survival.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>ATNM-400 Target Antigen
Compared to PSMA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, including enzalutamide-resistant
and PSMA-refractory mCRPC models, ATNM-400 demonstrated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The anti-tumor efficacy of
ATNM-400 was durable up to 100 days compared to 177Lu-PSMA-617 or Ac-225-PSMA-617. ATNM-400 overcame 177Lu-PSMA-617 resistance with approximately
5-times long tumor control and 2-times longer overall survival (&#8220;OS&#8221;) in tumor bearing animals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anti-tumor efficacy for up
to 100 days was also demonstrated compared to ARPI enzalutamide. Increased target expression with enzalutamide and combination synergy
with enzalutamide resulted in complete tumor regression in 40 percent of tumor bearing animals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In models that progressed on&#160;enzalutamide 177Lu-PSMA-617, subsequent
treatment with ATNM-400 achieved robust tumor control and extended survival, highlighting the ability to overcome resistance given its
novel antigen target and the potency of the Ac-225 alpha-emitter isotope.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These results were presented
at the Prostate Cancer Foundation (PCF) Scientific Retreat on October 24, 2025, and we believe provide for support for clinical development
of ATNM-400 as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">1.</td><td>Monotherapy in earlier disease settings prior to PSMA-directed radiotherapy,</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                          </table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">2.</td><td>Combination therapy with AR pathway inhibitors to enhance and prolong treatment responses, and</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                                            </table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">3.</td><td>Sequential therapy for the significant number of patients following ARPI or PSMA radioligand therapy failure or relapse.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ATNM-400 for NSCLC</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lung cancer is the most common
cancer worldwide with more than 200,000 new cases estimated in 2025 in the U.S. and over 2 million new cases globally. NSCLC accounts
for approximately 85 percent of all lung cancer cases with EGFR mutations detected in a significant portion of patients. Approved therapies
for EGFR-mutant NSCLC include the tyrosine kinase inhibitor (&#8220;TKI&#8221;) osimertinib (TARGRISSO<sup>&#174;</sup>, AstraZeneca) that
virtually all patients receive as first-line treatment and the Trop-2 antibody drug conjugate Dato-DXd (DATROWAY<sup>&#174;</sup>, AstraZeneca/Daiichi
Sankyo) and EGFR-cMET bispecific antibody amivantamab (RYBREVANT<sup>&#174;</sup>, J&amp;J) that are used in second-and-third-line treatment
settings. Despite initial treatment success with these therapies, nearly all patients eventually develop resistance within two to three
years, underscoring the urgent need for novel, differentiated therapies to overcome resistance and improve survival outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 targets an antigen associated with poor
prognosis, metastasis, and EGFR-TKI resistance in NSCLC. In preclinical EGFR-mutant NSCLC models, including Osimertinib-resistant models,
ATNM-400 demonstrated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Superior efficacy demonstrated by 3 to 5-times greater tumor growth
inhibition compared with currently approved first, second-and-third line EGFR-mutant therapies osimertinib, Dato-Dxd and amivantamab in
animals bearing human lung cancer NCI-H1975, which carry L858R and T790M EGFR mutations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The combination of ATNM-400
and osimertinib produced cures in all tumor-bearing animals with complete tumor regression, outperforming either agent alone and suggesting
synergistic activity. The clinical rationale for the ATNM-400 osimertinib combination is further supported by the Phase 2 multicenter
trial &#8220;osimertinib plus consolidative radiotherapy for advanced EGFR-mutant non-small cell lung cancer," (Sampath et al. The
Lancet eClinical Medicine) that reported a median PFS of 32.3 months. This reflects a notable 12.3-month improvement in PFDS with the
addition of external beam radiotherapy (&#8220;EBRT&#8221;) over the 20.0-month median PFS with osimertinib monotherapy, as reported by
Watanabe et al. in a real-world clinical setting. ATNM-400 offers a potentially more effective and potentially safer way to deliver synergistic
radiation than external beam radiotherapy given the significantly greater potency of Ac-225 compared to external beam, which on a per
cell basis deliver approximately 4-8-times more biologically lethal radiation than diffuse low-energy EBRT. Clinically, this may translate
to higher response rates, lower toxicity, and entry into previously untreatable market segments when osimertinib is combined with EBRT.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_009.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Osimertinib treatment produced a statistically significant increase
in the expression of the ATNM-400 target antigen in NCI-H1975 lung cancer cells. This increased target expression post-osimertinib notably
increased ATNM-400&#8217;s in vitro cytotoxic effect when combined post-osimertinib.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_010.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These data were presented at the AACR-NCI-EORTC International Conference
on Molecular Targets and Cancer Therapeutics on October 25, 2025, underscoring ATNM-400&#8217;s potential as a monotherapy or rational
combination therapy for TKI-resistant NSCLC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ATNM-400 for HR+/HER2- Breast Cancer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">ATNM-400 is also being evaluated
in breast cancer models resistant to both endocrine and HER2-targeted therapies. New data from this program, titled &#8220;Anti-tumor
activity of ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, in tamoxifen- and trastuzumab-resistant breast cancer models,&#8221;
will be presented at the San Antonio Breast Cancer Symposium on December 11, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This upcoming presentation
will mark the first public disclosure of ATNM-400 activity in breast cancer, extending its potential application into hormone- and HER2-resistant
tumors and reinforcing its pan-tumor therapeutic versatility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The expanding body of preclinical
data across prostate, lung, and breast cancer models supports ATNM-400 as capable of addressing key resistance pathways across multiple
solid tumors as depicted in the table below. ATNM-400 represents a differentiated, next-generation alpha radiotherapy product candidate
positioned to extend Actinium-based precision radiotherapy that could address major unmet needs across multiple oncology indications.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="padding: 5.4pt; border: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Program / Indication</b></span></td>
    <td style="padding: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mechanism &amp; Target</b></span></td>
    <td style="padding: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preclinical Highlights</b></span></td>
    <td style="padding: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent and Upcoming Data Presentations</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATNM-400 &#8211; Prostate Cancer (mCRPC)</span></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium-225 antibody radioconjugate targeting a non-PSMA antigen implicated in disease biology and linked to AR and survival pathways</span></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Durable tumor regression in enzalutamide- and PSMA-radioligand-resistant
    models</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Superior efficacy vs. Enzalutamide, 177Lu-PSMA-617, and 225Ac-PSMA-617</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Favorable safety profile</p></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate Cancer Foundation (PCF) Scientific Retreat &#8211; Oct 22-24, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATNM-400 &#8211; Non-Small Cell Lung Cancer (NSCLC)</span></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium-225 antibody radioconjugate targeting antigen associated with EGFR-TKI resistance and metastasis</span></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Potent activity across EGFR-mutant and Osimertinib-resistant
    models</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Superior efficacy vs. Dato-DxD and amivantamab</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Strong tolerability and synergy potential with EGFR-TKIs</p></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics &#8211; Oct 25, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATNM-400 &#8211; Breast Cancer (Hormone / HER2 Resistant)</span></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium-225 antibody radioconjugate targeting antigen associated with endocrine and HER2 therapy resistance</span></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Strong anti-tumor activity in tamoxifen- and trastuzumab-resistant
    models</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Expands therapeutic reach into breast cancer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2in; text-indent: -0.2in">&#9679;&#160;&#160;&#160;Supports potential in settings with unmet needs</p></td>
    <td style="padding: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Antonio Breast Cancer Symposium (SABCS) &#8211; Dec 11, 2025</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ATNM-400 Market Opportunity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>mCRPC</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prostate cancer is by far
the most diagnosed cancer in men in the United States and is the same in 118 of 185 countries. Of those diagnosed with prostate cancer,
approximately 5-7% exhibited metastatic disease at initial diagnosis, and among those exhibiting localized prostate cancer, approximately
20-30% will progress to metastatic disease. A majority of metastatic prostate cancer patients receive hormone therapy such as ARPI therapy,
as prostate cancer cells rely on androgen hormones for growth. Unlike localized disease, there are currently no known cures for metastatic
prostate cancer &#8211; there are only treatments to slow the progression of disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the approval of Pluvicto<sup>&#174;</sup>&#160;for
patients with mCRPC post-taxane therapy and post ARPI therapy and prior to taxane therapy, targeted-radiotherapy has become a prominent
component of the metastatic prostate cancer treatment paradigm. Pluvicto<sup>&#174;</sup> generated sales of approximately $1.4 billion
in the first nine months of 2025. In June 2025, Novartis announced expects to file an FDA submission in the second half of 2025 for Pluvicto<sup>&#174;</sup>&#160;in
metastatic hormone sensitive prostate cancer (&#8220;mHSPC&#8221;), that could add approximately 42,500 additional patients to the addressable
market for Pluvicto<sup>&#174;</sup>. With approximately one-third of patients not responding to PSMA-directed radiotherapy and that virtually
all patients will progress on PSMA-directed radiotherapy within 12 months, we believe this demonstrates the high unmet need for a non-PSMA
prostate cancer therapy such as ATNM-400.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2025, we received
a letter from Novartis Pharmaceuticals Corporation (the &#8220;Novartis Letter&#8221;) that is incorporated in this Form 10-Q as an exhibit.
In that letter, Novartis strongly objected to statements that Actinium made comparing ATNM-400 and Pluvicto<sup>&#174;</sup>. Given that
ATNM-400 is in preclinical development and that we clearly indicated as such, we believe that the Novartis Letter is highly unusual. We
believe the particular statements cited by Novartis were not misleading and were accurate depictions of our research findings that evaluated
ATNM-400 versus 177Lu-PSMA-617, the active agent in Pluvicto<sup>&#174; </sup>as well as 225Ac-PSMA-617, a targeted radiotherapy that is
not yet approved but is being evaluated by multiple companies including Novartis. As we have reported, ATNM-400 demonstrated superior
tumor control and improved overall survival in preclinical studies in prostate cancer bearing animals compared to 177Lu-PSMA-617. In addition,
ATNM-400 demonstrated efficacy in prostate cancer tumors that developed resistance to 177Lu-PSMA-617. Therefore, we do not agree with
any of the claims made in the Novartis Letter and do not believe Novartis has requisite legal authority or basis to challenge Actinium.
Therefore, we have not responded to Novartis but reserve all rights. We believe patients with mCRPC have high unmet needs that are not
addressed by current therapies including Pluvicto<sup>&#174;</sup> and intend to continue to develop ATNM-400 with the goal of addressing
these patient needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the only approved targeted
radiotherapy in prostate cancer moving up in the treatment paradigm with very few differentiated products in clinical development, we
believe there is a significant potential market opportunity for ATNM-400. Currently, over 30 PSMA-targeted radiotherapies are in various
stages of development, of which few offer a substantial efficacy advantage compared to Pluvicto<sup>&#174;</sup>. Re-treatment with PSMA-targeting
agents has not yet been supported substantially in controlled clinical trials and could be less effective than targeting a different antigen
due to potential reduction of PSMA surface expression as well as increased tumor heterogeneity following initial PSMA-targeted therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have demonstrated that ATNM-400&#8217;s
differentiated target is expressed and druggable following ARPI therapy and PSMA radiotherapy. We believe ATNM-400 can therefore target
a significant subset of the mCRPC patient population with aggressive disease who progressed on second generation ARPIs or have had no
response to or progressed on Lu-177 labelled PSMA-targeted therapy. As ATNM-400 does not target PSMA, xerostomia or dry mouth, which can
be a significant quality of life issue for patients with metastatic prostate cancer receiving PSMA-targeted radiotherapies as PSMA is
expressed on salivary glands, would not be expected. Additionally, the antigen targeted by ATNM-400 is implicated in a pathway leading
to ARPI-resistance in mCRPC patients and expression increases post-ARPI treatment; therefore, along with the tumor suppressing ability
of Ac-225, ATNM-400 displays a compelling mechanism for synergy with ARPIs. This mechanistic synergy is supported by the complete tumor
regression in 40 percent of tumor bearing animals treated with the combination of ATNM-400 and the ARPI enzalutamide. As a result, we
believe ATNM-400 has the potential to address critical gaps in prostate cancer treatment as a monotherapy or in combination or sequenced
with other therapeutic modalities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NSCLC</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of the approximately 226,650
new lung cancer cases expected to be diagnosed in 2025, 85 percent are NSCLC of which a significant portion harbor an EGFR mutation. Approved
therapies for EGFR-mutant NSCLC collectively generated approximately $7 billion in sales in 2024, including (TARGRISSO<sup>&#174;</sup>,
AstraZeneca) in the frontline setting that led the class with sales of $6.6 billion in 2024, the Trop-2 antibody drug conjugate Dato-DXd
(DATROWAY<sup>&#174;</sup>, AstraZeneca/Daiichi Sankyo) that was approved in January 2025 in the second line setting, and the EGFR-cMET
bispecific antibody amivantamab (RYBREVANT<sup>&#174;</sup>, J&amp;J) in later lines that had sales of $0.3 billion in 2024. Despite osimertinib&#8217;s
success as first-line therapy exhibited both in the FLAURA trial and through real-world evidence, disease progression is common, and the
resistance mechanisms are highly heterogeneous, creating distinct patient segments for targeted therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Following progression on osimertinib,
approximately half of the patients with EGFR mutant NSCLC are expected to undergo second line treatment where DATROWAY<sup>&#174; </sup>is
the approved standard-of-care. Despite the recent approvals of targeted therapies in the post-osimertinib treatment setting, a significant
unmet need remains for targeted therapies that can provide durable treatment options beyond chemotherapy. ATNM-400 produced superior efficacy
in the first-line setting as a monotherapy and in combination with the leading EGFR treatment osimertinib as well as superior efficacy
compared to second-and-third-line EGFR therapies DATROWAY and RYBREVANT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_011.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">EGFR-mutant NSCLC is a highly
competitive field with AstraZeneca and Johnson &amp; Johnson competing for market share for TAGRISSO<sup>&#174;</sup> and RYBREVANT<sup>&#174;</sup>
with chemotherapy combinations aimed at improving OS and PFS. These chemotherapy combinations are currently being studied in clinical
trials. AstraZeneca is conducting the FLAURA2 study to evaluate TAGRISSO<sup>&#174;</sup> combined with chemotherapy and Johnson &amp;
Johnson is conducting the MARIPOSA trial studying RYBREVANT<sup>&#174;</sup>. Improved survival outcomes have been reported in both studies
compared to either agent alone, however, the addition of chemotherapy also resulted in increased toxicities. Notably, AstraZeneca and
Johnson &amp; Johnson have acquired or developed targeted radiotherapy assets and capabilities, however, their current assets are focused
on prostate cancer. We believe the expansion into NSCLC represents significantly increases the potential addressable patient population
for ATNM-400 and is also strategically aligned with the growing adoption of targeted radiotherapy by large biopharmaceutical companies
and their therapeutics areas of interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We believe ATNM-400 could enable
the combination of targeted radiotherapy with EGFR therapies in a novel way, which could facilitate market share expansion and extend
treatment windows. Specific to TAGRISSO, ATNM-400&#8217;s target antigen is statistically significantly increased following osimertinib
treatment supporting a mechanistic synergy when used in combination. As noted above, preclinically the combination of ATNM-400 and osimertinib
produced complete tumor regression in 100 percent of tumor bearing animals. The clinical rationale for the ATNM-400 combination is further
supported by a Phase 2 multicenter trial that was supported by AstraZeneca that showed EBRT combined with osimertinib improved PFS (Sampath
et al. <i>Lancet eClinicalMedicine</i>, 2025) by 61 percent compared to osimertinib alone. We believe ATNM-400 has the potential to deliver
precision targeted, powerful alpha radiation via Ac-225 which on a per-cell basis is approximately up to 4 to 8-times more biologically
lethal than diffuse, low-energy EBRT. This may translate to higher response rates, lower toxicity, and entry into previously untreatable
market segments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HR+/HER2- Breast Cancer</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Breast cancer is the most
diagnosed cancer among woman in the United States with approximately 316,950 women expected to be diagnosed with the disease in 2025 according
to the NCI. It is estimated that approximately 200,000 women are living with metastatic breast cancer in 2025, which is expected to grow
to 250,000 in 2030. Of those diagnosed, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for 70-75% of breast
cancer, representing the largest subtype. In this setting, tamoxifen (endocrine therapy) and HER2-targeted therapy trastuzumab (Herceptin&#174;,
Roche and biosimilars) generated sales of approximately $4.0 billion in 2024. We believe ATNM-400 has potential to address unmet needs
in this patient population.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Actimab-A Solid Tumor Program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Potential Pan Solid Tumor Therapy in Combination
with PD-1 Checkpoint Inhibitors Including KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> by Depleting Myeloid Derived Suppressor
Cells</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immunotherapy is the leading
class of oncology therapies with PD-1 checkpoint inhibitors generating global sales of over $40 billion in 2024. PD-1 inhibitors have
significantly improved patient outcomes across several solid tumor indications, however, not all patients have robust or durable responses,
and the benefit of PD-1 inhibitors has not been realized in several cancer indications. As a result, there are extensive efforts to improve
outcomes for these patients with multiple therapeutic modalities studied in combination with PD-1 inhibitors in attempt to improve patient
outcomes. However, few combinations have produced a sufficient clinical benefit or have been approved. To our knowledge, our Actimab-A
solid tumor program is the only CD33 targeted radiotherapy being evaluated in combination with PD-1 inhibitors. The rationale for studying
Actimab-A in combination with the PD-1 inhibitors is based on the premise that depleting MDSCs, which express CD33, with Actimab-A may
work synergistically and therefore improve the efficacy of drugs such KEYTRUDA<sup>&#174;</sup> (Merck) or OPDIVO<sup>&#174;</sup> (Bristol
Myers Squibb).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDSCs are immune-suppressive
cells that help tumors evade immune detection and promote disease progression. They are overexpressed in the tumor microenvironment in
several different solid tumors and associated with poor outcomes. PD-1 inhibitors work by binding and blocking PD-1, allowing T-cells
to resume their anti-tumor activity. MDSCs function as a resistance mechanism by preventing T-cells from recognizing and attacking tumors,
which we believe supports our strategy for using Actimab-A to deplete MDSCs to reenable PD-1 inhibitors to work after patients stop responding
to or in indications where PD-1 inhibitors have had limited clinical success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Potential Mechanistic Synergy of Actimab-A
with PD-1 Inhibitors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_012.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Clinical and preclinical studies,
including studies we have conducted, have shown that MDSCs are overexpressed in patients with cancers. For instance, a study by Bronte
et al., in patients with NSCLC receiving PD-1 inhibitors evaluated the role of immune cells on patient outcomes. In this study, MDSCs
were the only immune cell subtype to show a statistically significant association with tumor response. The median level of MDSCs was determined
to be 1.9percent with patients above that level being classified as &#8220;High-MDSC&#8221; and patients below that level being classified
as &#8220;Low-MDSC&#8221;. In this study, only Low-MDSC patients had a clinical response, with no responses observed in High-MDSC patients
and over 80percent of High-MDSC patients having progressive disease. In addition, Low-MDSC patients had a statistically significantly
improvement in PFS of 8.39 months compared to 1.94 months in High-MDSC patients and OS of 15.15 months compared to 3.03 months in High-MDSC
patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Low MDSC&#8217;s Associated
with Statistically Significant Improvement in PFS and OS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_013.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is considerable preclinical
scientific evidence in the literature that depleting MDSCs could be a viable strategy in improving the outcomes of PD-1 directed immunotherapy,
however, there have been no viable clinical approaches that have been tried successfully to our knowledge.&#160; MDSCs are known to express
the CD33 antigen which is the target of Actimab-A.&#160; Actinium has also generated published and unpublished preclinical data showing
that Actimab-A can selectively deplete MDSCs in solid tumors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We believe there is strong
scientific and clinical rationale supporting the potential for Actimab-A to deplete CD33 expressing MDSCs and hence improve patient outcomes
with PD-1 ICIs such as KEYTRUDA<sup>&#174;</sup>&#160;and OPDIVO<sup>&#174;</sup>. Our Actimab-A MDSC solid tumor program is expected to
initially evaluate the combination of Actimab-A with KEYTRUDA<sup>&#174;</sup>&#160;or OPDIVO<sup>&#174; </sup>in a basket trial in patients
with head and neck squamous cell carcinoma (&#8220;HNSCC&#8221;), NSCLC, Glioblastoma Multiforme (&#8220;GBM&#8221;) and colorectal cancer
that are PD-1 inhibitor na&#239;ve.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The objective of this trial
would be to evaluate the safety and tolerability as well as following endpoints including ORR, PFS and OS. Further, the following biomarker
data would be collected including the pattern of depletion of CD33-positive MDSCs and T-cell activity in peripheral blood. We are completing
a regulatory submission to advance this trial and expect initial proof of concept data in the first half of 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Actimab-A Hematology Therapeutic
Program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Mutation Agnostic Mechanism of Action with Backbone
Therapy Potential in Mutation Rich, Highly Radiosensitive Myeloid Malignancies such as AML </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing Actimab-A
to leverage the mutation-agnostic mechanism of Ac-225 and ubiquitous expression of CD33 in AML. We believe Actimab-A has the potential
become a backbone therapy in AML, which is extremely heterogenous and radiosensitive, either as a single agent or in combinations with
chemotherapy, targeted agents, cellular therapy and immunotherapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our development strategy is
to exploit these properties of Actimab-A to address the unmet needs of patients with myeloid malignancies across the treatment journey
including the frontline, relapsed/refractory and maintenance settings. To accomplish this, we are leveraging our clinical development
experience, clinical data and preclinical work supporting Actimab-A&#8217;s mutation agnostic capabilities across multiple treatment settings
including currently planned trials in r/r AML in combination with chemotherapy CLAG-M and frontline AML in combination with Venetoclax
and hypomethylating agents We are evaluating multiple studies leveraging Actimab-A&#8217;s mutation agnostic profile in AML including
trials under our CRADA.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A + CLAG-M Phase 2/3 Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have aligned with the FDA
on a randomized pivotal Phase 2/3 trial to compare Actimab-A + CLAG-M, a chemotherapy regimen, to CLAG-M alone in patients with r/r AML.
This trial is supported by the Phase 1 Actimab-A + CLAG-M trial that produced favorable rates of overall response and measurable residual
disease negativity (&#8220;MRD-negativity&#8221;) as well as demonstrated improved survival outcomes in heavily pretreated, r/r AML patients
with high-risk features including TP53 mutations and prior venetoclax therapy, which are associated with negative outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">MRD Negativity and
Overall Survival Across Patient Groups</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_014.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the results above, seventy percent of eligible patients
proceeded to a BMT with Actimab-A + CLAG-M, with 24-month median OS reported in these patients. These results compare highly favorably
to the &lt;2 to 4-month OS reported in r/r AML patients with a TP53 mutation or prior venetoclax therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our interactions with the FDA, this trial will first complete
a Phase 2 portion where the Actimab-A dose will be optimized in combination with CLAG-M. Once we have the Phase 2 results, we will meet
with FDA to determine the optimized Actimab-A dose and obtain feedback on our Phase 3 protocol. We expect this interim analysis and meeting
with FDA will allow for an operationally seamless transition to the Phase 3 portion of the study, which may reduce time and resources
required compared to separate Phase 2 and Phase 3 studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_015.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect the primary endpoint of the Phase 3 trial will be OS. Event-Free
Survival (&#8220;EFS&#8221;) and other efficacy measures as well as safety will also be evaluated. We are actively seeking potential strategic
partners or collaborators to advance this trial.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><i>Actimab-A NCI CRADA Trials</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2023, we entered into a CRADA with NCI to develop Actimab-A for
the treatment of patients with AML and other hematologic malignancies. The NCI will serve as the regulatory sponsor for any clinical trials
mutually approved by both parties to study Actimab-A. The CRADA will provide support for and may accelerate the development of Actimab-A
alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel combinations. The CRADA studies will be overseen
by the NCI in collaboration with Actinium&#8217;s clinical development team, where we have the right to review and approve all protocols
and have full rights to all data. Under the NCI CRADA, we will supply Actimab-A and NCI will cover all clinical trial execution and development
expenses, which we believe will be a cost-efficient approach as opposed to a Company sponsored trial. The NCI Cancer Therapy Evaluation
Program (&#8220;CTEP&#8221;), which sponsors approximately two thirds of all combination cancer studies, will accept Letters of Intent
(&#8220;LOIs&#8221;) or concepts for Phase 1, 2 or 3 studies of Actimab-A in AML and other hematological malignancies such as high-risk
myelodysplastic syndromes (&#8220;MDS&#8221;).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, the NCI announced that its myeloMATCH program was
officially open to patient enrollment across the U.S. and Canada. MyeloMATCH is a portfolio of clinical trials to test precision medicine
treatments for adults with AML or MDS being designed and led by four leading cancer research organizations including the Alliance for
Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG Cancer Research Network in collaboration
with the NCI National Clinical Trials Network (&#8220;NCTN&#8221;). Collectively, the myeloMATCH program expects to open trials at hundreds
of cancer care sites across the U.S. and Canada with the goal of enrolling 5,000 or more patients over the next several years. Under our
CRADA with the NCI, Actimab-A is part of the myeloMATCH program and may be included in future clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><i>Actimab-A, Venetoclax &amp;
ASTX-727 &#8211; Frontline AML Triplet Phase 1b Combination Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we announced
the initiation of the first clinical trial to be conducted under our CRADA by NCI. The trial will evaluate the triplet combination comprised
of Actimab-A, Venetoclax and ASTX-727, a novel oral HMA developed by Taiho Oncology, an Otsuka Holdings company, in frontline AML patients.
Venetoclax in combination with HMAs (Ven-HMA) is approved for patients with newly diagnosed AML. We believe this trial is supported by
our Actimab-A + Venetoclax combination trial that showed that the combination was well-tolerated and showed supportive anti-leukemic activity.
The frontline AML triplet trial is expected to enroll up to 48 patients who are newly diagnosed with AML that are age 75 and above and
not eligible for intensive chemotherapy. The trial will evaluate various dose levels of Actimab-A along with dosing regimens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional clinical trial concepts for Actimab-A have been submitted
through our CRADA. We believe this supports the differentiated profile of Actimab-A for hematologic and solid tumor indications and presents
an opportunity to expand Actimab-A&#8217;s addressable market for a potential partner or collaborator. However, as a result of the recent
government shutdown that began on October 1, 2025 and ended on November 12, 2025, we expect to experience delays to our current and planned
trials under the CRADA. See Risk Factors &#8211; &#8220;Disruptions at the FDA, the SEC and other government agencies or comparable regulatory
authorities caused by the government shutdown, funding shortages or global health concerns, in addition to substantial uncertainty regarding
the new Administration&#8217;s initiatives and how these might impact the FDA, its implementation of laws, regulations, policies and guidance,
and its personnel, could hinder government agencies&#8217; ability to hire and retain key leadership and other personnel, or otherwise
prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from
performing normal business functions on which our business operations rely, including timely reviews, which could negatively impact our
business.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><i>Data Supporting Actimab-A&#8217;s
Mutation Agnostic Profile</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To leverage Actimab-A&#8217;s
mutation agnostic capabilities and support its broad development, we have conducted preclinical experiments studying Actimab-A in combination
with targeted agents including Bcl-2 inhibitors, FLT-3 inhibitors, IDH inhibitors, menin inhibitors for NPM1 and KMT2A AML, chemotherapies
such as azacitidine and in cell lines expressing TP53 mutations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We presented preclinical data in April 2025 at the AACR annual meeting
demonstrating that the combination of Actimab-A with standard of care targeted AML therapies including menin and FLT3 inhibitors and the
HMA azacitidine resulted in statistically significant antileukemic activity in AML cells lines with FLT3, NPM1, KMT2A and TP53 mutations.
Additionally, in animal models, Actimab-A showed statistically significant enhanced tumor growth inhibition, prolonged the duration of
response and survival when combined with the menin inhibitor revumenib, and potentiated AML cell killing in combination with the FLT3
inhibitor gilteritinib and HMA azacitidine. We expect to present additional data supporting Actimab-A&#8217;s mutation agnostic capabilities
and backbone potential at future scientific and medical conferences. In addition, we will continue to explore potential clinical trials
under our CRADA with NCI, investigator-initiated trials or under our sponsorship.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Iomab-ACT Targeted Conditioning
Program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Universal, Non-Chemotherapy
Conditioning for Improved Patient Access and Outcomes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-ACT is our next-generation targeted conditioning agent directed
against CD45, a target expressed widely across the hematopoietic system including normal nucleated immune cells such as lymphocytes that
are relevant to this program and uses the Iodine-131(&#8220;I-131&#8221;) radioisotope payload. We are developing Iomab-ACT to condition
or prepare patients&#8217; immune system to enable cell and gene therapies in both malignant and non-malignant hematologic indications.
Iomab-ACT utilizes non-myeloablative doses of I-131, to not fully deplete the patient&#8217;s bone marrow and immune system with the goal
of improving patient access and outcomes for potentially curative cell and gene therapies by replacing the need for the non-targeted,
chemotherapy-based conditioning regimens currently used, which are associated with toxicities that limit patient access. As an example,
in order to receive gene therapy, SCD patients receive Busulfan, a chemotherapy associated with infertility, that can therefore require
patients to undertake fertility counseling. Iomab-ACT is currently being studied in three clinical trials. These trials include Iomab-ACT
with a commercial CAR-T therapy, Iomab-ACT prior to allogeneic bone marrow transplant for patients with SCD, which could potentially inform
a trial design with gene therapy for SCD, and Iomab-ACT with a novel investigational CD19 CAR-T therapy.&#160;We expect initial clinical
data from the Iomab-ACT commercial CAR-T therapy and SCD trials in the first half of 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Iomab-B</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Targeted Conditioning
for Bone Marrow Transplant</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We previously advanced our targeted conditioning program Iomab-B through
the Phase 3 Study of Iomab-B in Elderly Relapsed and Refractory AML (&#8220;SIERRA&#8221;) trial, a 153 patient, randomized multi-center
trial conducted in the United States and Canada. Iomab-B is comprised of the anti-CD45 monoclonal antibody apamistamab with myeloablative
doses of I-131 intended to enable patient access to BMT, the only potentially curative treatment option for patients with r/r AML. T<span style="background-color: white">he
SIERRA trial met the primary endpoint with statistical significance, as 22% of patients (13/76) on the Iomab-B arm achieved durable Complete
Remission (&#8220;dCR&#8221;) compared to 0% of patients (0/77) on the control arm resulting in a p-value of &lt;0.0001. The SIERRA trial
met the secondary endpoint of Event-Free Survival (&#8220;EFS&#8221;) with a 78% reduction in the probability of an event (Hazard Ratio=0.22,
p&lt;0.0001 for both per protocol and ITT basis). EFS at 180 days for the Iomab-B arm was 28% compared to 0.2% for the control arm. In
the SIERRA trial, an event was defined as one of the following: a patient not achieving CR/CRp or crossing over, patient not receiving
BMT, a patient relapsing or death. The SIERRA trial did not, however, meet the secondary endpoint in achieving a statistically significant
improvement in OS in the intent to treat (&#8220;ITT&#8221;) population.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On August 5, 2024, Actinium announced that it concluded both its clinical
and Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) interactions with the FDA regarding the BLA pathway for Iomab-B based on
the SIERRA trial results. As previously disclosed, we had received what we believe to be positive feedback from the FDA regarding our
CMC package for Iomab-B and were also assigned a BLA number. However, in the third quarter of 2024, the FDA provided definitive feedback
that the SIERRA trial alone is not adequate to support a BLA filing for Iomab-B, despite (a) the SIERRA trial meeting the primary endpoint
of dCR with statistical significance (p-value&lt;0.0001) and other positive secondary endpoints including Event Free Survival (&#8220;EFS&#8221;)
and safety, and (b) our presentation of several additional analyses from the SIERRA study, including long-term follow-up demonstrating
a trend towards improved OS and evidence of survival benefit in patients with high-risk TP53 mutations, to support Iomab-B&#8217;s impact
on OS. The FDA indicated that demonstrating an OS benefit in a randomized head-to-head trial is necessary and has advised us to conduct
a study to evaluate allogeneic BMT using Iomab-B plus a reduced intensity conditioning regimen of fludarabine and total body irradiation
(&#8220;Flu/TBI&#8221;) versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI. This proposed
additional study differs from the SIERRA trial, which allowed physician&#8217;s choice of salvage chemotherapies and heterogenous conditioning
regimens in the control arm. Additionally, the proposed new study will not allow patients to cross over from the control arm, which was
allowed in the SIERRA trial and confounded the OS analysis in the ITT patient population, as nearly 60% of patients crossed over from
the control arm.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; background-color: white">Actinium
continued interactions with the FDA in 2024 and 2025 to further discuss the specifics of the additional head-to-head clinical trial required
by the FDA. Based on these interactions, Actinium has reached agreement with the Agency on a Phase 2 clinical trial protocol and has been
authorized by FDA to initiate the Phase 2 portion of the trial. We are actively seeking a strategic partner for Iomab-B in the U.S. to
execute the Phase 2/3 clinical trial. This planned study will consist of a Phase 2 dose optimization portion to demonstrate safety and
efficacy with the dose of Iomab-B based on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation
to the liver as was done in the SIERRA trial based on several interactions we had with the FDA before starting the SIERRA trial. Once
what the FDA considers adequate safety data to establish a treatment plan for the Phase 3 protocol is gathered, a meeting with the FDA
will be necessary to gain approval to proceed to the Phase 3 portion of this planned trial. The optimized dose established in the Phase
2 portion is then expected to be studied in the randomized Phase 3 portion to evaluate allogeneic BMT using Iomab-B plus a reduced intensity
conditioning regimen of Flu/TBI versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI.
The study population will be all adult patients age 18 and above with active AML with blasts counts between 5 and 20 percent. This is
a broader patient population than the patients enrolled on the SIERRA trial, which only enrolled patients aged 55 and above and with blast
counts that exceeded 20 percent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, we entered
into a License Agreement with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant to which Immedica licensed the exclusive product rights
for commercialization of Iomab-B in certain countries in the EUMENA region. Upon signing, we were entitled to an upfront, non-refundable
payment of $35.0 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. Immedica is responsible for regulatory submissions in the EUMENA region, and we continue to retain commercialization
rights in the U.S. and rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Hematology Portfolio Strategic Partnering Opportunities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At this time, we are seeking a strategic partner
for Iomab-B in the U.S., and we may seek to partner, divest, spin-out, or out-license Iomab-B, Actimab-A or Iomab-ACT individually or
collectively for all non-solid tumor indications. We believe our hematology portfolio represents an attractive partnering or licensing
opportunity that can establish a specialty radiotherapy franchise supported by robust clinical data, multiple value drivers and a large
addressable market opportunity. See Risk Factors &#8211; &#8220;We continuously evaluate our business strategy and may modify our strategy
as necessary to respond to developments in our business and other factors, and any such modification such as a divestiture, spin-off,
spin-out, merger or acquisition, if not successful, could have a material adverse effect on our business, financial condition, and results
of operations.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">2 Phase 2/3 Trials and 4 Phase 1 Trials Supported by NCI CRADA</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_016.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Key Value Drivers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 38.4pt"/><td style="width: 18pt">-</td><td style="text-align: justify"><b>Clinical Validation</b>: Data in over 500 patients treated with Iomab-B and Actimab-A</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.4pt; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 38.4pt"/><td style="width: 18pt">-</td><td style="text-align: justify"><b>Concentrated Commercial Market</b>: Addressable patient population primarily treated at the top 100 quaternary care centers in
the U.S.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 38.4pt"/><td style="width: 18pt">-</td><td style="text-align: justify"><b>Favorable Commercial Dynamics</b>: Strong synergy across Actimab-A, Iomab-B and Iomab-ACT given commercial call point overlap that
can be services by a concentrated commercial force</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 38.4pt"/><td style="width: 18pt; text-align: left">-</td><td style="text-align: justify"><b>Unmet Medical Need</b>: Provides opportunity for commercial
success with the only radiotherapies in development for these large markets</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe Actimab-A, Iomab-B
and Iomab-ACT collectively have the potential to be successful commercial products, if approved based on the high unmet needs of their
addressable patient segments. In total, we believe this opportunity exceeds 400,000 patients in the U.S. and EU based internal market
research and estimates</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_017.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R&amp;D and Platform Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our R&amp;D capabilities, we believe, have the potential to yield differentiated,
high-value targeted radiotherapy programs that demonstrate our experience across multiple validated cancer targets and isotopes and cover
broad areas of focus leveraging our clinical development experience across hematology, targeted conditioning, solid tumors, and next-generation
radiotherapies. We have internal R&amp;D capabilities with our research laboratory capable of executing in vitro and in vivo experiments
and translational research. We are working on several preclinical programs which include novel approaches to validated cancer targets,
as well as novel targets that we believe show immense potential for radiotherapeutic approaches. Preclinical pharmacology studies with
our targeted radiotherapeutics, such as HER2, CD33 and CD38, have shown improved tumor growth inhibition in various preclinical tumor
models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently believe that our targeted radiotherapies, which utilize
biologic molecules, are less likely than small molecules to face pricing pressure and negotiation from the Inflation Reduction Act of
2022 (&#8220;IRA&#8221;), given that small molecules are at risk for pricing negotiations seven years after approval compared to eleven
years for biologics with negotiated prices taking effect two years after selection. Further, a drug or biological product that has an
orphan drug designation, which our Actimab-A and Iomab-B programs both have, for only one rare disease or condition will be excluded from
the IRA&#8217;s price negotiations requirements until such time the biological products has designations for more than one rare disease
or condition, or if is approved for an indication that is not within that single designated rare disease or condition, unless such additional
designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. In addition,
regulatory barriers for generic large molecule biologic based targeted radiotherapies are much higher than for small molecule radioligands
such as those under development or approved, namely, Pluvicto<sup>&#174;</sup>, Lutathera<sup>&#174;</sup>, and Xofigo<sup>&#174;</sup>.
Generic versions of certain radiopharmaceuticals utilizing peptides, which are considered small molecules, have been submitted to the
FDA via the Abbreviated New Drug Application (&#8220;ANDA&#8221;) pathway. To our knowledge, only the biosimilar approach pertains to
large molecule biologic-based radiotherapies filed under 351(k) BLA pathway. The regulatory pathway for a biosimilar is much more comprehensive
than the pathway for generics, and it has not been proven that biosimilars are interchangeable with the innovator&#8217;s large molecule
biologic targeted radiotherapy. In addition, we are not aware of any regulations that would require us to provide Actimab-A or Iomab-ACT,
including their respective mAbs, lintuzumab and apamistamab, to any third party or potential competitor. Despite the above, we are aware
that one or more of the policies or regulations that afford our pipeline candidates market protections may change in the future and that
one or more of our product candidates may be disadvantaged by such change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to expand our capabilities and technologies across therapeutic
modalities, linker technologies and in vivo cancer models, and build visibility through presentations at key conferences and publications
in journals of high impact. Our R&amp;D efforts are centered on the advancement of key programs with a robust &#8220;fast-to-clinic&#8221;
approach. Underpinning our development programs is our expanded patent portfolio of approximately 250 issued patents and pending patent
applications worldwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Our Proprietary Ac-225
Cyclotron Manufacturing Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With our in-depth, long-term experience in clinical development of
Ac-225 based radiopharmaceuticals, we have developed an end-to-end technology solution for producing Ac-225 that has demonstrated radiochemical
and radionuclidic purity identical to current gold-standard methods. This patented technology has been used to produce Ac-225 in a cyclotron
that is essentially identical to that derived from a Th-229 generator and has the potential to be a lower-cost, commercially scalable
higher-yielding approach. Importantly, the Ac-225 material produced by our proprietary method contains no long-lived contaminants and
less than 0.001% Actinium-227 (&#8220;Ac-227&#8221;). Using the cyclotron-produced Ac-225 technology may allow for large commercial scale
production with estimated cost of goods sold including capital expenditures and operational costs for a single cyclotron facility to be
several times less expensive than the price of currently available Ac-225 material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our extensive know-how related to this production technology is supported
by 5 issued patents in the U.S. and 33 issued patents internationally and covers:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">End-to-end solution including processing and recycling of Radium-226 starting material</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production of up to 100 mCi of Ac-225 per production cycle</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization of a medium energy cyclotron</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected cost 10 to 20 times lower than currently available material</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiochemical purity &gt; 99%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radioisotopic purity 99.8% with no long-lived contaminants and &lt;0.001% Ac-227</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With our Ac-2225 based Actimab-A
and ATNM-400 programs and the rapidly increasing number of Ac-225 based programs in development, we believe that we are well positioned
to leverage this technology to produce Ac-225 to address the growing clinical and potential commercial demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing and Supply Chain</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium has established significant
manufacturing and supply chain expertise, having delivered over 500 doses for 18 clinical trials at 45 large cancer hospitals and have
never missed a dose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe this experience
provides us with insights that are highly relevant to the unique manufacturing and distribution requirements of radiotherapeutics. Due
to the short half-life of radioisotopes, our finished drug products are shipped &#8220;hot&#8221; and must be administered within days.
Actinium has established core competencies in the process of manufacturing radiotherapeutics, coordinating with the hospital&#8217;s care
team, and delivering &#8220;just-in-time&#8221; doses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We plan to establish our own
manufacturing capabilities and intend to commence the build-out of a facility that will be capable of supplying final drug product for
our current and planned clinical trials. We believe that having in-house manufacturing will provide enhanced control, flexibility and
scalability to serve our current and planned clinical trials and R&amp;D efforts as well as potential future activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Isotope supply is critical
for the manufacturing of radiotherapeutics, and we have engaged several sources for the procurement of alpha (e.g., Ac-225) and beta (e.g.,
I-131 and Lu-177) emitters. We also have multiple isotope supply agreements and qualified vendors in place to supply isotopes for our
active and planned clinical trials. In March 2025, we announced that we entered into&#160;Ac-225 supply agreement with Eckert &amp; Ziegler,
a leading specialist in isotope-related components for nuclear medicine and radiation therapy, to support our comprehensive development
including U.S. and international clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium has commercial agreements with Contract Development and Manufacturing
Organizations (&#8220;CDMOs&#8221;) with significant experience in mAb and final radio-labeled drug products. Our finished drug product
CDMOs are located in the U.S. and have experience in the international supply of radiotherapies. We have scaled deliberately for manufacturing
flexibility&#160;and are currently qualifying additional CDMOs to ensure readily available drug product upon FDA approval and the ability
to ramp up rapidly to meet commercial demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary technology
platform is supported by IP, know-how and trade secrets that cover the generation, development, methods of use and manufacture of targeted
radiotherapies and their select components. Our IP covers various methods of use in multiple diseases, including indication, dose and
scheduling, radionuclide warhead, and therapeutic combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of November 2025, our
patent portfolio is comprised of approximately 250 issued patents and pending patent applications worldwide, which we believe constitutes
a valuable business asset. Our IP includes 48 patent families, including key patents that relate primarily to our radiotherapeutic candidates.
Our patent portfolio includes 22 issued patents and 51 pending patent applications in the U.S., and 180 that are issued or pending internationally.
The effective lives of the issued patents in our portfolio, or patents that may issue from the pending applications in our portfolio,
ranges from expirations between 2026 and 2046.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our Iomab-B product candidate, we have four issued patents in the
U.S. and issued patents in Canada, Europe and Japan that relate to the composition. The basic patent terms of these patents expire in
2036 and 2037. Related patent applications are also currently pending in the U.S. and internationally. In addition, we own both U.S. and
international pending patent applications that relate to the use of Iomab-B or Iomab-ACT in the treatment of cancers and non-malignant
conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patents also cover key areas of our business such as manufacturing
key components of our product candidate, Actimab-A, including Ac-225 in a cyclotron. We have expertise in utilizing the alpha emitting
isotope Ac-225 including clinical experience in treating approximately 150 patients with our alpha-emitter-based therapies, &#8220;gold
standard&#8221; linker technology and 5 issued patents in the U.S. and 33 issued patents internationally related to the manufacturing
of Ac-225 in a cyclotron, which we believe has the potential to produce higher quantities of Ac-225 than currently utilized methods. In
addition, we also own U.S. and international patents and pending patent applications that relate to the manufacturing of Actimab-A and
its use in the treatment of cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Human Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of November 13, 2025, we had 25 full-time employees, 12 of whom
have Ph.D. or M.D. degrees and 20 of whom are engaged in research and development and clinical development activities. We believe that
we have been successful to date in attracting skilled and experienced personnel despite the competitive hiring marketing in the industry.
Our employees are not covered by a collective bargaining agreement, and we believe that our relationship with our employees is excellent.
We continue to engage external consultants on an as-needed basis to temporarily supplement existing staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Option Compensation Expense</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, our Board
of Directors approved the cancellation of certain stock options to purchase an aggregate of 4.9 million shares of common stock held by
certain current employees and directors that were initially granted under our Amended and Restated 2013 Stock Plan and 2019 Amended and
Restated Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock option expense for the
three months ended March 31, 2025 and March 31, 2024, respectively, three months ended June 30, 2025 and June 30, 2025, respectively and
stock option expense for the three months and nine months ended September 30,2025 and September 30,2024, respectively, is presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Three months ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Three months ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-size: 10pt">Three months ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine months ended</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">March
    31</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">June
    30</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">September
    30</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">September
    30</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><span style="font-size: 10pt">$ in thousands</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2025</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2024</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2025</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2024</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">2025</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">2024</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2025</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2024</span></td><td style="text-align: center; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 20%; text-align: left"><span style="font-size: 10pt">Research &amp;
    Development</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-size: 10pt">2,070</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-size: 10pt">340</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-size: 10pt">16</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-size: 10pt">337</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-size: 10pt">9</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-size: 10pt">215</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-size: 10pt">2,095</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-size: 10pt">892</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-size: 10pt">General &amp; Administrative</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6,657</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">887</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">33</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">885</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">24</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">891</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">6,714</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">2,663</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Total</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">8,727</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">1,227</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">49</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">1,222</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">33</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">1,106</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">8,809</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">3,555</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Results of Operations &#8211;
Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the <br/> Three&#160;Months&#160;Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,774</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,534</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,782</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">561</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,033</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">561</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,033</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,131</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,568</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the three months ended September 30, 2025 and September 30, 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Institutes of
Health awarded us a Small Business Technology Transfer cost reimbursable grant to support a clinical collaboration with Memorial Sloan
Kettering Cancer Center, or MSK, to study Iomab-ACT, our CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve
lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. We recognized other revenue during the
three months ended September 30, 2025 of $0.1 million. There was no other revenue recognized for the three months ended September 30,
2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, we entered into a License Agreement with Immedica,
pursuant to which Immedica licensed the exclusive product rights for commercialization of Iomab-B in certain countries in the EUMENA region.
Upon signing, we were entitled to an upfront, non-refundable payment of $35 million from Immedica, which was received in May 2022. Under
the terms of the License Agreement, we are eligible to receive certain regulatory and commercial milestone payments and royalties on net
sales of the product in certain countries that may result from the License Agreement. We continue to retain commercialization rights in
the U.S. and rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract liabilities are
recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in our condensed consolidated balance
sheets depending on the short-term or long-term nature of the payments to be recognized. Our contract liabilities primarily consist of
advanced payments from licensees. There was no Other revenue deferred-current liability at September 30, 2025 and December 31, 2024. Long-term
license revenue deferred was $35 million at September 30, 2025 and December 31, 2024, resulting from the receipt from Immedica; this deferred
revenue will be recognized upon the European Union&#8217;s regulatory approval of Iomab-B or provision of definitive feedback that Iomab-B
will not receive approval in the European Union.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock-Based Compensation Expense</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the cancellation
of stock options in March 2025 resulted in a significant decrease in non-cash stock compensation expense for the three months ended September
30, 2025. During the three months ended September 30, 2025 and September 30, 2024, total non-cash stock-based compensation expense, including
stock option compensation expense, was $0.1 million and $1.3 million, respectively.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
of $4.2 million for the three months ended September 30, 2025 decreased by $5.6 million from $9.8 million for the three months ended September
30, 2024. The decrease was primarily a result of a decline in outside CRO services and other preclinical R&amp;D expenses of $4.3 million,
lower compensation of $1.5 million due to lower headcount and lower non-cash stock-based compensation expense of $0.2 million due to the
cancellation of stock options in March 2025. In the second quarter of 2025, we conducted a workforce optimization that reduced our headcount
by approximately fourteen percent and announced a strategic pipeline prioritization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and administrative Expense</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expense of $1.5 million for the three months ended September 30, 2025 decreased by $1.3 million from $2.8 million for the three months
ended September 30, 2024. The cancellation of stock options in March 2025 described above resulted in lower non-cash stock-based compensation
expense of $1.0 million for the three months ended September 30, 2025 compared with the three months ended September 30, 2024. In addition,
compensation decreased $0.2 million due to lower headcount due to recent workforce optimization aligned with our strategic pipeline prioritization
that reduced our headcount by approximately 14 percent.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the three months ended September 30, 2025 of $0.6 million decreased from
$1.0 million for the three months ended September 30, 2024 primarily due to a lower average cash balance during the respective time periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss of $5.1 million for
the three months ended September 30, 2025 decreased by $6.5 million from $11.6 million for the three months ended September 30, 2024 primarily
due to lower research and development expenses and lower general administrative expenses, partially offset by lower other income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Results of Operations &#8211;
Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the <br/> Nine&#160;Months&#160;Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,827</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,096</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,382</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,923</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,616</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,025</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,025</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(27,947</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(31,591</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the nine months ended September 30, 2025 and September 30, 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized other revenue
of $0.1 million for the nine months ended September 30, 2025. There was no other revenue recognized for the nine months ended September
30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation Expense</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cancellation of stock
options on March 31, 2025, described above, resulted in a significant increase in non-cash stock-based compensation for the nine months
ended September 30, 2025 compared to its prior-year period due to recognition of previously unrecognized stock-based compensation cost
at the cancellation. During the nine months ended September 30, 2025 and September 30, 2024, total non-cash stock-based compensation expense,
including stock option compensation expense, was $9.2 million and $4.1 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
of $16.8 million for the nine months ended September 30, 2025 decreased by $8.4 million from $25.2 million for the nine months ended September
30, 2024. The decrease was primarily a result of a decline in outside CRO services and other preclinical R&amp;D expenses of $5.6 million
and lower compensation of $3.8 million due to lower headcount. In the second quarter of 2025, we conducted a workforce optimization that
reduced our headcount by approximately fourteen percent and announced a strategic pipeline prioritization. These decreases were partially
offset by higher non-cash stock-based compensation of $1.2 million, due to the cancellation of stock options described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and administrative Expense</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses of $13.1 million for the nine months ended September 30, 2025 increased by $3.7 million from $9.4 million for the nine months
ended September 30, 2024, as a result of higher non-cash stock-based compensation expense of $3.9 million, due to the cancellation of
stock options described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the nine months ended September 30, 2025 of $1.9 million decreased from
$3.0 million for the nine months ended September 30, 2024 primarily due to a lower average cash balance during the respective time periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss of $27.9 million
for the nine months ended September 30, 2025 decreased by $3.7 million from $31.6 million for the nine months ended September 30, 2024
primarily due to lower research and development expenses of $8.4 million partially offset by higher general administrative expenses of
$3.7 million as a result of higher non-cash stock-based compensation expense of $3.9 million for the nine months ended September 30, 2025
compared to the prior-year period due to the cancellation of stock options described above, along with lower other income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
selected cash flow information for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the<br/> Nine Months&#160;Ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(19,291</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(27,321</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash used in/provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(214</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net&#160;change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(19,505</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the nine months ended September 30, 2025 was $19.3 million, a decrease of $8.0 million from $27.3 million in the prior-year
period. In the nine months ended September 30, 2025, our net loss of $27.9 million excluding non-cash stock-based compensation expense
of $9.2 million was $18.7 million. In the prior-year period, net loss of $31.6 million excluding non-cash stock-based compensation expense
of $4.1 million was $27.5 million. This decrease in net cash used in operating activities of $8.8 million was offset by an increase in
net operating assets and liabilities of $0.8 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was no cash used in
investing activities for the nine months ended September 30, 2025. Cash used in investing activities was $11 thousand for the nine months
ended September 30, 2024 due to the purchase of equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash used in financing activities
for the nine months ended September 30, 2025 was $0.2 million. Net cash provided by financing activities of $29.3 million for the nine
months ended September 30, 2024 was primarily from the sale of shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2020, we entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading,
pursuant to which we are able to sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of our common
stock. On June 28, 2022, we entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement, or the Amended Sales Agreement,
with JonesTrading and B. Riley Securities, Inc. The Amended Sales Agreement modifies the original Capital on Demand&#8482; Sales Agreement
to include B. Riley as an additional sales agent thereunder. Shares of common stock are offered pursuant to a shelf registration statement
on Form S-3 (File No. 333-273911), which was declared effective February 5, 2024, including a base prospectus covering the offering, issuance
and sale of up to $500 million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus
covering the offering, issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued
and sold under the Amended Sales Agreement. During the nine months ended September 30, 2025, there were no sales of shares of common stock.
For the nine months ended September 30, 2024, we sold 3.5 million shares of common stock, resulting in gross proceeds of $29.9 million
and net proceeds of $29.3 million.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following the
date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management&#8217;s discussion
and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure
of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored
and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base
our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known.
Actual results may differ materially from these estimates under different assumptions or conditions. The Company does not have any critical
accounting estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the Financial
Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures,
to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily
related to the rate reconciliation and income taxes paid information included in income tax disclosures. We would be required to disclose
additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax
income (loss) by the applicable statutory tax rate. Similarly, we would be required to disclose income taxes paid (net of refunds received)
equal to or greater than five percent of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are effective
January 1, 2025. We adopted this standard effective January 1, 2025 and will report on it in our Annual Report on Form 10-K for the year
ended December 31, 2025. We will update all required disclosures pursuant to ASU 2023-09 at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, the One Big
Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension
of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable
tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025
and others implemented through 2027. We have evaluated the impact of the OBBBA and determined that it does not have a material impact
on our consolidated financial position and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, the FASB
issued ASU 2025-07, <i>Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements
and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</i>, which excludes from derivative
accounting non-exchange-traded contracts with underlying terms that are based on operations or activities specific to one of the parties
to the contract. However, this scope exception does not apply to (1) variables based on a market rate, market price, or market index,
(2) variables based on the price or performance of a financial asset or financial liability of one of the parties to the contract, (3)
contracts (or features) involving the issuer&#8217;s own equity that are evaluated under the guidance in Subtopic 815-40, <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity,</i> and (4) call options and put options on debt instruments. We can apply the
amendments in AUS 2025-07 either (1) prospectively to new contracts entered into on or after the date of adoption or (2) on a modified
retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the annual
reporting period of adoption for contracts existing as of the beginning of the annual reporting period of adoption. The amendments in
ASU 2025-07 are effective January 1, 2027, for annual for annual reporting periods, including interim periods within annual reporting
periods. Early adoption is permitted. We are evaluating the impact of ASU 2025-07 on its financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In September 2025, the FASB
issued ASU 2025-06, <i>Intangibles&#8212;Goodwill and Other&#8212; Internal-Use Software</i> (Subtopic 350-40): Targeted Improvements
to the Accounting for Internal-Use Software, which modernizes the accounting for software costs that are accounted for under Subtopic
350-40. The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages (referred to as
&#8220;project stages&#8221;) throughout Subtopic 350-40. Therefore, an entity is required to start capitalizing software costs when both
of the following occur: (a) a company has authorized and committed to funding the software project and (b) it is probable that the project
will be completed, and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition
threshold&#8221;). In evaluating the probable-to-complete recognition threshold, we are required to consider whether there is significant
uncertainty associated with the development activities of the software, such as determining whether (a) the software being developed has
technological innovations or novel, unique, or unproven functions or features, and the uncertainty related to those technological innovations,
functions, or features, if identified, has not been resolved through coding and testing and (b) we determined what we need the software
to do (for example, functions or features), including whether the entity has identified or continues to substantially revise the software&#8217;s
significant performance requirements. ASU 2025-06 specifies that disclosures in Subtopic 360- 10, <i>Property, Plant, and Equipment&#8212;Overall</i>,
are required for all capitalized internal-use software costs, regardless of how those costs are presented in the financial statements
and removes the requirement to disclose internal-use software information pursuant to paragraphs 350-30-50-1 through 50-3. ASU 2025-06
supersedes the website development costs guidance and incorporates the recognition requirements for website-specific development costs
from Subtopic 350-50, <i>Website Development Costs</i>, into Subtopic 350-40. The amendments in ASU 2025-06 permit an entity to apply
the new guidance using either (i) a prospective transition approach, (ii) a modified transition approach that is based on the status of
the project and whether software costs were capitalized before the date of adoption, or (iii) a retrospective transition approach. The
amendments in ASU 2025-06 are effective January 1, 2028 for annual reporting periods, including interim periods within annual reporting
periods. Early adoption is permitted as of the beginning of an annual reporting period. We are evaluating the impact of ASU 2025-06 on
our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, the FASB issued
ASU 2025-05, <i>Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract
Assets</i>, which permits a practical expedient whereby, when assessing credit losses on current accounts receivable and current contract
assets, we would assume that current conditions as of the balance sheet date do not change for the remaining life of the asset and would
not require us to consider adjustments to forecasts to also include anticipated changes in the future to the underlying conditions as
of the balance sheet date when measuring the credit losses for current accounts receivable and current contract assets. The amendments
in ASU 2025-05 are effective January 1, 2026 for annual reporting periods, including interim periods within annual reporting periods
and is required to be applied on a perspective basis. Early adoption is permitted in both interim and annual reporting periods in which
financial statements have not yet been issued or made available for issuance. The impact of ASU 2025-04 is not expected to be material
to our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In May 2025, FASB issued ASU
2025-04, <i>Compensation&#8212;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer</i>, which revises the Master Glossary definition of the term &#8220;performance condition&#8221;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#8217;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#8217;s goods or services from the grantor&#8217;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and nonemployees in exchange for goods or services to be used or consumed in the
grantor&#8217;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and nonemployees in exchange for goods or services to be used or consumed in the grantor&#8217;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2025-04 are effective January 1, 2027, for annual reporting periods,
including interim periods within annual reporting periods. We are evaluating the impact of ASU 2025-04 on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028, either on a prospective or retrospective basis. We are evaluating the impact of ASU 2024-03 on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Known Trends, Events and
Uncertainties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to risks and uncertainties common to companies
in the biopharmaceutical industry, including but not limited to, risks associated with completing preclinical studies and clinical trials,
receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key
personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to
fund operations. In addition, the consequences of the ongoing geopolitical conflicts, such as the ongoing conflict between Russia and
Ukraine and the ongoing conflict between Israel and Hamas, including related sanctions and countermeasures, and the effects of rising
global inflation, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions, the global economy,
and contribute to increased market volatility, which may in turn adversely affect our business and operations. The recent U.S. federal
government shutdown, that began on October 1, 2025 and ended on November 12, 2025, curtailed operations of key agencies such as the FDA
and the NIH, which includes the NCI, and may result in delays or disrupt our ability to advance clinical development of the current and
planned clinical trials under our CRADA, obtain regulatory interactions/approvals, or secure government-funded grants. Additionally, recent
changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the
future impact, among other things, the U.S. and global economy, tariffs, international trade relations, unemployment, immigration, healthcare,
taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes
to our business, they could adversely affect our business. For a further discussion of factors that may affect future operating results
see the sections entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statement Notice.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as discussed above
and elsewhere in this report, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Evaluation of Disclosure
Controls and Procedures</i>. Under the supervision and with the participation of our management, including our principal executive officer
and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of September 30, 2025, of our disclosure
controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange
Act. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that, as
of September 30, 2025, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are
required to disclose in our filings with the Securities and Exchange Commission, or SEC, under the Exchange Act (i) is recorded, processed,
summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to
our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely
decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Changes in Internal Control
over Financial Reporting</i>. There were no changes in our internal controls over financial reporting during the period covered by this
Quarterly Report on Form 10-Q that has materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8211; OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the United States District Court for the Southern District of New York. The Securities Complaint alleges that the
Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims
against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint
purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities
between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&#160;On June 24, 2025, the court in the
securities action appointed lead plaintiffs who filed an amended Securities Complaint on August 25, 2025. Defendants moved to dismiss
the amended Securities Complaint on October 24, 2025. Lead plaintiffs&#8217; opposition is due in late December 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On May 5, 2025, a derivative shareholder complaint (the &#8220;<i>Georges</i>
Complaint&#8221;) was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability
for the allegations made in the Securities Complaint.&#160; On May 13, 2025, a second derivative shareholder complaint (the &#8220;<i>Robinson
</i>Complaint&#8221; and, together with the <i>Georges </i>Complaint, the &#8220;Derivative Complaints&#8221;) was filed against the Company
and certain of the Company&#8217;s directors also alleging derivative liability for the allegations made in the Securities Complaint.
On June 24, 2025, the Court consolidated the Derivative Complaints (the &#8220;Derivative Action&#8221;). On July 29, 2025, the parties
to the Derivative Action filed a stipulation with the Court to stay the Derivative Action pending resolution of any motion to dismiss
the Securities Complaint. The Court entered the stipulation on July 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company and other Defendants intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. RISK FACTORS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><i>In analyzing our company,
you should consider carefully the following risk factors, together with all of the other information included in this Quarterly Report
on Form&#160;10-Q. Factors that could cause or contribute to differences in our actual results include those discussed in the following
subsection, as well as those discussed above in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; and in our Annual Report on Form 10-K for the year ended December 31, 2024. Each of the following risk factors,
either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely
affect the value of an investment in our company. The risks and uncertainties described below are not the only ones we face. Additional
risks not currently known to us, or other factors not perceived by us to present significant risks to our business at this time also
may impair our business operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;Summary of Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are providing the following
summary of the risk factors contained in this Quarterly Report on Form 10-Q to enhance the readability and accessibility of our risk factor
disclosures. We encourage you to carefully review the full risk factors contained in this Quarterly Report on Form 10-Q in their entirety
for additional information regarding the material factors that make an investment in our securities speculative or risky. These risks
and uncertainties include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a clinical-stage company and have generated no revenue from commercial sales to date;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to obtain additional financing, we will be unable to continue or complete our product development or product commercialization and you will likely lose your entire investment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We are highly dependent on the clinical, regulatory and commercial
success of Iomab-B, Actimab-A, Iomab-ACT, ATNM-400 and other pipeline candidates which we may never achieve;</td>
</tr></table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continuously evaluate our business strategy and may modify our strategy as necessary to respond to developments in our business and other
factors, and any such modification such as a divestiture, spin-off, spin-out, merger or acquisition, if not successful, could have a
material adverse effect on our business, financial condition, and results of operations;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>We may expand our business through the acquisition of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217; ownership interests in our company; &#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business could be adversely affected by the effects of future health epidemics;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business is subject to cybersecurity risk;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not demonstrated that any of our products are safe or effective for any indication and will continue to expend substantial time and resources on clinical development before any of our current or future product candidates will be eligible for FDA approval, if ever;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary, Interim, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the regulation of the U.S. healthcare system could have a material adverse effect on our business, future revenue, if any, and results of operations;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the healthcare industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial condition and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may rely on third parties to conduct certain aspects of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently depend on single third-party manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions at the FDA and other government agencies caused by leadership changes, changes to regulatory approach, layoffs, funding shortages or global health concerns could negatively impact our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">Our ability to advance clinical development of trials under our CRADA,
obtain regulatory interactions/approvals, or secure government-funded grants may be delayed or disrupted by federal government shutdowns
such as the recent shutdown that began October 1, 2025 and ended on November 12, 2025, as it curtailed operations of key agencies such
as the FDA and the NIH;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent position is highly uncertain and involves complex legal and factual questions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on our key personnel, and the demand for&#160;talent in the biotechnology industry is highly competitive; if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement or execute our business strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in our stockholders&#8217; interest; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a clinical-stage company and have
generated no revenue from commercial sales to date. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product
sales to date. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If
we do not address these risks successfully, our business will suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred net losses in every year
since our inception and anticipate that we will continue to incur net losses in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not profitable and
have incurred losses in each period since our inception. As of September 30, 2025 and December 31, 2024, we had an accumulated deficit
of $403.8 million and $375.8 million, respectively. We reported a net loss of $27.9 million and $31.6 million for the nine months ended
September 30, 2025 and 2024, respectively. We expect to continue to operate at a net loss as we continue our research and development
efforts, continue to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no
assurance that the products under development by us will be approved for sale in the United States or elsewhere. Furthermore, there can
be no assurance that if such products are approved, they will be successfully commercialized, which would have an adverse effect on our
business prospects, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain additional financing,
we will be unable to continue or complete our product development and you will likely lose your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following the
date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required
to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or
otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred
cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms or indeed on any terms.
In addition, from time to time, we may not be able to secure enough capital in a timely enough manner which may cause the generation of
a going-concern opinion from our auditors which can and may impair our stock market valuation and also our ability to finance on favorable
terms or indeed on any terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To raise additional capital,
we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock.
We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal
to or greater than the price per share paid by investors, and investors purchasing shares or other securities in the future could have
rights superior to existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities, clinical
studies, or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may
require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights
to future product candidates or certain major geographic markets. We may further have to license our technology to others. This could
result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business, financial
condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of funding we will
need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope
of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary
to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative,
licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited access to the capital markets
and even if we can raise additional funding, we may be required to do so on unfavorable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited access to
the capital markets to raise funds. The capital markets have been unpredictable in the recent past for development stage radiopharmaceutical
and other biotechnology companies and unprofitable companies such as ours. In addition, it is generally difficult for development-stage
companies to raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often depends
on variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at all. If
we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate funds
are not available on acceptable terms, or at all, our business, including our technology licenses, results of operations, financial condition
and our continued viability will be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the clinical,
regulatory and commercial success of ATNM-400, Actimab-A, Iomab-ACT, ATNM-400 and other pipeline candidates which we may never achieve</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the drug candidates we are developing, or have developed, have
received regulatory approval. Based on the current status of our pipeline candidates, it will likely take several years and additional
clinical studies before we can seek approval for any drug candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">ATNM-400 is currently being
studied preclinically and has not yet been studied in human subjects. There can be no assurances that we will advance ATNM-400 into clinical
trials and even if we successful in doing so, our preclinical results to date may not translate in human subjects. Our Actimab-A drug
candidate was studied in a Phase 2 clinical trial as a monotherapy, and we are now studying it in combination with other therapies. We
believe we have aligned with the FDA on a Phase 2/3 trial that is intended to support a BLA filing. There can be no assurance that the
Phase 2 portion of the trial will be successful and support advancing to the Phase 3 portion of the trial. In addition, our Iomab-ACT
drug candidate has only been studied in a limited number of human subjects in a Phase 1 trial with a novel CAR-T therapy. While we believe
the initial results from this trial were encouraging, there can be no assurance that future results with Iomab-ACT from the commercial
CAR-T trial at UTSW or sickle cell conditioning trial at Columbia will be positive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As for Iomab-B in particular, as previously disclosed, we completed
the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory AML) and presented the trial results in February
2023, which were expected to support a BLA filing. The SIERRA trial met the primary endpoint of dCR with statistical significance (p-value&lt;0.0001)
but did not meet the secondary endpoint in achieving a statistically significant improvement in OS in the intent to treat population.
On August 5, 2024, we announced that the FDA determined that the SIERRA trial alone is not adequate to support a BLA filing and is requiring
an additional randomized head-to-head clinical trial to demonstrate an OS benefit in an intent to treat population. Further, the FDA is
also requiring an additional dose optimization trial to calculate the dose of Iomab-B based on absorbed dose by the bone marrow, rather
than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based on several interactions with
the FDA prior to the start of the SIERRA trial. Based on this revised approach now required by the FDA, the safety and efficacy data generated
from all Iomab-B studies, including the SIERRA trial, are inadequate to seek regulatory approval for Iomab-B, as dosing based on maximum
tolerable dose of 24 Gy to the liver will lead to variable doses to the bone marrow (the target organ), result in underdosing or overdosing
of patients and translate to a global patient safety risk. We are seeking a strategic partner for the U.S. in order to conduct the additional
studies required by the FDA; however, we may not be successful in our efforts to find such a partner, or the trials and studies may not
be successful. Further, there are no assurances that we can satisfy all of the FDA&#8217;s requests, and there could be additional regulatory
hurdles that may result in either non-acceptance or non-approval of a future BLA filing. The U.S. commercial opportunity for Iomab-B may
thus never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed and
noted above, Actinium has licensed to Immedica the exclusive product rights for commercialization of Iomab-B in the EUMENA region. We
are evaluating the impact of the FDA&#8217;s 2024 determination of the SIERRA trial results in the context of global regulatory submissions
for Iomab-B. At this time, filings for regulatory approval, obtaining regulatory approvals, and successful commercialization of Iomab-B
in the EUMENA region and on a global basis are highly uncertain and may never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disruptions at the FDA and other government
agencies caused by government shutdowns, leadership changes, changes to regulatory approach, layoffs, funding shortages or global health
concerns could negatively impact our business</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The ability of the FDA to review proposed clinical trials or approve
new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy
changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise
affect the FDA&#8217;s ability to perform routine functions. In addition, government funding of other government agencies that fund research
and development activities is subject to the political process, including executive and congressional priorities, the impacts of which
are inherently fluid and unpredictable. Disruptions at the FDA and other agencies may slow the time necessary for new product candidates
to be reviewed and/or approved, which would adversely affect our business. Recently, the U.S. government shutdown from on October 1, 2025
to November 12, 2025, which curtailed operations at key agencies such as the FDA and NIH. Based on this shutdown, we expect trials under
our CRADA with the NCI to be delayed. There can be no assurances if additional shutdowns will occur in the future. For example, over the
last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current
administration has enacted and continues to propose substantial reductions in force at various government agencies including the FDA,
which could significantly reduce the FDA&#8217;s capacity to perform its functions in a manner consistent with its past practices and
could delay reviews and negatively impact our business. There has been significant turnover and recent changes in senior leadership at
the FDA and other government agencies including the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;), which is the division
of the FDA that would oversee and review biologics-based targeted radiotherapies like those we currently develop and plan to continue
to develop. We believe these changes could result in changes in the FDA&#8217;s perception of the approvability of therapies, the perceived
value of certain therapies or therapeutic modalities, which could create material challenges for our development efforts. At this time,
there is significant uncertainty and risks associated with future FDA regulatory policies and actions that could have a material negative
impact on our business. Any or all of these factors could cause us to amend, suspend or terminate the development of certain of our preclinical
or clinical programs, which could have material adverse impacts on our business, our product candidates or our ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to establish sales, marketing
and commercial supply capabilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates ultimately become approved and we
do not secure a commercial partner, we would have to build and establish these capabilities in order to commercialize our approved product
candidates. The process of establishing commercial capabilities will be expensive and time consuming. Even if we are successful in building
sales and marketing capabilities, we may not be successful in commercializing any of our product candidates. Any delays in commercialization
or failure to successfully commercialize any product candidate may have material adverse impacts on our business and ability to continue
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business could be adversely affected
by the effects of future health epidemics.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be adversely
impacted by the effects of future pandemics, epidemics or infectious disease outbreaks. The full impact of such an event cannot be predicted
at this time, and could depend on numerous factors, including vaccination rates among the population and the response by governmental
bodies and regulators. Given the ongoing and dynamic nature of the circumstances, it is difficult to predict the impact of a future pandemic
on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A future pandemic could adversely
affect our clinical trial operations, including our ability to conduct the trials on the expected timelines and recruit and retain patients
and principal investigators and site staff who, as healthcare providers, may have heightened exposure to a future pandemic if their geography
is impacted by the pandemic. Further, future pandemics could result in delays in our clinical trials due to prioritization of hospital
resources toward the pandemic, restrictions in travel, potential unwillingness of patients to enroll in trials, or the inability of patients
to comply with clinical trial protocols if quarantines or travel restrictions are implemented that impede patient movement or interrupt
healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party
service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and a future
pandemic may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us,
which may result in delays or hinder our ability to collect data from our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a future pandemic
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB&#8217;s
or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to cybersecurity
risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are increasingly
dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks and
cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks, utility
outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systems are maintained,
repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">theft
or misappropriation of funds;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss,
corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including
supplier, clinical data or employee data);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
or impairment of our and our business operations and safety procedures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
to our reputation with our potential partners, patients and the market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
to litigation; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
costs to prevent, respond to or mitigate cybersecurity events.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we utilize various
procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.
Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers, and
others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed for a period
time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have cybersecurity insurance
coverage in the event we become subject to various cybersecurity attacks, however, we cannot ensure that it will be sufficient to cover
any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA, EMA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
rigorous regulation by the FDA, EMA and numerous other federal, state and foreign governmental authorities. The process of seeking regulatory
approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the effort and expense
incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products from the regulators, we
may never be able to generate significant revenue and may be forced to cease operations. In particular, the FDA permits commercial distribution
of a new antibody radiation-conjugate product only after a BLA for the product has received FDA approval. The BLA process is costly, lengthy
and inherently uncertain. Any BLA filed by us will have to be supported by extensive data, including, but not limited to, technical, preclinical,
clinical trial, chemistry, manufacturing and controls and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and
efficacy of the product for its intended use. The lengthy approval process as well as the unpredictability of future clinical trial results
may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business,
results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve any of our product
candidates for fewer or more limited indications than we request, may not obtain the price we intend to charge for our products, may grant
approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that
does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the
foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For instance, as for Iomab-B, despite the Phase SIERRA 3 trial meeting
the primary endpoint of durable Complete Remission (dCR) with statistical significance (p-value&lt;0.0001), the FDA has determined that
demonstrating an OS benefit in a randomized head-to-head trial is required for a BLA filing. In addition, the FDA is also requiring that
an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based on absorbed
dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based
on several interactions we had with the FDA before starting the SIERRA trial. The head-to-head Phase 3 trial will evaluate allogeneic
bone marrow transplant (BMT) using Iomab-B plus a reduced intensity conditioning regimen of fludarabine and total body irradiation (Flu/TBI)
versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI. This is different from the SIERRA
trial, which allowed physician&#8217;s choice of salvage therapies and heterogenous conditioning regimens in the control arm. However,
there are no assurances that the additional trials will be completed or successful or that we can satisfy all of the FDA&#8217;s requests.
There could also be additional regulatory hurdles that may result in either non-acceptance or non-approval of a future BLA filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed and
noted above, Actinium has licensed to Immedica the exclusive product rights for commercialization of Iomab-B in the EUMENA region. We
are evaluating the impact of the FDA&#8217;s 2024 determination of the SIERRA trials results referred to above in the context of global
regulatory submission for Iomab-B. At this time, filings for regulatory approval, obtaining regulatory approvals, and successful commercialization
of Iomab-B in the EUMENA region and on a global basis are highly uncertain and may never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also evaluating Iomab-ACT,
which uses a lower dose I-131 for conditioning prior to cellular therapies such as CAR-T and gene therapies. We are currently studying
Iomab-ACT in three clinical trials including two investigator sponsored studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A
(lintuzumab-Ac-225) product candidate has also been studied in several Phase 1 and 2 trials under our sponsorship and
investigator-initiated trials in patients with r/r AML and we plan to continue to study Actimab-A in clinical trials. Actimab-A is
also being developed under a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) and we
expect clinical trials to be initiated that will study Actimab-A as a single agent or in combination with other therapies. Product
candidates utilizing the lintuzumab antibody would require BLA approval before they can be marketed in the United States. We are in
the early stages of evaluating other product candidates consisting of conjugates of Ac-225 with human or humanized antibodies for
pre-clinical and clinical development in other types of cancer such as ATNM-400. The FDA may not approve these products for the
indications that are necessary or desirable for successful commercialization. The FDA may fail to approve any IND, BLA or NDA we
submit for new product candidates or for new intended uses or indications for approved products or future product candidates.
Failure to obtain FDA approval for our products in the proposed indications would have a material adverse effect on our business
prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval process in the
United States and in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other
resources. The FDA, EMA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical data, conduct
additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In addition, even if we
obtain approval to market our products in the United States or in other countries, the approval could be revoked, or other restrictions
imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA,
EMA or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and
cash flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited. Additionally,
even if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications that
we request. The Company&#8217;s products may not be approved for the specific indications that are most necessary or desirable for successful
commercialization or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Disruptions at the FDA and other agencies may slow the time necessary
for new product candidates to be reviewed and/or approved, which would adversely affect our business and may cause us to amend our business
strategy or. From October 1, 2025 until November 12, 2025, the U.S federal government was shutdown, which curtailed operations of key
agencies such as the FDA and the NIH. Our ability to advance clinical development, obtain regulatory interactions/approvals, or secure
government-funded grants may be delayed or disrupted by this recent federal government shutdown. For example, the NCI with whom we have
a CRADA with for the development of Actimab-A was not operating during the shutdown. As a result, trials active and planned under our
CRADA are expected to be delayed. For example, over the last several years, including for 35 days beginning on December 22, 2018, the
U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees
and stop critical activities. In addition, the current administration has enacted and continues to propose substantial reductions in force
at various government agencies including the FDA, which could significantly reduce the FDA&#8217;s capacity to perform its functions in
a manner consistent with its past practices and could delay reviews and negatively impact our business. There has been significant turnover
and changes in senior leadership at the FDA and other government agencies including the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;),
which is the division of the FDA that would oversee and review biologics based targeted radiotherapies like those we currently develop
and plan to continue to develop. We believe these changes could result in changes in the FDA&#8217;s perception of the approvability of
therapies, the perceived value of certain therapies or therapeutic modalities, which could create material challenges for our development
efforts. At this time, there is significant uncertainty and risks associated with future FDA regulatory policies and actions that could
have a material negative impact on our business. Any or all of these factors could cause us to amend, suspend or terminate the development
of certain of our preclinical or clinical programs, which could have material adverse impacts on our business, our product candidates
or our ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not demonstrated that any of our
products are safe or effective for any indication and will continue to expend substantial time and resources on clinical development before
any of our current or future product candidates will be eligible for FDA approval, if ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplated biological
product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval, and commercialization
of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approval is received. The research,
testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product candidates are, and will remain,
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, as applicable. We
are currently not permitted to market any of our current or future product candidates in the United States until we receive FDA approval
(of each) via the BLA process. To date, we have three product candidates in clinical development and have not-yet submitted a BLA for
any of our candidates and, for many such candidates, do not expect to be in a position to do so for the foreseeable future, as there are
numerous developmental steps that must be completed before we can prepare and submit a BLA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceutical and biological product candidates under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and
the Public Health Service Act (&#8220;PHSA&#8221;), as well as their respective implementing regulations. Such products and product candidates
are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent
compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and
financial resources. The process required by the FDA before a drug or biological product may be marketed in the United States generally
involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
of preclinical laboratory tests and animal studies in accordance with FDA&#8217;s good laboratory practices (&#8220;GLPs&#8221;) and
applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
to the FDA of an Investigational New Drug (&#8220;IND&#8221;) application, which must become effective before human clinical trials in
the United States may begin;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s IND regulations, good clinical practices (&#8220;GCPs&#8221;), and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with current good manufacturing practices (&#8220;cGMPs&#8221;) and assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval, or denial, of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before testing any biological
product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate.
The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and a proposed clinical protocol, to the FDA as part of the IND application. Some preclinical testing may continue even
after the IND application is submitted. The IND application automatically becomes effective 30 days after receipt by the FDA, unless the
FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time
period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA
may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or
non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized
by the FDA. Accordingly, we cannot be sure that submission of an IND application will result in the FDA allowing clinical trials to begin
or that, for those that have already commenced under an active IND application, that issues will not arise that suspend or terminate such
trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events
should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND application. Clinical trials
must be conducted and monitored in accordance with the FDA&#8217;s regulations composing the GCP requirements, including the requirement
that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional
review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting
the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed
consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until
completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for
severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers,
the initial human testing is often conducted in subjects.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the completion of clinical
trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA
must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition
of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial
waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept
the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Before approving a BLA, the FDA
will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical
trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant
must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the submission
of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and
deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret
the same data. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our product candidates
or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in
part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our proposed endpoints for
any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trial process is also lengthy and
requires substantial time, effort and expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that the clinical
trials we need to conduct to be in a position to submit BLAs for our product candidates currently in-development will take, at least,
several years to complete. Moreover, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon
or repeat clinical trials. Also, the results of early preclinical and clinical testing may not be predictive of the results of subsequent
clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials
due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and preclinical and clinical
data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed
satisfactorily in preclinical studies and clinical trials have, nonetheless, failed to obtain marketing approval of their products. Success
in preclinical testing and early clinical trials does not ensure that later clinical trials, which involve many more subjects, and the
results of later clinical trials may not replicate the results of prior clinical trials and preclinical testing. Any failure or substantial
delay in our product development plans may have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay, suspend,
or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could delay or disrupt
the clinical development of our product candidates and potentially cause our product candidates to fail to receive regulatory approval:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
in receiving, or the inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation
in our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling patients into clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding cuts to the NCI, which could delay and/or pauses or termination of our ongoing and planned clinical trials under our CRADA;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may suspend, or the FDA
or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if we or they
believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs based on similar technologies,
are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimal factors related to toxicity, clinical
efficacy, imbalances in safety and efficacy profiles or for other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result in
perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation of the
study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in the analysis of clinical
data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for
and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials may also be
delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated
by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB (Data Safety Monitoring
Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretation of data by the FDA or similar foreign regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue the clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Modifications to our product candidates
may require federal approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The BLA application is the
vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United
States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products may require
additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket approvals before
we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for a particular use or indication,
we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results.
If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conducting clinical trials
and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect our ability
to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects, financial
condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials necessary to support approval
of our product candidates are time-consuming and expensive. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initiating and completing clinical trials necessary to support FDA
approval of a BLA for ATNM-400, Actimab-A, Iomab-ACT, Iomab-B, and other product candidates, is a time-consuming and expensive process,
and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results,
and any product candidate we advance into clinical trials may not have favorable results in later clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For instance, we worked with
the FDA to develop the SIERRA clinical trial to test the safety and efficacy of Iomab-B in patients with r/r AML who are aged 55 and above
prior to a BMT. Even though the SIERRA trial met the primary endpoint of dCR with statistical significance (p-value&lt;0.0001), the FDA
has determined that the analyses from the SIERRA trial do not support a BLA filing for Iomab-B. The FDA now requires an additional head-to-head
Phase 3 clinical study. We have further discussed the specifics of this additional clinical trial with the FDA. Based on these discussions,
Actinium believes it has aligned with the FDA on the patient population for this additional clinical trial, which can include all adult
patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%. This is a broader patient population
than the patients enrolled on the SIERRA trial, which only enrolled patients aged 55 and above. Further, the FDA is also requiring that
an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based on absorbed
dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based
on several interactions we had with the FDA before starting the SIERRA trial. We are seeking a strategic partner for Iomab-B in the U.S.
to advance these additional trials. Even if we are able to secure a partner, there are no assurances that the additional trials will be
successful or that we can satisfy all of the FDA&#8217;s requests. There could also be additional regulatory hurdles that may result in
either non-acceptance or non-approval of a future BLA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preliminary, Interim, and &#8220;top-line&#8221;
data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
publicly disclose preliminary, interim, and top-line data from our clinical trials, which is based on a preliminary analysis of then-available
data, and the results and related findings and conclusions are subject to change as more patient data become available or following a
more comprehensive review of the data related to the particular study or trial. We may also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all
data. Our clinical trials may be open label studies and certain of our clinical development and/or operations staff may review interim
or preliminary safety or efficacy data during routine data collection, cleaning and analysis from time to time. Interim or preliminary
results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such
results once additional data have been received and fully evaluated. Preliminary, interim or top-line data also remain subject to audit
and verification procedures that may result in the final data being materially different from the top-line, interim or preliminary data
we previously published. As a result, top-line, interim and preliminary data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
also disclose interim data from our preclinical studies and clinical trials. Interim data from preclinical studies are not necessarily
predictive of future success in clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one
or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse
differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by
us or by our competitors could result in volatility in the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret
or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the interim, top-line or
preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating
results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if our preclinical studies or early
clinical trials are favorable, later clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates,
which would prevent or delay regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our preclinical studies are favorable and our clinical trials
are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign
authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure
that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials
and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the
proposed indicated uses. If the FDA concludes that any current or future clinical trials for ATNM-400, Actimab-A, Iomab-ACT, Iomab-B or
any other product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness, we would not receive
FDA approval to market that product candidate in the United States for the indications sought. In addition, such an outcome could cause
us to abandon the product candidate and might delay the development of others. Any delay or termination of our clinical trials will delay
or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product candidates and generate
revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part
of a product candidate&#8217;s profile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intellectual property related to certain
antibodies we have licensed has expired or likely expired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The key patents related to the humanized antibody lintuzumab, which
we use in our Actimab-A product candidate, have expired. It is generally possible that others may be eventually able to use an antibody
with the same sequence, and we will then need to rely on additional patent protection covering alpha particle drug products comprising
Ac-225. Our final drug construct, Actimab-A, consists of the lintuzumab antibody labeled with the isotope Ac-225. We currently own issued
and pending patents relating to methods of manufacturing Actimab-A, methods of treatment using Actimab-A and production of the Ac-225
isotope. In addition, we possess trade secrets and know how related to the manufacturing and use of isotopes. Any competing product based
on the lintuzumab antibody is likely to require several years of development before achieving our product candidate&#8217;s current status
and may be subject to significant regulatory hurdles, but such development by others is nevertheless a possibility that could negatively
impact our business in the future. We own 4 issued U.S. patents, 2 issued Canadian patents, 2 issued European patent (each validated as
a national patent in several countries) and 1 issued Japanese patent that relate to the composition of our Iomab-B product candidate.
Patent applications relating to Iomab-B are also pending in the U.S. and internationally. We have and may continue to file patents related
to Iomab-B that can provide barriers to entry but there is no certainty that these patents will be granted or such granting thereof will
adequately prevent others from seeking to replicate and use the apamistamab antibody or the construct. Our patent portfolio includes pending
applications related to radioimmunoconjugate composition, formulation administration, and methods of use in treating solid or liquid cancers.
This subject matter includes composition, administration, and methods of treatment for our product candidates Actimab-A and Iomab-B. Any
competing product based on the antibody used in Iomab-B is likely to require several years of development before achieving our product
candidate&#8217;s current status and may be subject to significant regulatory hurdles. Further, if approved, Iomab-B would be entitled
to 12 years of market exclusivity in the U.S. and 10 years in Europe, during which time no generic biologic or biosimilar product referencing
Iomab-B can be granted marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Actimab-A program clinical trials are
testing the same drug construct. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A program is comprised
of several clinical trials conducted under the CRADA with NCI, Actinium sponsored trials, investigator-initiated trials in AML and other
myeloid indications and solid tumors that will study the same drug construct consisting of lintuzumab-Ac-225. Negative results from any
of these trials could adversely impact our ability to enroll or complete our other trials studying lintzumab-Ac-225, including future
studies conducted under our CRADA with the NCI. Additionally, negative outcomes including safety concerns, may result in the FDA requiring
amendment to certain clinical trials, placing a clinical hold on certain or all clinical trials or discontinuing other trials utilizing
lintuzumab-Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are currently developing, and in the
future may develop, product candidates in combination with other therapies and that may expose us to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently developing,
and may develop future product candidates, for use in combination with one or more currently approved therapies. For example, Actimab-A
is expected to be tested in combination with KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> for treating HNSCC and NSCLC. If any
of the approved therapies we currently or may, in the future, use in combination with a current or future product candidate is found defective,
removed from the market, or otherwise becomes unavailable, our clinical trials may face significant delays, be suspended, or terminated.
Any such events would likely have a material impact on our operations and the development of the affected product candidate(s) and may
ultimately prevent the approval of such product candidate or render continued development efforts too costly to proceed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if a current or future
product candidate were to receive FDA approval to be commercialized in the U.S. for use in combination with one or more existing therapies,
we would continue to be subject to the risk that the FDA or similar foreign regulatory authorities could revoke approval of the therapy
used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with any such existing
therapies. This could result in our own products being removed from the market or cause material delays in, or the suspension or discontinuation,
of our production and/or distribution of the applicable product, as our ability to market any such product will be limited to the extent
specified in the FDA&#8217;s approval, if granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iodine-131 is a key component
of our Iomab-B drug candidate. We source medical grade I-131 from multiple suppliers, including two leading global manufacturers. Currently,
we believe there is sufficient supply of I-131 to support additional trials we may undertake utilizing I-131 and for future commercialization
of potential I-131 based products. We continually evaluate I-131 manufacturers and suppliers. While we consider I-131 to be commoditized
and obtainable through several suppliers, there can be no guarantee that we will be able to secure I-131 or obtain I-131 on terms that
are acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium-225 is a key component
of our Actimab-A product candidate, technology platform, preclinical R&amp;D programs including ATNM-400 and other drug candidates that
we might consider for development with the Ac-225 payload. We have secured multiple suppliers that are expected to provide cGMP Ac-225
for our planned clinical trials. There are adequate quantities of Ac-225 available today to meet our current needs via our present supplier,
the Department of Energy (&#8220;DOE&#8221;), who has been our primary supplier of Ac-225 historically. The Ac-225 currently supplied
for our clinical trials from the DOE is derived from the natural decay of thorium-229 from so-called &#8216;thorium-cows&#8217; and is
able to produce sufficient quantities that are several multiples of the amount of Ac-225 we require to supply our clinical programs through
to the early commercialization phase. The DOE is also producing Ac-225 from a recently developed alternative route for Ac-225 production
via a linear accelerator that is currently being evaluated by us. Initial preclinical and modelling results have indicated that the linear
accelerator sourced Ac-225 does not impact labelling efficiency and expected distribution. In accordance with representations made by
the DOE, the capacity of Ac-225 from this route is expected to be sufficient to supply all of Actinium&#8217;s pipeline and commercial
Ac-225 needs and support new program expansion by not just Actinium but also other companies that are developing Ac-225 based products.
Additional routes of Ac-225 production are being pursued by the DOE including the generation of new thorium cows and production via a
cyclotron. The cyclotron production method for Ac-225 production leverages Actinium&#8217;s proprietary technology and know-how and presents
an additional path towards production of high-quality Ac-225 at a scale that would be able to satisfy commercial needs. In addition, we
are aware of at least ten other government and non-government entities globally including the U.S., Canada, Russia, Belgium, France and
Japan that have, or expect to have, ability to supply Ac-225 or equipment for its production within the timeframes relevant to the potential
first commercial approval of our Ac-225-based drug candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract for supply of
this isotope from the DOE must be renewed yearly, and we renewed our contract to extend through the end of 2025. While we expect this
contract will continue to be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the
contract or that change its policies that allow for the sale of isotope to us. There can be no assurance that the DOE or our other suppliers
will be able to supply all of the quantities of Ac-225 we request in the future. Failure to acquire sufficient quantities of medical grade
Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates that we
may develop and would materially harm our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to conduct clinical
trials to advance our drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other isotopes we may
choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our isotopes. These suppliers
may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers are subject to regulations
and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217; compliance to these
standards. Failure to comply with regulations and standards may result in their inability to supply isotopes and could result in delays
in our clinical trials, which could have a negative impact on our business. We have developed intellectual property, know-how and trade
secrets related to the manufacturing process of Ac-225. While we have manufactured medical grade Ac-225 of a purity compared to the cyclotron
sourced material in the past, this activity was terminated due to operating cost reasons, and we currently do not have experience in manufacturing
medical grade Ac-225 and may not obtain the resources necessary to establish our own manufacturing capabilities in the future. Our inability
to build out and establish our own manufacturing facilities would require us to continue to rely on third party suppliers as we currently
do. However, based on our current third-party suppliers and potential future suppliers of Ac-225 we expect to have adequate isotope supply
to support our current ongoing clinical trials, current and planned preclinical R&amp;D activities and commercialization should our drug
candidates receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of clinical
trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain in the trial until
its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility criteria defined in the protocol;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and expertise;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials for similar or alternate therapeutic treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&#8217;s and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients enrolled in clinical trials will not complete a clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, refractory patients,
which several of our trials have or are expected to enroll, participating in clinical trials are seriously and often terminally ill and
therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events related
or unrelated to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in our clinical
trials, delays in patient enrollment will result in increased costs or affect the timing of our planned trials, which could adversely
affect our ability to advance the development of our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our product
candidates on a timely basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the data generated in our clinical trials will be acceptable to the FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to the FDA. Certain modifications to a clinical trial protocol made during the course of
the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification
is evaluated. In addition, depending on the quantity and nature of the changes made, the FDA could take the position that some or all
of the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial. This might require
the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval of a product
candidate. If the FDA believes that its prior approval is required for a particular modification, it can delay or halt a clinical trial
while it evaluates additional information regarding the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any delay or termination of
our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required
approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays
or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in
costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product candidates or
result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays
in obtaining regulatory approval for Iomab-B or completion of our ongoing or planned clinical trials would adversely affect our business
and prospects and could cause us to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have obtained orphan drug designation
from the FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in the
future, but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations we have
received or may receive in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received orphan drug
designation for Actimab-A and Iomab-B for treatment of AML in both the United States and the EU. Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects
fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will
be recovered from sales in the United States for that drug or biologic. Similarly, the EMA grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation neither
shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory
review or approval process. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities
for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition, if a product candidate receives
the first FDA approval for the indication for which it has orphan designation, such product is entitled, upon approval, to seven years
of orphan-drug exclusivity, during which the FDA may not approve any other application to market the same drug for the same indication,
unless a subsequently approved product is clinically superior to orphan drug or where the manufacturer is unable to assure sufficient
product quantity in the applicable patient population. In the EU, orphan drug designation entitles a party to financial incentives such
as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may
be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain (or have
obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for such candidates
for the applicable indications due to the uncertainties inherent in the development of novel biologic products, and, an orphan drug candidate
may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is broader than the indication for
which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product
to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, even if we successfully
obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the product from
competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) the FDA or EMA
can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphan drug if the later-approved
drug if deemed clinically superior to the orphan drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval of
our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may
also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our
product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials
that we conduct post-approval. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker
information. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result
in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product
recalls;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
warning letters or holds on clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license
approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
or the imposition of civil or criminal penalties.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage and reimbursement may be limited
or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage and
reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement for newly
approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products
are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed all or part of the
product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as
a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement approval generally
does not occur prior to the filing of a BLA for that product and may not be granted until many months after BLA approval. In order to
obtain coverage and reimbursement for these products, we or our commercialization partners may have to agree to a net sales price lower
than the net sales price we might charge in other sales channels. The continuing efforts of government and third-party payors to contain
or reduce the costs of healthcare may limit our revenue. Initial dependence on the commercial success of our products may make our revenues
particularly susceptible to any cost containment or reduction efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures intended
to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the regulation of the U.S.
healthcare system could have a material adverse effect on our business, future revenue, if any, and results of operations.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The Affordable Care Act, for
example, substantially changed the way healthcare is financed by both governmental and private insurers. The Affordable Care Act contains
a number of provisions that could impact our business and operations, primarily, once we obtain FDA approval to commercialize one of our
product candidates in the United States, if ever. The Affordable Care Act may also affect our operations in ways we cannot currently predict.
Affordable Care Act provisions that may affect our business include, among others, those governing enrollment in federal healthcare programs,
reimbursement changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion
of state Medicaid programs, fees and increased discount and rebate obligations, transparency and reporting requirements, and fraud and
abuse enforcement. Such changes may impact existing government healthcare programs, industry competition, formulary composition, and may
result in the development of new programs, including Medicare payment for performance initiatives, health technology assessments, and
improvements to the physician quality reporting system and feedback program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been significant
judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable Care Act since its
enactment. For example, during his first term, former President Trump issued several Executive Orders and other directives designed to
delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health
insurance mandated by the Affordable Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part
of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation
of the Affordable Care Act have been passed. For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision
requiring individuals to purchase and maintain health coverage, or the &#8220;individual mandate,&#8221; by reducing the associated penalty
to zero, beginning in 2019. In December 2018, a district court in Texas held that the individual mandate is unconstitutional and that
the rest of the Affordable Care Act is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the
individual mandate but remanded the case back to the lower court to reassess whether and how such holding affects the validity of the
rest of the Affordable Care Act. The Fifth Circuit&#8217;s decision on the individual mandate was appealed to the U.S. Supreme Court.
On June 17, 2021, the Supreme Court held that the plaintiffs (comprised of the state of Texas, as well as numerous other states and certain
individuals) did not have standing to challenge the constitutionality of the Affordable Care Act&#8217;s individual mandate and, accordingly,
vacated the Fifth Circuit&#8217;s decision and instructed the district court to dismiss the case. As a result, the Affordable Care Act
remained in effect in its then-current form; however, we cannot predict what additional challenges may arise in the future, the outcome
thereof, or the impact any such actions may have on our business. This uncertainty has become even greater given the new Trump administration
and its proposed agenda.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Affordable
Care Act, there have been numerous other Congressional initiatives and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drug products. Pharmaceutical product prices have been the focus of increased
scrutiny by the government, including certain state attorneys general, members of Congress and the United States Department of Justice.
State or federal healthcare reform measures or other social or political pressure to lower the cost of pharmaceutical products could have
a material adverse impact on our business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Biden administration also
introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, former President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative
front, the American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid
drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, which began on January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, the
Department of Health and Human Services (&#8220;HHS&#8221;) released a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221;
that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as
well as potential administrative actions HHS can take to advance these principles.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2022, former
President Biden signed into law the&#160;Inflation&#160;Reduction&#160;Act&#160;of 2022 (the &#8220;IRA&#8221;), which, among other provisions,
included several measures intended to lower the cost of prescription drugs and related healthcare reforms. Specifically, the IRA authorizes
and directs the HHS to set drug price caps for certain high-cost Medicare Part B and Part D qualified drugs, with the initial list of
drugs announced on August 29, 2023, and the first year of maximum price applicability to begin in 2026. The IRA further authorizes the
HHS to penalize pharmaceutical manufacturers that increase the price of certain Medicare Part B and Part D drugs faster than the rate
of inflation. The IRA creates significant changes to the Medicare Part D benefit design by capping Part D beneficiaries&#8217; annual
out-of-pocket spending at $2,000 beginning in 2025. Further, on July 4, 2025, President Trump signed the One Big Beautiful Bill Act into
law which, among other things, is expected to reduce funding to federal healthcare programs, imposes additional requirements to be eligible
for healthcare, and clarifies exclusions for orphan drugs under IRA&#8217;s Drug Price Negotiation Program</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">More recently, the current
Trump Administration is pursuing policies intended to, among other things, reduce regulations and expenditures across government (including
at the HHS, FDA, NIH, CMS, and other related agencies), lower prescription drug prices, and enhance drug price transparency. These actions,
such as those directed by executive orders, may propose policy changes that create additional uncertainty for our business. For example,
on April 15, 2025, the Trump Administration released an executive order entitled, &#8220;Lower Drug Prices by Once Again Putting Americans
First,&#8221; which among other things, included multiple directives to various agencies aimed at lowering prescription drug prices. Additionally,
on September 30, 2025, the Trump Administration announced the first agreement with a major pharmaceutical company that requires the drug
manufacturer to offer, through a direct-to-consumer platform, U.S. patients and Medicaid programs prescription drug Most-Favored Nation
(&#8220;MFN&#8221;) pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient
discounts and repatriation of foreign revenues. Other recent actions and proposals include, for example, (1) reducing federal agencies
workforces; (2) directing program cuts; (3) rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid
Innovation to consider new payment and healthcare models to limit drug spending and eliminating the Biden administration&#8217;s executive
order that directed HHS to establishing an AI task force and developing a strategic plan; (4) directing HHS and other agencies to lower
prescription drug costs for Medicare through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation
Program and establishing MFN pricing for pharmaceutical products; (5) directing certain federal agencies to enforce existing law regarding
hospital and price plan price transparency and by standardizing prices across hospitals and health plans; and (6) as part of the Make
America Healthy Again (MAHA) Commission&#8217;s recent Strategy Report, working across government agencies to increase enforcement on
direct-to-consumer pharmaceutical advertising. These actions and policies may significantly reduce drug prices, potentially impacting
manufacturers&#8217; drug pricing strategies and profitability, while increasing operational costs and compliance risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the state level, legislatures
have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Current and future legislative
and regulatory changes aimed to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for
healthcare products and treatments. Any reduction in coverage or reimbursement from Medicare, Medicaid, or other government programs may
result in similar actions taken by private payors such as reductions in payments. The implementation of cost containment measures or other
healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Changes in the
healthcare industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial condition
and results of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and research efforts rely, in part, on funding and support
from U.S. government agencies such as the NIH, NCI and HHS. Government funding for these programs is subject to annual budgetary decisions,
which can be unpredictable and influenced by shifting political and economic priorities. Reductions in government support for cancer research
or other healthcare initiatives could limit grants, contracts, or other financial resources that we or our research collaborators depend
on, potentially delaying our clinical programs and increasing our reliance on alternative funding sources. From October 1, 2025 until
November 12, 2025, the U.S federal government was shutdown, which curtailed operations of key agencies such as the FDA and the NIH. The
NCI, with whom we have a CRADA with for the development of Actimab-A, was not operating during the shutdown. As a result, our ability
to advance clinical development, obtain regulatory interactions/approvals, or secure government-funded grants may be delayed or disrupted
by the federal government shutdown. For example, active and planned trials under our CRADA are expected to be delayed.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, with the change
in presidential administration that recently occurred in the United States, government spending programs have become even more difficult
to predict and may be subject to greater risk. Considerable uncertainty exists regarding how future budget and program decisions will
unfold, including the spending priorities of the new U.S. presidential administration and Congress and what challenges budget reductions
may present for our industry generally or for our company. In particular, President Trump recently attempted to place a widespread freeze
on most federal grants and loans. Any freeze on government support for our products, programs, or studies could significantly impair our
research and development activities, business, and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Disruptions at
the FDA, the SEC and other government agencies or comparable regulatory authorities caused by government shutdowns, funding shortages
or global health concerns, in addition to substantial uncertainty regarding the new Administration&#8217;s initiatives and how these
might impact the FDA, its implementation of laws, regulations, policies and guidance, and its personnel, could hinder government agencies&#8217;
ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or
commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which our business
operations rely, including timely reviews, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA or comparable foreign regulatory authorities
to review and approve new products can be affected by a variety of factors, including government shutdowns, which recently occurred from
October 1, 2025 until November 12, 2025, budget and funding levels, ability to hire and retain key personnel and accept the payment of
user fees, and statutory, regulatory, and policy changes that may otherwise affect the FDA&#8217;s or comparable foreign regulatory authorities&#8217;
ability to perform routine functions. In addition, government funding of the SEC and other government agencies or comparable foreign regulatory
authorities on which our operations may rely, including those that fund research and development activities, is subject to the political
process, which is inherently fluid and unpredictable. Further, continuation of the current government shutdown or future government shutdowns
could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue to fund
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA and
other agencies, including substantial leadership, personnel, and policy changes, may also slow the time necessary for new drugs to be
reviewed and/or approved by necessary government agencies, which would harm our business. Changes in FDA staffing could result in delays
in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement
or enforce regulatory requirements in a timely fashion or at all. Similar consequences would also result in the event of another significant
shutdown of the federal government. For example, over the last several years, the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government
shutdown occurs, or if geopolitical or global health concerns prevent the FDA or other regulatory authorities from conducting their regular
inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could materially adversely affect our business, financial condition, results of operations and prospects.
Such changes could significantly impact the ability of the FDA to timely review and take action on our regulatory submissions, which could
have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or substantial
leadership, personnel, and policy changes could impact our ability to access the public markets and obtain necessary capital in order
to properly capitalize and continue our operations. If the FDA is constrained in its ability to engage in oversight and implementation
activities in the normal course, our business may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the change in the U.S.
Presidential Administration in 2025, there is substantial uncertainty as to whether and how the new administration will seek to modify
or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. This uncertainty
could present new challenges and/or opportunities as we navigate development of our product candidates. Some of these efforts have manifested
to date in the form of personnel measures that could impact the FDA&#8217;s ability to hire and/or retain key personnel, which could result
in delays or limitations on our ability to obtain guidance from the FDA on our product candidates in development and obtain the requisite
regulatory approvals in the future. Moreover, the new Administration has proposed action to freeze or reduce the budget of the National
Institutes of Health, or NIH, as related to its funding for medical research, which could decrease the ability of facilities that rely
on NIH funding to enroll and conduct clinical trials or increase the costs to us of conducting clinical trials. There remains general
uncertainty regarding future activities. The new Administration&#160;could issue or promulgate executive orders, regulations, policies
or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic products.
Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory
frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations,
policies or guidance as a result of the new Administration, there could be a material adverse effect on us and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our relationships with
customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties,
including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare
programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits
and earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare professionals and
third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing
approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we conduct research, market, sell and distribute any products for which we obtain marketing approval. Federal and state
healthcare laws and regulations that may affect our operations, directly or indirectly, include the following, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Anti-Kickback Statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual
for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal
and state healthcare programs such as Medicare and Medicaid;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal false claims laws, including civil whistleblower or qui tam actions under the federal False Claims Act, which impose criminal
and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the
federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation
to pay money to the federal government;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to
defraud any healthcare benefit program or making false statements relating to healthcare matters and also imposes obligations, including
mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses,
and their respective business associates that create, receive, maintain or transmit individually identifiable health information for
or on behalf of the covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission
of individually identifiable health information;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or
state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of
a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception
applies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Physician Payments Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which requires certain
manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s
Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value
provided to physicians and any ownership and investment interests held by physicians or their immediate family members. Beginning in
2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value to physician
assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and
certified nurse midwives during the previous year; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
state laws and regulations, including (among others) state anti-kickback and false claims laws, which may apply to our business practices,
including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services
reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the
pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States
federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state
laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking
gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require
the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in
certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating
compliance efforts.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to comply with applicable
healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance under these laws and regulations
are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight (if we become subject to
a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws), and the curtailment or restructuring
of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities
with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party payors may not adequately reimburse
customers for any product candidates that we may commercialize or promote and may impose coverage restrictions or limitations such as
prior authorizations and step edits that affect their use.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products
and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other
third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend
in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring
that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage
and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement
may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate
for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may
not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining reimbursement approval
for any product candidate for which we obtain marketing approval from any government or other third-party payor is a time-consuming and
costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products. Moreover,
eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Even when a payor determines that a product that we may commercialize
or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitations that preclude payment for some
uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements, or may simply deny coverage altogether.
Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be
based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other
services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Furthermore, the Centers for Medicare and Medicaid Services frequently change product descriptors, coverage
policies, product and service codes, payment methodologies and reimbursement values. Commercial third-party payors often rely upon Medicare
coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain and maintain coverage
and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our
overall financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S. and some jurisdictions
outside the U.S., there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system
that could impact our business. Generally, there has been increasing legislative and enforcement interest in the U.S. with respect to
drug pricing, including specialty drug pricing practices, in light of the rising cost of prescription drugs and biologics. Specifically,
there have been U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency
to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare,
and reform government program reimbursement methodologies for drugs and biologics. In addition, the concept of most-favored nation pricing
has been raised that would seek to establish drug prices in the U.S. to the lowest level paid by comparable countries. Such policy action
could cause us to amend, suspend or terminate the development of any or all of our product candidates if a viable commercial market did
not exist, which could have a material adverse impact on our business and ability to operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If future legislation were
to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial
results. Managed care organizations, as well as Medicaid and other government authorities, continue to seek price discounts. At the state
level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biologic product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. Due to the volatility
in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory,
payor or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material
adverse impact on our business and ability to operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may rely on third parties to conduct
our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply
with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the ability
to independently conduct our clinical trials for our product candidates and we must rely on third parties, such as contract research organizations,
medical institutions, clinical investigators and contract laboratories to conduct such trials. Our reliance on these third parties for
clinical development activities results in reduced control over these activities. Moreover, the FDA requires us to comply with regulations
and standards, commonly referred to as GCPs (good clinical practices), for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our
reliance on third parties does not relieve us of these responsibilities and requirements. If we or any of our third-party contractors
fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable
foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing
practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our consultants, contract
research organizations and other similar entities with which we are working do not successfully carry out their contractual duties, meet
expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there are a number
of other third-party contractors we could engage to continue these activities, we may not be able to enter into arrangements with alternative
third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our planned clinical trials and delayed
development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors, we
cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry
out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data they obtain
is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical
development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory
approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results
and prospects would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The protection against generic competition
for our biologic drug candidates and reimbursement by CMS may be subject to future change</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any existing
or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our targeted radiotherapy product
candidates. Our ARC product candidates are regulated by the FDA as biologic products, and we intend to seek approval for these products
pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for
the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the
FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based
on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA
until 12 years after the original branded product was approved under a BLA and in Europe a biosimilar product cannot be approved until
10 years after the original branded product was approved. The law is complex and as a result, its ultimate impact, implementation, and
meaning are subject to uncertainty. Even if a biosimilar gets approved for one of the antibodies that we use, the final constructs of
our drug candidates consist of an antibody, radioisotope and in some cases a linker and we are not aware of any regulations that would
require us to provide the final constructs or components to third parties or potential competitors. Therefore, based on the current regulations,
we do not believe that the final drug product of our candidates can be subject to competition from a biosimilar as outlined in BPCIA for
at least 12 years in the U.S. and 10 years in the EU. We are aware that generic versions of certain radiopharmaceuticals utilizing peptides
have been submitted to the FDA via the Abbreviated New Drug Application (&#8220;ANDA&#8221;) pathway, however, those products are not
covered under the BPCIA and therefore that generic pathway is not applicable to Iomab-B or Actimab-A. We expect this would also apply
to other biologic drug candidates we may seek to develop in the future based on the current provisions of the BPCIA. Additionally, the
Inflation Reduction Act (&#8220;IRA&#8221;) that was enacted in August 2022, states that reimbursement by the Centers for Medicare&amp;
Medicaid Services (&#8220;CMS&#8221;) for high-expenditure single-source biologic drugs, which we expect Iomab-B and Actimab-A to be,
can only be negotiated after at least 11 years following approval compared to 7 years for non-biologic drugs with negotiated prices taking
effect two years after selection. Therefore, we currently believe that our ARCs are less likely than small molecules to face pricing pressure
and negotiation from IRA. Further, a drug or biological product that has an orphan drug designation, which Iomab-B and Actimab-A both
have, for only one rare disease or condition will be excluded from the IRA&#8217;s price negotiations requirements &#160;until such time
the biological products has designations for more than one rare disease or condition, or if is approved for an indication that is not
within that single designated rare disease or condition, unless such additional designation or such disqualifying approvals are withdrawn
by the time CMS evaluates the drug for selection for negotiation. In August 2023, 10 initial drugs were identified with negotiated prices
expected to take effect starting in 2026. In 2027 and 2028, it is expected that CMS will establish negotiated prices for 15 additional
drugs in each respective year. We do not believe there is a high likelihood that Iomab-B or Actimab-A would be identified by CMS for negotiated
pricing under IRA but there is potential that IRA and other additional state and federal healthcare reform measures will be adopted in
the future and the implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or successfully commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may never achieve
market acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A, Iomab-ACT, ATNM-400,
Iomab-B and future product candidates that we may develop may never gain market acceptance among physicians, patients and the medical
community. The degree of market acceptance of any of our products will depend on a number of factors, including the actual and perceived
effectiveness and reliability of the product; the results of any long-term clinical trials relating to use of the product; the availability,
relative cost and perceived advantages and disadvantages of alternative technologies; the degree to which treatments using the product
are approved for reimbursement by public and private insurers; the strength of our marketing and distribution infrastructure; and the
level of education and awareness among physicians and hospitals concerning the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating specific
cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide patients with
sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the use of each product candidate
from influential physicians will be essential for widespread market acceptance. Our product candidates are still in the development stage,
and it is premature to attempt to gain support from physicians at this time. We can provide no assurance that such support will ever be
obtained. If our product candidates do not receive such support from these physicians and from long-term data, physicians may not use
or continue to use, and hospitals may not purchase or continue to purchase, them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure of Actimab-A, Iomab-ACT,
ATNM-400, Iomab-B or any of our other product candidates to significantly penetrate current or new markets would negatively impact our
business financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our third-party
service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial
cost and be a distraction to our management and employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently depend on single third-party
manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party
manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently operate
manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturers
to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonal
antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect to continue
to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing or future manufacturers
could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory approval of our product
candidates or commercialization of any approved products. Further avenues of disruption to our clinical or eventual commercial supply
may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen circumstances that might occur
at any of our suppliers or contract manufacturing partners including an inability to come to terms on renewal of existing contracts or
new contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on single
manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuity we are
evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing partners,
however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we would be able
to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity and support
our growth plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates require
precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers we may engage in
the future to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls or withdrawals,
delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our business. Contract manufacturers
may encounter difficulties involving production yields, quality control, and quality assurance. These manufacturers are subject to ongoing
periodic and unannounced inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and
other applicable government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&#8217;
compliance with these regulations and standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently plan to build
out a manufacturing facility in the future to operate for the purposes of manufacturing our own products. We have never built, owned or
operated a manufacturing facility. There can be no assurances that we will be able to successfully accomplish this and in doing so we
may experience delays, cost overruns, or other problems that could seriously hurt our business. Even if we successfully build out our
planned manufacturing facility, we may not realize the expected benefits of these efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on vendors with
specialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered into manufacturing
and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be the exclusive manufacturer and
supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail to comply with required regulations
or breach their contractual obligations it may be difficult, or we may be unable to identify suitable alternative third-party manufacturers.
While we identify and evaluate third-party manufacturers from time to time, even if we do identify suitable alternative third-parties,
we may fail to reach agreement on contractual terms, it may be prohibitively expensive and there can be no assurance that we can successfully
complete technology transfer and development work necessary, or complete the necessary work in a timely manner. Any of which could prevent
us from commencing manufacturing with third-parties which could cause delays or suspension of our clinical trials and pre-clinical work
that may have a negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, these third-party
contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shutdowns, employee strikes, or
any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct (either
ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-party manufacturers
to consistently supply quality product when required would have a material adverse effect on our ability to develop or commercialize our
products. We have faced delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such
delays and risks in the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company,
including delays in clinical trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are successful in obtaining marketing
approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party
manufacturers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our product candidates
have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or other regulatory
agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party
specialized manufacturers to produce commercial quantities of approved products. These manufacturers may not be able to successfully increase
the manufacturing capacity for any approved product in a timely or economic manner, or at all. Significant scale-up of manufacturing may
require additional validation studies, which the FDA must review and approve. Scale-up for commercial product may require financial commitment
or investment by us, which we may not have sufficient capital for or may elect not to undertake. If third party manufacturers are unable
to successfully increase the manufacturing capacity for a product candidate, or we are unable to establish our own manufacturing capabilities,
the commercial launch of any approved products may be delayed or there may be a shortage in supply, which in turn could have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will
be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure
and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for
or market our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have conflicts with our partners, such as conflicts concerning
the interpretation of preclinical or clinical data, pertaining to the global patient safety profile or efficacy results of our products,
the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership
of intellectual property developed during our collaboration. We may seek to amend, modify or terminate agreements with partners, suppliers
or service providers related to ATNM-400, Actimab-A, Iomab-ACT or Iomab-B, but there can be no assurance that we can do so successfully
or negotiate terms that are favorable to us. Failure of which can increase the risk of or result in litigation or alternative dispute
resolution options taken against us. Further, we may exercise our decision-making authority under certain circumstances pertaining to
global patient safety related to our products, which our partners may disagree with and may result in potential conflicts and public disclosure
of our rationale and position. If any conflicts arise with any of our partners, such partner may act in a manner that is adverse to our
best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development
or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a partner
to pay us milestone payments or royalties we believe are due under a collaboration; uncertainty regarding ownership of intellectual property
rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by
the partner to cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness
on the part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public
disclosure of the results of those activities; initiating litigation or alternative dispute resolution options by either party to resolve
the dispute; or attempts by either party to terminate the agreement.&#160;Litigation or alternative dispute resolution options can be
lengthy and expensive, require significant time and attention from our management and are highly uncertain. There can be no assurance
that if we pursue, or a partner pursues litigation or alternative dispute resolution options, that we will prevail. Monetary and equitable
damages awarded against us could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If in the future we are unable to establish
U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates,
we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive regulatory approval.
In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution,
managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with
technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming
and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the commercialization
of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with
third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution
systems or in lieu of our own sales force and distribution systems. If we are unable to enter into or maintain such arrangements when
needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory
approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates,
either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant
additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face significant competition from other
biotechnology and pharmaceutical companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates face,
and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academic and research
institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii)
emerging competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with
our product candidates and technologies and may develop and commercialize additional products and technologies that will compete with
our product candidates and technologies. Because several competing companies and institutions have greater financial resources than us,
they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development, or R&amp;D,
and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we do and have substantially
greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory approvals, and manufacturing
and marketing pharmaceutical products. They also have greater name recognition and better access to customers than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The drug-related side
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even if any of our product candidates
receives marketing approval, as greater numbers of patients use a product following its approval, an increase in the incidence of side
effects or the incidence of other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result
in a number of potentially significant negative consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
authorities may withdraw their approval of the product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
authorities may require the addition of labeling statements, such as warnings or contraindications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may elect, or we may be required, to recall or withdraw product from the market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
could be sued and held liable for harm caused to patients; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
reputation may suffer.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or could harm or
prevent sales of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon securing and protecting critical
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are dependent on obtaining
and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages of
development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether the commercial
versions of these product candidates will incorporate proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our patent position is highly uncertain
and involves complex legal and factual questions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, we cannot predict
the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our licensors might
not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors
might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative
technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications
of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially
viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and,
we may not develop additional proprietary technologies that are patentable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the issuance
of a patent, while presumed valid and enforceable, is not conclusive as to its validity or its enforceability and it may not provide us
with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors may also be able
to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods.
We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors,
former employees and current employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent rights are territorial,
and patent protection extends only to those countries where we have issued patents. Filing, prosecuting and defending patents on our products
and product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual
property rights in some countries outside the United States could be less extensive than those in the United States. Many countries, however,
do not protect intellectual property to the same extent as the U.S. or Europe, and their litigation processes differ. Competitors may
successfully challenge or avoid our patents, or manufacture products in countries where we have not applied for patent protection. Changes
in the patent laws in the U.S. or other countries may diminish the value of our patent rights. As a result of these and other factors,
the scope, validity, enforceability, and commercial value of our patent rights are uncertain and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indeed, several companies
have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems
of some countries do not favor the enforcement of patents and other intellectual property rights, which could make it difficult for us
to stop the infringement, misappropriation or other violation of our intellectual property rights generally. Proceedings to enforce our
intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk
of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that are initiated, and
the damages or other remedies awarded, if any, may not be commercially meaningful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of pharmaceutical
companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and
enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed
unenforceable, invalidated, or circumvented. A third-party may submit prior art, or we may become involved in opposition, derivation,
reexamination, inter partes review, post-grant review, supplemental examination, or interference proceedings challenging our patent rights
or the patent rights of our licensors or development partners. The costs of defending or enforcing our proprietary rights in these proceedings
can be substantial, and the outcome can be uncertain. An adverse determination in any such submission or proceeding could reduce the scope
of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, or
reduce our ability to manufacture or commercialize products. Furthermore, if the scope or strength of protection provided by our patents
and patent applications is threatened, it could discourage companies from collaborating with us to license, develop or commercialize current
or future products. The ownership of our proprietary rights could also be challenged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, our owned and licensed patents may be held invalid, and
we may not be able to obtain and enforce patents and to maintain trade secret protection for the full commercial extent of our technology.
The extent to which we are unable to do so could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or our licensors have applied
for and will continue to apply for patents for certain products and methods. Such applications may not result in the issuance of any patents,
and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible
that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because
of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain a preferred position, we
could become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration of our
patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we license from third parties, or subsequent
related filings, would adversely affect our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents issued or licensed
to us may be infringed by the products or processes of others. Our ability to enforce our patent rights depends on our ability to detect
infringement. It is difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may
be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product, particularly
in litigation in countries other than the U.S. that do not provide an extensive discovery procedure. Any litigation to enforce or defend
our patent rights, if any, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management
and key personnel from our business operations. We may not prevail in any lawsuits that we initiate and the damages or other remedies
awarded if we were to prevail may not be commercially meaningful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of enforcing our
patent rights against infringers, if such enforcement is required, could be significant, and we may not have the financial resources to
fund such litigation. Further, such litigation can go on for years and the time demands could interfere with our normal operations. There
has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry.
We may become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor,
could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively than we can because
of their substantially greater financial resources. Litigation may also absorb significant management time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although
we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of
confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means, these measures may
not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access
to, the same or similar information. In addition, we cannot guarantee that we have executed these agreements with each party that may
have or have had access to our trade secrets. Furthermore, if the employees and consultants who are parties to these agreements breach
or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade
secrets through such breaches or violations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our patent rights
are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents may
be terminated, and we may be unable to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are found to be infringing patents
or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the
development or sale of our products, and/or pay damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not have identified
all patents, published applications or published literature that affect our business either by blocking our ability to commercialize our
products, by preventing the patentability of one or more aspects of our products to us or our licensors, or by covering the same or similar
technologies that may affect our ability to market our products. For example, we (or our licensors) may not have conducted a patent clearance
search sufficient to identify potentially obstructing third party patent rights. Moreover, patent applications in the United States are
maintained in confidence for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the
U.S. Patent and Trademark Office, or the USPTO, for the entire time prior to issuance as a U.S. patent. Patent applications filed in countries
outside of the United States are not typically published until at least 18 months from their first filing date. Similarly, publication
of discoveries in the scientific or patent literature often lags behind actual discoveries. We cannot be certain that we or our licensors
were the first to invent, or the first to file, patent applications covering our products and candidates. We also may not know if our
competitors filed patent applications for technology covered by our pending applications or if we were the first to invent the technology
that is the subject of our patent applications. Competitors may have filed patent applications or received patents and may obtain additional
patents and proprietary rights that block or compete with our patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others,
or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases
that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other
persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the
affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required
to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process.
Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved
in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to infringement
or other intellectual property claims against us, we may become a party to other patent litigation or proceedings before regulatory agencies,
including post-grant review, inter parties review, interference or re-examination proceedings filed with the U.S. Patent and Trademark
Office (or similar proceedings before corresponding tribunals in other jurisdictions) that challenge our patent rights or the patent rights
of our licensors. The costs and efforts of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings
can be substantial and the outcome can be uncertain. An adverse determination in these proceedings could weaken or invalidate the patent
claims that cover our technology, which adverse determination could harm our business significantly and dissuade companies from collaborating
with us or permit third parties to directly compete with the same technology.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to protect and enforce our patents
does not guarantee that we will secure the right to commercialize our potential products and respective patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent is a limited monopoly
right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention.
This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making, using and/or selling
its invention. While a patent gives the holder this right to exclude others, it is not a license to commercialize an invention covered
by the patent where other permissions may be required for commercialization to occur. For example, a drug cannot be marketed without the
appropriate authorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if
patented itself, cannot be commercialized if it infringes the valid patent rights of another party.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on confidentiality agreements to
protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our
competitors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on trade secrets that
we seek to protect through numerous measures, including non-compete and confidentiality agreements with our employees and other parties.
If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. Any remedies
that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we
may have to expend resources to protect our interests from possible infringement by others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to damages resulting from
claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees may have been
previously employed at other companies in the industry, including our competitors or potential competitors. Although we are not aware
of any claims currently pending against us, we may be subject to claims that these employees or we have inadvertently or otherwise used
or disclosed trade secrets or other proprietary information of the former employers of our employees. Litigation may be necessary to defend
against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be
a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual
property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product(s),
which would materially adversely affect our commercial development efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining patent protection
depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case
of non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance fees,
renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the relevant patent agencies
in several stages over the lifetime of the patents and /or applications. The relevant patent agencies require compliance with a number
of procedural, documentary, fee payment and other provisions during the patent application process. In many cases, an inadvertent lapse
can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which
the failure to comply with the relevant requirements can result in the abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our
technologies and know-how which could have a material adverse effect on our business, prospects, financial condition and results of operation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future operations and
successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon
to manage our business. If any member of our current senior management terminates his or her employment with us and we are unable to find
a suitable replacement quickly, the departure could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the third quarter of 2024,
our overall headcount was reduced by approximately twenty percent, with a majority of departures coming from our clinical and CMC groups.
As a result of these departures, we expect our personnel expenses to be reduced by approximately $3.7 million in 2025, which may be offset
by additional hires or consultants. We do not expect these departures to have a material impact on our operations or ability to execute
our operating plan and are actively seeking a strategic partner for Iomab-B in the U.S. to advance the additional studies and trials required
by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An overall tightening and
increasingly competitive labor market has been observed in the U.S. employment market generally. Specific to the biotechnology industry
in which we operate, there is significant demand and competition for highly specialized talent that we require. A sustained labor shortage
or increased turnover rates within our employee base as a result of general macroeconomic factors of <i>force majeure </i>events, or due
to dynamics within our industry, could lead to increased costs, such as increased wage rates to attract and retain employees, and could
negatively affect our ability to efficiently conduct our clinical development, R&amp;D, business development and potential regulatory
and commercial activities. If we are unable to hire and retain employees capable of performing at a high-level, or if mitigation measures
we may take to respond to a decrease in labor availability, have unintended negative effects, our business could be adversely affected.
An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, general macroeconomic factors or as a result
of biotechnology industry dynamics could have a material adverse impact on our operations, results of operations, liquidity or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to identify, attract, hire, or engage, retain, and motivate other well-qualified managerial, technical, clinical and regulatory
personnel. This activity is likely to create additional demands on the time and attention of our senior management personnel as they identify,
hire, and train external and internal candidates to fill the sizable number of positions required to execute our business plans, including
submitting a BLA and building a commercial organization. The market for talent in our industry is very competitive. Many of the other
biopharmaceutical companies we compete against for qualified personnel have greater financial and other resources, more favorable risk
profiles and a longer operating history in the biopharmaceutical industry than we do. They also may provide more diverse opportunities
and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates than what we have
to offer. There can be no assurance that such professionals will be available in the market, or that we will be able to retain existing
professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base in relation to such compensation,
which may include equity compensation, may increase significantly, which could have a material adverse effect on us. Failure to establish
and maintain an effective management team and workforce could adversely affect our ability to operate, grow and manage our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Managing our growth as we expand operations
may strain our resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to need to grow
rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates as well
as potential commercial operations in the future, which will place a significant strain on our financial, managerial and operational resources.
In order to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities.
Moreover, we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase our
expenses and may require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm
our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us
to liability for claims arising from the use or misuse of these materials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials,
such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations governing, among
other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely eliminate the
risk of contamination or injury from these materials, and we could be held liable for any damages that result, which could exceed our
financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future
claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the
costs of complying with such federal, state, local and foreign environmental regulations are not significant, and consist primarily of
waste disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our
research, development, production and commercialization efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not have any
international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant
opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries involves
inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected changes in
regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating
intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to experience any
of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition
may suffer and cause us to reduce or discontinue our international development and registration efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to expand our development and
regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and, as a result, we may encounter difficulties
in managing our growth, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to experience growth
in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory
affairs and, if any of our product candidates receives marketing approval, sales, marketing, and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that are potentially able to obtain
regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales,
distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we
may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales or
marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be
expensive and time consuming and will require significant attention of our executive officers to manage. We will also have to compete
with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of
any of our product candidates that we obtain approval to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To manage our anticipated
future growth, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and
continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our
management team in managing a public company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may
divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans
or disrupt our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We continuously evaluate our business strategy
and may modify our strategy as necessary to respond to developments in our business and other factors, and any such modification such
as a divestiture, spin-off, spin-out, merger or acquisition, if not successful, could have a material adverse effect on our business,
financial condition, and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continuously evaluate our
business strategy and modify our plans as necessary to achieve our objectives in response to changing circumstances. As part of such a
process, we may delay, modify or discontinue the development of certain of our drug candidates and choose alternative approaches if we
believe such changes would be in our best interest. We may also expand or alter our research and development activities from time to time
and redirect allocation of our resources. We have implemented such changes in our business strategy and may continue to do so in the future.
There can be no assurances that any product development or other changes that we implement will be successful or that, after implementation
of any such changes, that we will not refocus our efforts on new or different objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may expand our business through the acquisition
of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217;
ownership interests in our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so. Acquisitions
involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt
and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating
acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business
concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key
employees of the acquired companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
product, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated
with some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired products,
businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business
or companies may require a substantial capital investment by us. We may not have these necessary funds, or they might not be available
to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute
each current stockholder&#8217;s ownership interest in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Ownership of Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The sale of securities by us in any equity
or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additional capital
through the sales of stock and warrants in order to expand our level of operations to continue our research and development efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any sale of common stock by
us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional shares
of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing strategic relationships
with targeted customers and vendors. In order to do so, or to finance the cost of our other activities, we may issue additional equity
securities that could dilute our stockholders&#8217; stock ownership. We may also assume additional debt and incur impairment losses related
to goodwill and other tangible assets if we acquire another company and this could negatively impact our earnings and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>Our common stock is subject to price volatility which could
lead to losses by stockholders and potential costly security litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading volume of our
common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock to fluctuate
substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating
results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and
the financial markets or other developments affecting our competitors or us. This volatility has had a significant effect on the market
price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The trading price of our common stock may
be highly volatile and could fluctuate in response to factors such as:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
or anticipated variations in our operating results;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
of developments by us or our competitors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
actions regarding our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption
of new accounting standards affecting our industry;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
or departures of key personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
of new products by us or our competitors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
of our common stock or other securities in the open market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inaccurate
or unfavorable reports from securities or industry analysts; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
events or factors, many of which are beyond our control.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market is subject
to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&#8217;s securities,
securities class action litigation has often been initiated against such a company. Litigation initiated against us, such as the Securities
Claims further described under &#8220;Legal Proceedings&#8221;, whether or not successful, could result in substantial costs and diversion
of our management&#8217;s attention and our resources, which could harm our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends on our
common stock, so any returns will be determined by the value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations
will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. As a result, the
success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common
stock will appreciate in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain provisions of our Certificate of
Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to
complete, even if such a transaction were in our stockholders&#8217; interest.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our
management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our
stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock.
Among other things, the certificate of incorporation and bylaws:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
that the authorized number of directors may be changed by resolution of the board of directors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote
of a majority of directors then in office, even if less than a quorum;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide
the board of directors into three classes;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at
a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content
of a stockholder&#8217;s notice;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are governed
by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging
in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own,
15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing
a change in our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face risks associated with litigation
and claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
legal proceedings, as further described under &#8220;Legal Proceedings.&#8221; In addition, from time to time, we may become involved
in various claims, disputes and legal or regulatory proceedings that arise in the ordinary course of business and relate to contractual
and other obligations. Due to the uncertainties of litigation, we can give no assurance that we will prevail on any claims made against
us in any such lawsuit. Also, we can give no assurance that any other lawsuits or claims brought in the future will not have an adverse
effect on our financial condition, liquidity, or operating results. Adverse outcomes in some or all of these claims may result in significant
monetary damages that could adversely affect our ability to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with the reporting requirements
of federal securities laws can be expensive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission
and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with the
preparation of registration statements and related documents with respect to any offerings of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to utilize our
federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, or the Code.&#160;The limitations apply if we experience an &#8220;ownership change&#8221;, generally defined as a greater
than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period.&#160;Similar
provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously occurred.&#160;If we
have experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability to utilize
our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in our stock ownership,
which may be outside of our control, may trigger an ownership change and, consequently, the limitations under Sections 382 and 383 of
the Code.&#160;As a result, if or when we earn net taxable income, our ability to use our pre-change net operating loss carryforwards
and other tax attributes to offset such taxable income may be subject to limitations, which could adversely affect our future cash flows.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to establish and maintain adequate
finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal
controls requirements for publicly traded companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, we operate
in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporate oversight
and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary
for us to produce reliable financial reports and are important to help prevent financial fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts. We complied
with Section 404 at December 31, 2024 and 2023 and while our testing did not reveal any material weaknesses in our internal controls,
any material weaknesses in our internal controls in the future would be required us to remediate in a timely manner so as to be able to
comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section 404 in a timely manner
each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory authorities which would require
additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot
provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose
confidence in our reported financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Multiple
securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publish inaccurate or
unfavorable research about our business, the price of our common stock would likely decline. If one or more of these analysts cease coverage
of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could cause the price of our common
stock and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated&#160;bylaws, as
amended,&#160;designate the U.S.&#160;federal&#160;district courts as the&#160;exclusive forum&#160;for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated&#160;bylaws,
as amended,&#160;provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities
Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasing or otherwise acquiring
any interest in our security shall be deemed to have notice of and to have consented to such provision. Such choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees, which may discourage such lawsuits, if successful, might benefit our stockholders. Stockholders who do bring
a claim in the federal district courts of the United States of America could face additional litigation costs in pursuing any such claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tariff policies and potential countermeasures
could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">President Trump has increased,
and has indicated his willingness to continue to increase, the use of tariffs by the U.S. to accomplish certain U.S. policy goals. Such
tariffs and any countermeasures could increase the cost of raw materials and components necessary for our operations, disrupt our global
supply chain and create additional operational challenges. Further, it is possible that government policy changes and related uncertainty
about policy changes could increase market volatility. Because of these dynamics, we cannot predict the impact of any future changes to
the U.S.&#8217;s or other countries&#8217; trading relationships or the impact of new laws or regulations adopted by the U.S. or other
countries on our business. Such changes in tariffs and trade regulations could have a material adverse effect on our financial condition,
results of operations and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c12" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-9278"><ix:nonNumeric contextRef="c12" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-9279"><ix:nonNumeric contextRef="c12" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-9280"><ix:nonNumeric contextRef="c12" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-9281">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copies of the following documents
are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed with the SEC on April 17, 2013).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022322/ea125571ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws, dated August 9, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea026204701ex31-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea026204701ex31-2_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea026204701ex32-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea026204701ex32-2_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.1*</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea026204701ex99-1_actinium.htm">Letter from Novartis Pharmaceuticals Corporation, dated August 5, 2025</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Label Linkbase Document </span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 37%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">Date: November 14, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Sandesh Seth</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer<br/>
(Duly Authorized Officer and<br/>
Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Steve O&#8217;Loughlin</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer and<br/>
Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 87; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-6" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-7" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-8" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-9" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-10" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-11" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-12" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-13" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-14" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-15" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-19" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-20" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-21" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-22" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-24" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-31" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-32" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-34" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-35" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-36" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-37" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-38" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-39" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-42" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-43" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-45" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-47" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-49" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-50" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-51" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-52" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-53" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-54" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c69" id="hidden-fact-55" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-56" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-57" name="us-gaap:FinanceLeaseInterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-58" name="us-gaap:FinanceLeaseInterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-59" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-60" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-62" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-63" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-66" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-67" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-74" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-76" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-78" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-79" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-80" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-81" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-9366">0001388320</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-9367">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-9368">Q3</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate" id="ixv-9369">--12-31</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnm-20250930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:GrantRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:GrantRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:GrantRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:GrantRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:VestedUnissuedSharesOfCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:VestedUnissuedSharesOfCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2012-06-15</xbrli:startDate>
    <xbrli:endDate>2012-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">atnm:OperatingLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">atnm:FinanceLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-11</xbrli:startDate>
    <xbrli:endDate>2023-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
<!-- [WMV6][6I2t0SIpKuXB2IOOD6xZp6PUbQ60M74+Gs45WfBY4Ax3ieWncXb7xaBG2bW+GwGsiCGswcLMfe3i5tupUE3ycS58nvOXo1siDHvDBB+MeeJYhjIshnNrOrC+ftppNYyKJxuOVaXtk7wyPKq5/cRGTbTKWT95mS2ojsw7jjXjZMPyeUUdOGh9qmQmZwqzKb/WhR0IsE56a5f1/G2Gpeso5QeNulo1sxs6l9ZNYelwPbzP2xWngcAz+ITy+Klk5b2Z+e2QQbZrblZWZG2uw+ZPkZm5UeQ5TmIwRsGxIy6iYBX+kmYuVxGxoRQfHx88jw0igeNP/v9r5t9UR9QYk47tL0eRVxqQw0rLTrp5f09t75OJh1WEfCzQDwQ=] CSR-->
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>
</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ea026204701ex31-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT><B>Exhibit
31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO SECTION
302 OF</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: November 14, 2025</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%">/s/ Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;</FONT></TD>
    <TD>Principal Executive Officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ea026204701ex31-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO SECTION
302 OF</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Steve O&rsquo;Loughlin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: November 14, 2025</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%">/s/ Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ea026204701ex32-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2025 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Sandesh Seth, Chairman &amp; CEO of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: November 14, 2025</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%">/s/ Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ea026204701ex32-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2025 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Steve O&rsquo;Loughlin, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: November 14, 2025</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%">/s/ Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ea026204701ex99-1_actinium.htm
<DESCRIPTION>LETTER FROM NOVARTIS PHARMACEUTICALS CORPORATION, DATED AUGUST 5, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 10%">&nbsp;</TD>
<TD STYLE="width: 20%"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 51px; width: 280px"></TD><TD STYLE="width: 40%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Novartis Pharmaceuticals Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">One Health Plaza</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">East Hanover NJ 07936-1080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">USA</P>

</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B>Elizabeth McGee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Vice President &amp; Head,
US Legal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Elizabeth.mcgee@novartis.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">August 5, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Paul Diamond, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Vice President, Patent and
Legal Counsel Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">100 Park Avenue, 23rd Floor
New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Dear Dr. Diamond,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">I am writing on behalf of Novartis
Pharmaceuticals Corporation (&ldquo;Novartis&rdquo;) to raise serious and urgent concerns regarding the egregious pre-approval promotion
of ATNM-400 by Actinium Pharmaceuticals, Inc. (&ldquo;Actinium&rdquo;) in a wide-ranging set of materials, including but not limited to,
your social media channels, your corporate website, and your investor relations materials. These materials make conclusory representations
in a promotional manner regarding the safety and efficacy of a drug that has not been approved by the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) and whose clinical profile has not yet been established. Additionally, these materials purportedly compare the safety
and/or efficacy of ATNM-400 and Pluvicto&reg; (lutetium Lu 177 vipivotide tetraxetan) based solely on pre-clinical data and without substantial
evidence or clinical experience. Such claims risk misleading healthcare professionals, payers and the public, and may give rise to regulatory
scrutiny and potential enforcement action. In view of Actinium&rsquo;s blatant disregard for compliance with U.S. law and regulation of pharmaceutical
advertising and promotion, we request that immediate corrective action be taken by Actinium to remove such claims from existing materials
and to refrain from making such claims in future materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Actinium&rsquo;s public statements
represent that ATNM-400, an investigational new drug, is safe and effective for the purpose for which it is being investigated, is superior
to Pluvicto and/or otherwise promote the drug. As a result, ATNM-400 is misbranded under section 502(f)(1) of the Federal Food, Drug,
and Cosmetic Act (&ldquo;FD&amp;C Act&rdquo;) and in violation of section 301(k) of the FD&amp;C Act. ATNM-400 is an investigational
new drug for which there is no marketing authorization in the U.S. Under section 502(f)(1) of the FD&amp;C Act, a drug shall be deemed
to be misbranded unless its labeling bears adequate directions for use. Under FDA regulations, adequate directions for use means directions
under which the layman can use a drug safely and for the purposes for which it is intended.<FONT STYLE="font-size: 10pt"><SUP>1</SUP>
</FONT>As shown below, Actinium&rsquo;s materials describe the use of ATNM-400 for treating prostate cancer. This use is one for which
a prescription would be needed because it requires the supervision of a physician and, therefore, for which adequate directions for lay
use cannot be written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.55pt 0pt 37.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.55pt 0pt 37.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.55pt 0pt 37.05pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0pt 37.55pt 0pt 37.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">21 CFR 201.5</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.55pt 0pt 37.05pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;of 5</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 36.55pt 0pt 37.3pt; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Although 21 CFR 201.115(b) provides
an exemption from the adequate directions for use requirement in section 502(f)(1) of the FD&amp;C Act if a new drug &ldquo;complies
with section 505(i) ... and regulations thereunder,&rdquo; your investigational drug fails to do so.<FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT>
Among the requirements for this exemption for investigational drugs, 21 CFR 312.?(a) provides that, &ldquo;[a] sponsor or investigator,
or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new
drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug. This provision is not intended
to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific
or lay media. Rather, its intent is to restrict promotional claims of safety or effectiveness of the drug for a use for which it is under
investigation and to preclude commercialization of the drug before it is approved for commercial distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">As summarized
in the chart below, your materials include claims and presentations that inappropriately promote ATNM-400 as safe and effective for the
purposes for which it is being investigated or otherwise promote the drug and make comparative claims without substantial evidence or
substantial clinical experience:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37pt 0pt 37.35pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 3pt 3pt 8pt"><B>Source</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 3pt 3pt 8pt"><B>Selected, representative examples of violative language (emphasis added,<BR>
 unless otherwise noted)</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="width: 35%; border: black 1pt solid; padding: 3pt 3pt 8pt">July 31, 2025 press release titled &ldquo;Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit&rdquo;</TD>
    <TD STYLE="width: 0.25in; padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 significantly improved survival compared to</B> the approved prostate cancer treatment <B>Pluvicto&reg;&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 is more efficacious than Pluvicto&reg; </B>(Lu-177-PSMA-617) with potent tumor control&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 significantly improved survival compared to Pluvicto&reg; </B>with continued follow-up ongoing&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 is highly effective in prostate cancer tumors with acquired Pluvicto&reg; resistance, </B>halting tumor growth and producing potent tumor cell killing <B>after Pluvicto&reg; stops working&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 3pt 3pt 8pt">June 23, 2025 press release titled &ldquo;Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Radiotherapy at the Society of Nuclear Medicine &amp; Molecular Imaging Annual Meeting&rdquo;</TD>
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 is more efficacious than </B>... <B>Pluvicto .</B>.. in prostate cancer in vitro and in vivo models and overcome resistance in prostate cancer tumors that failed Pluvicto therapy&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 is more efficacious than PSMA-directed Radiotherapies&rdquo; </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ANTM-400 was more potent than both Pluvicto</B> (177Lu-PSMA-617) and 225Ac-PSMA-617 <B>in prostate cancer cell killing&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ANTM-400 exhibited more efficacious tumor growth inhibition compared to both Pluvicto </B>(177Lu-PSMA-617) and 225Ac-PSMA-617 <B>in prostate cancer in vivo model&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 3pt 3pt 8pt">April 28, 2025 post on Actinium Pharma&rsquo;s X account (@ActiniumPharma)</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 3pt 8pt">&nbsp;&ldquo;Actinium Presents Data Showing ATNM-400 is <B>More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance </B>in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 3pt 3pt 8pt">April 28, 2025 post on Actinium Pharma&rsquo;s Linkedln account</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;Actinium (NYSE: ATNM) Presents Data Showing ATNM-400 is <B>More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance</B> in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37pt 0pt 37.35pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37pt 0pt 37.35pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37pt 0pt 37.35pt; text-align: justify; text-indent: -0.05pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0pt 37pt 0pt 37.35pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify">21 CFR 201.100 offers another exemption from the requirement
for adequate directions for use for prescription drugs provided certain requirements are met; however, ATNM-400 does not fall within
that exemption because it is an investigational new drug for which there is no marketing authorization in the U.S.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.5pt 0pt 37.2pt; text-align: justify; text-indent: 0.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.5pt 0pt 37.2pt; text-align: justify; text-indent: 0.1pt"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;of 5</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.5pt 0pt 37.2pt; text-align: justify; text-indent: 0.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border: Black 1pt solid; padding: 3pt 3pt 8pt; width: 35%"><B>Source</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 3pt 8pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 3pt 8pt; text-align: center"><B>Selected, representative examples of violative language (emphasis added,<BR>
unless otherwise noted)</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="6" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 3pt 8pt">April 28, 2025 press release titled &lsquo;Actinium Presents Data Showing ATNM-400 is
    More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American
    Association for Cancer Research Annual Meeting&rdquo;, available at https://ir.actiniumpharma.com/press-releases/detail/502/actinium<BR>
-presents-data-showing-atnm-400-is-more-efficacious &nbsp;</TD>
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition </B>achieved with a single 40 &micro;Ci/kg dose of ATNM-400&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;ATNM-400 was <B>well tolerated with no apparent toxicities </B>at two different dose levels, with efficient clearance from essential organs&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;ATNM-400 <B>leverages the alpha-particle emitter Ac-225, which is more potent than Lu-177.</B>.. and <B>has a shorter path length that could result in fewer off-target effects.&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;In vivo studies demonstrated that <B>ATNM-400 is more efficacious than Pluvicto and produced a statistically significant (p </B>&lt; <B>0.0001) reduction in tumor volume </B>in 22Rv1 prostate cancer models <B>demonstrating its transformative therapeutic potential.&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;Expression of the target receptor for ATNM-400 persists following Pluvicto therapy and <B>ATNM-400 demonstrates sustained tumor control after Pluvicto stops working&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 demonstrated greater efficacy than Pluvicto in prostate cancer models with 99.8% tumor growth inhibition </B>achieved with a single 40 &micro;Ci/kg dose of ATNM-400&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 3pt 8pt">Page on Actinium&rsquo;s corporate website titled &ldquo;ATNM-400&rdquo;, available at https://www.actiniumpharma.com/product-pipeline/atnm-400</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 is differentiated from Pluvicto as it targets a different marker than PSMA that has been shown to be overexpressed in patients with prostate cancer and uses the alpha-particle emitter Ac-225, which is more potent than Lu-177 but has a shorter path length, which could result in fewer off-target effects such as xerostomia.&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 3pt 8pt">&nbsp;</TD>
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;In vivo studies demonstrated that ATNM-400 is <B>more efficacious than Pluvicto and produced a statistically significant (p </B>&lt; <B>0.0001) reduction in tumor volume </B>in 22Rv1 prostate cancer models. In mice bearing Pluvicto-failed tumors, ATNM-400 was administered on day 14 following Pluvicto treatment, <B>demonstrating robust antitumor activity and tumor growth inhibition in Pluvicto-resistant tumor models.&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 3pt 8pt">&nbsp;</TD>
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 Shows Significantly Higher Anti-Prostate Cancer Activity than Pluvicto&rdquo; </B>(emphasis in original)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 3pt 8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 Demonstrates Potent Efficacy in Pluvicto Resistance </B><I>[sic] </I><B>Prostate Tumor Models&rdquo; </B>(emphasis in original)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.5pt 0pt 37.2pt; text-align: justify; text-indent: 0.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.5pt 0pt 37.2pt; text-align: justify; text-indent: 0.1pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;of 5</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.5pt 0pt 37.2pt; text-align: justify; text-indent: 0.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border: black 1pt solid; padding: 3pt 3pt 8pt"><B>Source</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 3pt 3pt 8pt"><B>Selected, representative examples of violative language (emphasis added, <BR>
unless otherwise noted)</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="3" STYLE="width: 35%; border-left: black 1pt solid; padding: 3pt 3pt 8pt; border-right: black 1pt solid">April 2025 Investor Presentation, available at https://d1io3yog0oux5.cloudfront.neU - 71258897dd67d52ade4742994d37243c/actiniu mpharma/db/206/1183/pdf/Actinium+lnvestor+P resentation_April+2025+AACR+.pdf &nbsp; &nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;ATNM-400 is a <B>first-in-class, non-PSMA prostate therapy demonstrating potent efficacy preclinically in Pluvicto resistant tumors and superior anti-prostate cancer activity compared to Pluvicto&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 Shows Significantly Higher Anti- Prostate Cancer Activity than Pluvicto&rdquo; </B>(emphasis in original)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt"><B>&ldquo;ATNM-400 Demonstrates Potent Efficacy and Sustained Tumor Control After Pluvicto Stops Working&rdquo;</B> (emphasis in original)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding: 3pt 3pt 8pt">&nbsp;</TD>
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;ATNM-400 showed <B>greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition </B>achieved with a single 40 &micro;Ci/kg dose of ATNM-400&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-left: black 1pt solid; padding: 3pt 3pt 8pt">&nbsp;</TD>
    <TD STYLE="padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;ATNM-400 produced <B>robust antitumor activity and sustained tumor control after Pluvicto strops</B> <I>[sic]</I> <B>working&rdquo;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 3pt 3pt 8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 3pt 3pt 8pt">&#9679;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 3pt 3pt 8pt">&ldquo;Expression of the target receptor for ATNM-400 persists following Pluvicto therapy, <B>ATNM-400 demonstrates sustained tumor uptake, clearance from essential organs and is well tolerated with no apparent toxicities&rdquo;</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 37.5pt 0pt 37.2pt; text-align: justify; text-indent: 0.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The above materials, along with
the ANTM-400 abstract on your corporate website<SUP>3</SUP>, contain numerous conclusory statements about the safety and effectiveness
of ATNM-400. To cite one example, your April 28, 2025 press release touts &ldquo;ATNM-400 is More Efficacious than Pluvicto,&rdquo; an
efficacy claim of clinical benefit that has not been established. These claims are promotional in nature, suggesting that ATNM-400, an
investigational product, has been shown to be not only different from - but also superior to - Pluvicto&reg;, an FDA-approved therapy
for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, and is safe or effective for such use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The benefit
and risk profile associated with ATNM-400, an investigational compound, is currently under development and not fully known. The conclusions
made in Actinium&rsquo;s materials, especially considering the serious nature of prostate cancer, create a misleading impression regarding the
usefulness and regulatory status of this product. Indeed, the overall takeaway from these materials is that ATNM-400 is expressly superior
to FDA-approved Pluvicto. In short, these materials represent the drug as having an established role in treating prostate cancer, when
ATNM-400 has not been proven to be safe and effective within the meaning of the FD&amp;C Act and has not been approved as a drug under
that authority for any use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19.95pt 0pt 18.4pt; text-align: justify; text-indent: -0.1pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0pt 19.95pt 0pt 18.4pt; text-align: justify; text-indent: -0.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>3</SUP></TD><TD STYLE="text-align: justify">Available at https://d1io3yog0oux5. cloudfront.neU_654515b0f8718f7af5bc69536e50a53c/actiniumpharma/files/pages
/product-pipeline/atnm-400/AACR2025_ATNM-400_e-poster_578_Final.pdf</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.55pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;of 5</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 1.85pt; text-align: justify; text-indent: 0.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 1.85pt; text-align: justify; text-indent: 0.3pt">We request
that Actinium inform us in writing within 5 business days of the immediate corrective action taken to remove relevant language from existing
materials and to ensure such language will not be included in any future materials. This letter does not represent the full extent of
our concerns regarding Actinium&rsquo;s public statements about ANTM-400, and we expressly reserve the right to take further action as circumstances
warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 1.85pt; text-align: justify; text-indent: 0.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.8pt">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Elizabeth McGee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75pt">Elizabeth McGee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75pt">Vice President &amp; Head, US Legal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75pt"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $> FL# 2(  A$! Q$!_\0
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M>_G%Q/;WD]MYVT*7".0"0.,X]*B5)Q5QJ:;L=-1116184444 %%%% !1110
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M;E!IGV2V_P"?>+_O@4+EZB?/?2WXB_:K?_GO%_WV*/M5O_SWB_[[%)]DMO\
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M(OVJW_Y[Q?\ ?8H^U6__ #WB_P"^Q2?9+;_GWB_[X%'V2V_Y]XO^^!1[GG^
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MH:S8M.\>+%:V:S72Q+;R132O/&Q=BLGS9SD$-LQUX].E>DT57*3S^1Q.C_\
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M+)%$%.4#+N!.XCYAV]*7N@N8]#\]?^>2?D*//7_GDGY"N2F\90O::?/IUO\
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MVG/TZC\:TZ?*B7*2)O/7_GDGY"CSU_YY)^0J&BCE0<S)O/7_ )Y)^0H\]?\
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MZ#\C1]G7_GH/R-%XARR,LZ5IY@,!LH/),WV@Q[!M\S.=V/7/-0'PYHIC6/\
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MLJE5/X*Q'XTT^'=',LLIT^'S)7WNW/S-O#YZ_P!X _6MO[.O_/0?D:/LZ_\
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ML>Y*+N045/Y47_/4?E_]>CRHO^>H_+_Z]/F1/*R"I8/]8?H:=Y47_/4?E_\
M7I\4<88D2 \>G_UZ3DK%1B[E9OO&DJ<Q19/[T?E_]>CRHO\ GJ/R_P#KT^9$
M\K(**G\J+_GJ/R_^O1Y47_/4?E_]>CF0<K(*E_Y=_P#@7^%.\J+_ )ZC\O\
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MF^\VLH4CYN0.@I@346>0A+HM(=SG#98@YR?7FG:7<5Z=](LMS:#+!;2W+W4
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MN4^W]?>=_P"79_\ /=O^^?\ Z]'EV?\ SW;_ +Y_^O7 ?\)/J/K%_P!\4?\
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M075C#Y;>7/B1G_>C//W@./05U>EV3Z=I5K9R3M.\,80RMU;%:/V2X_YXR?\
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MH553NPQRSM_>;_"M^LIM-Z%05C8\.<:B2/[A_D:MRZO+"<R7"Q@MM7>^,D]
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M ?\ :&0>NVO2?)LO^FGYC_XFCR;+_II^8_\ B:6G8:H5EH><-X!Q&\,.H>5
MR[=@0]/+2,GKU(#\^K>U6;SP9]IT<:?'>"-/MLET4"L$*MD!, YP 1CGJ*[[
MR;+_ *:?F/\ XFCR;+_II^8_^)HT[![&L>9WG@F],T\D-U!-]JD@1ED5@L$4
M9!.,MEMP10W<FEE\!7CR0,FLJB0J^Q5A(V,P?(7!^YE\@>V*]+\FR_Z:?F/_
M (FCR;+_ *:?F/\ XFC3L'L:QYM=?#_S;>2WM[V*.&3<OEO$S*@*(@91N^^
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MP_N-_P!]?_6H\NP_N-_WU_\ 6HYO(/JM0RZ*U/+L/[C?]]?_ %J/+L/[C?\
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M>39?]-/S'_Q-:?69=C'^RW_3/,_^$?U/_GV_\>%;FB:$+/%S= &X_A7J$_\
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M[E90=HSC)_'BLF7P)I<ML8&EN-I14)!&<"$1#M_='YTZZ\#:7=JXEDG^9Y)
M01PS.KYZ<X*#@^]&H:FJ_B#1H]V_5+0;$61LRCA6^Z?H>U(OB#2F?:;^W3,O
MDH6D7$C8!&W!YR&'YUG1>#-.MK<Q6TMQ P>&2.1"N8WB!"D#&.=QR,=ZKS>
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M1;Z^G#-' BLP0<D;JXO_ (6AI'_/M>?]\+_C6M.-9WY"XJ;^$WO^%>Z+_P!
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M ->J7]K1?W7_ "%']K1_W7_(5C:9%I%W^Q!_S[?K_P#7J2WT9$ERUMQ@]_\
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M$KB[C6T=%B4J-P(/^L*'.,8W5/H6L^)#K%G87=C(UF[R%[B:)@Y7?)@YQ@8
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M26_B_1;EW5+Q%$:EI&<X"8"G'O\ ?7IFBR#0ZC[3!_S[_P#CYH^TP?\ /O\
M^/FL!O$FC QJ-2MR\B;XU#\L.?\ XDCZBF0^)]%G0D:C;JRQ>:Z,XRBX!.?H
M&'YT60'1?:8/^??_ ,?-'VF#_GW_ /'S699WUKJ%OY]G.D\6XKO0\9!P1^%6
M*.5!8M_:8/\ GW_\?-'VF#_GW_\ 'S52BCE06+?VF#_GW_\ 'S1]I@_Y]_\
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M9_%D<,4DD^K!)@2F7?D X)Q3^I_WD'L?,]W^T0?\^Q_[[-2V\T3286 @X/\
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M_9K6UM),KA7\II'R%9E1<G '3RU/UKJJ*+(+&7H&E2Z1IK07%S]IGDGDGDD
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+R*W:YJKO8RD?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #H G # 2(  A$! Q$!_\0
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M_!=W_@MIX\O?'_C+]B;]CSQS>>$/"?@RXG\-_';XR>$;^:R\2>)_%,)V:O\
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M7M7"TW&E3H34'%)>TB[I2N?ZF'GGC[_I_K.2?^^>./Y?6D\\_P"W_P!_#_\
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M^^+KWQGXZ\*> _@#?>%/@?#I,$/@[X>_%7X9_!/X<_#Z\UK6O$$<UU<^-I=
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M)!X$AT;PC?O\39-/U20V.OCX=#Q1_P (W<0W2Z^=-%I<F+R#XP_%7X+?M/\
MC+X">%/A#\9/A;J7Q(\)?$<_$GP!IWB#X;>/O']Y;>)M-^&T&M:)XXTRWT"[
M\/Q^']$TWP5\0G:7Q=XDE?P;<7'BC3]#-XGB-K:RKQWQ;_P3#^&VH?$NRNY_
MVF_$UE\5=/DN/%O[-MKKNF>"=9\2?#N.QUW^VOB7K4NE7H@O?BM;ZYJ7B2]M
M[_4_$$*1^&8_$%M';R&[6SF;M_V?/V$_V6OA#\>+/Q7\#_B]>Q?'+X93Z-HG
MQ!M],UOPUJOB#7/ACIGPL\*?#<?"/XC:/';N4\-&Y\-^&?B!8S_9K'6]$\9
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MRLJ_C[]DG2+":X\(?$KXD?LH:;%JNA_&OQ3<CQ5\(/&NF>';C2OVEO%.B?\
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ME_X:"_9W\$Q_!:SU?PU.WC.QUF]\5^$O$'C"8+K%F/%G@OXT?#+4M#M]>LM
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M7A\V.L?%+4_VA;;6O%-CK.F>";'2Y?!>M>)M5TEM'\/V$$>BI:6:!/H;6/\
M@C9\&=3\!R> K/XF>+]"DM?&5EXMT/QII'AOP9#X_P!(CTZW\9VVD0SZ_+IL
MJ:UJ^G'QIK+P^)-7L+BZO26BU6UU&)W0?4?QN_9K^"7B[XK?#7Q5\3_B*=.U
M[7M=\!>'?!_A+7F\*2Z?X^\2?#;PS\5[FQTBVT[6=-GDUC5+K2_&WB+7[^SL
MP98AX<M;RTCMHK>[,B^O14HQI8RI.+51R2P4(R7)&+IN*4I*2E%UE)2TIJ-Y
M7BN8?U&3C*53!TX->S47+&SE%\\FJBD^6+3@U2Y6M:C=HV;Y3PWX;^._!/[!
M-SXS_P"&BOVEO@9=:=\9K3Q9^T'H?AKX:_">_P#!&I>)-4COM#3XF_%%6L_&
M'C>/Q!;:G!K7A%?L]@FFVB0PR7>EPW$$5X+;]'=,^*OPQUJ7PQ;Z/\0_!.J3
M^-8;VX\'P:?XHT2\F\40:<TZZA+H$5O>R/JZ6+VMTEVUBLXMWM;E)=C02A/S
MZ^+/_!/CX%_$S1/V<O@AJ_Q4U;1_$'P4_9OU[X)Z!:K8> M0\6^-_A6]A\,]
M!U36;VTUG0[QK&ZL=0\ >'IWU/P[;V-K#+JVJZ>\/V._\I.)\0_L-_LD_ #X
MW^#/C]\0OC-I_A&YM?&'BKQ]I7AWXBS^#['PW)>>&?$OB_XS ^"3/#I<_@^/
MP$^OZOJVH2^'71;_ $.R$GB&*ZB^URS<LXX/$6FZV(^LRC4;C#"IQJN'M(4>
M2$%>*G"G2E*5ZEKRB[.":ZJ<L9A[P5'#_5HRII.>*?-24_9SK<TYNTG"=2JH
MQM3O:,DFIM/[YTS]I[X-:OXGB\'V'B6>77YOC;XC_9XCLSH^JQJWQ6\*> M2
M^)>M^'_M#V@A$%KX/TF^U%=5+_V;/)$+.&Y>Z=(CG_#W]JWX.?%'XN>/?@KX
M+U/7]5\7?#C4M?T/Q)??\(GK]OX27Q#X3N=/LO%GAZS\536*Z1/K7AR[U6QM
M[^RDG@:X:6632FU*"SOI;;QMOV&[>V^-6I_%KP_\9_&6AZ//\4_&/Q\T/X<K
MX7\"ZCH>@?'+QM\);_X/:EX]37;[0W\4:I9V_A[5-0U"S\(:CJ<OA^/6;@7+
MP/%%' ,;P_\ L"IX:_:,\1?M-:9\<?%=O\0=8M?$MG;7-GX ^%NCSR67BW5=
M#U'5-,\:ZEH'A?2KWXHZ3H\&EW^G>!;7QZVL77@FWUB232[^2XL+&2/'V> Y
M9_OJG,Z"=.\9V6(<H>Y-*GK%1YTVFDFXM.231KSX_FA^YIN/MVJEI0UPZC/W
MH-U-).7(TFKM*2:BVF?H;1117 =X4444 %%%% !1110 4444 %%%% !15:]-
MXMG=G3TMWOQ;3FQ2[>2.U>\$3FV2Y>)7E2W:;8)GC1I%C+%%9@ ?RD_:E\5_
MMDV/A_X?3RV/B[P9\2;/XK^$T\#V'[+B>,/B;X'^)&BP^*O"]SXNTOXOOJOP
MZBA\ QWOA0ZQ9>'XO$\]WX- BU[5=4\0QW4>G6VG[X>@Z\U!5*=.[M>I*W23
MNHZ-Q7+:4D_<3YFFDT85ZZH0<W3J5+*]H1NMXJSEJE)\WNII\[7*FFTS]9*S
M=99%TC56D<1QKIM\SR,'9406LI9V6-'D8*H+$1H[D#"HS8!_FBUSQ_\ \%,C
MI'CY[*^_:LAT7_A)+T6]['X%OF\:V7[2[^$_B4^A?#WPOI]MX)F$_P"RS<>-
M(_ =E>ZW#;7/A)+::PW^,([6_NY1^AW[+^O_ +<9_:>O(/VG=/\ &B?";6['
MXPV7P@7P=I5U)X0TC6="\;QSZE)\<KN?1X;NU.N>'+C33\ ;^*ZMO#CZ#I>O
MV%U-J/B:^@E?LJY;*C"51XK"SY(RGR0J>_+E4&XPBY/FE[S;5URQ7-[W-&)Q
MTLRC6G&FL+BH<THPYY4_<CS.:4IRY5RQO&R=GS-V]WE<C\/O@[\"_&G@#PWI
MNB6_QFT;0=5\/_ G]L'X=6?B#4_BC\9/'?A5]>^/VGW\O@1O@_X$A^ 'AVZ^
M!)L?$A\/ZIXP\4IKOB/4#I^DWNE6=G.FJ/)']"Z'X2T;X:_'OX7ZKX ^(B3?
M#/PGX0^$=UX<UZ/QA\>+ _"KQ=X&\)^*5^*_A+4-&U/P9JGB#QSX4^-_Q U^
M/6]=NK;4()M5TV^U2._?39M"T G[.TG]JW_@IWXSUKXMZ-X>^ Z^'--T/Q5X
MGN_ 'BSQ3\$?'L"76@^'OAS^T%K7_"'7VAS:S9P7&KZAXY^&WPR\-:5K6E^(
M=<M;I_B3ILHGFEU2PTRUM>)OVLO^"G>A:G>:W!^S6]_X0O+C6IFTJV^%GC&3
M5_!FA>$O%WP-:_U-[F/4YI?$U[XG\(^./B<-!TF"QCNI9/ $]Q9Q7ES;7L1]
MN=?%5)RYOJ5ZD9*4?KF&2?M(:7_=_&E.?*G*R;G"2:DE/QH4,+3C#D^NVIR3
MC+ZGB';V<U=+]Y\+<(<S4;M*$TTXMP_)'3/AC\6)/@W\8+#Q)\1-)L_$GC3X
MD?!?QSX9^&?@'QM\4K#PUI%UX(\(_$/PGXYBALO$/PVU?0M1\,Z[JWB'PYXA
M2Q\4:G>^)]8L+5]:O];M_%VC:=N_3/\ 8N\;_#WX(?''X\?$/XL^)O![ZC\;
MO@=^R_H>J^/O >E?&;4;>#QY\)OAJ? ?CGPO!H/B3PA=ZX^DOJ:IKNA>)+[5
M;N>]LECANPMTTC&S\0?VOO\ @I'XGCO?#'@W]G[X@^'X?$_PX_:"CM]3LO@E
MX[TOQ7H]\D_QUL_@SXO\/:E?0:GIEGK,=EX/^&<LVB^*K/09!JGC#3I%L=<3
M6K.'3_MSXO?';]IOP%\3_ACX8\.^!M?OO!<GP>T_Q5JE[I_P:\6_%+6?B-\1
M<W=MKW@*74_#VO\ AO1?AQ>>']+M8?$2W/B"[M1K5Y="RM9)4C>S;+$UJU6#
MHU(85>WC5DXTL52348+#R:YHPDEK0I\L9<[E)3E.3BFXZX:A0I356G/$MT'2
MBI5<+5:E*;KQORRDF_=KU'*4>113A&*3<5+\J/!/C'XA_#G]FFQ_9HT*Y_91
MU+3O@O\ !#XS?#SX7_%'6-"^.5YXT^*GB'Q=>M;>$KD6.E?#;PWJGP1@U[0)
M[NY^)T]IXO\ $%SKOB/['##=0Z:)Y:^>/!?P4U36O 'C'P_\4/C3I5M$_A#]
MKF^^$?A6W\6_'2WMO GQ&^,NF_#!O@U)J,?A#X>Z;HMI9^!]9\.^+KZ[ATTZ
MEI'A>_GTR^T>VU*:5Y8_T%\#?ML_\%-+RZ^$3^)/V:+Z]TC7/BWJV@^)GL/@
M]\2-+U[Q%\/[[_A"YO#>KV=KKEGHN@>'([&VUKQ1'XBOM4U[2VTN;PY<ZG:Q
M^)-%TZ>;4[EK^VE_P4S@\#?#3Q7J_P"SO92:EK7QGCT'QWX/T3X1?%R?QCHG
MAVXTGPS?WGA&ST_5M+TGP]=R^']:U#Q)H">+O^$IM-'UVPTFVU2S\0?;K34-
M.N]%4Q--SY88*,JM55)3CC<.Y.JI5)2:;C-1<Y*;E90C>HX1Y8R<8Y.&%FH<
MT\;*-.DZ<82P==15-JG%)J+AS<D7!1NYR_=J<N:45*7R%XG@\7:SJ7[0VGV_
MQ*T&7XA?%3P-XJB\$?M<7'Q!_:-T[Q!X'M/$'P2\)^!].^"]A\,=*\"0V4EK
MI/CK0-<F/C*ZF^Q6F@Z^GB_3[$>+FDBA] _99^&O@G6_C/\ LL:Q\1_&.HZ9
MX3\#>)/CGXAMO@;+X]^-.N6OA7XB^/7^#=I\+4T5M)\'>'O#.JZ'!J?@7QAX
MMNM(U;43H7AG6/$Y:.&\^WW2VWZ<?M'_ !!_;3\+_$GQQI_[/_A&[U+29K?3
MKC2-9\2>#-<\:^$H[;P]\!OC+XZO+#1M/TF_T5H-5\3?$GPQX"\!-=C4)T75
M/$^GVWV2:ZN;:)_G[]M3Q[_P4(N[[X,O\"CX_P#!:>//V??!.L>)?#?@KX72
M>*I= ^,\_P <?@<_BZQU;5[FVO)]!AT#X;ZYXUN+W2-4: :AX;\/^*;.&==1
MG%U98PQ%2M"%*+PU%8BG*U1XB"E34</R/F2I2=.].;45'D491J<BIN<U4VGA
MJ=&4ZDEB:SH5(MP6'FXU.;$*:Y6ZB52U2"<G+FE*,J?.ZBIP=/\ :ZBOR-^%
M/[27_!0#6_VBOA=\-_B-\$-&\._#BXMM3T[QIXJN_!7Q T\^*X=-\3_$_1-0
M\<:'JEAINO:#X.DLK+PM\/-4L/"_BO5-,M]8L/'SW5IJ5RITU(X/ ?Q9_:;T
MS]I+3O!?C.S^/6H^%?AY\:/VOO&/Q+D@^%OB;4O".K? _6K&V7]FG3/#OB#3
M/"DECXTDMKS4HTT'0O"-]J'B&WFTK6AK43II=P3XSP%1<R=7#MQH^VM"M&IS
M1;J123BTE)RA%<K;=ZM.Z5Y<OL+'TVHM4L0E*M[&\Z4H<LDJ<FVI)MQ2G)\R
M25J51IM*+E^O-%?C5^RK\0OVC] _:^^-NF?%'3OVD/'7PRU[4?&!T[Q!XD\$
M_$/1M"^'E_J'QA71OA[X5N/!-YH^K^$+^P;PEJ=O<:!\1?A!XFNM 7X>:'<>
M)OBCINC:E/-=6G[*UCB<.\/.,'.%12IPJ*<'>/OQ4G'XI-2BW9IV?5*S3>V'
MQ"Q$)34)TW&I.FX37O7A)QYK\L4XR2NG&ZW3=TTBBBBN<Z HHHH **H:CJNF
M:1;_ &O5=0LM,M<LOVB_NH+2$LD,MPR+).\:,ZP03S%%);RH99,;8V(^;/C3
M^U;X&^"/@/P=X\\2:5J[V/Q&\=V7P^\"1WM[X?\ ">G:KJNHZ'X@\2:?J.O>
M*O&>KZ#X4\"Z#J6D>%M7?2M4\9:QHT6J:G)H6@62RZ[XET73KO54*SHO$>SF
MJ$9QINJXM4W4DI-4XRERJ<[1E*4:?M'"*YIJG%IRP>*PZQ,<'[:F\5*E.LL.
MI*5548.$959PCS2I4^:<(1G5]E&I.7)2=62DH?45%> >&OVG/@[KW@S_ (33
M5/%-KX'@LK6SF\3:'XYDM] \0>"KR\\&2?$,:5XKL9)YH],OHO!,,WB@XN)K
M6?0475[6YGT^6&X>'2_VL/V<=:/A5=+^+_@Z\?QG?ZIIF@Q1WLRS/>Z-?II6
MH1:M#);I+X;6+4Y8-/AG\2)I-O>WEU96UC+<S7MHDV1N?0M%?+4?[:7[-#:>
MVO3?%CPQ:^%9?[)&D^*+BZECTK73JC>*#)<:2I@^VW6D:5:^$=8U/5O$:VH\
M.66CP2:Q-JJ:;!<747LO@'XJ_#SXI)XDE^'GBS2_%UMX1\2:IX0\07NC/-<Z
M?8^)=%NIK'5](74/)6RO;G3+VWGL[TZ?<745M=PRVTLBS1L@ /'/B)^S[+KO
M[0WPT_:0\(+X3L?&_P //A?\9O 4LNMV5\USXC?Q]!X)G\)6%]JECNNK;PQH
M>L>%+F\U6SMU\Z8WZSVB&Y1G/S[\(?V,OB/\.OBW^U+\0?\ A+?!OAW2?C]H
M7BXQ:9X.OOB#?W.I?$/QC,]S+\2/$X\7ZMJ:>']8T&$6^@6%IX,NXM/O]*MK
M>X:VTM[2ULH_8?CO^W=^S=^S]X<\;ZYXK\;IK6H> ?$/@?PEKGA7PC97FO\
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M? :E_P $C_CYXEU?X@ZQXJ_:%\%:@_B_4_B?J.GZ;;:%XM30-)O/'7P[\<>
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M\T1-=:9>0WUG+OADBE79/ @D19 EQ;M-:7"RVMQ/#)XE^U'X9\!>(/ 6D/\
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M))HEAH7ACXD>!/"^I?!W0?&FJ? WQD?$/C'4?[9^(OB#Q3\*M=\-1_$#PO\
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M'[/5?"&G^(/$>N^*%^(>KV_Q/^Q:IIR^&KNZ^'5BGBC4Y;?4SINH?JA7Y/\
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M;^+_  )H_CGXDWFF>(]"TUM%TF/X66M]>:?<C6Q)-K_B!-,\+V%NFM:BT=J
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M,T49E0'(24H#(H/<*V0#W J6BB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^"?[6UG7[ZWU> 6<ANK2&*]\9MH'[STU$2-52-51$4*B(H554# 554 *H'
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MI\/A[^TOZ *9Y<?F>;L3S=AC\S:OF>66#%-^-VPL Q7.W< <9H _!OPWX_\
M^"G^I>(/%=KXJ\#?'S0OAD-6T>YBO_#_ (=^#>H?%VSUW4/"?Q=AM[/PT=8U
MJW\(ZUX1L/B-HWPL/BG=I^F:+!I&IW*6DDGA2_O/$+_7/[%&K?MW:E\3OB9_
MPU8OV+PO#I>K16>D+X*TW2M'L_&,/C[5H] N/!'C"Q\:ZLNO>&+SX7G09+VU
MMO#=O;KK8N+N\U.RUE]1T&V_2ZB@#\H?VE=?_P""C6G_ +1L'A3X#:0+KX(:
MSJ?P]BG\8R:+X?ODT+0OBG8ZY\//&=_%+=7D=Z^K_ 3Q)I.@_&&/3Y;:&V\0
M>'/$&H:7+=:C);V^GCXRO_A-^WU'\9O'7BW13^T!X<N]&\-Z_P#$#X:KI5WI
M%]\,_P"U[#X*^)?"VE>#M+\/:C+J&FZ/<^(/B38:;>^)/#TEK;W&NVUQ9ZK]
MH0:M)J2_T5T4 ?+?QSO?CQ=?LI:]J?PT>^T+X\S> /#VHPPZ1X:M/$>H6GB)
MX])N?%.G:=X>N]<T5)[LV[:Q96B6VL)?V<QBN--2_OH+>SN?QK^,7B'_ (*I
M_$;P1HGA#_A3WQATBW\1_#^R\*^.;*2?P%JL.JZ+K7A'Q#-<^*8=3\+7NC7W
MA;QG!XE70K9[&=;WQ1IEW 8[RPM=&N)-0F_HXHH _!1-;_X*OV_@[XHG5[?Q
M'8ZQH\NFV>G^'_"7PUT6_=I[7QK<VVB0_#CQ3-\1W;4]#U#X<3:.-=U-/"]S
M/I^MQ'4]=LHKI?$&A0?JUX_U+X\2?LO7FJ>#-'N]/^/\_P .-!NCHK'PIJNL
MZ9XJN+72V\56NGB6ZL/ ^I^)=-@DUG^Q(I;RV\+WVO6]E%)-'I4K,/I&B@#\
MD/V4_ W[2OB#]L6_^,_QJTKXL6?P[TO]GCQ5X&^#K_$:?1['54T+6/C'9ZWI
MK_$OPMH$USH6F_&6YTJQN8[Z^TPV]S)X%M/"\6K1V^J3ZCI]MB?M"_#7Q_J7
M_!2WX%>-=+^%OQ7\>^$KCX=^-O#GB/4+G5M:L/ACX=\)76C:1%K^K^%/$?A?
MQKH\>B:^\I.DZS\//&OAG4[3QG?WFCZ[H-XM]91W.@_L510!\:?L+?!G6/@_
M\$!-XMT[6-$\>_$[Q;XG^)_C/PUJNO>(]:MO!U[XCU%X]#\%:'#XCUWQ#<:-
MI'A/PG9:#HJ:;:ZA) U]:WU^[2W%[-(WV7110 4444 %?!W[9G[;$'[)NI>!
M-%/PB\5_$N^\<>%O&OBRTO-!N](@L-'M_ _C?X-^#+VQO;>ZG_M2YOM6F^,.
MG'2O[/M)HQ=V<=M=%(+R:[L?O&O!?C1^S/\ !W]H#4_ NL?%'PS-KNH_#FZU
M6X\+W%OJ^JZ48(=<N?#]_JVFWR:;=VT>IZ3?:IX3\*ZM-I]\DT']I^'-'O$5
M9+12P!\U)_P4X_9&.N6F@7^O^)M,\00)?6_B72]0\&WQU3P!KL-_XJTJ'PKX
MML[-KR[MM>U?4_!^OV>GQZ)%K>FS&.RN[K4[;3]9TB\ON5^(?[?W[('B.PT[
MX>_%;PG\2XK;XB_#^T^(6D^%]?\ AOJGV_Q9HUAX;TCXJZ9IFFV&B7]UJ^H:
MM)X>_LK6[.WM$;39]2B?PF^HGQ=:7WAR#Z!_X8;_ &;8_$>I>*;+P5J.DZIK
MX\3#Q6NB^+_%NCZ;XT;Q1?\ B#4[I_&6DZ=K-MIWB9M.O?%7B*31/[6MKE=,
M35I[>%6MHK2&W\W^*/\ P37_ &8_B*?$FKVGA27PMXV\0>&=!\*+XNTW5-::
MZTW3M$\%Z%\+C=V=HNJ6T*:W>_"GP_8?#YM;#KJ%IHT,4]A-;:@DEU, 4;C]
MI#]FGX@^-;IK71/$5O\ '2QT_4?@=X:\+^,;;7_#&I:7X@\::[JFA:QX8M[7
M3]6ELM"O;76-'TQ_&?C+0(FU72?#>M>'KBSUNYL=4M[9NHL?VP_@#\)_@-\"
MO&5UH>O^#/ /C#X9:OXAT+P_X?\ #S:Q9_#CP=\+?!T6L^,K;Q#+I<TEG80>
M![.!-!-C9S7VL:QK*PZ3H.F:KJ$C0+9TW]ASX;^&/B9\,_B/X+^QZ)>?!SPG
M\8+7P"^I:;<>)O$C_$7XUW-E/XQ\?^,O&>MZK=:[XN%P--L9!H6HR^3]N@@O
M(;VW%E9V\/J&F_LK_!Z+X7> ?A-XCT!O&?AKP!\.==^&-FWB"YF-WJ_A_P 6
M^'K?PYXQEUF33WLA<:EXHM(#<ZC?QB*[CU":2_M)H+LB< 'A.B_\%'_V;/%&
MH^%='T;_ (39?$WB^W\8"SL=7\#WU@-(NO!DZ6>H6NL:@9);2^W7-S8LO_"'
MW/BK[-87B:IJ'V'3H;RZMJVG_P#!1#X2>(;ZWT7PGX+\?>._$^E^*_A3X5\4
MQZ#X?M[?3/#\WQ,ET1;G6K:_UJ]L[NZL/#L>N6ETUE]AM]8\1)/!_P (U9ZM
M!]LN[/T*_P#V"?V;=;@\!VWBCPYXL\9P_#O59M=T6/QI\2?'WBN*]UK[?;ZM
MI^K:[!KGB&]M]5U'0-7LK#4_#UY+$D^CW5C;K9NEKYUO-#=_\$_?V6K[4=:U
M:\\!ZE<ZCK6A>%/# O)_&7B^2ZT3PYX0O=%U&PT+PS<OK)N/#VCWUYX?TJ;6
M--TN6WLM0-NZM!&MU="8 XH_\%+_ -FT:;K6I>3\377PUJFOV7B.TM_ 5[>W
MF@:7X7\->'?&6O\ BC6%L;RY@L-"TKPKXHTK5[Z*XN$\06DC7&A7&A1>)X&T
M,]9JO[7^GVGPMTOXG6WP9^(FJ66K_M!O\#M*\):3IFF>(/%?B",>*M2\,6/C
M;0K#1;V]TYM*U6+3QJ]H-7U/2H[*PD<ZK>60AWNSP5_P3O\ V3_A_P"'M;\*
M^&OAY=VWA_Q!X1O? NI:7=>*_$^H6G_"*WWA?0_!+Z190WFJ31Z9;P^$/#/A
M[P]!_9RVS"QT>TEE::_-S>3^AZU^R-\$M=^'U]\,KG1_$=GX6NOB3'\7+)-&
M\;>+-%U7P_X^AO(]0M];\-ZWIFKVVJ:,EO?1O<Q:9:W(TH27%T&LFCN)$(!\
M[W?_  5)_9(MM&E\3V=[X\UCPQ-K.FZ)IWB/2/A[JD^F>(=7F^$_AWXYZS::
M,9FMKV_N_!_PP\4Z)XE\06SVD5Y))<_V'X;@\0>(XVTD=3XB_P""B/[,?A?4
M?'>F:A+XL-QX!T?0=?NGB\(K!;ZUI/B/Q':^%M/O]*FU&]L%TZU;7+N&#[7X
MO_X1:UNK=H]2TV>_TZXM+NX[J7]A+]F-/#%MX/T3P%>>#M#L?%-KXNTV/P-X
MN\7>#K[2]3@^&WA;X/WD&FZOX?UNPU6STW6OAGX.T/PAK=C#>+'J%A#-<N4U
M29K\<VW_  3I_92CU/QWK&F^"=?T+4?B(OB=?$5QX?\ B#XYT</_ ,)IXG/C
M3Q8;>"RUZ*VSXA\5RWVN:L+N&\6]NM3OX)E:PE2SB .G\/?M=> -0^'OQ,^*
MNM>#?&OA+P?X'\<^%O ^BW&HZ';SZ]\3-7\?6'@$^";3PGX7LKB3Q!'KWBGQ
M+\1_#_@FR\-^(+#2=43Q-<I:7(CB>6:#A/&W_!0_]G;X=>)-%\)_$/2OBAX.
M\1:OX=U[Q!:Z7XB^&>KV>HP7?AKPCXN\=:IX;%@3)J%YKT?A?P)XCU&"?1;7
M4_#ES):66G0^(6U/5M(LKWU_2/V0O@!H'P\\6?"?1O!']F_#CQ?:>";6\\(6
MFM:Y%I6D3?#K2=!T?P7JOA51J'VCPMKN@0^%O#-]8:WHD]GJ46M:!I.MBY_M
M2T2ZKR]?^";_ .R%_P )#%XKF^&5Q>>(UTNUT^[UF_\ %OBN_P!1UB[M?#'B
M?P7_ ,)%KMY>:Q/<:UXFN/"?C/Q-H$^L:E+<3G3M7N4A6&39*@!HQ?MU_!*#
M^THG\/\ Q6LKGPP/$%]\3]/3X9:U<WWP@T7P]?C3;KQ/\3[72A>OH6B7DBS3
MZ?<V?]K7D^G:?J^HS6=O8Z%K4^G\KX%_;$_9=_:OU[X<>&/"FB>-O'>N+XLL
M/''A>)?"6H6L7A,^'M&T'Q5X?^)NIZU%J$&EV'A6^T3QAH\NG71U&\>_FU.Y
M\+ZEHZZ];ZEH5OZOXQ_8K_9P\>^([[Q3XH\!/?ZIK.K:WJOB=(/$?B73=-\9
MKX@6$ZCH_C/2]-U:TL/%/AW[5;PZA:Z#K4%WIMI?"::WMT2]OH[KK?A!^S/\
M)?@:]K+\/]*UVWN+'3M3T73[G7_&/BKQ9-IN@:E_PC4:^'=+/B35]333-!TR
MR\'>&=.TC2[!+:ULK+28 $DN);JXG />&BB==CQQNF -K(K+@'(&T@C /(XX
M-"PPJI18HU0J4*+&H4H<Y4J!@J<G*D8.3D<FI** (TAAC):.*.-B""4C5206
M+D$J 2"S,Q!_B)/4DTYE5QM=5=<@[6 89!!!P01D$ CT(!'-.HH P]>\-Z+X
MFT+6/#6LV7GZ-KVGWFEZI:VUS=Z;+/97T+6]TD5]I<]GJ%G*\3$)=65U;W<#
MA98)XY41UXOX6?!GX:_!;P]<>%_AOX9CT'2KW7]5\5:BUSJ6L>(-5U7Q+K<L
M<VJZ[JVO>)-0U?7-3U.\:&%'NK[49WC@M[:U@\JUMH(8_4** (?LUON#^1#O
M"L@;RDW!&W%D#;<A6+,64'!W-D<G+TCCB4)&B1H,X5%5%&>N%4 #/?BGT4 <
M3\0$\?R>'9!\-)_#EOXH-[8QQMXJ@O)])&GW$XMM1G(L98IUN]/MIVU2T7;-
M%=S6*Z?+&J7AGA^.OVO?A]K%M\//A# /"_Q-^+GPH\,_%U/%'[1_@SP!/K&J
M?$;XB>"3\/OB!:V%Q%H&@7-IXA\:0:=\6[_X=^)]2\%^&)K>\FL='6:RM;G2
M]'N='O?ONOC#]M[]JG5_V2OASX1\=Z3X/T7QBNN^/].\,:S#KGB6?PY;Z)X=
M;1M<UK6->MA9Z3K%]K-[8P:0J)I5G:!UMI[K5;F6.PTR[8=3Q=1X2&"4*,*4
M:TZ\ZD*,8XBO*2BJ<,17NYU:6'M-X>E:$*4JU:;]K.494N%8"BLPJ9E*IB:E
M>6&IX6G2JXB<\)A81E.56IA,*XQIT,1C.:G'&5U*K4KPPV&IIT*=.<*_PGX*
MM_\ @H;X"\*6/A3X#>!]:T+X>_$#5OC?XO\ A)H_Q7CTK4-=^!7@[P+J?B#Q
MA\*?AU\0!XGN+G6]*@^.VG:OX:^'^D:'?W6J:S\(X-$U"74;F*]9WBYOP9X]
M_P""N^M^%=8U"Z75!J.F?"SXG:[H,>M?!WP/X9OM?\;6&K_LR:;IFAZK8ZOI
MFDW?]J:+9ZU^TGJ/@.TM-#\,V7C6;P]H+7C>)=(@L;_7?>K[_@H=\6/$/B+6
MO 7PO^!/A&Z\<>#=9USPSXY/Q$^(OB3PIX4T?Q#:> _B/\8?#=KIVJZ3\-_$
M6I:K:>+/@YX(T/QYIER=(M)OL/CWP^6M?L\=S<#R+4O^"N'C:_UG6M'\#_ 3
MPO<W5QK7@_P/X2M/&WQ.O?#%_;>,M?UWP5H-[K7C6RT_P;K][9_#.XN/&EG<
M^%/$OANSU_4];L&TZ]N]&TR+5K8+RG<+X[^*7_!2ZULO$\GPPT[XSZU=S^$_
M%.L?""/QG\#?A+8+XCT6P\(?&&X?5_BM'9V.F-X(^)-KXP@^&$/@;P&L^CWG
MB?19=*_M;P9-JEWXRL]+Z'Q]?_\ !4?P1X:\47?@?QIXC^)NHVWB:'287\3?
M"GX5:=>Z=\/K+PC\"?%&M^./#VG>#?!D<WB7QP-=U[XO^%=*\.G3K[3M7M-"
M-II_A^7Q)865WJ)J7_!3KX@0:\=*F^&GPS5Y/$6KV>E>'] ^-"/XVTR3POXQ
M\8^ K[P]\8M#\1?#RUMOAK<^(-<\*OJ.CR-J$V/#]P+V\O\ 3I;#4(%Y+0_^
M"J7Q%U*;PIXJU;P!X*/AQ_AEXI\1^*?AQX(\2:SJWQ(N/&W@[QL^F:EH_A0Z
MYX0LK3Q+I;:!)IT,J:=%&YU?40D>K6[6KP2 'KO[.7Q!_P""AEQ\;?@[I7QQ
MTOQ/K7P\\4?#ZYO/&OE?#/POX!T7PQJ%O=?$0Z;XGUW6H]#U>XN]9UG3[/X?
M1:EX#'B+X=>(] U75'NX?!FK:;)K-EX;_7"OA7P[^UKK]W^S#\7_ (]7FF_!
M_P =ZU\';'7?$6N:+\!_B=JWQ+\'WWASP_H6G>--0L-/\83>"M"ENO&EKX-N
M[B:?0[71[JQ&NQVE@-5^RWAO(/S_ /'_ /P5F^*.O_ CX]_$?X0_"CPUX?UC
MX.6_BO38-7\7^)-2U+PS>^(D\'>+_BWX O\ [-;>%(7U[PAXP^ L/P]^)]OJ
M.D:I:&TU#Q9=:!=7/V?0I[S40#<DF_X*3>#;W]L:+X>7?Q+N%T'XG_&+QK\-
M;/Q9X$\'^(]*UW0_%WQ6T>Z\,Q_#C5M3T^[OO$5EX7^$4^I:IX=\(Z<9%'B:
M ^'[NRO;J+^RYN7\9^/?^"IOBWP[I?@!?#GQ-M+KQW\/->T(>+=$\#>#O#UM
M=V_C'3OBWI^B^*/$3/X%BU#X9^-M!\WX<IJ<5YXI\#7NC7T<6II\/5M'U.>7
M[<_9!_:W^*'Q>^(.J?#3XJ>&OA^C:CX3\<_$CX=>-?AWXIO];M=?\'>$OC%K
MGPQN8]?TR\\.Z38Z;)+-%I5YX8O]#U?7H=<T/?J&JKH^H2+9R>$^'_\ @IC\
M6?B/XJUOP/\ #+X"^!V\2ZG\4;+X>^ 8_B%\4-7\+6^E1_\ "4>)?">HR?%Z
MRTCP-XE\0>%-=:]\,WNH:1I/AW1_$UK=V"7$5QJ=K?6KP. <A\+-0_X*87GA
M_1-3NO&?Q;L-*T^W$&F^&/&7P8^$ECK=_IGAGQ!\!]+TR#Q'+?>&U\2V]_XJ
MT&^^+=SK=U/>IJ)%K-?Z?)87%C9,>>\'^,_^"O7B;55TWQC=:IX*5?$>OV_B
MVZ\*_"+P!>V'AO6-(^'OQ UBV\.>!]9\8>'EA\8_#74O%J^#-,T[QDNEZU>7
M<D=K90^,);BZUB,=_;_\%3/%6IP^.M?T?PC^S[>^$?"OPP^'VN1,GQSUV3QA
M8_&'XBR:$NF_![7_  RGPV"2W^CV>I76M^)-7\/:GJMOHFG77A>QOH8=<U^3
M3=.X:U_X*_ZEH_PVU_XQ^,? WA+1]#NO@/\ $GXE^'_"FN^-HO#$.G^._A%\
M)/&'CB\\ 1>)]0T,3:Q/\1_$GALZ+H*W.F66MZ9:J\T&AZI>)<6$8!]]_L11
M_'1-)^.UQ\?8/&MMXGUOXUQ^*- M_%=E;6NE6GAC7_A%\*)I--\%-:;H1X<T
MSQ?!XML38F5Y].U2"_BG^>7S9O9?VE[SXNV7P@UN3X&2WMM\1Y]<\#V&F7VF
MZ)H_B*^TW1]1\;^'K'Q;JEKH^OPW&D7DNF^$[C6KU!?0311&#S_*D>-4;\R]
M)_X*B^/=#\3?##P5XR\%?"+Q)X@\6?$7QUX7\:6W@?X@^(!J?@O3IOBCXQ\$
M_"^SN=.U'P<EG:>(Y[/0]-/B>QUK4M/"BZ@O-.>9[ZWM*PO$?_!4;X\^![#2
MY/BC^S_\/M!3Q$N@VVF?\*R^,6L>,/$,6LZ[X&^'OQ8L=/\ L/B3X1Z-ID\*
M>#_&%WX=U&2*2XNI?&%C%%HUM=:+?Q:Y:@%#Q5\2?^"L6ES?'XVD'B%[3P9X
MIFMO"D>D?!7PQK=Q=^'QX]LXO"4G@2^MO#E\?%L/BCX?M=W'C/6-*T#XI7O@
MS4F@>7PSI4]K<Z?/GV?B'_@IE;^)8[&/X>^,O#FD?$WQ9XTM?$GA/0O#/@B*
M6.ZU?P9H,:^-M8^+Z^'?$&DV TN\%W]GMA9?"NTUJ[@5-$UF/48I-"@G\4_\
M%;_B'X5\_6O^%<?"37[;Q+8^&+WP?X?T3XLW%WIW@RUN$^,GB+5M#^-7BQ_!
M]L_@/XR:KX>^'ECH.C_#=M.U#2X_$TK/)XD.GFZN8_H_]OG]LCXT? 7X6? +
MQ_\ "6P^'/A__A;&F>/KSQ%;_%/4+A+W1[K3_@1XH^)'A+0/#DFFVU[H^K>*
MY_$FD6^F)IES<1VVN21M96$I^TF>$ ^.-'^)_P#P55M-)\&^ _!WA7XXZ3#%
MX%\$^&+[Q3X[^&/P\UO5=*FM],^"UAJOCQWO? UOI;>)[^:?XJ:C-I.K^,/&
M2VTL<HUKPSHKP:5:0^X:SXY_X*C:?)\2]&TZQ\6ZWXCTVV^+NF_L]RVGPS^%
MMMX5^((\+?$GX_Z-I'B?X\>(K^R@LO ]W/X$TOX&ZS\/M/\ "DFB+XXN]8GG
MD\/ZC9SZ[_94EG_P5*^)VG?$OP3\&/%'P!\,S^/HO&,7A3XE7OAKXA:K)X4U
M07_B_P (^%[&7X,ZAKW@S1+KQ;K6FV'C"T\3^+- \0VGAR72+"RNK6SN=2>Y
ML+B?W;]M/]MSQC^RM\1_#_A_1?"NC^++'Q?X)T8:/%XAO+CPYX3T#Q;JGC+4
MK%M<\=>,[+3]8O=#\/OH>D7.F:9!!I-V^H>(;NRAS#'YTJ 'N'[$GB#]HSQ/
M\(=5UC]I@W[^,9_B#XE7PK-J_@JW^'VM3_#V.UT<:%)K'AB*RTBYL[U-3.NP
M+-J6@>'[^[M(;6>32_(>WOKWMOVK?$_Q<\'? [Q1X@^!^@:YXD^(=IJG@R*Q
MT_PU9Z;J.MP:'?>-- L?%^KV&FZGH7BF/49-#\)W.M:N]C9>%O$VL745E)#H
MN@:KJK6EG+^9NH?\%?=0'Q-7P+I?P?\ "R66K?#KP[J]EJ>N?$>_L1X"^(.K
MW7P"M-9T_P"+]_9^#K_0O#OP]\$Q?'_1O$/B_P ::'J6N2Z3X1\-:[X@;3)(
M?+BC\R\!?\%8/CUJ?B+4/!*?#WX+_$'Q>FD_$CQ9-K6E_%N^L/A.OAWX:W7C
MO5=5B\%:]H7PQUW6/$<=_P"'/"AM_#^MZDL-KJ]Z]E<7\'A^%[XH =_HWQ _
MX*R:AX#T+Q+;Z5XD'C2.[\*^&+OP-XF^&OPPTZRU.VU?P]\3)?$_CK5-332]
M$N;74M"OK;P+-I-O:/H&@2:D;2QUC0Q!J&IV<?W3^PS9?$P>%OB]X@^)DOQ=
MNKKQC\7[KQ)X=OOC;X3T?P%XWN]!N/ G@:RD,O@GP^(M%\-:=;Z]8ZU:65C8
MV=@)A!)>S6HEN6EE\^_9C_;PUG]HCXW6_P /F\#>!_#/A3Q'X#^*?C?PW;1?
M$B75OC3X9C^%OB[X7^$9[+XO?# >&;.T\$?\);)\1GUCPK<VOB?64O-+TI79
M=]R_V;YG\?\ _!1'XQV'Q4_:$T70/"^M:=\*[X^*_AQ^R]X]U#PCI6G>'?%?
MQ@^$&I>&-*\;Z-X?\=:O>77AWQ%J7CRXNOBL_A1]9M5\-Z3#\)[*>>6XEUR[
ML) #]&?VR['XD:C^SWXHM/A+X=;Q7X[D\7?!R33=#2PBU)KC2[?XT_#VY\5W
M7V.:YM(Y!I7A&+7=7:1KA#;+8FY59&A$3^;_ +#?BW]J;Q'H7Q*T[]J'3/$4
MFK^&_%5EI_A7QGKOA;0? 4/BVS:TN5UF/2O!.DZ!I-SH]IHE];01&^?6/'>A
MZV;]+[PSXZUJQ$UOI_YW2_MG_MA'XS^#O@C+IOQ.TK5];_:&^)_PZU7X<O8_
MLZ:C^TEH_A?P=^S)'\4-#U^_UJWL1\%+_P"'GBKQ:1K7A'Q+IFBVNLZOX<&H
MZ/=2PW^F72VOZ'_L:?%WX]>/M>^-/@+]H8^%(_'WP@@^!VC:Y9^$+.&#3++Q
M7XL^#^A>*_'$,5S!<W<=[;GQ->7CV1CN)X+:W(M[:>>!(Y& /NRBBB@ HHK@
M_B%XE\4^&-'M+OPEX*O?'&IWVJV.D#3[*]M+(::NI2?9H];U![MX]VC:9</%
M<:RULSW<.G+//;0W$L:POOAL/4Q=>EAJ3I*I6GR0=:M1P]).TI7J5\14I4:4
M5&$FY5*D(Z6NY2A&?+C<91R_"8C&XA5W1PU-U*BPV&Q.,KN*E"-J6%PE&OB:
M\W*I"*IT:-2;YN9J,(5)TNHU30]%UQ+6/6M(TO6(["]M]2L8]4T^TU!+/4;-
M_,M+^U6[AF6WO;60"2WNH0D\#C=%(K<T#0]%#RR#1]+$D\CS3N-/M \TLDTM
MS)+*WD[I))+B>>=W<EFFFEE8EY'9OSP_;I\<_&GX9^%O@G'X)^,6F^"9M8\7
M^)!\1&N+O0_ U]XYL].\&ZIK5KX?\&_%+QIX)\=_#CX::I8ZM;1:KI-CX\L]
M,TSQI;:<_A1->AO+Q[>_\(\.?\%!/VA-3M-&\#Z+\*-(U;XBCX7_ +/GQ5N-
M1^(VF>)O!<TOP_\ VC-:^%7P\^'^M^+- \-V>KV>@^.;7X@:W\5)/B)X+T.\
MO;;PUH/@S2]0M)Q'K1@M,IQ4)SC&<:BC*454AS*,U%M<\>91ERRM>/-&+<7%
MN,6^5;TIRJ4Z<Y4YT93A&<J51P=2DY14G3FX2G#GA?EFH3G%34DIR4>:7[!6
MGAWP_I\EY+8:%HUE+J&H7&KW\EIIEE;27VJW<1@NM3O'A@1KG4+F!FAN+V8O
M<S1$QR2LA*UJQQQPQI%$B111(L<<<:JD<<:*%1$10%1$4!550%50   *_">7
M_@J?^T@GB>\\-Q_LQ^&&7PUX?\>Z=K>HW?BOQ%ITGBGQOX.U3X^^'&UKX?Z%
M=:"NL:MX(AUKX(65[J<(BN+FST3QW9+<:Y:ZK8Z;9^(SXV_\%'_VGOAMXT@^
M&VJ?#_X8:)XB7Q]K'P]O](\.W_BV_P#B+=R^#5\!:WJ/Q)\,:!K?A?5-.N/A
M%XQT_P 7W&E>&]6O[*76)HM'U"^C6'4#-9:/)9^[=%?SK?$?_@IO^U=?Z?\
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M+6\TZVLM530(]<'PI^%_BFQUSQB)H/$ T2UM?#-YJ<UOJ<-E-]4_!_1_V/\
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M+-8T#Q1IGQ O[2SL_P#A)]!U6UG_ -"GMH["U,6F7$%[H<X22&_TR\MII87
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MV\$4]TR/=31Q1I+<O&@CC:>15#S-'&!&C2%BB (I"@"IZ* "BBB@ HHHH \
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M1 ''6G_!3K]FJ^UVZTY? ?QICU/PUX2UOQSXPNKKX600Q_#KX76]GX-UV_\
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MC^$M'\"Z;X(%[JS6-KX3T""TM=(T9+]M0;67ALH+&TC2>74GNW$*F:XD9G+
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M#7=*LK/58UNQO:9\#OA3H_P3M_V<]/\ !FGP_!2V^'#_  BB\ R7.IW6F?\
M"N)?#S^%9/"TEY=WT^KSV<GA^233)+B?49-0>%VD:\,Y\V@#Y<N?^"B'P)M-
M&\-2KX5^+=]K'B/5=?\ #NC^!M+^'WVGQ0?$?@SQEX;\":UH0T\ZK%I\5[IO
MB;Q)IMM$1J(M6A@N[N*Y$5KN;F]%_P""DO[/GBS23=:3\.?CAJFI?\(Y;^/;
M?P?_ ,*JA/B>Y^'L&@W'BG4/B+#83:T+&/PKX;N(3HVK7ESJ%OJ%MXKN;33+
M+3KR:[@GD]E\,_L)?LJ^$=?M/%&B?"YTUW3WTN:PO]4\=_$KQ";*ZTDZ'+%?
M6EMXA\8ZI:6^I:C>>&]&U;Q+J<-NE_XNUVT;7_%5SK.M7=[?W"ZG^PE^REJV
MG6&EW'PGAM+?3+'0=*LKC1/&'Q!\.:K#HGATZG]A\/-KGA[Q9IFM3>&[N+6-
M1M?$7AR?4)=#\76-PNG^*]/UJR@MK>$ ] ^ /[0?@']H_P ,ZKXW^&-CXG?P
M5:ZU)I6B^+-;T(:+HOCFVCM;>YA\1^#9)+F6ZU;PW=6UQ UEJ=U:6#3JR[+<
M*,CWBN-\"_#WP5\,M#;PUX!\.Z?X6\/MJ-_JJ:-I2RQ:=;WFI3>?=FSM7DDB
ML;9G"K!86:P6%G"D=O9VUO;QI$O94 %%%% !7Q9^UC^RFO[2VI>&[6\U6:P\
M.:I\(?VAOV?_ !V()K:*[L? _P ?-)\!WVH^)M)AN+.YCU/6=)UWX3^&M&@T
MF>:ULIM,\4:Q?W#S2:9;02?:=?$7[7/PN^.WC[Q!\)=7^$,9UO3_  S_ ,)A
M#J'AV3XW^//@9IVB^-]8D\*2^ /BOX@OO -AJ%_\1O#WP^32/$]KJ7PPU&)M
M.\0+XHCG>VO6M-D(!YQXM_X):_LP>,OBM%\0-5\+:3'X2E\3Z7XIUCX/V7AS
M1K'P#KE]I7P/^+7P-B^VVUE%;7,<K:+\6M0UM;ZV>*]MM8T/26MIHE5V&G8?
M\$T/V=[3POX'COM!TCQ-\6_A9\*_$7P:^&7QY\4^&M+U'XC>$_!&K1OIFAJE
M]8OI7VSQ#X.\-%- T#Q$LUGJ")]HU"Y,M[?7CS?)?@?]C']M_7=,^(=I\5_B
M-X@TB+6-<\0>-O"^E^$OVEOBY:Q6_C2/X=_&CP[X7CN=9T[5(]<_X16V\9:W
M\+O%+:+:WVCZ#=/I(;6/"-RVC2VNKUO$_P"RM_P4-U/2=4#>*9=3\2-XC\/>
M(/B'X@MOVHOB;HX^/7AV:?2[NT^'7A;PKIUAHGASX"P_#>!=0T[4/$OAB6PO
M/'\UM;RW2W%KJEZ+4 ^S_$/_  3G^!GB'5?$?B.6W%KXMU[XD^$?B'!XPCT3
M19/$^C+X.^ 7AK]G[3O#.GZQ);_:QHTOASPY_;$X9Q(=5U345 ,$H%<GX0_X
M)K_#?3_AI\.O@_X[F^'GB_X>_#7QI\/_ !E9:%H?P8T7P6OC.?X?>"_%G@BP
MM?B8W_"2^)+7Q?)>:?XJEOI[Y;+29(=3M!/%#Y=R\4:>!/V8OVD_#7P2_:0T
MS4OB_P"*=6^.WQ&\/^$]!^'?C37/BGXOUJTTC2O#WP1^%WAF[L+6T9(- \#:
MMJWQ!T7XAW-YXM\+^'%UZ>Y\0+XONKZ[OGAL[3YAU']F3_@H+=_$KX4ZMX06
M'X9_#+PJ%,_AEOVO?B_\1?%6EZ=K4'CFS\8:3XB\5>*+0VGBO41=:KX?UKPI
M?77A_P 0P6$1>Q-SI<NB:<9 #Z[\%?L$-X$U/X2:1IWQEUG6?@]\$M"\2>&?
MAS\+O$GA=9;CPCIOB/4=?(UKPWXW\.^)O#.JZ?\ $/0/"NO'P%X8^(U]8:MX
MET+PW9"YL)XO$FK>(M>UCUGX2_LXGX;?';Q1\1+;4/$4_AK3_@A\.?@5X(_X
M2SQ[XG^)OBK6]%\,^+?'?Q#U;Q#XL\7^.[W6_&U]K":]X[N=#MGUOQ-KLESI
MFFP7/G6^4@7\T? _[(7_  45T_4_A!%KWQ-U>U\)^&];UN&6Q@^/_C._\3^#
MII?B!H/B&P^(7BK5;^?5;3XJ-=^"K6^\$S^!]3&H:+$L4NK06.GW6MW:6OW9
M^P7\(/VCO@[X?^+ND?M">(KCQ"NM?$AM7^'DVI_$?Q%\2]<C\.'1K*VU.XU7
M5]>DD6S;5M>AO=5L]/TU+"T@M;I(CH^E/%]FH \\_:0_X)C>!_VH/B]J_P 2
M?B'\6/'D>A:A%K<UEX'TF.*"VTC5=<^#6I_!B>:TU":^FL#I46DZG)KW]GGP
MXFI76M>=#?:]<Z1<?V=%O^+/^"?$/CV+Q3#XO^,E]-'\2/#>D:#\2O[ ^%/P
MQT)]0_X13Q%X[\3^#D\"M-I&K#P!HVFZCX]OH=<L0OB/6?$UCIMBMSXFLM0N
MM;U+5OT<HH _,'5?^":6CZU=:YJ]Y\8]9MM>^(NLZ#J_QBFT;P+X;TC0/%[>
M%?$GP)UOP]!X2\,6]TUC\-EBLOV>O ^D:N-,FU:VU=K[Q1K)M+36-7BNK*E;
M_P#!*_X6Z7X<TWPWH?C6]LK2T^$'PN^"]^FH>!/!&O6&L^&/AC\+_'WPRCNM
M0T;4["33)=4\36GCI]2UZ[E@F>1M.:TMS&U\;RU_4NB@#PC]F[X'Q?L\?"30
MOA5%XPUWQQ!HM[KMY%JNO/<G[+%K>KWFJKH>BVU_J.M:CI_AK1A=FQT+2]0U
MW6[C3K"..T749+:*W@@^)?$__!*CX6>)_P"W-,G\>Z_9>%?%.HZ9XG\1:/:>
M&_#<6JW'C'PWHOC;PYX6U#3?$L44-WI?AJQT?QM<)K7A'[+=VWB"^TNQN'U&
MPLKG5M,U#]4:* .;TWPW!HGA&R\):)<?V1!IGAZ#0-+N[&UM(6TY;73UL+2\
MM;-8A9));%$N([<0_9A(@0QF/*U^>_C/_@FC\/\ Q1X3^&GP_L/'NOZ+X)\/
M?#/3/@U\5-.?2K>^UGXM?#O2/'^D_%>QAA\0VNI:/=> _%X^(NER:S<>+M*M
M]5EN+#6M<T_^S([R;3=7TK]+** /D]/V2?"MIXCT#6M/\=?$>:S\*?"KXO\
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MK)1?3ZE!ME@W+%K>G:-<7EK-;ZAIT-[I\HNAX7XS_P""AWPP^%'Q0^,_P_\
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MX!D^)_\ @HS\ O!JW=YXDTOXG:9H.D7'A5O$_B63P=!-I'A#0/'WB/Q#X4\
M^,?$J6^LS:M9>%?&FM>#_&$6A7UOI=Y=_8_#&I:IJ5AIVF3Z5=ZCZ[^S5^UO
M\&/VL-*\3ZM\(=8U'4(_"%WHD&M6NJZ>ME=0VOB;2O[:\-ZG&;>YOK.2SUK3
MEFEA@-VFJZ?/:W5CK>FZ7?0M;'Y=_:?_ &)_V=_$/BCX._$KXL?$C1?AE\(/
MA->^#+/5?"VN3Z1H6C>.KGPOKVJZQX'T#Q1XQU/5+*34]*&OZ[>SOHNL0ZP"
MCW<6CMI":EK$MU]:_ 'PK^SY\/X?&7@#X$:MHETWAS5[$^,]$TWQUJ7CB_\
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M_4+SPY=?#N]^ ?QS^)7C#XJ#P[XUL;35+WPQXZ^(&A_$;X?OX;BM]--KJR>
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M7+:?)>6]K'!!:Z5#<)I>GPQ6-I @_+QHOVM_A;^U#\-/A#XNU_X_^-[?Q/\
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M_MD^*/%EU\(_$OQ \06'A+PU\(OACXB\;:AX>\2>._#/@^Z^-3^+-/T$^%/
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M>\2WFMZ3H_AS3=#MKU_$L5GI>D1:)+XHTA+&WT^Y\7ZWI.AZ)._JOCG]@/\
M:%L]'U>+X4?$&[TNUNO$6IZYKW@NY^)GB%=.^(7A.T^+6J>*= ^%7]I>(]*\
M8Z=X0T.+PC>:?;V4\'AZ_M-/ETRX\.&"'2==O[R  _03X<_ #X7_ +.]_8^+
MK+Q-J=E;Z-\/-3^'D*^(+W18-/.BR^//%_Q:N[DI::9I\L^K07_B#6AF%RAT
MBS$CVCW,=W>S<)^T7\ ?AEKGQ!L?CG\2?B[K?@;PS!HGPT\+>+/!5[)X%L_A
MSX\@^$GQ*U3XT> [;Q3K&N^$-7\4Z5!:^+9+F?5QH'B'2;75-%MWLKVWD3S6
MD^(I/^"?/Q_B\+:[?:OKFE?$GXK?\)SX/N/ _C'X@?$_Q%XDUKP/X,L/V?O$
MOPXU Z3XCF\-:+$^L:1XUUZ+58Y+;PQH;>(;2V>_U#;J!4R5OVE_^"?7[3_Q
M*\/7^C_#;XC6-@_CFT\52?%"+Q)X]\6SV/B;5+WQ[\0M5\,DQS)J(L=.TGP=
MXHTO08K;2X+2*QLK4:?;6[P65J* /T#_ &'_ -G=?V;?@78^$;K6++Q%KWB;
MQ+XJ\?ZWJ^F:[J/B?1XHO%FMWFI>&?"_ACQ!J^EZ-JM]X)\!^#Y- \%>!X+O
M3+%=-\+Z%IFG6EK!:6\,8^OZ^*_V'_@A\4/@=\.M>T/XE3Z/I"ZKJV@3^&/A
MKX:\5Z[XY\-?#O3]#\$>&O"VLII'B?Q'9:?J=S_PG7B?1=9^(5_IHLX['1K[
MQ)-96KRL)WK[4H **** "OS:_;?UO]H_PK\6OV??%'P(7XKW%CIOP_\ VAK?
M6M)\ ?#2+XE^$_$OCN\U/X$R?#'PO\4+:XNK:+PMX;U>.R\;[/%T$VG:CI=M
M;:M'8Z_HQNIFNOTEHH _#+P_\8?^"CWAO1;+2-/^%WC6UUFS34[72_#E[\,#
MX@\(7W@V_P!$\=:[KOQ#UKQPS7FO6GQ'\+>.;72/#/A;P#'.UOX@\-/IM\G@
M[7KC7+2>WY73/BU_P4UUG5_$^N:7X!^)'AJ]@^"TUQ'KFL?"_1;Z7QCXN^&>
MG_ML:[X?T6TTK4M&T+3+>#X@^(= ^!.ER:A#X#\#>)-4T/QEI*#0?"VI:K9C
M2_WWHH _GH^*WB;_ (*32?%SX6SR>"/BUXPT?X=:YX6\5:CXG\'^![/0G\8P
MS>"/A'\1M4\(:GH6E:UX<\-:GI6E>-/%OC_X>0:7>WFF/JD/@BRMM>\0K?P:
MGK,_M7@'XO?\%(/$_A3X@76KZ5XU\.7/@^P\=Z_X1N->^#5C'KWCL2Z7\*AX
M,\/:E:1?#ZPE@&GZKXB^)1FE\*> =1U2>+PMIY@3Q:EC>)XB_:VB@#\I_@K\
M:/VD=4\2Z;>^)]$UB/QQ+^Q]\0_&GC3P%\0(K3PA%8?$3P=\5_$OA[X2ZYK6
MF66FZ9#H[_$KP]9RR7ES'9>'7/AZTL=7N/"OA^XDETRQ^"?!_P"V_P#\%)?B
M7XD\3Z3\#[.'XG^%_#/B7X?#5O&GB7X43Z4NCZ_XD^"'PH\=WG@9[/X:?#_Q
M['KOP\N_&'BCQS9P:] NAZQ%8:3IFE7'Q.TJ^LI]1\0?T?KI>F)<W]ZNGV2W
M>J100:E="VA^T:A!:QR16T%Y+LWW,,$<TR0Q3,Z1K+*$4"1\YGA?PAX3\$:9
M_8G@SPSX?\):-]IN+P:3X:T?3]#TT7=W)YMU<BQTRWM;83SO\TLHBWN0 Q(5
M0 #\=/C#\7/^"G_A'1M/N? WA6;Q/)XXM='U3Q%<K\/8XW^"%M;>/_B%I-YI
MOA5?#G@+XC:QXPO-5\.6'@274WU_P)XLDMK2^OO$%C;Z'9W(&G9_COXT_P#!
M3/0/AM)XJ;PEXTNOB#J6MW#VWA+X:_!O3->\':%I_A#X(:3XGBT]IM7\*Z]\
M2+NW^)GQ-O[[1)+N\\,Q36TFG_\ "/6M]X!F275YOV]HH _ +0_BQ_P5A\(^
M+]&\-^&?!VN_$'3M3^*7QL\0W-Q\9?#-YI.G7-MX@^->H7?@OX<R>(_!?PQ\
M16FA?#WP]\'-3TG5?!.KZGXE\"R66J7,VD:IXGU?2/#$V@VWT3\'/&G[8]Y\
M/?VKO'VIP_%.?XH/\+?@O+\/K'XF_"&Z\*Z9I'Q*CT+QA<_$?P[X#\%:#I=[
M)XGT3PQJVI6=E:^(K#1/$5]JYM].2\M?&4VF-'JGZZ44 ?@/XA^/W_!2+Q?I
M'AGPZWPD^.>@6FI^"=:\+^-;F;X7:)9/XC?7O!7QMAM?'6A>(/#?AX:GHGB#
M2?$^A?"];2/4A\'Y+1?$4$DG@'4&U0'1:FG_ !R_X*UVGAWXEVMW\./^$>@\
M/6>A:7X>CB^'_C'Q-XKL+;2/$'A_3+&]\)7S_!S6] UF\\7>$QK6I^+=5U&_
M^-46CZT("NF>$[&2ZN+#^@.B@#\S_C%\8OVO;+P%^SUK_@;P%\1M"\4>*?A'
MKWBCQGX6L_A5H?CF_/QJLG^& \(_#'XH3:=J>I6?P[\(:_:ZU\0Y_$>NZ R3
M:?<Z%;_9O%&BBP.G:Y\<_%GP)^T-X<_X)U*WQ"US]H+4OBIJ/Q_\>>-_'%M8
MZ9XJU77=6MM3^(/B63PUX0U^Y^"]UX6\;Z=X)>-?#ECX/\9^'--UF+1YXO#6
MM:[X:U?24GM5_?:B@#\EO@#>?ME:Y^W;X9\6_%?X:?%KP%\"-0_8Y\6>&M)\
M.ZKXY\+>+_A[X5\7:-\1_A/=^&=2\2ZA:7T7BC5_C/XST67Q;/KEYKVD6MW9
MZ196^E6]HCZ9KNIZE\FWVN?\%!]0\/>"/ MCX;^._B72-+LM8/B;Q+XB^&TO
M@7Q3X-\5W'A_QI%:>&?"^LV.H177COPM]F@T*\;QGK$>I7::_=0VT6HI#J,&
MEZ7_ $-T4 ?AS9>-_P!NOX?:UXVMM/\ "OQ>@TF74/&&H^'-8M/A8_Q0U+Q/
MXDT[6?B#J?@#P7K:ZE=2Q>&_AWX@DOM-T[6_$FG6]GJEII<6C65EK_ALA;Z?
MZ9^#'BC]M+7_ (?_ !;U/XT:=J@U[7/@K\1=<\*^"H_!>D:*GA#XB:?\1?C'
MX;\.>$?#VL:1%9:GX@AU3P+I'P\U>%];DNM0O9[^/6;.ZL;;5UTZU_2VB@#\
MHOV#?&?[<6HWO@BV_:/T+Q#HW@[4/ WQ5TV\\.:YX!T[0Y? =Y\+T_9[TKX8
M3)X@MV?7]6U'XC6GBSXN7^IGQ'>:L-1D\(PG28]+;2]2?5OB/Q#8?&/5K3Q-
MXR\.^'OVZ?#GP?USQ]XATO6?A3KEO\0[[XK-XCT;X8?'"/X6_'#5=2FG_MBV
MU_XF?'&_^&"+X8\'SR>%/!VC^"/A9>>+5M&U/Q'I]E_1S10!^%_AP?M8:[\1
M/B/+\/O"_P"T+HGC"+P5I?PR\>WGCF_U'0;?XF:UKU]X3?Q]\7/AC?\ BN_L
M/AOX>M_@KHMOK/@OX'V<>I:1K_C'5=5U;Q=K5T=&T>VC\6_J1^R-#X]MOV7?
MV?K3XI:;XKTCXC67PB\!V'C;3_'>H6VJ^-(?$MCX=L+357\5:C9W%U;WNOW-
MU#)=:K<).[27DTQEV2^8B_1%% !3'ECC5GDD2-%(#,[JBJ3C 9F( )R, D9R
M/45QGQ!MO'MSX<DC^&VHZ#IGBC[;8^5/XDLY[W2VT^6=;?4MZ6SI-'<VUI-)
MJ%D561)[NRALIT6WNI98OAS]M;]GGXN_$_2_V2_"7P67PW?IX4_:9F\;?%?6
M/BAI4?C+P;/X-3]G;]H'0+G6/B#X1.M^'Y_&BZCX]\1>"K/3K"REN3I/B2\T
M+74TZ+3/#\DUCTNA3CA(8AXFC*K4K3I1PD.:5>G&DH.=?$7A&%*E4]I&.&Y9
MU9UI1K-QHQHMU.*.*K3S"I@U@L1&A1PU*O/,*O)#"U:E>52-/"X3EJ3JUZ]'
MV4YXWGI8>GAH3PRC/$SQ*5']&>O2BOQ%L/@!^W-\#M$U+P!X3^*7Q_\ &OPO
M\'^+/!'@71[CP+?_  =7QK>_#&+]G[6O$VI>,?AK9_$C^TI+/5D_:EO_  YX
M2U^R\<^*KTV/PBTS6+#P[92 V>H#+MO#_P#P4V\3>*A+\4Q\8H-)L]:^"WCJ
M]C^#GBKX1>#[)+WP;XS\&3^(O VAQ:E=7\>IZ+XLT#4-=;QK'=/#97MAIFLV
M9W7T.C'4>8[3]SJ*_G8U+PA_P5HUO7-$\=VT/QDL?$7@/4?B+XG\)^'M9\8_
M"=/"=]K_ ,1/@GXRL8?"_CG1=%U6UA\8>!_!7CJUT>V\-P6\MI-I>JZGH=]9
M7=W"FJZA9_9_A&Q_;[C_ &0_#&C^/]2\87GQ3;XQG2/&^M> ;/P+8?'2U_9^
M9KZV.I>$9?%^L7WP^O/B;'K(TV8ZQK'DV3^#I;^[BT!=;M[>SE /U8HK\.)8
M_P#@J3XK^.^FZ?ID7Q?\ ?!77]*T#PUXLUCQ%=_L_7>N>'+#3?&/[.OV;QEX
M3&C76IV-KXKU;P?JOQWG\:PSZ9JL0U'2'M-,M8X;7PS+JG1>)=/_ ."FWA_P
MWXLTWP;>_$[Q3\4/"GP^\;:#\!-6UVY^!@^$WC+4!:^.X='\3?M,SJ=.\37G
MCLW6E^$)/#O_  KW2]"T-H-0LI]4LX;C5-=AT< _:6BOS"_8H\+?MV3>(;#5
M/VK_ !QXB3PWX5T;Q,/#.A6EGX1T[_A*[C5?$^O6NF0_$\Q/K^M:KJ_ASP[/
M9W6D7^BZCX?T^^5=+N-1M/MEE>6EU\;V]G_P6 \$6/P7UO5O&.H7.C67PFG\
M9?&>]\=6GP_\17FE?$6]\6?&&7XC>'-4A\#R:)I]KX7\/_#J'X17/PRN-+L?
M$MQIFKKKDMX=<N!=VLP!_0+17X3Z1)_P4U\:>'M/\:?#37?C';Z)'\'_ !=\
M1?!EE\85^ FD:IXO^-NK_#C1+[0_"OB_3?"$6H.?@V?$.JW<_@31;6]T'Q F
MKV-W9>)O$5IHL-A=7-?PDO\ P5]T6W^%LVKI?>,-5TF3XFVITZXC\#:!H6H6
MNK66G6/@>_\ C#J%]XAOM2U6Z\.:W'KNH21:!#8+J/AVXT22Q6VU:*[MR ?O
M!17X<_"KPA_P56UCP(\_Q0\?>,-&\0>$]#^(/B[PUIGAFS^&>F:KXQ\?0Z-X
M,U7PMX'\?:AXAF\46^I>";SQ-)XKTK2X= _X1EHM&:6RU'6HVL--U2\VOV5_
M O\ P4!^%/Q3^!OA[QM>_&CQK\)K37_CI8_%.W^(GBKX9ZK;Z?%XJ^)GQD\1
M>%?&(\765[=>(/%&@Z?H$GPWM?"OAH:;I^N:+!>?V<9/L"WD&E@'[645^9GP
M?U#]N.7]L_XKR^//#WC"Q_9JUCPA\8E\.Q>(]1^'5_H.C>+?"?C7X<Z5\%Y/
M \GAZ^3Q#!IWCKP5J'Q$US5(M:L+BZ2YTRT7Q#-I=Y%IUK>?,=WX%_X*K^&_
M#&H:AH/Q#^*7C+Q:?#VABWT_Q)=? ./3?[6\4^ O%.I?$![>WLM%TU%O/"?C
M+2/"6D?#^&:^^PZ<^L7Z:A+X@L+R?4-) /W/) ZD# ).>.!U/T'>@$'&"#D9
M&.X]1[5^ WQ&^&W_  4-^*GB)?B!-I'Q]\*PZ=\7D?P[X=T;QC\(?#>LO\*T
MN;HV6D>*M'T[Q+J/AW5M!@O;DW]_IUUJ%WJ-W9/)'=M?>5;6<7HOQ<\"_P#!
M0$>.?V>O%_A[0O&=CJW@/X"?$/P[I*_!OQ-X&N/#&H?%.[M/AV?A_IG[2FD_
M$/5=-@F\#3ZYINHW'C%_AG9:MJ,>D0:PNC:K:3KIT5Z ?MF64#)90"< DC&<
M[<9]<\8]>.M+7\_WQ!^ 7_!0.[^*'P_\9>%_#GB"2YTOQK;7FKRCQ=X.C\,P
MZ:?CS\(-6FENM!NM?6TGTU? &B>*;K,.FRZI'86]UY&S7[NW%QZ/X<\.?\%/
M]?\ "_B>'4O$WQ=\,7&D_#.\\86#ZQ-\ HO%NN_M(V'A+P[JFH> ]#NM*BUK
M0F_9ZU7Q[;ZE8>%$U*WTOQ,/#\^J:5J>KV4-QIVK6@!^W5%?F%\=_"/[<?C7
MXB>"=3^'_C3XA_#WPC)X1_9/T3Q=HG@2\^%,.DQ:GXY^+7CS1_VL]>W^+M*U
M[6?[?^''PBG\+ZQX1N;.Z?3K?6$T^]TK3_%-]::AI-Q\B:_)_P %?=:UWPGI
MNC:;\1_"\-Y\/M2\#_$'63?_  (N],LKBT\%:#=:!\1/!+MJ%Q'#X_OO&<FH
M6^N3:OI5Y8N8=3@M=%MM#_LZ=P#]^**_";Q?X"_X*F^!-*^,'A7X6ZIJVK:1
MJOQDN[WX9^([G4O"&H:[#\'=<^-GCS4/B%JWBBZN+^QOY/C!JVF77@K6O!-U
MHMI:^$-)^&EUK.C_ /".V7BRQ:"3[G_8<\+_ +2>@V7Q.U;]I_6_'FM>/_%\
MOPDUZ8ZS>>&U^&NGW\?P>\(Z3XNL?A1X9TC4=6U;P99#QGIVO77BS0-9U/4;
M0:]<_;= U"\L+J24@'WE1110 4444 ?GG^WIXB_:C\+R?!?5/V7]#UK6-=_M
MWQ+I_B&XL=+U/Q#H^BVNMCPSH-KK7B#PO;ZWH^D>(8-)LM5UW6+&RUQ;J".[
MTT7%I)87,8NU^?O%OQ:_;@^&$5KIOQ%^)4\.F>)?BE_PA&C^/_#O[,4&N:CI
MMCHWCSXV^&M,-GX,TOQ;?S:]/\2/!_@WP!XVN[Z-"GA\ZU/)IUDND7JG3_LW
M]J[]J;5_V;7^'EEX>^$][\6-8\=P?%'5GT^V\9Z-X)BT?P[\(_AWJOQ)\4W_
M -MUBQU!-2U*XTC2I++1=(BAMTN]1FC%YJ.G6BRW2?*DG_!3W25UF;1_%W[/
MU_IU_P##KQMX-\._%*)?B%X4UZ]\'ZG\1/B+H_PM\"ZG\-[&/2H;WXH227OB
M_1[SQ9-I<7AL>#-*OM02ZO+Z2 17@!Y)IGQY_P""G(\.7OB3X@^$+SP+K5UK
MWC&TT_P9X8^!0\?VR>(?"GP*^!_BCP/X&M=0L_%4=ZOASXJ_%_Q+\6?"=QXW
MOWEL])3PQ:Z>-:T98SJUR?%SX^?\%5= \/\ B)/"?PMT:RU;P=\0XOASJWB&
MZ\ 3ZYH/B.&?PIXY^)MA\2O UKI%Y?ZSK/@6XNK[X;_ B[FGT>*Z7Q?HVOZH
MT%C:^(XM6\/7_$/_  5)^*FMZ5J5MX-^!6@^"_%>E?"BV^)^I:7XO^)NB:V8
M=,\>_#KPS\2O@ZNG7%AIEA9ZGJ^N:7?ZOIOBWP\A#^'YH8]2L=4UJPM;AY/H
M_0O^"A<UQ\9/AG\%_%_P4O\ PAK7C+QGKOPT\5:ZOCF#Q%X;\(?$;1=7U;3?
M^$6T_4]*\*"#76O8+?0+^SO]<?P/%??\)$FFZ1%JFJZ9=V; '.?LU>.?VO/'
MW[3NCWOQTA\7>%_#VC_"KXN6>N?#G3_AMJGA;X9Z)JM]JW[/5S\-_$,WC2?Q
M%JMCXN\3>([*+XG2:=I+"^U#PG#!XDTR:73 CC5O _$'P-_;N\5?$O\ :Z^(
MMAXW\4>#_!7A7Q_\>-5^$-K8_%OX^2?$7QWHTOP0BT/P;X"\/_#"35X_@?I'
M@"\\8:C-JOAWQ9H=H_CC2?$&EI>:9]BOV^U#USXD?\%5O!WA3XK_ !$^ -I\
M+/')^(W@_3OB?#+J%EJ/AB_L++6/AS<OJ&I0R6\EP3!J2?"B2'X]6&E:W'IW
M]H_#B.6]1F2.60>:?"C_ (*6?&OQ'\0].7Q-\)O".H?"R/P5H.K>(;C1?'VC
MP^-M"L_$GQAT;X;:%XWOM+-A):WM[<0:[92:KX$LIK+RV636=*UFXTZZL[0
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MNG^3/ /_  N7Q0?"?@]O%/[5VC)J/[1?CFZ^#_QEO=4_:7TSX>>'_@-:^-/
M/B&UG\5>&/%GVOXE>,_'<\FFWOPK\,^'_C@[>#[BV?QCXP$=KX0E9-5^E;C_
M (*F1Z3XWB^&?B']GGQ1I_CW1]5OX_'NB:;XVTSQ#::!X>M-;\"Z&FI^'-;T
MWP^=,\5ZX)_',%W?>&;R;PL;2QTZ>6WU;4);FW@/G/Q#_P""I7Q!\!ZO\-==
M\4? V'PUX,\=>%+;QOX8\-Z9\3?!_B/QCXML;[X1_M+?$33K#7FN-,T^U\):
M?J47P:TMDOM*;6KO2]2GAMM0:33[R]^Q@'T3XDU;Q/XR_;;^'D/@W7?CYX1\
M+:&NE^+/&>OZ]-\4+?X2^+].;PGXH\/Z?\'/ OP]AT>+X>--?:I=CQI\0OB#
MXY@77=%O-.TG2_#.J&:[TU-'S/VA?$G[>B?$_P"*<7P3UNR\/_#[P[H6HKX)
ML[CX-67CBXU_5+3X">)?'<%Y;ZU<^*-%,DMW\5M$\/>!;>T>TN+<Q:]JEFZ_
M;9=+O=/\8^*G_!1WXN:)\6?AQ\-_"GPU\,Z'XRN/BE-X"\?^ _&/Q!\,0>$Y
M['2=:\4Z=J%SI'Q7DL;1M+U'48=+TZZLFN_#$]M;1BXLGM9;^177]4O@O\3]
M/^-'PI\ _%72M+U#1+'QUX:T_P 01:/J@4WVF27<9%S8RRHJ1W26UTDT5O?P
MHD&H6RQ7T"K#<(  ?EC>?&K_ (*/:_XCTC0=)T'_ (1C5?$OC0>'O'.G)\$)
MM2\/_ _P)%XVTG2O"/Q#T7QIJ/B5--^(NK_$CP-?S^*-<\*E)1X!U$SZ?>SV
MG_",W=MKO%Z7JO\ P4?\3^/9/$$_C7Q[X1U_2_A9X@UT>&Y_A%#=_"^;Q'X;
M\)>,],TZUM]!.O:?:W>I_$+Q#X=\/:E/I][KNH7'A^?Q!)!H\,$5U:ZA:?NA
M10!^??[*OQ5_:C\:?&WXU^&OCAX:U&P\"Z38V6J> ]0B^'[^#M#TB>37=0TT
M^%+B^U74+C7-9\0'2+:SUN6\M3K'AW4--NK;5;/5-*NKN?PY8_,VL?'[]O2-
M-6%W9Z]X:NG\6?$-/%<6E?LS:MXLT[X3P^';OXI)\'O"?AC48O% F^*T7Q@M
MO#WPYF\2^(;*RFLO!J>++0MJFF-K\J>$?V=HH _&GP'\1O\ @IYXAU%?$WBR
MUL?"6GCQ'\2;V[^&9^"NG7C1:;\/?'7P-T;PSX5M?&'_  F/GM9?$WP]X\^*
MFIKXB^RWMY80> ;1]):X2UU"ZU'QC7/VO?\ @H)?_!OQ)XU^%FB^(_B3=:AH
MESJO@G7[#]GI=#CMOB=I6B_'N_N?A%>:5>:]>R:WX2NM6\%_!;2+'QSI-E.F
MM7OC_5=-AU[2\KJ6A_O[5:SLK/3K6&RT^TMK&RMD\NWM+."*UM8(\D[(;>!$
MBB3))VHBKDDXR30!^(?Q,^-W_!57PO-\,-3\(^#/#^L6/CGQ-X_U+Q)I&K?"
MJ[EF\'3^&OBAX<\*>"OA!%#H.LWM_>6/C[P#?^+?'[_$'5Y]&72AX?L+!=0"
MI)_;/T%^QYXF_:@\8_M+_%[7_C=J'Q!3PQ/\%OAN@\&ZMX"U/P+\-_AE\5CX
MO\;+XT\ >";JXU?4]-^(TFAZ=!HQD^(UASXBTJXTV^:<17L6FZ9^H=% 'XW_
M  G^)G[>F@_%7PMX$\0S>(_&?@RT^+"Z%%J'BWX0W$&I?$GX?Z]\0OBI'\2O
M%^O^-K&[TS1OAS#\&-+TGP5;^!+1;6Z7QKHVKZ<MK::S'JD=SH77?M?1_%[6
MOCI/H_P)UO\ :#\*?$#1/AW<>+(?$UOJ7CU_@]KDUEX2\=6&@?!WP#X0TZT/
MPOU7QMXTUC4X]8\7^-?B&X;P=#I/A[^Q]3BUF?18M,_6*B@#X3_82OO%6I>$
M?B)?7%S\7+SX8W/BOPZ_PJF^.3>/F^(WEQ?#SPG;?$R'4?\ A:./'2Z9;?%B
M#QC;Z2NJJNG^5',_AKS/#CZ9/+]V444 %%%% 'G_ ,0-<\;Z-::/'X&\*1^)
M]0UK6(-%N;B?4(;*S\+P7L<F/%.JQ2E9;[1]*,;27]E8.=2N2T%O9QL\S21?
M"G[>7Q8_:5^'.@_"OP!^RYI7C3QC\5YYO$WQ7\6:EHOAW0-;MKSP'\)M*74+
MCPCX@&O*+#3+/XI^/-<\(^%6CTB2+Q(OA2/Q:/#%S::I96U_;_I77PO^VK^T
MA\6OV>[3P-<?#'P-X=\06&M6'Q!UOQMXP\2:1\0/&>G^"=,\$Z3I-[IL=[X"
M^$&E^(?BE>:7XANM6N!J?CG1/#.O>'? -MHY?Q19I_PD&D2KTSQ$98:AAHX>
MA3=*=6I5Q$%-U\5*<E[)5I3G*,(8>GS4Z5.A&E"7/*K656LH2AQ4\).&.Q6,
MGC,56C7IT*5#!U'26$P,:47[=X>%*G3G4J8RKR5J]7%5,14A[*%##.AAW4A4
M^._&'C_]J+QO:?&;Q)\$?CM\7O"7_"3W7[&5Y\#X/'?@'X?:QH'@J'X[ZK8Z
MCXTL_$.CP_#BUUF_LM&BD7P]XFBN-:N]1\):>^IR+.VJ6T$X\=\1_MW_ +7E
ME^T/X$\;-X6\?Z'\)?!'AWXX>'_CM^S^_P .UOX)_BGINH_LJ?"/PPFD^-H?
M#$^NW?A/PI\5_B-XO\2:-XCT35&TSQ/X*UB\U2\DN;#0F?2_NF/_ (*>_ :W
MU1O"UQH'C'7/&%IX?T75;G3?AS+X)\=:1J6J:IK/PG\/?V3X6U.#Q=I.IZA;
M2ZM\9/"4^B:YXB\/>$M/U_06O-<LBD4:6\OV;\$_C#X5^//P[TKXE>$++7=-
MTO4K_P 1:-<:1XHT^WTWQ%HNM>%?$&I>%_$.C:O:6=[J=BEYI^LZ1>6TCV&I
M:A8SK&DUM=SQ.K5S':?DO8?M._MQ^&?^">$=W??##XZ_$O\ :D?P]XYTG7OC
M%X4^&/PTU&'POJMOXJ\<V-SXMM/AS=>*?!=GKMUX$T_2K#3K#2+;2I+;5KE=
M/U4V^OVPO+6^Y#X@_M4_M:0^+?%%QX?U[XD^&;N7QUX7\-7GPF\4^!O!FD:W
M\-_V9-5^&W[-&M^,/VDM1@@\->*9[7QOX&UCQY\:KB6_O=?U?P#JFK^#[OPY
M9:#<OX2OX[OZF\8_\%/?AIX!_:O^,OP#UZ'0-0\)_"3X7:WK<]YX:\1V.I?%
M?6/BSX+\-:1\2/&_@"P^&US/9&XT2W^&GBSPSJ&A^+WU.TTS4?&,7B/P8\B:
MGI$XBVKK_@HMH=M\=[+X0W'P ^+\=QJ7PS&O"RDTWP8WCV3QK<_$WPWX&T?P
M!_8B>-)/#[0:CH_BA?&B:Q-XLCTZVTBWNDN6AOE>TH \I\8?M"_M#>'_ -E+
MPQXZ\+?$FW2_'[9X^&V@_&CXB>%+?5-%\6_L_#XHZ_H5EX\\;:=X1\/:9;?\
M(W=:'"L+^)?#^E>&[6^TS3;#78=2L;+4)-7EXGQU^WY^V+I'P]TCXD:/\)/A
M1HNC^(]2\%>&-./C:+XCZ)IFDWESX$\>^.M6\<>(]6DTR2;3?"GQ&;PGH&E?
M##3+K2[75+"U\9:?#XCN7\9/I?AC5/HW4_\ @I9\(+SP1\0=>\->"_B98:;X
M%T?Q;I^H^*O%?@G2G\#:!X_\(>%_&FO:O\/-=LM'\:/XEO-<T-_A_P"+-)U:
M#0M,N-%.H:'<V=GXC>.XL+NY^B_@I^U9\.OCYXFU7PCX<\,^/=#N+;P[-XRT
M2^\::!I&FZ/XV\)67C?Q#X"D\1^%9;#7]9N)["+Q'X8NPL.M6>B:D+.YTN_6
MQ\F[4H ?FOX@_P""D7[3<?CCXA>&- ^%?P\M['2/AI<:Q8ZCXGL/B-X=T[P=
MX\TCQA\&/#.J:5JNN:MIEM#K.E:EI_Q0\0Z]X7UKQ+I7PUT+6X/!<<W]HV>B
MCQ+J^C>W?L]_M<_'[QK\*_VN?C/XC\-R>,+_ ,&^%_AM\0/@Q\$;7X?^(OA[
MXDL](US]G[PGXJU*SN8]=6[\2ZOI6N_$/_A+$M&DM-0UFUDT77;'3#J8?2;&
M+I/V]/VO_B[^S9XZ^''A/X5>#?A[XALO$7P3_:,^.7Q N_&?A3XO^,-0N?#O
MP!U3X(Z7_P (IX=T[X1:%K3Z->^)(/BW?23^-/'ILO!/AN/1H/[4N/+O'VS:
MQ_P5+^ ?A2/PS_PDW@KXL6E]XK@\13:.^@Z#X7\1:5KVD^ ;[P;HGQ \2^$M
M4M/%UO/XK\'^#?$WQ \-:#+J6FZ<-2U>;4TO]!T'4--6YNX #Y1^(7_!3OX\
M^ +GP5IVA>%OA[\:K\-8MXUN? '@#XOZ)X;UFQ\51^(HM)U'P+XA\21A-=/@
MS4M&CT_QG#X>LO$MCI]T3#KVK^%Y;RRB?M]!_;N_:UM[GPCX?^(?@7X4>$[G
M6;'0?'%[\0/^$6^+EUX1U&P\0_#[PUXWTWX&>'- M;6ZU^X^+]]>ZMJNB:??
M3W!L=3CTV./3=%O->-SID/LFO_\ !63]E7PU=^,;271/B7?MX O;:TU.[T70
M/!-[I4&E:GK7BK0W\176N+X\BT;P=X?CU#P?>+J4WQ O_!M[:"^TA;O3DGN)
MH;7ZU_9O^/UG^T;HGQ&\0V7A*]\/Z-X)^+GBCX>Z#?WUUI&HVOB_2_#EKH]Y
MIOC/2+C2K_4;<6&K0ZJLEJ#*'C6,,C.K!J /SL^!G[=W[77QE^)WPO\ !%[\
M,/A-X,TOX@?$9AXCN%7XE:[XD^%?@>P\.>(/$6K> ?'6FSZ'H>E:)\6K>3PZ
MVA$WNJBT@U&\GN+K18;!-&N=9U/BQ^V!^TC\*?VD_P!JCP6-4\"VOP^\+:K\
M)=0^$UQ\2? GC7^P[71S\#4\:>*O">CZOX#TVXU7Q3XD^*'C:VUC0_#%[>R3
M6FC:AH&M:+8Q:EK\^C>'[OZD\9_'[XW2?&[XE^"OA5X7^"5MX"^!,WPDG^*V
MJ_%CQCK7A37/$R?$]'U.]D\&:CI=G>:+X=;P_P"&H3]EOO%]G>6WB7Q RZ1:
MM900S7J<9I'_  4V^ WBNXU_3_"7@3XO^-M:\/ZJ+*XT3POH?P_UJ\N;.U\.
M_$'Q?-X@AO(?B/\ V)9Z5IVE_#3Q/+/!K6K:5K\%\NGV::(;N_B0 ',_M2_M
M8_'OX2ZA^SUXK\!^#+*1_''PB\0^,O$G[/?B71=>O?'GCKQJ=?\ @O;Z?\)?
M!'B'1;!M$T?XEZ;IWC#Q>(DUO44LKPZ/>W2Z1>Z;I^JZCHLW[-'[9/QP^*O@
MK]J/Q;\1_ ?P\\.2_"+POJ7B_P %:-X<U+QA/JUD]O\ \+,0^"OB19^(?#^C
M0Z5XATR/P+HVH7D=K?C5GB\2RM?:%HNG1Z!J.O\ 1^(?^"G/[/NAZ58^)9O"
M/Q@U3PGK'C&S\!>"/%]GX1\.1:!XX\?7#>'XYO"_AFZUGQCI5S;:II\'B3S[
MJ[\2VGAS29K;2M=_LS5-0>TBBNO;O@3^TI\)OVN]'\<V'@CPEXWN/!=MHOA:
MU\2ZGXT\*P>'-"US_A9?PZ\-^-SX:BM;G4WUJ\U&T\)>,M)M_$7GZ3;Z=#=3
M3V5EJ>H+!YI /SLT[_@H1^UIJT%[>^%_AE\+_B'H/AGX:>)OBQ?^,_"WA_XL
MV/ACQS':>!?!?B.V^'/A--5T]];TWQ!X/UOQB]KXQU.]TV_N'T71YHK+04\4
M1:IHUE1D_P""D_[47AQOAU+K_P &OAQXYBU'3/B1'J^G_!>;XB>.]=^(OB'P
MY;7C>#[7X?V7_".Z;;6VE:U?V4^CZUX@TV\\<Z7X>U:WE?5OL>CW=GJ*_7W[
M7W[3GQ*_9CU7P7H_PY\!^!(_AII7P]\4^,_'WQ \86?C_6_#/@73_"VH^';'
M1]!UK2?A+HWBCQ;X \.ZOI5UXAU._P#C+XG\-7GPO\%P>'93XNU#3DF25[VL
M?\%#O@IH\EYI^E^ _BQXR\0^&]4UG0==\.> _"OAS6M0\,ZKIVI^*[6WM;^:
M[\6:18:?#XK\.>#M3^(G@ZYN+JUC\2?#J[T7Q%;K')JUMIU 'QYX!_;X_;3\
M<7NF6D'P[^ 4UGHGA;Q)\1?%GB#PX?BUXBT7Q%HNC:QX"6'P%X<OCH.EVVB^
M-DTKQAJ$%^UT^NI8WNDVRW]G9ZB-;T;3.(^%G_!0S]L[3;;0/#_BOX<>$/B1
MK.DO\7AXCBUG3?%O@7XE?$2^L_BA\<;+PQ8_#CPEH'A;4])EL_A[X5\ ^&M,
M\2FY5;F^CO/[0U"XTV75?#MWKWV58_\ !4KX!7-[K.G1_#;X\V8\'>!]3^*G
MQ%GN/ _A6"Q^&GPML-*\(^)+GXB>+Y4\>.$\/3>'_&=CK\<'A]-?\0O9V&L)
M-H<>H6]O9WDFH?\ !4S]G+3-,37KOPA\88["XLO#_B'0]1F\)>%K33]:^'WC
M#6/'WA_1?B?;Z[?^-K30M"\"ZCKWPUUS27O/&&K>&=:BO;G0$NM#C75K=U .
M=^&_[6?Q=MOV;?VI?C?XSUWP;X_UGX<:[8IX&N/ G@/Q\_@'R[WP'X$OUTNR
MT2>QT[QKK5KH_B/Q#>VOB>_6]N+6UNK34BVLZ?:V%['IMO\ 80_:D^/7[2/B
M[QS+\6(O#W@6RT;POXE\.^'/ MKX2U.VF\0^(/AK\=OBK\+]<^,&B^(KR\DB
MO/"_BK1O#_@O5?\ A&[>ZU.RLE\0:3<:/KEY8W+7M]ZY8?MT_"6P\$?$'Q;X
MFCUF72O /B:TT75CX=\+NT1L?$GC'Q9X3\/&"UN=8F;4IO/\)ZK)JUS:R"SG
MB5;O38YX9O*CT?@A^W#\//C;XQ\,^"M,^%WQI\ :CXJT@ZAX>O\ XB>%?">D
MZ1=H_@'PC\4K;2TNO#OC?Q//!?WO@/QEH'B&""2TCM4C:XL+NYMM6LY;!0#\
ML_@]^WK^WMX5^$.D_%'QKX-TW]H)M4\/>'] NO"$'@7Q!X$\:6GQ+?X-:GXV
MU6Z-OHNB266EZ!H7B/1)-(\9Z==6-_K NKC45TB&RN[.TTFY_77]C7XQ_%'X
MW_"&X\6_%SP_X$T3Q18>,-;\.07OPVU_4O$/@_Q1I&FVFDW-MXBTR[U+3;!K
M:1KS4+_1+^QL[K7-/BO]$N9;;69Q.]I9/_:G_:?\,_LL:3X$\3^*;2^N]$\2
M^)M9TJ^L-$\/SZ[X@U!=,\):[XE:TT&--6T?3[35KI]*6.&XUBY-A+O>WD,,
MDR3Q^I?!OXM:)\7_  [K&K:1X7\6^"KGPSXHU'P=K_A/QOINDZ7XAT36M/LM
M,U;R;FWT+6?$&D/;WNDZWI.JV4]CJUTDEI?Q";R+E9[>( ];KY!_:_\ VE-5
M_9O\.>!M0TK3_!BS>-/$7B'2)?%/Q+UZ^\-?#[PW%X8^'_BSQ^UIJNJ:;97U
MW+X@\7?\(M_PBWA'356VCN-4U&2_DGN!I8TG5/KZOAS]NS]K'PO^R?X/^#VH
M>,?#?P_US0OC'\:K/X2S:E\4_%VH^#? 'A*[@^&7Q/\ BUIWB+Q!?Z/\.OBE
MJMX&OOA5!H6E6-CX3FE76M;T[4GO;.'3I&< ^*] _P""LNO>(+O7A_P@WPIT
M&TC\?ZYX"6+7OB+J=M<_"=-"\5?"'P\/&7QUN!H2Q>'O"FO0_%*:?1)K*UAN
MY+_0++3Y(F'B*:X\.T]5_P""MOB^S\$WOC>P^#W@^]ET^.WT33OA_/XUU>R^
M(7Q$O+S2M8O(OC3\/M)/A^>.]_9QM+RPLX;OQ9+]HU)K'_A);Z/9)X8BM->[
MC]F+]HK]F_XC:'\5M/\ %?[/EW\'=2FUVT_:F\;Z#=7FH>,&\6>(-1MOA3\3
M]=\975Q=:#X=OFTZ+Q#\7?"EYX;TK5M/MUUS0;Y=:&AZ+'<W>C6WK?B[_@HG
M^RQX9U;X??;]/MX-'U?0?%6G>*M4UKP[=V>M?#K2]'TGXCSQ?#^30;#P]K5Q
M<^+-8\2_":_\/2_#R>]T*2%I=&N@;V[O]$TO40#Q'Q#_ ,%)_&WP2UC]H;1_
MC6GPJU;5O \R7WP\TGP]+KGA..ZO&^"_[,_CBT^'BRZU-JMWXBUG6=6^+WBO
M4-.OX$M[J>TT.[MX; P6;"UXCQE_P4K^/>H? 'QU\0=)^'7A;P'XH/P0\:?&
M?X9WEO<ZUXLL-/3P[H?QML4T7Q[H=UING3:M<Q:U\--/U^&/1KRQBN;;58=*
MF3?8RW6H_5J_MV_"'6OBMXO^&'B+]G+XWQ:_X9\._"7Q;H5CJ7P1U34_&WBK
M6/'LOQ=TQ].TWP&--E\06-SX%T/X5:]JEWXAN"=)O/#]\9-&OI8#:KJ>[^SY
M^U/#\=/B9XBTK0?A9I$?P8MO#<WB/P+\0;'1KI5USP3=6-AK'A7Q5;^=;"&\
MT#QUI>LW%[HUI;:=IUS!*UW;8U(QW-PP!+\&?VPO%?Q2^(OB#X77&A>!M*U;
MX7:KX3T/XH>*KO5-9TWPKJNJ?$![;Q#\/+7X:27L#OKTWC?X8ZCIOC'1&6YO
M;*6\;4-&-YYMBTK]U^W?\:?'GP8^ =^WP@T_Q!JOQN^)WB/1?A/\';+PKX2'
MCO7[3QAXJ6]NK_Q;:>$'FM;;Q#;?#?P7I'BOXE:MI5W>6=O?Z1X0OK/S_/N(
M(9OGSP%^VI^Q#X1\'V/Q2\.Z%X]T[P_\:OBS/)=:UKOP\\1S7]KXBTV;P_X8
MT_6]4L-7\W4/"?AG08]6\.:5H>C6EI9S>%;2[EBC\.Z7]DUO[-HVG_!5C]DY
M=8U#PSXYN]?T7X@^#[+XBZYJ_AW0_!_B7XB'1#\/[/XAZCJ5G9ZMX;T"9YO$
MMYX%\"ZYK[:79V2R017:>'7NYM5N8;6[ /AGQ_\ MJ_M>>+]%^&7Q>^'C>//
MAYHWAGX0_"'3_CE;:YI_@"U\ ?"3XRW_ ,;/''PR^*][\=?!VK:'K'Q(D\/:
M1!X;2XU*+P',)O".ESVVJ710++?Q7=3_ &B_VZ-"^!'QK_:'TCQMXWNO"MCX
MT^(6B)=>.?"WPE;PKHO]G?M.>&_AQ\/(?@W8^%[K4/'6JPS^$IM<L_$UQX^L
M-/L'M<:G:&ZOQ82U^KJ?M2_!!OA)X/\ BSI/ACQ9KVF_&75[S1/"7@GPM\/)
M]?\ B+X[UM+#7=?UNQM?"&DI<3ZM+8Z'H'B+Q'J]S)/):)I&F7U_)<R H)?G
MK5/VZ);SX(_MD_$OX=_LSZQXN\"_LUP>&Y?AYI5P\FC_ /"ZXM6^'GASXD:M
MKR>&6\(W%WX5T#PO-XBMENDM[3Q1K]S;:;>ZFVCZ=>K'IR 'V5^TQ\6M6^!?
MP,^(/Q7T/1-+\1:KX/T_3;NUTC6M>TGPUIEQ]OU[2M'FGNM7US4M&TR);"WU
M&748[*XU;36U>:UCTBVOK6ZOH)D_**Z_X*O>*?&+-X3\'>%/"UIK.K_!?QAJ
M5UJVDS>+I=6\%_$FQ^$_COQMI>I1:;XR\+^&H-=T>'5O"!LHM#T:T\2V\\-S
M'>7'C"-$@M=2^R?!/[;5M\1-=_8]\$WWPOT7Q!HW[8'ACXL3WGCOP?\ $'0O
M&OPK\-:G\-/"%]XDU'PO:27VCZ/XG\8MX@M;#4+:2/4?"/A8: +>YL/$D-MK
M2#19>=^.?[6L/P+^*WB7X=:_^S_X"EN8OAQ9:]\+-:N_&]OI7_"4>%M+\9>!
MO 1F\5/_ ,*SOM,\"^"/#&J_$+6-1OXM'USQQXB\/>$_#>O^);SP19:7?VTD
MP!\T:I_P5<^).G^%O'_B5O@OX%TZR\)>++;10-;^+7@\^)_#NE6OB3XF>&M4
M7Q7X M=?@\5W_BJ\7X<0:]IOA^PLM#U!K+Q6UAI>F>);WPI=?VY^IWB/XV1:
M9^SA?_M":!X;OO%5NGPBC^*VC>%K$ZC97FLV]WX5B\3V&F+)JNBV6KV"S13Q
M1W$^H^';34K&#S9KS1(;J&2P7Y@M_P!L/X;ZK\%OAE\7;WX*7WBO2OCA\4O&
M?P^\9:-\.M#/Q0==:^$P^(EGJ_C. :;X8M[OXA>$K27X17%UH'B&]TK1KK_A
M')=&U"6TTZ]A31E\;3_@K3X'U;XEWO@KP=X L_%_A4VS:GHGQ(T_QMJ<&D:K
MI%QX=^+'B?2+U]'G^'O]JH=1TKX:65SC31J]LD7BVT:WN[V32[N*4 ZCX(_M
M/?&/X^_M0_#/PS;>*OAQ;_"GPAX.^/-_XUOOA+)>^,_ /QL\3:+IWP!/A2[\
M)>/M4@M9[31_ B_%_5]*\0:/#:FXG\9:%=R3WTMI';6-G0_X* ?M.?$OX"?'
MC]D_1_#'Q1A\&_#_ ,4W/C:\^(GA'0_"WAGQ=X_\7M;7GA/1/#MS8:!XK_LP
MZ[X+TJXUZ]M?%EKX+\2V/C;2+O5]!U^RT;Q!;63VT'I6I_\ !1#]E;P3+HFE
MZ-X=^)6IKJWB+5/"/PO3P)\%?$E_IWQ(:+6=1L/%VH_"B[L=.MM.\3>'-$\1
M:'<6WBW4-*GCAM;L:?J-S'-87^G:A/VWQ'_:H^ %CIWP+^)VN^&F\<^'?&.B
M)X]^$VMV7@W4/$7CFPUKQ!?>%?!VA)X4\,2:#-J5AK>M'QY'I%],NHZ1J6GK
M+):S6T]M)>RV0!\4?&K]JW]J+P-K7QD\)ZO\2/"7@O2M!_:@^,OAG1?BOHW@
M/3XM&\#> /A]^Q1\+/VB_AG\/M2L_&-SJECKFK^//'7B35_#VN:[<3I?ZM-]
MLTGPO#IZBTAMOMW]G/\ :)^.'Q5^(.M>$/B)^SMXA^'7AK3/A-\%_&UGX_N]
M4T233-1\4>/O#NL:IXJ\/FR75Y=3/]D:A86]E910::+JP_TD>(%LGGTY9\+X
MK_M2^$C^S9I_[17P^^&/A'XD_#W59M5\2^)5^*OB&P^%-OH5]X*CO;2/3]4T
MW5_"?C#Q+JWQ2N/%_AZS\!>$O"NE>%-0U*X\5BQM6U+3K>"UN)>8L_VX?B3K
M$5MJ>F_LXVNC^&_%5KX[N? VM?$'XS>'_ _V&+X0>(=*\.?&+4OC#;7/AC48
MOAIHG@NXD\2W=K=Z3>^/]0UFU\-@R:3I4FJ(EF 8W[8W[7/C_P#9M^/WPNTK
M19_".J^#-8^#?Q)\8ZK\/->NI]/\5?$OQ)X8\7> ].TGP;\)Y[6SN'U/XG:W
MI^N:G9^%=!NI!I^I:BT%K<6[?:4O=/\ B7XF_P#!0SX]>!?CWX/L(?[=U7X<
M7OBZWTF\\%6.E:<FN7V[XR?LP>!XH1KQT>=VCDMOB!XR9[1($DN+34EM%G2:
MQBNT^^/A#^W!X)^.WQ7^!GPVE^%VFV7B[QI\,_%OQ0UW4=6\4>'+Z3X9ZEHE
MSI+>!M%T6PU+3-/\7:]>?$_PGJUY\2/"NH_V'X5NK+X>#3M8U?3K.^UB32;#
M[^?PYX>DGBN7T'17N8)DN(+A]+L6GAN([BWNXYXI3 9(YH[JTM+E)48.MQ:V
M\RL)((F4 _';PI_P4\^*/CC0/%&J^$OA#\/_ !!'X%^%2?'/Q=K>F>,O$%SX
M:L_"MQX6^'OBMOA7:7,6@R2S?&CP[)X]M_"_BNPGDM],TVYCM_$3VL4<[^'(
MOTD_: ^.NF_ _P#9X\=_'NY@M'T_PCX.@\41VVM'6X[0F_>Q@L8M0'AG0_$V
MM[1<:C;K+%INCWLLCCRFDM(6DOK?V:W\.^'[2WFM+70]'MK2XDU&6XM;?3+*
M&WGEU>Y%YJTLT,<"QRR:I>*MWJ+NK->W($]R990'K0N+2TNK2:PNK6WN;&YM
MY+2XL[B&.:TGM9HS#+;36\BM#+;RQ,T4D+HT;QL492I(H _&+1_^"I'Q&O/
M!^)K?!#1=<\+^#O$5IX7^(-GX7\17M_XLUO5M4^,/Q*^$>E6WP_T2UBU33TN
M[A_ MEXIFLM4U_4S##J__"/I=37*Q:L_U%^P_P#M(^.?VB_$/Q_O_%'B'X;:
M]H/A?5OA7%X1A^%>IWFO>&="B\3?#FR\0^(-!N==U&QL+^^\0Z1K=S/IVN1S
MPJD-U:">"WTZ.\_LRR^Z;;PWX=LXE@M-!T6UA5[218;;2[&")9+!M]A(L<4"
MH'LF :T< -;,-T)0\U8TW1='T9;A-'TG3=*2ZGENKI--L+6Q6YNIY9)Y[FX6
MUBB$T\T\TTTLT@:226621V+NQ(!I4444 %%%<)\0?&5]X)T>UU#3O"/B'QE>
MZCJEGHEEIOAZ&"9X;_4V:"PNM5>69)+'0TNS$FJZK#!>?V7:N][-;/#$];X;
M#UL77I8:A&,ZU:?)3C*I2HQ<K2E[U6O5HT81483E*52K"*C"3NW:,^7&XS#Y
M?A*^-Q<Y4\-AJ;JUIPHXC$34%*$%R4,+0Q.(JRE.I3A&%&A5G*52*44G*=/>
MUCPOX9\0RVD^O^'="UR;3X=4MK";6-(T_4Y;*WURPETK6H+22]MYWMH=8TN:
M;3=4BA*)J%A++9W:S6\C1GD[SX-?!_4=?T'Q5J'PI^&U]XH\+:AJ6K>&/$EY
MX%\+W6O^'-4UF*&#6-2T'6)]+?4=(U#58+:WAU*\T^XM[F^BMX8[J25(D"_$
M'[?W[3WQ?_9M^$_P[T3X4:7K7CO]HOXI>,1!X?T#P)\*/$_Q;U$^'_!EA<^.
M_'IL/A_X3M[W6Y]$NM-TNT^':^)+T1P^'Y/&-CXBO[Q;VSAAF^8[SXY?M0^-
M'^(?Q6^"'[7BZIX0\5?"[]GOXH_!/X?^-O@W\)9O!?AR\_:<^)#>%-%\-^+=
M=T70=&^(FH:/\/XI;33&@NM9T_Q1)=1:E#X@OY]2MAMRG%0G."G"HHRE%3IM
MN$^5M<T'*,).$K-Q;C%N-I<JYDEM2FZE*G4=.I2=2$9NE548U:?-%2Y*L8SJ
M1C4C=*<5.:C)2CS2<6W^NUY\$O@SJ,UE<:A\(_AC?3Z:^CRZ=->> ?"MU-82
M>'="O?"_A^2RDGTEWM7T+PSJ>I>'='>!HVTS0M0O=(LC!I]W/;R6KCX0?":[
M\6Z1X^N_A?\ #NZ\=Z!<ZI>Z#XUN/!/AJ;Q;HEYK9W:U=Z1XCDTQM8TVYU=N
M=4GL[R&74#S=O,:_#7Q;_P %3_BWHW[1?PICU+^Q? ?P>\(^/_BMX5_:[^&^
MN^&(M2\9> 9?A]\*_A+IFKZ9I?B..6TF6P\+_&'XL>'O&Q\:I!/HVL_!V\C\
M0F*/3KJWN+?T/X>_\%+OB]HO[(_CGQG\6/AQ\0M9_:!AUSXM0Z%?^'/@3\0[
MWX+^"7_X6+J&@>!_"_CKQSX1T#7- &L?##1K_35^(6G6MW<>)-7C\,:_J%AI
MCM<0H)-#]DK_ .%_PTU75;S7=4^'?@74M<U&ZN;[4-9O_"6@7FJW][>>%'\!
MW=Y>:C<:?)>75U=>!Y9/!MS<3S/+/X4D?P[*[:0[69S=,^"_P=T6]UG4M'^$
M_P --)U'Q$FDQ^(+_3/ GA:PO==30(M+AT)-9NK72HI]3318=$T6+25O9)QI
MT6D:7'9B%+"T$7XF^)O^"C7QTTOP)+\7/"?C+PIXS.E_#_X56FD_!>;P)!X?
M\3>/H?'/[+%C\:?$_P >;G3M4FLO&7ANU\'^,Y;]+O3(5D\"0>"M)U'3;TCQ
M/)!?VWUOX<_;5\7^ /@)XI\7>+QHWQFU'PW^U/#^S/X+^*\NL:'\//AY\0;'
M7?$NDZ1HOQ5\<>)_#6B:_P"&O!/A+P_)J]UHOB_7O#N@ZMI:ZIH$IM-,MGOG
M@LP#]!-;^$?PI\2^)IO&GB/X8_#W7_&-SX8O_!-QXLUOP7X;U7Q-/X,U03+J
M?A&;7K[39]4E\,:BMQ<+?Z ]TVE78GF%Q:2"5]U71_@K\&_#VG:;H^@?"7X9
M:'I&C65QIVCZ7H_@/PMIFG:5I]Y#J%O=V&FV-EI4%M8V5U!JVJP7%K:Q103P
MZGJ$<L;)>7*R?@'XH_X*B?M,ZE^T%X-\9^'HM"T']G"T@UYO$GPJT.Y\-^*_
M$?BZ;X?_  :\5^/];N=$\93_  ZOM4N/"_B;Q7#I\=OXPT.XB@;X9Z1%XHTS
M1+"_N[^.;[0N?^"G?C#_ (1;Q1XJTK]GKP]K-AX)\*6WB;Q#=VOQO,>G7T%_
M\4+/P!9WG@V:7X7?;O$NAQ:;/>:Y?7,FFZ5K[ZMIESX4T7PQK4\MMJDH!^E^
MK?!KX/Z]JNC:[KGPI^&VLZWX=\07/BSP_K.K>!?"^HZKH7BF]M+"PO/$NC:C
M>:7-=Z7X@N['2M,LKG6;*:#49[33;"VEN7AL[=(X-5^"'P7UW4=%UC6_A#\+
M]9U;PWHK^&_#NJ:KX \*:CJ.@^'9;?4K.30=%O;O29KG2]%DM-9U>U?2[&6"
MQ>WU74H&@,5]=++\"_''_@IUX1^#_P"SE\"/CW:>#=*\2S_''P9XA\=:;X2N
M/%^OZ)]ET;P7X;M-?\9MI^H0?#?7-9U!-&>]M[3[=J_A/PUI\44D=WK5QHC3
M16K]Y^T?^V]XK^#7Q*\.> ? OP?\-?$:TUS2?V;KF;Q%KWQ<?P''::K^U-^T
M+'^SG\-;.UTZP^'?CI]2TRT\4SPZWXDU:.\@>WT,3+I.G:M?K#;3@'UQXN^
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M\)_MB7'[.6L^)?A5\/?C/\'/&OQB\9ZGX9^+GQ&\!Z;\/(+BV\4Z3X.^&/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %9 ;T# 2(  A$! Q$!_\0
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MW5Y=J)(I%C"('8<KG.0#@U7F\.N4FDC%NTS7OVD!Q\KKV1JZ^6@TE>ST//\
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M\ZS+2(V)DVQ*'MOEFM,9^TQ9_P!8I/?_ /5534+?4(X[B&:^2Y6+$A6= "Z
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MQHA< 9.2!C/K5>6S2>[BGD8D1<HO8'UJS1719,XU)IW04444R0HHHH ****
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M7#K9GDMBL<I@M'?;(6((],#&2<]ZNQ>"--M9]#MGN%N+^XU&:UG1U81OLR"
M1T Q^.:3='^5?<'LY=W]Y;_X79K'_0/M?UH_X79K'_0/M?UK M_ _P!J^SQ-
MJ44&HWZRR65GY;$.J$]7_A)VG%-7P0K:4+C^U4%VVFMJ2VQA.#&IPP+= ?2J
M_<]E]P<DN[^\Z'_A=FL?] ^U_6C_ (79K'_0/M?UKFM>\%MH>B0:@;UI_,"'
MY(#Y1W#/RR=#CH<XKE:J,*4E=17W$N,ENW][/3_^%V:Q_P! ^U_6C_A=FL?]
M ^U_6O,**?LJ?\J^X5G_ #/[V>G_ /"[-8_Z!]K^M'_"[-8_Z!]K^M>844>R
MI_RK[@L_YG][/3_^%V:Q_P! ^U_6C_A=FL?] ^U_6O,**/94_P"5?<%G_,_O
M9Z?_ ,+LUC_H'VOZT?\ "[-8_P"@?:_K7F%%'LJ?\J^X+/\ F?WL]/\ ^%V:
MQ_T#[7]:/^%V:Q_T#[7]:\PHH]E3_E7W!9_S/[V>G_\ "[-8_P"@?:_K1_PN
MS6/^@?:_K7F%%'LJ?\J^X+/^9_>ST_\ X79K'_0/M?UH_P"%V:Q_T#[7]:\P
MHH]E3_E7W!9_S/[V>G_\+LUC_H'VOZT?\+LUC_H'VOZUYA11[*G_ "K[@L_Y
MG][/3_\ A=FL?] ^U_6I'^,^KK!%+]AMOG)XYXP:\LJQ+_QXVWU?^=4J5/7W
M41+F3C:3W[OLST?_ (79K'_0/M?UH_X79K'_ $#[7]:\P/ S7?7W@NPM_ XG
MC9SK]O;QWUS#NZ0.Q&,>H&*SE&E&UXK7R-5&3^T_O9H_\+LUC_H'VOZT?\+L
MUC_H'VOZU22U\''P._B(Z!=?)="U,7VUN21G=G^E6[SX?Z?)I7AW4=/5RLY@
M.H0>82PCD(&\>@SQ47I+>/X%>SETD_O8[_A=FL?] ^U_6C_A=FL?] ^U_6I+
M?P)HMS#XHB6.47-I=R6]B?,. 1'O /KT-9.O^$=-TGX=:?J2I(-6>2(7&7)
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M=Y/7K77?\*0L?^@I-_WQ_P#7H_X4A8_]!2;_ +X_^O63G0:M?\S=2JWORO\
M#_,\T/C#4FTDZ<T5JZ!'BCF>+,L<;-DJ#G'Z9JCK6MW.O7<5U=10).D2QEX4
M*E]HP"W)YXKUG_A2%C_T%)O^^/\ Z]'_  I"Q_Z"DW_?'_UZI5:*=TU^(KU/
MY7^'^9YQ<^.-9NM.EM7^RB2:(037:0 7$L8_A9^XX%-NO&NJ7=E);O':+),B
M1SW*0XFF1,85VSR.!T SBO2?^%(6/_04F_[X_P#KT?\ "D+'_H*3?]\?_7I>
MTH=U^(7J_P K_#_,\SG\8:G<2WTDBVQ:]N(;B4>5D;HON@ GIZBK4GC[5FFM
MGB@L8$MC*R111$)ND7:Q()/;\*]"_P"%(6/_ $%)O^^/_KT?\*0L?^@I-_WQ
M_P#7H]I0[K\0O5_E?X?YGG$7C?58K#[+Y-D[_9&LC<M#F8PG^'=GMVI+GQMJ
MEU';B6*S\Z)XG,XB_>2F/[NXY_EC->D?\*0L?^@I-_WQ_P#7H_X4A8_]!2;_
M +X_^O1[2AW7XA>K_*_P_P SS>S\;:I937\JQ6DAOKA;J198B0L@.05Y_GFI
M?^$\U8SPSM!9--!>O>Q.8CE7?[P'/W3Z?K7H?_"D+'_H*3?]\?\ UZ/^%(6/
M_04F_P"^/_KT>TH=U^(7J_RO\/\ ,\WMO&^K6UJD21V;2PB1;>Z>',T"N26"
M-GCJ>H/6H5\6ZFJHH$&$TY]-'R'_ %3')[_>]Z]._P"%(6/_ $%)O^^/_KT?
M\*0L?^@I-_WQ_P#7I^TH=U^(7J?RO\/\SS2\\8:A>:+)I7D6<$$PC$S01;6E
MV?=SSC\@*Y^O:_\ A2%C_P!!2;_OC_Z]'_"D+'_H*3?]\?\ UZ:K45L_S$_:
M/>+_  _S/%**]K_X4A8_]!2;_OC_ .O1_P *0L?^@I-_WQ_]>G[>E_-^?^0K
M3_D?X?YGBE%>U_\ "D+'_H*3?]\?_7H_X4A8_P#04F_[X_\ KT>WI?S?G_D%
MI_R/\/\ ,\4HKVO_ (4A8_\ 04F_[X_^O1_PI"Q_Z"DW_?'_ ->CV]+^;\_\
M@M/^1_A_F>*45[7_ ,*0L?\ H*3?]\?_ %Z/^%(6/_04F_[X_P#KT>WI?S?G
M_D%I_P C_#_,\4HKVO\ X4A8_P#04F_[X_\ KT?\*0L?^@I-_P!\?_7H]O2_
MF_/_ ""T_P"1_A_F>*45[7_PI"Q_Z"DW_?'_ ->C_A2%C_T%)O\ OC_Z]'MZ
M7\WY_P"06G_(_P /\SQ2BO:_^%(6/_04F_[X_P#KT?\ "D+'_H*3?]\?_7H]
MO2_F_/\ R"T_Y'^'^9XI17M?_"D+'_H*3?\ ?'_UZ/\ A2%C_P!!2;_OC_Z]
M'MZ7\WY_Y!:?\C_#_,\4JQ+_ ,>-M]7_ )U['_PI"Q_Z"DW_ 'Q_]>HD^#UE
M//+9G4I0+;!#;.N[GUJHUZ5G[WYF<U.\?=>_EV?F>0V,EO#J%O+=QO+;)(K2
MQH0"R@Y(&:[M?BK=R:[/+<V4+Z1.&B:V6-1+Y1& N_OBNH_X4A8_]!2;_OC_
M .O1_P *0L?^@I-_WQ_]>LI5*$MW^9LG46T7^'^9YHVOVP\#W'AV*VE#/?\
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MB_P_S/';;_47?_7(?^A"JU>S2_!^SM)(H1J4K"Z;RB=G08+?TJ7_ (4A8_\
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M.K_\_MI_X#-_\71Y.K_\_MI_X#-_\76A11[1]E]P>Q7=_>S/\G5_^?VT_P#
M9O\ XNCR=7_Y_;3_ ,!F_P#BZT**/:/LON#V*[O[V9_DZO\ \_MI_P" S?\
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M@*<$C(S4K^$=!D-L6T]/]&6-8P'8 ",YCR ?FVD<9SBK7DZO_P _=K_WY/\
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MU[^79^9O45G>3J__ #]VO_?D_P"-'DZO_P _=K_WY/\ C6?(OYE_7R-O:O\
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M]J_Y7^'^8:C_ ,?NF_\ 7<_^@-6C6!?Q:F+O3]UU;$^<=N(CP=I]ZO>3J_\
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MN"6&UAVK,=TA=B[.<8Y)))X %45\':"OD?Z I$ "HI=B"%8LH89^8 GC.<4
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M-]A'*R)CS&PJR?? &< 'J<=ZLW?A[2[TS&>U#/,R.SAB&#(-JD$'((!(X]:
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MY%#(P[@]#4E=A\V]]0KG]5_Y"[?]<$_]">N@KG]5_P"0NW_7!/\ T)ZZ,/\
M'\CBQG\->J_4=H\>J'1[0Q7%J(_+&T-$Q('O\U7O+U?_ )^;/_ORW_Q5&A_\
M@.R_ZY"N1.L:N?"\WBS^U&41R,PT_P I/*\M9"GEDXW;R!USU/2BK/WWHMWT
M"A23I1U>RZ^2.N\O5_\ GYL_^_+?_%4>7J__ #\V?_?EO_BJY^\\>V]C;3R3
M6<ADM1,;F)3DQE'"*.G\988]L^E):^-;J[FM;6/2'%S-<-"=[-&@41^9O!90
M2,<8QUK/VC[+[C;V*[O[SH?+U?\ Y^;/_ORW_P 51Y>K_P#/S9_]^6_^*KF+
M#X@MJ-O-/;Z1.8A;-=0LVY0Z*1D%F4*&(Y&"1VS4\/C6XO[>SN-.TGSXKR*:
MYB+SA#Y,9 R>."V>G;O1[1]E]P>Q7=_>=!Y>K_\ /S9_]^6_^*H\O5_^?FS_
M ._+?_%5S,GQ! MY;N+37:UW010OO)9Y)55@"H!( #')YZ<42?$!H[2VF?29
M8@[R)*\Y:.-2C <,5[YR"VT<&CVC[+[@]BN[^\Z;R]7_ .?FS_[\M_\ %4>7
MJ_\ S\V?_?EO_BJYR[^($-A=ZBEW9-%#:)(ZDOAY0N,%5QA@V1@J3COBEM?&
M]Q>-':Q:1)_:$LWEQ)(6CC8;"Y8,R@\ 8(QU(H]H^R^X/8KN_O.B\O5_^?FS
M_P"_+?\ Q5'EZO\ \_-G_P!^6_\ BJP=.UN^D\#V&HWKN+N6ZCBDV;<C=<"/
M'3& #CBK&B^*I]4OK:&;33;PW:SFWE\X,6\E]C9&.,Y!%'M'V7W![%=W]YK>
M7J__ #\V?_?EO_BJ/+U?_GYL_P#ORW_Q59)\5RQZG)%+IQ6Q2^%A]H\X$F0@
M$';Z<XZUAW7Q O;BUN(["RA2[002QEI=Z%'F6,@G&-WS=LCGK1[1]E]P>Q7=
M_>=EY>K_ //S9_\ ?EO_ (JCR]7_ .?FS_[\M_\ %5RL_CXV'^CK8W%Y<*;B
M60 $D(D[QA5V*<D[>,XX')S5QO&%U)<3)#I>VW^T26D4[RX)E$)E!*8R!P0>
M^:/:/LON#V*[O[S>\O5_^?FS_P"_+?\ Q5'EZO\ \_-G_P!^6_\ BJY?3/&U
MYY>B0ZG8QQR7MO!))<>9MC9I/[A(QD=P2#SQFM+7O%IT/4+B%K)I;>ULA>3R
MA\$*6*A0N.3D"CVC[+[@]BN[^\UO+U?_ )^;/_ORW_Q5'EZO_P _-G_WY;_X
MJN9_X3V;^SY9FT>=9(YDC8LL@C56!(8DIG Q@X'!QVHE\;M"L]U%:O/&RVQ
M$@:.'S$9B2R*3CY<9YYQTH]H^R^X/8KN_O.F\O5_^?FS_P"_+?\ Q5'EZO\
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M<P23R0)*C2Q@%T!Y7/3(I\[[+[A.E%;R?WE3R]7_ .?FS_[\M_\ %4>7J_\
MS\V?_?EO_BJFU#4+;3+-[FZD"1K^9/H/4UEZ#=:KJ5Q+J%T!!92+B"W(^;']
M[-:14G!SLDEY;^2,)RA&HJ2<G)]GLN[[+\R]Y>K_ //S9_\ ?EO_ (JCR]7_
M .?FS_[\M_\ %5H45E[1]E]QT>Q7=_>9_EZO_P _-G_WY;_XJCR]7_Y^;/\
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M_?EO_BJN01>3!'%O>38H7>YRS8'4GUJ2M_:/LON/+=%?S/[V9_EZO_S\V?\
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MJDCJ0 :3_A$]%^RFW-K(5,@DWFXD,@8# (DW;A@9'7H:L[-9_P">]C_WZ?\
M^*HV:S_SWL?^_3__ !5')YK^OD'M7_*_N_X(L.AZ;;Z5!ID5JJV4#*\<6XX5
ME?>#G.?O#-.MM&T^T:V:"V5#;"00X)^3S#N?OW(IFS6?^>]C_P!^G_\ BJ-F
ML_\ />Q_[]/_ /%4<GFOZ^0>U?\ *_N_X)0M/"&G0ZK>ZC<)]HGN+AIU#LVQ
M,J%^YG:3C/.,\TY/!?A^.&2); ['A$!S/(2(PP8*"6RH# $8QC%7=FL_\]['
M_OT__P 51LUG_GO8_P#?I_\ XJCD\U_7R#VK_E?W?\$KS^%-%N$1)+,X3?\
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MFZ2(Q+(<Y"$Y(';J!5>ST'2["\>[M;1(IW#AF!/1FW,,9P,MS1LUG_GO8_\
M?I__ (JC9K/_ #WL?^_3_P#Q5')YK^OD'M7_ "O[O^")8:#I>ES++96BPND;
M1*0Q.U&;>5 )X&[G%6UL[=+V2\6,"XDC6-WR<E5)('X%C^=5=FL_\]['_OT_
M_P 51LUG_GO8_P#?I_\ XJCD\U_7R#VK_E?W?\$CB\-:1";@I9@?:$E20&1B
M"LARX )X!//&*:/#&CB\2Z%GB1<8 D<(2%VABF=I8#C<1GWJ;9K/_/>Q_P"_
M3_\ Q5&S6?\ GO8_]^G_ /BJ.3S7]?(/:O\ E?W?\$JW'A'0[J*&*6Q!CAM_
MLRJLKJ/*_N'!&X>QS4%CX.T^SU2YU!E\V9YA+"&9ML6$"+\N=I( ^\1FM'9K
M/_/>Q_[]/_\ %4;-9_Y[V/\ WZ?_ .*HY/-?U\@]J_Y7]W_!(M T1-$M;E=Z
MR7%W<O=7$BIM#.QYP.P  'X5K5G;-9_Y[V/_ 'Z?_P"*HV:S_P ]['_OT_\
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M=$C: I9!5AV[8P[;&*MN4LN<,0Q)R>] &%;_ !'AGB>8:9,8G0O:E7_UAWA
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MHV:Q_P ]K/\ [X;_ !K1HH]IY+[@]BOYG]YG;-8_Y[6?_?#?XT;-8_Y[6?\
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&^)M_,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "' CX# 2(  A$! Q$!_\0
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M/!&CZ3J,-Y:B<-"F%C:4E"^W:9".[E>": +X\1Z*US#;KJEH9IMHCC$H)?<
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M\(612<2L@9'P<[2">,]_KWK1\0?\@6;_ 'H__0UH TZ*** "JMQ_Q_6GU?\
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MK=K=OQ%72=?U;0)+?4KX6MT;G>K6XZ(#D#)K>N-'L[N&:&>(/'-%Y3J>C"L
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M_P!:M7Q!ID^KZ+/96UT;:63&)!['.#[5B:??:Y:ZBO\ ;>IZ8L 8B1$D ()
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MG! XP,#\J** +4'@_2+:QELXHI!%*B(PWG.$8LN/3!)]JK_\('H(MQ#]GDV
M(%_>'*[<8(/8\#FBB@!EYX#TJ:T>*U+VTK$XF'SD9()X/TKH[2V2SLX+6,DI
M#&L:D]< 8'\J** )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BNK>.\M
M)K:4$QS(T;@'!P1@T44 <[=>!-)NLL6G$I&#(7R3DKD_7Y1^569/"6FO')''
MYL4<MT+F14;@L%VX'H,444 0_P#"#:)E"(I04R%_>'@$ 8^G J>Y\):7=W<M
MS,LIDE.6P^!TP?S%%% %;_A ]#XQ%-P691YAP-Q)./3[QK5T32$T33_LD<SS
G#S&D+N #DG..*** -&BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ", D(# 2(  A$! Q$!_\0
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M8]P<Y]: .NM]7T^YCB9+N(&6+SE1V"MLQG<5/(%3V]W;7D9DMKB*9 <%HW#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <KX\8VNA"\@_=W*SQJ)(P/,QGH#7
M2VQ+6L).<E 3GKTKGO&@M)M-AMKN^AM0\H93*I(8KSVZ&MZPR=/MR91+F-3O
M"X#<=<4 <-=>'_%\UU+)!?F*(M-B-KHG@D;<''!Q^5:&GV_B+15\S4-02<2W
M<:8;+[E/!QTV_3VI]S\0=.M+B6":UNP\;LGW1@D=,'/?].],?Q7IVN10);^8
MC+>Q*HD7&_G.1^O6@#L:*** "BBH+BZ6WD@0H[&9]@*CH<9YII-NR GHHHI
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MA5 P !@"EH **** "BBB@ HHHH AFM+>Y9&G@CE,>2A=0=N?2I@ !@<"BB@
MK"\11ZDD-J='CC#M=(9N%R1Z\_\ ZZW:R]:MTN$L@^["7<;#:2.1FDW97-*<
M5.2BW8U,5RVK)XE&N(]B$:S\Z, [5RJ8^<$GG&?Z4MY/XM:6Z-I;6J*DI^SA
MR#YB8XW<\'/\ZK6]_P"./*NFFTJR+A!Y"B7'S9YS]!3,SL&SM..N.*Y#P_\
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MENJ("$.,#GOCI^M=S10!7L?M']GV_P!KQ]I\M?-Q_>QS5BBB@ HHHH ****
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M5-I5[XAEU$1ZE:6D-MM8LR2Y8'/R\?G3DDFTMAR^)FPUA9LQ9K2 L>YC%6*
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M0 THA&"BD?2@QH0P**0XPW'7ZTZB@"&*UMX8EBCAC5%7:%"\8]*EV@]A2T4
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MNBTA96E;)5>@%:E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #& A # 2(  A$! Q$!_\0
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M718D1I-3ME5PI4F0<Y)48^I5A^!J>PU?3M4,PL+V"Y,+;9!$X;:??\C6'8^
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M_P F_?\ ],O]9C_]5=QI>H7\VK7]A?); VX1T> MRK9ZY[\5L5AV'_(WZO\
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M!B@#L**Y*&+QNMW$)+BP> 3)YAQ@F/<=Q QU*X_&NMH **** "BBB@ HHHH
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M&B$QFT5V3:?FE/4!OX0/<9XJ>P\1:Q<ZG;VT_A^:&&20J\Q8XC 3.3D?WN*
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MINMTGF%=N-W&/I3[BVANH]D\8=0<X-3[&/*U;<W_ +1K>UIU%+6"25DNA0$
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M6QMKFUAE@.,QN@*G\*?;VT-I;I;V\210H,*B# 4>PK!DU7Q,B2L/#UL^R+S
M%OCES@_(/DZ\?K2/JWB9=^/#MNVV'S1B^/S'^X/D^]7)8SYI-<M]#I**YAM=
M\1"YDMQH%NTJ6PN-HO3SDD;1\GWN*D.J^)AG_BGK?B'S?^/X\G^Y]S[WZ4$G
M1T5S?]K>)L?\B[;_ .H\W_C^/7^Y]S[WZ4JZKXF+JO\ PCUL 8?-R;XX!_N?
M<^]^E '1T5SB:KXF<IGP];KNA\TYOC\I_N'Y/O5$NN^(C<V]NV@6ZRS6[3[3
M>GY<;<J?D^]\WZ&@#J**YR/5?$TCPJ?#UL@DB,A+7QPA&/E/R=3G]#1'JOB9
MV@4^'K9?-0L2;XXC(_A/R=30!T=%<W%JWB:0V^?#MNGFH6;=?']V1V;Y.II4
MU7Q,S6X/AZV7S58L3?']WC'#?)W_ *4 ='17+KKOB(SV<$F@6\<ET'(#7I^3
M;_>PG?/%2IJOB9_L^?#ULOF[MV;X_NL _>^3O[>M '1D9&#4;6\#Q^6T,;)G
M.TJ",_2L"/5O$S^1GP[;IYI8-NOC^[QW;Y._:B/5O$SB'/AVW3S'93NOC\@&
M?F/R=#CCZB@:;6QJ:GHVGZQI_P!AO;99+;(.P?*!CITJQ965OIUE#9VL?EP0
MJ$1<YP*PXM5\32)$Q\/6R;W9"&OCE ,_,?DZ''ZBHCKOB)'MDD\/VZ-<3M"H
M-Z>, G<?DZ$+Q]12Y5>_4MU9N'LVWRWO;I?N=117.)JOB9PI/AZV7,K1D&^/
M !/S?<Z''ZT@U;Q,=N?#MN,S&(YOCP!GY_N?=X^O-,S.DHKG%U7Q,P&?#ULN
M9C'S?'@#^/[GW:3^UO$V3_Q3MOQ/Y7_'\>G]_P"Y]W]: .DHKGHM9UM)XA>Z
M)## ]R+<NET7;!. X&P<?B*Z&@ HHHH **** "BBB@ KA/B8B266GJ9SO,K[
M;7RI'6;Y>I$9!RO45W=<%\3M/GO+73988)9Q;R.[1I$SC&W&3M92* .J\/(T
M?AW3T:>:=E@4&692KMQU(/(-:=9/A>5)O"^F21XV-;J1@$=O0DG\S6M0 445
MRWC?7[W0K&U>S>*(RNX:69=RKM0L%^K$8H FUFY@B\7^'TDGC1OW_P K. >4
MXK)_X6/9R^+[SPY'"/-A# 3>9D$@9Z 5SGBO2$\0>,= U"[TC4RYBSLB= LF
MU=^!DY')P:O:>VC6&M)KMGX,U..\NI&ME?Y<;N0>"W'3K74H8;DNY2O;HDO>
MOHFWNK=5J:1FH7]U._>^GGI^NAA?#VWU'Q6OB.SU*:1K<ML F)89)/8FO4?"
MGAZ/PQH$.EQ&-A&22Z)MW$]S[UC1^+A:I+)%X4U&("X^SN4CC!,A..QY'/6I
MY/&L\(NB_AO5,6I EP$.,],?-SU[5-6LI-JFN6+L[*]KVM_7J*K4G5G[2H[O
M^NQTZV\*SM,L:B5A@MCDU+7*2^,KF&2X1_#6J;K>(2R8"'"G/3YN3P>*/^$R
MN/-6/_A&]4W-!]H&=F-GKG=U]JYR6V]SJZ*Y&W\;RW8LS!X=U-UO$,D)^3!4
M=<G=QUI8_&T\J6SIX;U7;<2&./(0989SGYN!P>:!'6T5R1\:SA-Y\-:KCS_L
MW1/OYQC[W3WZ4DOC>:%+EW\-ZKBV=8Y<!#@G&,<\]1TH ZZBN3E\:3P-=J_A
MO5<VJ"27 0X!Z8^;GIVI?^$SG^T&#_A'-2\T0?:"N8\^7TS][]* .KHKE(O&
M5S,ULJ>&M4S<Q&6/(0948Z_-P>1Q38O&TTRVC)X;U7%TS+%D(,D9SGYN.AZT
M =;17(CQO,T:./#6J[7N/LP^5/OYQZ]..O2E?QK.B3NWAO5=L$HA? 3[QQC'
MS<CD<T =;17)S>-9;;[69_#VI1I:!6G<[,*#T/WN?PKJU8.@8=",B@!:***
M"BBB@ HHHH **** "N5TC5M6N?&6I6-R&^R1;]J&':(P"NPAOXMP+'VQ755A
MZ/K5WJ.NZU93V+P064J)#*1Q*"N2?S_2M(4Y2C*2V6_WV%<W****S&%8BO?C
MQA.IN$^P"R4K%@Y#;C\U;=4EAB&M/,)P9C %,7<+N/S5+BW:QO1FH\U^J:_+
M^KGG</BSQ#-)$UK<27$#W3)&6LMKR$% $88^4'+D'K@<FO4:**HP$9@JEF(
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M.UNH(."/S%6Z ,_0[B[N]"LKB^C\NZDA5I5QC!QZ=JT*** "BBB@#SW4]?\
M$]G+,BG<5OWCB,5J2) %0I'WX.6^;VK9\&ZMJVIMJ']J*P\IU #0[/+<[MT8
M_O!<+S[UU-% !1110 4444 %%%% !7 >);+6M:\17=E_8EOJ.FP1QO"9[AH
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M>]:5YX<TC4+G[1=V,<LFS9\Q.,?3./QJ&'PAX?@P8]*MP05*G&2N.F/3\.M
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M_,F[S,^B@!?RK>/CW2?^$9_MM2Q0OY:P9'F%MV/7W!_&K;^"O#C[<Z3!\J[
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MSBN(]&#I(05='8JV54^6IV\R?,1Z<'FO0F571D8 JPP0>XIL,,=O"D,**D:
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "= @ # 2(  A$! Q$!_\0
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MC:CG.?-7_&JOG:=_T%+7_OX/\:QVU&\3[UM;CDC_ % ZCK3?[4NL<6]O_P"
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MQUK Z)9?^ RU _CW6QT6Q_\  5:/J%7R-%*YZGY^G?\ 04M?^_@_QH\[3O\
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MCVU+L+V%7N9C:K(5($:J?4$\?3TZU#=ZG)<1HAC5=K[N.];'_"/W7_/I:?\
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M:_GUN^TZ"\MY)+=A&\S2D+(S'"J">I)XQ1&"M93!O78]'NO#^EI<9BT:S%S
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M=-'H^F0SF>/3[5)CG,BPJ&YZ\XIL6BZ7 6,.G6D9=2C%(%&Y3U!P.AH]SS_
M-3)T?QSHNK)*C7,=G<P?ZZ&>11M]PV<,/<&MRSU&ROPYL[N"X"'#&*0-CZXK
M(U7P;H>JV#6K:?;P$\I+!$J/&PZ$$#].AJKX;NH]/NFT/4+2UL]3 W+)!$(X
M[U!_RT7'?U7M]*3Y>EP)+CQC:6VKS:>]O*3$[1EPZDEA'YGW<YQCOC&:N1^*
M-)DM$N7NEC5A\RL#E2%#$''H&!J1?#U@LVH3^7F:^SYLA W*"H7"G&0,"J4'
M@S389PXDN&3:P\IG!0[HQ&QZ=2H%:?NFNH:EN7Q+ID<\D;7*[8E)=QD\A@NT
M #).2.E0CQ=HYN)8_M#CRTC?<8FPV_.T+QDG@\5C>'M,T+7=)CFTUKZ-+1WM
M$DD($@>.7<7[Y.X=3US6L_A.U><7'VR]%P!'B7S 6W)NPW(ZX=AZ8-.U+NPU
M+%KXAMKS4$MK=&>.3[DP^ZWR[L_2K=_K&G:9_P ?U[!;G:7"R2 $@=P.IJ**
M'3O#NCKN=(;2U3F60]!U))]R?UK ATP>,M2@UC4[+RM-MSFRMY8P))O^FDG<
M+Z)^)K-\M_(-2MI&L:9K.JCQ!J6HVL*1Y33K62=08D/!D89X=OT'UKJ/^$DT
M/_H,6/\ X$+_ (T[_A'M%/\ S"+#_P !D_PH_P"$=T3_ *!%A_X#)_A3_=^?
MX!J-_P"$DT/_ *#%C_X$+_C1_P ))H?_ $&+'_P(7_&G?\([HG_0(L/_  &3
M_"C_ (1W1/\ H$6'_@,G^%'[OS_ -1O_  DFA_\ 08L?_ A?\:JVOC'0KS5)
M-.BU"$W*$  L-KY_NMT-7/\ A'=$_P"@18?^ R?X5#9^&-%L;^2^MM.@2Y<Y
MWA!\O^Z.@_"C]W9[_@&ILT445F,KW=U#8VLMS<.$AB0N['L!6,_BW2(O*+RN
MHDMEN^5^Y&2H!;T/S#CTJSXA.EC27&L9^QLR@@;L[LY&-O/;-8-CH'A.:9X[
M02.UI"J2-O<J5&T\D\$_**UIQBU>5Q,V)?$]A#I,6I;9VMYI1%"0HS(2< C)
MZ''4T67BW2+Z&25)S$D:!V,J[>" ?ZBLJ*;PK=Z=! )V>V-T+B&)T;#,6X55
M(Y7)Z"K&KZ-X>\^ZFO+O[.SIYDR+,%^15 QMZXPHZ>E5RPV:8M33?Q'I4;P
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MZPL?DG(8,H P.G/KSZU/>^%H=7U6ZNY;W-O+%&/+11D,%<!B?3#YQW[U)?\
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M17/?V1XB_P"AG'_@O3_&C^R/$7_0SC_P7I_C0!T-%<]_9'B+_H9Q_P""]/\
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ML,@CTQ4+Z;92'<]I S8QDQ@\8QC\N* ./A^(]K+J5O8'3+I9Y)?+D (;R_F
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4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #$ 9P# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]J?;Y3$QDD#G=U)'([5Z30 4444 %%%% !1110 4444 %%%% !1110 4444
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MHDD2-Y$5W^ZI8 M]!WIGVNV\LR?:(M@;86WC ;TSZT@.9\:?\?OA?_L,1?\
MH+5UE<GXT_X_?"__ &&(O_06KK* "BBB@ HHHH **** "BBB@ HHHH ****
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M_%%@9/)M9TE<]&4%\_[H'+5YEX"T/2#XP\0>2+O5)?,^070*(RD@L[9X)W'
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MWXH[94^6,97WO^!YKKFA>)=,N-)CMO&.L3+=WJ6\I\F,^6A!);A>.@ZUL?\
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M]E:PMU_:,TD(5F=<X,LI 4,W^ZH/XG/:@#H[FZTMQ#)<26TH6<1QLVUMLO0
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M!W#'0$G.?0U*WB71[)+"&U^>&YD\J$6Z?*H#;<_3<0./6K-SX<TFZ@BB>RC
MBC,<3(,&,'T/XFG-X?TI[6UMC91^7:IY<&!@QKQT/X"@![ZM#'KD6E&.7SI8
MFE5PN5 '7/IUIMMK"7%UJ,/D2HMBVUY."K'&<#'?&/SIS:)IS:BNH?95%V H
M\T$AB%S@'U R>*E73+-96D6!59M^X#@-O(+$CN3@4 8MIJV@W6A7/B*/3U\H
M*_FD6P,K =1ZG-7-&UW3-0GGL=.7:+..,R*B@+'N&0G'<#J.U6;?1--M;:6V
M@M(TMY0%:(?=('M^)I\6D:?!?F]AM8XKA@0SH-N[@#G'7@"@#*L/&>EZCJEO
MI\ G$\X<@/'MP%+#GZ[&Q]*Z*J46CZ=!<QW,5G"DT:E4<+RH))/\S^9J[0!5
M_LRP\Z2;[#;>;("'?REW,#UR<<YJ>&&*WB6*&-(HU&%1%"@#V I]% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M-^*=1UFSN+"'2()'\W>9&6V,HR,;5)R-H.3ENV*Z2B@#AAXK\3NXD_X1B6.(
M!@58,6)RN#P.GWAC'H:??Z]XF_M.-(=*N;:-8E9XS;B8-G.XB13@%<#"]3FN
MVHH XK2-<\5W-UI\%]I1A,A,ETYB(6-0I^0'IG..<]S@4ND^*->O-<BLKO1?
M(2XRZAMRF&-0NXMD<Y+%1[CTKM*,#.<<^M 'GFH:IXMFM8)/LJVY.J1H@;]V
M2N3\O)Y!XY[\UZ$I)4$C!QR/2FR11R[?,16VL&7<,X(Z&GUK*HG",+;7^=S2
M4TX*-MK_ (A11161F-2-(EVQHJ+G.%&.:4@'J,TM% #!+&9#&)$,@Y*Y&?RI
M]>97.@ZI)XKO)K;2;A+HZHES%J)<*@@"#<N<Y.>1C&.<U4DU+QIIMJ\\S7"3
M37,<-K:W#*6D,BLK 8SG8VUO3 - 'K%,66-W9$D1F7J P)%<AH<?B6V\87,-
M\]S<Z9Y>$GE*JH("XP!U).>PK#L?!VNV::EK-O+Y.IK)=?9H%4!I [C!9LX;
MY1\H/0F@#TZD9U12SL%4=23@"O-9!XU5;-[<:B\ N6V0S%!*T?R8\U@<#G?C
MKQBIY=&U8_#_ %?3YK>]NKMK]Y%CDD#-+'YP;"'/3;V.* /0T=9%#(P93T(.
M0:&8*I9B !U)->8G3O$=G%<R:597]AIMQ<O)%9V[IYT1\M0A()(5"X8D ]Q3
M[F#QO+<:C!/%+<)+;+C!58DDPF0@SSSN]* /3**\TU!_%^G6EW>RW=RL3++Y
MFXIB)1*NS9Z,4+<G\<5TO@6_NM2T"6XN99Y1]LF6%Y\%S$'(7)'!X[B@#IJ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0JK$$J"1R
M"1THHH 6BBB@ HHHH **** $*AE(8 @]0:%544*JA5'0 8 HHH 6BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 6$# 2(  A$! Q$!_\0
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MZU#!Y7B SR0.'C6]@4JK>8K%@5 P0!@<>OK0!TS>+- 26_B;5K4/8#-TI?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-LFH>592V\DTD1B4_<*_Q'D [C^52VFI7PUC4XKZ6S2RLPK!U5E;# D9)..
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MTNI)-=NK(8[&-8+7G@_(N=Q'J3F@#M*Q[SQ1I-AK<&CSSR?;I@K+&D+L &.
M6(&%&0>M;%<-KWA74K_Q='J%C%#;EVAW:@ERZR)&A.^,Q_=8,#@?7F@#;B\9
M:!/;WL\>HH8[+F9MK#@G:"O'S D$ C.3Q6=XMU.SUCX9ZO>6,PE@>V<9P000
M<$$'D$'J#7.0> =<^P&.0VJ2V-M!;6@64D7'E3^;N;CY<C QS@YI?$/A26'X
M?:S>:E-/#>-)<7A@MKEA$ID<-M8# ?''4>M,#TRU_P"/.'_KFO\ *I:BM?\
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M%O9K=2HB X+,JK'U^^2PX]ZSG\+6%EX>U30VU<S7^H;$\VY(5BP4")<  =$
M]3@TR^^'6C/>3:G=7UU:7%W'L=1<$H)F96W+N[[E&!TH Z;3O$EA?Z7#?.S6
M@EG-MY5QA768,5*'MG(/2J-QXULA?+:Z=:7FJE4$DSV*!Q$I8J">1DY!X&3P
M:QSH4&J^&[2PT#7(KJ:UU5;JYO-RNV_>6<X QG)X'2K%M\.X[*.-+/7-0MRT
M?E7;Q;0;E0[.,G'RGYB,KC@T 7KWQQIMCY?F)(P:9HB4*D)B18\L<\<L/?@U
M?/BK0O-@A75+9IK@ PQAQF3)(7'U(./6N:N? _A^[DO='NM2:5[V42M;,R[M
MHD\TJ!UP<\GTQ52Z\$:A8:G;2P7R?V9!);SW$MQ( 2(,[01MXPN!D'MDT =9
M9>+M&OFT^-;M(Y[^-GBAD(#?*<$'T.>/P-;E<=H?A/1+)]'-ZEI-K,$4LJ.
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M/AGPK!87TL<MVK,TLR$G?D\9)Y/%)<>,(3XE70;18WGD'RS&0%0<9Z=37/\
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M#Q!V'"DC&:I:/X4BTBZCN%U75KAD3;Y=S>-)&>,?=- '04444 8?BW2;G6=
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MT.0P/<&E:6-)$1W57D)"*3RV!DXK@YO U_:W\$6DW(@L84C6WD-PX>!%#;T
M P=Y.2>WX"HM$\%:M9WND7-\+67[!=R.H\UBX1XPN[. "=PST'6@#LUU_2'U
M5M+74;8WZG!M_,&_.,XQ]*T:X*Y\)ZQ=:Y=82SALY-234$O0Y,R;4 "A=OJ.
MN>F:SYO _B)],>);F)7S'F,73E9I%#;IFR.K9'R^W6@#TF.>*5Y$C<,T;;7
M_A.,X_6I*\[N_!6N7SSFXO(SN$S((YY%42&!$0CO@.I-1Z#IFM0>/(FNXKJ1
M(O/:>]=G"2AE0(N#\IP0V,>] 'I%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #+ :L# 2(  A$! Q$!_\0
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MV^S,\4 NH3+*&,:!QEMO7'TS5B@ HHHH **** "BBB@ HHHH **** "BBB@
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M1CGA&J3+!),91$%&%!7!'J:CD^%UJRJJ:E/&@E60H@P&P9#@_A)C_@(KOZ*
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MI_6O1*^PRW_=H_/\S[S*?]SA\_S84445Z!Z@4444 8_BH(?#-]YD_D((\F3
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M *_[G_T:U;= !1110!Y[XM_Y#TG^ZO\ *L*MWQ;_ ,AZ3_=7^5854!L>&?\
MD.6_U_H:\'\?_P#(_:Y_U]O_ #KWCPS_ ,ARW^O]#7@_C_\ Y'[7/^OM_P"=
M?:<'_P"\U/\ "OS.;$;(YRO3?@=_R.EU_P!>$G\Q7F5>F_ [_D=+K_KPD_F*
M^QSS_D6UO\+_ $.:'Q(LR?ZQOK3:=)_K&^M-K^6#X$]*^%O^IU#ZI_6O1*\[
M^%O^IU#ZI_6O1*^PRW_=H_/\S[S*?]SA\_S84445Z!Z@4444 9^N+*VBW7D7
M#V\H0E9$(# CL,]STJGX0FNKCPW;2WAG,Y+;O/(+]3UQ5CQ$L;:%<^;;RSJ
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MS@,K1R@[ Q R1VY ]: .PM[F&ZB$D$BR(?XE-2UG:+;6\%@KVV_RY0K .>0
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MD%@" -O'4Y[^E==10!RMCXBU6\O;&*33?LZ2R$2$@GY0&Z<<8(&<^M=5110
M4444 %%%% !1110 4444 %%%% '%^*HO$]_J\6FV,42:9,GSS!R"1QN5N.".
MH]>171:'HMOH>GK:P'<W5Y",%SZUI44 8'B?7Y-!AMY/L<D]O*Q65T."@QV]
MSSCZ55\+^&CIJO+<R>>HDWVOF#YXA@@DGU88R.GYUU! 888 CT-+0 5S!TW7
MF\2W'FW*3:/."=L@5A&.,*%]>H)[@UT]% $<$$5M D$*!(HU"JHZ >E2444
M016=M!<2SQ0)'+* )&48W8Z9_.IZ** *=[I5EJ$D,EU;K(\+!D)ZY!R/PSSC
MVJ:[N8[.TEN90QCB4LP49.!Z#O4>HZA!I=B]W<EO+4@8499B3@ #N22!7&WL
M>J>*]7.GR-);6,#!Y4VX!] 2.I!'W3ZGT% %W4;>7Q)K&FWNAZXT<$2D70A8
M,-C#*Y4\$DC!!Y -=19V<%A:I;6T:QQ)]U%& ,G)Q3-/TZUTNU6WM(EC0<G
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MHUG7+'1;*6>ZNHHF1<A6.3D\#@<XH ?K6I2:5ILEW':2713DHA P "223T
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "/ C # 2(  A$! Q$!_\0
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M (3;Q1_T,&I?^!+_ .-/_P"$$\6?]"[J7_@.W^%'_"">+/\ H7=2_P# =O\
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MWBC_ *&#4O\ P)?_ !H_X3;Q1_T,&I?^!+_XT_\ X03Q9_T+NI?^ [?X4?\
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MWBC_ *&#4O\ P)?_ !H_X3;Q1_T,&I?^!+_XT_\ X03Q9_T+NI?^ [?X4?\
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MJE_X69I'_/CJG_?A?_BJ\WHH_LFCW?X!_K%B?Y8_B>D?\+,TC_GQU3_OPO\
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M_P!D=?RK15J_6!F\/A^DSG2K*Q5E*L."",$4WH:NZG=B_O?M 5P2BAMQR25
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MMX [\DC/M6+CVI<8Z"KCAVI7YG8SGBE*'+R*_<Z:#5$>RTA+R=&B,SBX! Z
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M_GQE_P# N;_XJC_A7_AK_GQE_P# N;_XJNIXHXH]K4_F?WL/JU'^1?<CEO\
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MM:G\S^]A]6H_R+[E_D,@\"^%[F%9HK.5D<9!^U3#_P!FJ3_A7_AK_GQE_P#
MN;_XJND@@CMH$AB7"(, 9J7BCVM3^9_>P^K4?Y%]R_R.6_X5_P"&O^?&7_P+
MF_\ BJ/^%?\ AK_GQE_\"YO_ (JNIXHXH]K4_F?WL/JU'^1?<CEO^%?^&O\
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M >A%'M:G\S^]A]6H_P B^Y?Y%:'P]X%N)"D7S.+47A NYL^2<X?[W3BD;0?
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M%MJA=QZG%25RNB:5JEAJZ22SW<EL?M2.)[DR +YJF# )_N;N>OK754 %%%%
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MO+7[-/=%^7^7;NV9V@]^ *O_ /".:'_T![#_ ,!D_P */^$<T/\ Z ]A_P"
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MX^Q2/(\$,;[!;^8,.%P<$$Y(!!QD]JAN/#"7MNJW>OL\\4;QP3(D:&(D)L8
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M*I+RL<KGGB9AVZ UT5H\5M:10/>I,R(%,C,H+'U(& /PJ+_A'-#_ .@/8?\
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M=)]NM?\ GY@_[^"C[=:_\_,'_?P4 6**K_;K7_GY@_[^"C[=:_\ /S!_W\%
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MBSF9$8\[$+$G:HP!GGOWK9-Y9L,-<0$>[BA;RS486X@ ]G% %FBJ_P!NM?\
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M0N_.WW(_EFI;J_O&O[J"UEMX4M8TD=IP2&W9[YX  ZTG1DG9Z#6+IRC>+O\
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M_P!\R?XT8\3?WM)_[YD_QH<I-W;U!4X*/*EH:4EM#),DKQJTB*RJWH#C(_'
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K\BMJ7_7$TF/$W][2/^^9/\:JZC8>(=2T^>SEETM(YEV,RI(2![<TBS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "P 7(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH S->URU\/:6]]=Y*@A51?O.Q["J&F:]H/C&Q:
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M&\Z"7''4,I_Q%?2-C<B\L8+E>DL:OCTR,UTXN.JD<N&FM8EBBBBN([ HHHH
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MPE0HK[AM89!-8O\ PCVW1WL1<O)_HWDHL@&Q6 QN QD'\:EU'1VOX+&(NA2
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MY ]%?J/H:LV/B&TNI_LMPKV=YW@N!M)_W3T8?2J4^CT+517M+1FQ32ZJRJ6
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M$X]P<COFJB[,F2NK'!>!;L^+5D:'3Y+;P[8OY=DTC?-<XZLP[G/)/OCUKTD
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MQP2;@U:=K$V,D'G@#UKH!H=J&R,C\*M06,$#;E7+>I[5T3Q<6M#&&&:>HME
M8+5$;[W4U)-!%/&4EC5U/4,,BI**\YR;=SMY5:Q@R^&((Y3-IT\ME+_TS.5/
MU%2QW>JV.%O;874?_/:WZ_BO^%;-%6ZC?Q:F*P\8N\-/R^XB@N([F(21DD>X
G((J6BBLS=>84444#"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $5 E(# 2(  A$! Q$!_\0
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ML8+N($1S('4-UP:<8X),H8HVXY!45*BA5"J J@8 ':@!]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U
MNB_44ZFMT7ZBG4 %9NN_\@2Y_P!T?S%:59NN_P#($N?]T?S% $>M/:0QVDMS
M:).?M421Y S&S, &!]JK10QQ^-YFCC1"^GJ6*J!N/F'D^M6]9:U2WMC>1NZ&
M[A"!.S[AM/TS4*_\CM)_V#E_]&-0!M4444 %%%% !1110 4444 %%%% "$'.
M1BCYO44M% "?-ZBCYO44M% "?-[4?-[4M% #<'VIU%%  >E(O0?2E/2D7H*
M%HHHH R-+C231'29%DC,DVY&&01O;C%9VHQ65WX*%REE'&HMD,2E03&,C !]
MJT]'P-';=T\R;/\ WVU4+UK=O S-:HR6YME,:MU"\8S0!T@Z44#I10 4444
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M[;(7ROOMSRQ'3.,=ZYP@@D'J.#6E)4:FT5]R[M=C*M+$TGK-V]7V3[^9I?\
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M!VR$8W<FM&LC18;:S-WI]M)<.+:7D3-NV[ANPI].: ->BBB@##U;_D9O#_\
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M-3U$PN[3%T\Y3T4[!C'X8K1K%\R/3=>V,)6;4W^5@!M1D3H><\@$T ;5%%%
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MNV:5%;<L9<L<#@9('..V:Z&BE9#N<OJW@72K\6HM8Q9^5?K>RA&?$I!)88W
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M+T'TH 6BBB@#-T+_ )!@_P"NTO\ Z,:M*LW0O^08/^NTO_HQJTJ "LTW*?\
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M110 C?=/TK)\,?\ (M6'_7+^M:YY&*YVTT/5[&U2VM]="PQC"!K-20/<YYH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&MT7ZBG4UNB_44Z@ K-UW_D"7/\ NC^8K2K-UW_D"7/^Z/YB@#2HHHH ****
M "LO7&LULHC>J[1?:80H3KOWC;^&<5J5F:W#!-I^;@3E(I8Y<0J68E6!' Z\
MB@#3HK-AU>WGMYYDBNPL(RP:W=6;_=!&3^%%MJ\%X9!'!=KY:;SYENZ9'H,C
MD^U &E169::S;WLXAC@NU8J6S+;.B_F1UI+?6[:YN5MT@O%=B1E[9U48]21@
M4 :E%98UNW:[^S>1>A_,\O)M7VY]=V,8]ZL6^H6]S=W-K&6\ZV*B164CJ,@C
M/4>XH N4444 %%%% !1110 4444 !Z4B]!]*4]*1>@^E "T444 9NA?\@P?]
M=I?_ $8U:59NA?\ (,'_ %VE_P#1C5I4 %%%% !1110 4444 %%%% !6=>RQ
M1ZAIR20"1Y)66-R?]6=C'(_ $?C6C5*^MGF6.:%(C=0,6A,I.T$C!SCV)H N
MT5G6_P#;&R;[0+$/M_=>67QN_P!K/;Z4MI_:WF-]L%ELV_+Y)?.[WSVH T**
MS+7^V?/7[4+'R<'=Y)?=[8SQ20MJXO56Y2Q-J=V6B9@X].#P?>@"K?0:E#X@
M34+*TAN8S:^0RO/Y94[MV>AR*D^W>(/^@+;?^!O_ -A6U10!'&6,:EU"N0-R
M@YP?3-/'WC2T@^\: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &MT7ZBG4UNB_44Z@ K-UW_D"7/\
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MI.<>U 6(/[9L_P#IY_[\/_A2'6+,D'-UQ_TPD_PK4HH S/[9L_\ IZ_[\/\
MX4?VU9_]/7_@/)_A6G10!D2:]81!3(]P@9@H+0.,D]!TJ]:74=W&SQ;\ X.]
M"I_(UC>(=773I;>.XL/M$;G=$P?&)5Y4'T^OZ5K:;>#4+&&Z"%!*@;:3G![B
M@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 -;HOU%.IK]!]:YRP\8V>H7$<,,$K,]V;8%"& &TL'..
M@(!H Z6BL";Q9IMO,T<C2KM<Q ^6WS.&VD#CD9[U9TG7+;6'N$A5M]O(T<@(
MR%()&"?7'./0T 7196PO6O!!']I9-AEV_,5],U9HHH **** "BBB@"I)IUG-
M.DTEM$TJ2>8KE>0V,9^N*GF8I#(XZJI(_*I** /.K'QMJ;I8?:(X6<1LET=I
M13(=I1L_PJ%8$_6KEQXSOC;3O!90*4)B60R%@7"EMP&.4P#S7:&&(KM,:$$8
M(VCI1Y,6W;Y:;>F-HQZ4 <6GC&_M[0/=6L$AR7\U9, 1[V7)7&2?E[9ZUVR,
M'16!X89%,-M"P :&,@= 4'%34 9L>A:7%()$L8%<2F8';T<]6^M:5%% !111
M0 4444 9_P#8^G>;YOV* R>;YVXISO\ 7ZU?7[HI>U(OW10 IZ4B]!2USNH^
M*[73-2FL9(9)&BMFG)C()) SL"]<[>: .BHK%NO$5E9-"LPE5I(EF.8SA58X
MY('7VJ&S\5Z??:C#90^87GB$L65Y89()QV QUZ<B@#7N+.VNS$;B".4Q.'C+
MKG:WJ*LT44 %%%% !1110!5N;*WO 1<01R@J4^=<_*>H_' J6*)(8EBC541
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MP(P!G'(ZBK]9/EW?_"0^>$7['Y&TMM7.[/3IN_I6IYB^M #J*;YB^M'F+ZT
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MCWY_E5\??;\*R]82]EA@%B$+K,K/O4' '?D?RY]*TUY9B.E #Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "5 G # 2(  A$! Q$!_\0
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M[9%;0UA)?,QGI.,OE_7S1KT445B;!1110 4444 %%%% !1110 4444 %%%%
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M_GX_P_R.W_X6/<_\^$7_ 'V:/^%CW/\ SX1?]]FN(HH^H8;^3\_\P_M?&_\
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MG*N#,^'<.W/5AT/UJQ=7=]YCQ7,K[P-K*<=#S_A6M%J>GFTN%D;!D611%Y?
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M+,HE,D\3[)QY>S:V,X ],$<T?VGB>Z^X/["P7\K^]G)_\*YOO^?VV_\ 'O\
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M6.#].,8[UZ#7FOPML[:"\U>2".5"6"-E"J9#'[O KT.\O(;"TDNKAML48RQ
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M'VNW_P">\?\ WU4N!Z"C ]!1[H>\1?:[?_GO'_WU1]KM_P#GO'_WU4N!Z"C
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M*=6\5FU256D_=P-*,6P_?$3*H!R!CY2>@'K7=>?+_P ^S_\ ?0H\^7_GV?\
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M5/SK3_GF_P#W[;_"CSK3_GF__?MO\* +E%4_.M/^>;?]^V_PH\ZU_P">;_\
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G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "K 9<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^O"M0_Y"
M-S_UT;^=>ZUX5J'_ "$;G_KHW\Z]#!;R/&S7:'S*U%%%>B>(%%%% !1110 4
M444 %%%% !116SHZVRV-Q/<BWVK-&&,R%LH<Y"X[FID[*Y<(\SL8U%;D]I:7
M-E"8EE246[2H!C!7S, 'OG!ZTK:-:I+ 'DE3S/,3RRZY\Q2 %W8P,YJ?:(OV
M,NAA45K3Z7;V^G^;+.4N&0NJ$^C8VXQU]\U&I5=#<SP1+N(%NP3#L0?F8GN,
M<4^9/8GV;6C,VBBBK,PHHHH **** "BBB@#>\.Z^VF2BWN"6M'/_ '[/J/:N
M_5E=%=&#*PR".A%>15U/A'5;E;@:<R-+"<E2/^6?_P!:N>K3O[R/1PF(::IR
MVZ':T445RGJA1110 4444 %%%% !1110 4NU@,[3CUQ0GWU^M>;:/I]]?R&X
MLK&YCNUU1RVIO=G8(UD^9=F3G*Y7&.]2W8:5STCI17 :5K^IZ7HMH]W-9O!-
M:3RPM('S&4;C>>2V0>@%3)XIUMDN[<6ZO<07$2E_LVV3RW0L2(2V6((]<X[4
MN=#Y6=S2@$] 3]*X*3QKJ,H#6-O%<+!;133,D3;968D$98CRP-IY.>?I6_XD
MLUU&U2)"9;H1O)!9M<^0)6Q]YB.?EZT^;L%NYNT5F>';K[;X;TVY,KS-);H6
MDD&&8XY)K3JD2%%%% !5NSNC$VQONFJE%)I-68TVG=&^"" 0<@T5G65P^?+(
M+#VHKDE!IV.J,TU<TJ\*U#_D(W/_ %T;^=>ZUQTWP]L9YWE:\G!=BQP!WKHP
MU6--OF.#'X>I64>1;'F5%>E?\*XL/^?VX_(4?\*XL/\ G]N/R%=OUJEW/,_L
M_$=OQ/-:*]*_X5Q8?\_MQ^0H_P"%<6'_ #^W'Y"CZU2[A_9^([?B>:T5Z5_P
MKBP_Y_;C\A1_PKBP_P"?VX_(4?6J7</[/Q';\3S6BO2O^%<6'_/[<?D*/^%<
M6'_/[<?D*/K5+N']GXCM^)YK17I7_"N+#_G]N/R%'_"N+#_G]N/R%'UJEW#^
MS\1V_$\UIP=Q&8PQ"$Y*YX)KTC_A7%A_S^W'Y"C_ (5Q8?\ /[<?D*/K5+N'
M]GXCM^)YR)Y0 !(^ NT#/;.<?3-3?VE?>8'^V3[P" WF'(%>@?\ "N+#_G]N
M/R%'_"N+#_G]N/R%+ZS1_I#6!Q*Z?B>=_:[GR&@\^3R6.2FXX)Z]*=]NNS:_
M9OM,OD8QY>\[<?2O0O\ A7%A_P _MQ^0H_X5Q8?\_MQ^0H^LT?Z0?4<3V_$\
MUHKTK_A7%A_S^W'Y"C_A7%A_S^W'Y"G]:I=Q?V?B.WXGFM%>E?\ "N+#_G]N
M/R%'_"N+#_G]N/R%'UJEW#^S\1V_$\UHKTK_ (5Q8?\ /[<?D*/^%<6'_/[<
M?D*/K5+N']GXCM^)YK17I7_"N+#_ )_;C\A1_P *XL/^?VX_(4?6J7</[/Q'
M;\3SRTM)KZZ2WMT+2.>/;W/M7H^D:1#I%IY4>&E;F23NQ_PK3TGPK8Z1$PA+
MO(Y^:1NI'I]*T?[.B]37/4Q,9:+8[\-@I4US2W,NBM3^SHO4T?V=%ZFL?:Q.
MSV<C+HK4_LZ+U-']G1>IH]K$/9R,NBM3^SHO4T?V=%ZFCVL0]G(RZ*U/[.B]
M31_9T7J:/:Q#V<C+HK4_LZ+U-']G1>IH]K$/9R,L<'-16UK!9Q&.WB6)"Y<J
MH_B)R3^-;/\ 9T7J:/[.B]31[6(>SD<X^BZ9+;I;R64+0I&T:H5R K?>'XU!
M_P (SHODO%_9\6UV5V/.XL!@-NZYQQFNJ_LZ+U-']G1>IH]I ?LYG,2>'='E
M^S[].MR+=0D8VX 4'(&.XSS@U/J&E6.K1HE_;).J$E=W52>#@]>>_K70?V=%
MZFC^SHO4T>T@'LY&3%''#$D42*D: *J*,!0.P%.K4_LZ+U-']G1>IH]K$7LY
M&716I_9T7J:/[.B]31[6(>SD9=/CC:5PJBM'^SHO4U/#;I #MZGO2=56T&J3
MOJ);P+ F!U/4T5-17.W?5G0E;1#9'$43R-]U06/T%<S_ ,)[HH.-T_\ W[KH
M;W_CQN/^N3?RKPEOO'ZUUX:C&HGS'G8[%5*#BH=3U7_A/M$_O3_]^Z/^$^T3
M^]/_ -^Z\IHKJ^J4SSO[2K^7W'K">.]&DD5%:;+' _=UTU>$6?\ Q^0_[X_G
M7MNH,18R8.-V%/T) /\ .N3$48P:4>IZ6"Q,ZRDY]!/MIDR;>WDF4'&]2 #]
M,D9H^U7/_0/E_P"^T_QJTJA5"J % P .U+7-==COL^Y4^U7/_0/E_P"^T_QH
M^U7/_0/E_P"^T_QJW11==@L^Y4^U7/\ T#Y?^^T_QH^U7/\ T#Y?^^T_QJW1
M1==@L^Y4^U7/_0/E_P"^T_QH^U7/_0/E_P"^T_QJW11==@L^Y4^U7/\ T#Y?
M^^T_QH^U7/\ T#Y?^^T_QJW11==@L^Y4^U7/_0/E_P"^T_QH^U7/_0/E_P"^
MT_QJW11==@L^Y4^U7/\ T#Y?^^T_QH^U7/\ T#Y?^^T_QJW11==@L^Y4%U<=
M["8#UWH?ZU/!.EQ'O0G@X((P0?0CM4E51A-48+QYD66]R#@?SHT8:HM4445)
M04444 9NKZY9Z)'&]X7"R$A=JYZ5D_\ "?:)_?G_ ._=9_Q(_P"/*R_WV_I7
MG->IA\)3J4U*6YYM?%5*=1Q1ZM_PGVB?WY_^_==%:7,=[:17,.?+E0.N1@X-
M>#U[7X=_Y%S3O^O=/Y5GB\/"E%.)IA<1.K)J1IT4UW2-2SLJJ.I8X%0?VA9?
M\_EO_P!_5_QK@2;V.UM+<LT56_M"R_Y_+?\ [^K_ (T?VA9?\_EO_P!_5_QI
M\K[!S+N6:*K?VA9?\_EO_P!_5_QH_M"R_P"?RW_[^K_C1ROL',NY9HJM_:%E
M_P _EO\ ]_5_QH_M"R_Y_+?_ +^K_C1ROL',NY9HJM_:%E_S^6__ ']7_&C^
MT++_ )_+?_OZO^-'*^P<R[EFBJW]H67_ #^6_P#W]7_&C^T++_G\M_\ OZO^
M-'*^P<R[EFBJW]H67_/Y;_\ ?U?\:/[0LO\ G\M_^_J_XT<K[!S+N6:*K?VA
M9?\ /Y;_ /?U?\:/[0LO^?RW_P"_J_XT<K[!S+N6:*K?VA9?\_EO_P!_5_QH
M_M"R_P"?RW_[^K_C1ROL',NY9HJ&*ZMYFVQ3Q2'T1P:FJ6K#O<**** (+W_C
MQN/^N3?RKPEOO'ZU[M>_\>-Q_P!<F_E7A+?>/UKTL%M(\/-?BC\Q****[SQR
M>S_X_(?]\?SKVS4?^/)O]]/_ $(5XG9_\?D/^^/YU[9J/_'DW^^G_H0K@Q?Q
M1/9RSX9_(MUS>HSWMOJ>IQQ6]U(9[/%LR1%XPX5N">@YQUKI**\T]LX:4^*R
MT3^9<X$N\(D2 #!=0IXY4C:3GZT/JGB6XN%\N+4+?_6LBFT4HX"#8K';E26S
MR2.!7<T4 <6+KQ3>NTD9N+2+?&JJUNFXJS[7)R.,+DU0OKOQ?<EK<V]VL7DX
M=XXAG<I4AEXZGGC/X"O0ZJ:CJECI-M]HO[J*WBW!0TCA<DG'>@#F;]/$NIZ)
M'8I$(WG?BY:0Q2"-22"X5?E8X48&>IZ5%+?:U-:W)U'3KZ4>4H^RP1X1B,#.
M\?,<MNR.?EQQS6U/XEBACNKA;.XDL[<2!KA "I9 =PZYQQC/K5J]UJUL=4LK
M"7=YEUG:PZ+Z9^IX% '(_9;N3%NJ:N&2RVR7/E29FROW5#'"A1G@\D_K-/::
MN]AIP2VN$94=85B!3RW\P%7<9^7*9SGN:Z73M<349PBVTT<;QF2*1\?.H.,X
MSD>V>M5['Q58ZA<6,$23"6[:90K+C9Y?7=Z9XQ]10!CZQ;ZE/K%Q/9P7;K+&
MH;='M"Q ?,(VSD.2",$9YS422>)(K5K&TM[I(Y6#6[.O,49:3(9C]TXV8SR/
MPKNJ* .,2&\*I%IUA?V\$H,<QN"<@D*"RY.1_$<]R,UEW.K^(=%TQ(KN26!]
MY$!2)9"X_A4Y'?G=Z<5Z/3617QN4-M.1D9P?6@!1T&>M5C_R%5_ZX'_T(5:J
MJ?\ D*K_ -<#_P"A"JCU)9:HHHJ2@HHHH X?XD?\>5E_OM_2O.:]&^)'_'E9
M?[[?TKSFO?P?\%?,\/%_QF%>U^'?^1<T[_KW3^5>*5[7X=_Y%S3O^O=/Y5AF
M'P1]3; ?&_0GAB6YFDGE <*Q2('D*!P3CU)S5KRX_P"XOY5!8_\ 'NW_ %T?
M_P!"-6:\F3U/4BM!OEQ_W%_*CRX_[B_E3J*5QV&^7'_<7\J/+C_N+^5.HHN%
MAOEQ_P!Q?RH\N/\ N+^54=8U:+1;$W<UO<S1*<-Y";BON1D<4Z'6+"78INHH
MY6;9Y,DBAP_4J1GK[47"Q<\N/^XOY4>7'_<7\JSSXAT=94C_ +2M<N&((E7'
MRXW<YQQD?G4@UK2VB:5=2M#&I"LPF7 )Z#.:+A8N>7'_ '%_*CRX_P"XOY51
MDUS2XY5B-_;F5IE@V+("0Y. "!TZ5+)JNG12R127ULDD6-ZM*H*YZ9&>*+A8
ML^7'_<7\J/+C_N+^558-7TVZF6&WU"UEE;.$296)P,G@&KE%PL-\N/\ N+^5
M'EQ_W%_*G447"PWRX_[B_E1Y<?\ <7\J=11<+$,MK#,FUHQ[$#!!]0>U)9N[
MVX$ARZ,48^N#C-3U6L_N2_\ 79_YT^@NI9HHHJ2B"]_X\;C_ *Y-_*O"6^\?
MK7NU[_QXW'_7)OY5X2WWC]:]+!;2/#S7XH_,2BK+V3QV:7+2( XRJ9.XC./Z
M56KN3N>0TUN3V?\ Q^0_[X_G7MNH_P#'DW^\G_H0KQ*S_P"/R'_?'\Z]RN(1
M/;O%G&X<'T/8UP8QVE$]G+%>,_D2T53%^L2A;I'CD'!PA8'W!':C^U+3^^__
M 'Z;_"N#E?8]CF1<HJG_ &I:?WW_ ._3?X4?VI:?WW_[]-_A1RR[!S+N7*KW
MEE;:A!Y%W DT>0=KC/(.14?]J6G]]_\ OTW^%']J6G]]_P#OTW^%'++L',NY
M0N?#%K<BZC-S=1V]P'+0(^$#N"&8<=>3P>,\XJ.3PG973M-?337EW\@2YEVA
MXMIR-N  .>OK6G_:EI_??_OTW^%']J6G]]_^_3?X4<LNP<R[F?%X4TY;@22^
M9<1HACBBE.5B4D$@=SR!C.<=J=8^%]/T^_6\A\WS5)(W-D9*E3^8(_(5>_M2
MT_OO_P!^F_PH_M2T_OO_ -^F_P *.678.9=RY15/^U+3^^__ 'Z;_"C^U+3^
M^_\ WZ;_  HY9=@YEW+E%4_[4M/[[_\ ?IO\*/[4M/[[_P#?IO\ "CEEV#F7
M<N55/_(57_K@?_0A2#4[4G 9R?3RF_PI;=9))WN9$*;E"HAZA>N3[G^E-)K<
M+I[%JBBBH*"BBB@#A_B1_P >5E_OM_2O.:]&^)/_ !Y67^^W]*X*YLGM8T:2
M2,E@#L4G(R,\U[V#:]BOF>)BT_:OY%:O:_#O_(N:=_U[I_*O%*]K\._\BYIW
M_7NG\JQS#X(^IK@/C?H6K'_4-_UT?_T(U9JM8_\ 'NW_ %T?_P!"-6:\F6YZ
ML=@J$W4(NC;;QYPC\S9WVYQG\ZFK(O=.O9-82]M98 C0>1*DJDG;NSE<=^:D
M9>;4+1(U>2XC0,5 WL <MT'U-2M/"A :5%). "P&:XY? $:PH/.A:1=N]FA!
MW[0@&?IL./3-+_PAMXUU#)//8W,<<R2;9(#D;$"*0?48S]<>E '3:I;V^HZ?
M+9RW C64 ;@PSU!X_*L#4?#&D-<_VE+>B/87N'.%;*[]^1QV/>JZ>!'EB=;V
MZAF;R1%&?*^YC8 WUPGZU'>?#^6XN<QW\<4"K(L<8A&$5E==O^[\V<9QQTH
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MB(I)4.5898G:./>HI$\0O;7!OM-EOI/*4" 3((6(P,XSG.X%CR."!3=1@O\
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MSV%'V ?\_-U_W]-.L?\ 4-_UT?\ ]"-6:\UMIV1Z"2>K*GV ?\_-U_W]-'V
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M -_3_A1RAS%FBJWF7O\ S[P_]_3_ (4>9>_\^\/_ ']/^%'*',6:*K>9>_\
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M:X\HHCGA=J[2 .@Y&?Q% &QI2W::5:+?G-V(E$QSG+8YJW110 4444 %%%%
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MY^__ "&O^%'U6?=!]9AV._HK@/\ A(]6_P"?O_R&O^%'_"1ZM_S]_P#D-?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !S >$# 2(  A$! Q$!_\0
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M^TAC#=,X5MK;7/!]*],\'QB;0(WD9V82-SO/K]:\MM[2*U,ACWDR$%BS9Z#
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M._;OB \KD612+S)95^6/<4.\)'C/\.%;/?=BN^6.DFU9')3P]X)\W3L>*?\
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M_P"Z/^^A_C64VM:>(+B9;M)%MT9Y/+.X@*,G^50P>(]*GB63[=''N .V0[6
M/3([4?,++L;?V.?^Z/\ OH?XT?8IO[H_[Z'^-8#^*M%21$_M&-M_1ER5'#'D
M]ONFK,.N:9<%A!J-O(RQF4A7R0@ZG'H,&B_F%O(UOL4W]T?]]#_&C[%-_='_
M 'T/\:Y=_'&AH$)N9?G17 $3$X8L/YJ<^E;Z/O17!.& (SZ&C?J#26Z+/V*;
M^Z/^^A_C2K9S!A\H_P"^A_C5?)]:52=PYIZBT-W5H7EAB"@$CW ]*R/L4_\
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M'NS>2&V,846^?E#=S^57!QUU:_KT,JD9NVB?Z?B(FI:;%&L<=U;JB@!55@
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MH]SNPO4[+[W_ )%RBJ?]DZ?_ ,^4'_?L4?V3I_\ SY0?]^Q1[G=A>IV7WO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #/ ;L# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I"P! ) )]Z"0!DG '<UQFJ^#QJ&I3W<.L?9_,NOM"A6)*'RU0
M@?-CG:3TXSQZT =GN&,Y%+D'H:X<^$9Y+&QM9-7@ LT9%==V7!*MC[W )!4C
MGY>XK5\-Z VC7,TC7Z7!>)$PH(^ZH'.6/IQZ ]Z+ ='1110 4444 %%%% !1
M110 457OKI;'3[F[9&=8(FD*+U;:"<#WXJIH.LC7-.-X+2:U'F%!',,-@=#C
MMD$<&@#3IKNL:EG8*HZEC@4ZJ6JZ9#JUD;:?@;E=6 R58'((H G6[MFF\E;B
M(R\_('&[CKQ[9IG]H66S?]LM]H4OGS5QM!P3UZ9X^M<U:>!(M/NY+FWU&=Y'
M>1R9U5CE\@_, #W;ZG'I5'_A5UCL(&H7&XCKM&,C(''IACQZ\T =Y14=O"MM
M;10(6*QH$!8Y) &.:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_%9
M(\):L02#]DDY'^Z:^;?/G/263\S7TEXK_P"12U?_ *])/_037SGIT\D%]'Y;
MJ@9L/N^[COFO9R[X)>IU49.,&T%PEU;>5ODD_>('')XSVKNOA%*[^)[@,[,!
M;-U/N*YS4]6CGLG^Q2@%7VOD8)7U'M70?!__ )&>Y_Z]C_,5UXG^#(J[Y&M[
M'MM%%%?-G&%%%% !1110 4444 9OB"*.?PYJ4<RAD-M)D&/S/X3CY>_TK)^'
M[1-X4A, B$>\D>4NU><'C\\'WS6CXI\L>%M3,L_D*+=B)-X3#?P\G@<XZU0\
M!PW,/AB/[5&R.\C.,N&#*<892/X3V_.@#IJ**HZO=W5E8F>T@69PZ@JQ(^4D
M D8ZF@"]17%V/C&_GO");-#:*TJ^8L4BE]N<8STYP.>NX$5F'QWXD$#M_8"Y
M$>=WEO@<M\V.I P%QUR<]* /1Z*CMY'EMHI)(S&[H&9#U4D<BI* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH Y[Q%I.J7TOFV%TZK]F>(PF=HU+$C#97G(P:S;G0?$DFGWUL-49I;@
MQF"82%3"%&,$=\\9QU(.>N*YG4]1ODU2Z5+NX"B5@ )#QR:QAXEO#K9TW[;<
M;Q#YG^L/7/3\J]%8!M7YC=T;6N]ST>Q\-ZG9:Q;W7]H2/$9Y)9D:XD90""
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M9Z$@?B 2/4"M^WGCNK>.>%MT4BAT;U!Y%>>'4? SHV=(E(=64G;U#')YW_\
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M ,A9W@C:5-DA4%ESG:<<BGT44 %%%% !1110 4444 %%%% !1110!R7Q"_Y
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MEV$EA$"W5N=N?O9"C']TDT >A45' 9&@C,RA92H+J#D XYJ2@ HHHH ****
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M&;IU%=5XKU#3M.\$:/)?VL]QN2)8Q#+Y94^7R<\]O:N!_P"$G\/_ /0)U/\
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M>Q26D8\B*)8QN^7C+-74Z<O8\U]".M_Z_P"&-B]T#3M0O%N[F%FG4 *XD9<
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M,X8_#AB<_P!H#_OBC_A7#?\ 00'_ 'Q6GXS\.:QKZ0C2=8?3G2*6-F5V&=X
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M?1_,!#L"&P%W9SG.%'-;>T75LCE\C$T<>%K2UN;*VU*9A<6Y$IE< A'+?-G
M ))/^%+)I?A:35/MK:H\MQ(D16,S C:!L7C&<9;IGKZ5LKX.T)5*BR&TC!&]
MN?3O2CPCH@VG[&,@YSO;).[=D\]<\T<\;WNPY6<OIGAGPY(L:W&N"\N9S(B-
M&RH&W +@+@\@=/7/>MVV\":5:3I-'-=EEN/M'S.IW-N#8/R],J.G/O4R^#M+
MBO[.YMU>$6I!"*QPVW[N?IBNAI2J/HQJ*ZH****Q+"BBB@ HHHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 <D# 2(  A$! Q$!_\0
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>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>atnm-20250930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 14 19:35:07 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://www.actiniumpharma.com/20250930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:atnm="http://www.actiniumpharma.com/20250930" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" id="atnm_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="atnm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" id="atnm_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" id="atnm_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" id="atnm_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies" id="atnm_r_CommitmentsandContingencies">
        <link:definition>995307 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Leases" id="atnm_r_Leases">
        <link:definition>995308 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/OtherRevenue" id="atnm_r_OtherRevenue">
        <link:definition>995309 - Disclosure - Other Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Equity" id="atnm_r_Equity">
        <link:definition>995310 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" id="atnm_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/LeasesTables" id="atnm_r_LeasesTables">
        <link:definition>996002 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/EquityTables" id="atnm_r_EquityTables">
        <link:definition>996003 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" id="atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable">
        <link:definition>996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" id="atnm_r_ScheduleofDilutedNetLossPerShareTable">
        <link:definition>996006 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" id="atnm_r_CommitmentsandContingenciesDetails">
        <link:definition>996007 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/LeasesDetails" id="atnm_r_LeasesDetails">
        <link:definition>996008 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" id="atnm_r_ScheduleofComponentsofLeaseExpenseTable">
        <link:definition>996009 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" id="atnm_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable">
        <link:definition>996010 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" id="atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable">
        <link:definition>996011 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails" id="atnm_r_OtherRevenueDetails">
        <link:definition>996012 - Disclosure - Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/EquityDetails" id="atnm_r_EquityDetails">
        <link:definition>996013 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" id="atnm_r_ScheduleofStockOptionActivityTable">
        <link:definition>996014 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" id="atnm_r_ScheduleofRestrictedStockUnitActivityTable">
        <link:definition>996015 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" id="atnm_r_ScheduleofWarrantActivityTable">
        <link:definition>996016 - Disclosure - Equity - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWarrantActivityAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="NonCashActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonCashActivityAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageDiscountRatesAbstract"/>
  <xs:element name="LeasesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesTextBlock"/>
  <xs:element name="OtherRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueTextBlock"/>
  <xs:element name="NatureOfBusinessPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
  <xs:element name="LicenseRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LicenseRevenuePolicyTextBlock"/>
  <xs:element name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
  <xs:element name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock"/>
  <xs:element name="LesseeLeaseLiabilityMaturityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LesseeLeaseLiabilityMaturityTableTextBlock"/>
  <xs:element name="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable"/>
  <xs:element name="EquityScheduleofRestrictedStockUnitActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
  <xs:element name="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MilestonePayment"/>
  <xs:element name="NetSalesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetSalesPercentage"/>
  <xs:element name="OtherRevenueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_OtherRevenueDetailsTable"/>
  <xs:element name="NonRefundablePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonRefundablePaymentReceived"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsTable"/>
  <xs:element name="NetProceedFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetProceedFromIssuanceOfCommonStock"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="FinanceLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeasesMember"/>
  <xs:element name="GrantRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_GrantRevenueMember"/>
  <xs:element name="OperatingLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingLeasesMember"/>
  <xs:element name="OtherRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueMember"/>
  <xs:element name="RevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RevenueMember"/>
  <xs:element name="VestedUnissuedSharesOfCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_VestedUnissuedSharesOfCommonStockMember"/>
<!-- [WMV6][9LCdBimTQvv07iiSvdaXLe+ZkheIBE4Gwig/iqxbXET+NK/Au7fdaVTDUHDe8mpLH0J3DPeZIkRMyOi6S718Z5+bho9xzhwV4fmWsz9tIX4gp+VsuItPxtBh+//avSXO/RD5mkhhWRudN1aLgjktolaj5n0Vct0UvoVU/AyUrUKjlC56RmSse/0+faniydbcQ/A3nLQ/O7/8bkKtR9mKpQO6tkbNl4pA+FwHes5UhGccJTNAGMTIixpUyQ2A2buoAWKoJ9m6egWWVlkfuHfWgqmoupoYNnS3QSBoKpFFAKS6lpxMQNT9I/NF6ngWRvd6jeLz6tNG0P2e11wNKNjxQRMNLoGtevDydD42BeGWR+2mzGwnLX4YwAix] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>atnm-20250930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 14 19:35:07 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
<!-- [WMV6][G+IzaXXCeDyfA5eExPKhMDeCZOtSXBdPPoMkYjJgKWPZMA+tL7w8T3d1c2MLEZ6R0lb8Ek7Zr/PLwMnUA66baEFM7OS5FRDWMcI/Uj3tyBsGvML4XCwSbDLl8Vpoi8i/0HjhkGYcDJCk8wfLIPJ4tJ4qGuLcDB5UmSS1guoTxQpba1c4TeXgh6GDdDwAvipD7YkbRBMzXIm1bmN5fhk5zO0TRHzosYCISrgNiPxqOStHeWeRNVdK3gl3k34fyxUIMTorU/YObvfPV0gutP0MQVfXU42eDVFKrltTbzs69jD7xhZeZ5oU/5uGBtn90As7f9XqODgdlMQsc48iOI3Q4ZQcfUBk+Zyg9r5m0pCWYqCdw0/f2533Aclm] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>atnm-20250930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 14 19:35:07 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_Leases" roleURI="http://www.actiniumpharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_OtherRevenue" roleURI="http://www.actiniumpharma.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_Equity" roleURI="http://www.actiniumpharma.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_LeasesTables" roleURI="http://www.actiniumpharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_EquityTables" roleURI="http://www.actiniumpharma.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofStockOptionActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofRestrictedStockUnitActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofWarrantActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_LeasesDetails" roleURI="http://www.actiniumpharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_OtherRevenueDetails" roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_EquityDetails" roleURI="http://www.actiniumpharma.com/role/EquityDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueMember" xlink:href="atnm-20250930.xsd#atnm_RevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_RevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueMember" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_OtherRevenueMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20250930.xsd#atnm_LeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_LeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_OtherRevenueTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_LicenseRevenuePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20250930.xsd#atnm_LesseeLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_VestedUnissuedSharesOfCommonStockMember" xlink:href="atnm-20250930.xsd#atnm_VestedUnissuedSharesOfCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atnm_VestedUnissuedSharesOfCommonStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:href="atnm-20250930.xsd#atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeasesMember" xlink:href="atnm-20250930.xsd#atnm_OperatingLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="atnm_OperatingLeasesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeasesMember" xlink:href="atnm-20250930.xsd#atnm_FinanceLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="atnm_FinanceLeasesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250930.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="atnm-20250930.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenueMember" xlink:href="atnm-20250930.xsd#atnm_GrantRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_GrantRevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20250930.xsd#atnm_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_MilestonePayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetSalesPercentage" xlink:href="atnm-20250930.xsd#atnm_NetSalesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_NetSalesPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueDetailsTable" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="atnm_OtherRevenueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_OtherRevenueDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenueMember" xlink:href="atnm-20250930.xsd#atnm_GrantRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_GrantRevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NonRefundablePaymentReceived" xlink:href="atnm-20250930.xsd#atnm_NonRefundablePaymentReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="atnm_NonRefundablePaymentReceived" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20250930.xsd#atnm_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250930.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250930.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<!-- [WMV6][E0GpMylXDJuWdjaNLqWzdcWS8mizYxqxpUr3yQVQUO5aTwey9L/w+jNHFcENtSlKM3+rWDjkyj/ZXGv8uWrzmGonjl46p1PhE/QEzBXt+6vP8GX2eqxERpyTPI+oZhZrzsf7MVGuZZ1HrWp87FoqE/j2RSWisjtvGQGU1pMFKDdVsDeiBgtqxPx2lRpyHx9/SmASomJbENBecrvb1LqOfDLUySu8MsOAk6xx3zPN4EB7cWH+WWyTm0AzWICZ4S/bKY/MIihovrcQBjMLEUV9AErhzk9mesQf2BnYf8LyHPVAGphm9OEYoJEt/fqcTbX2+l8JKtLUJyNsa50Dgx7eNcHBbmQRddi89zAe9e1oaB1MsIUPj+fkZDhk+A==] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="21" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>atnm-20250930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 14 19:35:07 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in/provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Components of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Operating Leases payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance Leases payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Other revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Schedule of Stock Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Outstanding, Ending balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">RSUs Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">RSUs Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0" xml:lang="en-US">Number of Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $1,030 and $891</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted cash &#8211; long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term finance lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share &#8211; basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract" xlink:href="atnm-20250930.xsd#atnm_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in/provided by financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Sales of shares of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Restricted stock units withheld to cover tax obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Restricted stock units withheld to cover tax obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueMember" xlink:href="atnm-20250930.xsd#atnm_RevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RevenueMember_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueMember" xlink:to="atnm_RevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueMember" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueMember_lbl" xml:lang="en-US">Other Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueMember" xlink:to="atnm_OtherRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20250930.xsd#atnm_LeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xml:lang="en-US">Finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20250930.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20250930.xsd#atnm_NonCashActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonCashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="atnm-20250930.xsd#atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20250930.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20250930.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rates operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rates finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20250930.xsd#atnm_LesseeLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Operating Leases, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Finance Leases, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Leases, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Operating Leases, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Leases, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of finance lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueTextBlock_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Issuance of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Stock option grant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Operating Leases, Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Finance Leases, Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Cancellation of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="atnm_VestedUnissuedSharesOfCommonStockMember" xlink:href="atnm-20250930.xsd#atnm_VestedUnissuedSharesOfCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_VestedUnissuedSharesOfCommonStockMember_lbl" xml:lang="en-US">Vested unissued shares of common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestedUnissuedSharesOfCommonStockMember" xlink:to="atnm_VestedUnissuedSharesOfCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeasesMember" xlink:href="atnm-20250930.xsd#atnm_OperatingLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingLeasesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeasesMember" xlink:to="atnm_OperatingLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeasesMember" xlink:href="atnm-20250930.xsd#atnm_FinanceLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeasesMember_lbl" xml:lang="en-US">Finance Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeasesMember" xlink:to="atnm_FinanceLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20250930.xsd#atnm_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetSalesPercentage" xlink:href="atnm-20250930.xsd#atnm_NetSalesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetSalesPercentage_lbl" xml:lang="en-US">Net sales percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Current annual rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonRefundablePaymentReceived" xlink:href="atnm-20250930.xsd#atnm_NonRefundablePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonRefundablePaymentReceived_lbl" xml:lang="en-US">Non-refundable payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Base prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250930.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price minimum (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price maximum (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US">Aggregated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Cancellation of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xml:lang="en-US">Grant Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenueMember" xlink:href="atnm-20250930.xsd#atnm_GrantRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_GrantRevenueMember_lbl" xml:lang="en-US">Grant Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenueMember" xlink:to="atnm_GrantRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250930.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Capital on Demand Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:href="atnm-20250930.xsd#atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable_lbl" xml:lang="en-US">Leases - Schedule of Maturities of Lease Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:to="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250930.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Restricted Stock Unit Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Warrant Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="atnm-20250930.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueDetailsTable" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueDetailsTable_lbl" xml:lang="en-US">Other Revenue (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueDetailsTable" xlink:to="atnm_OtherRevenueDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Other Revenue [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20250930.xsd#atnm_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LeasesTextBlock_lbl0" xml:lang="en-US">The entire disclosure for leases liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of lessee lease liability maturity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for license revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MilestonePayment_lbl0" xml:lang="en-US">The amount of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for nature of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Net proceeds from issuance of common stock..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetSalesPercentage_lbl0" xml:lang="en-US">Net sales percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NonRefundablePaymentReceived_lbl0" xml:lang="en-US">Represents the amount of non-refundable payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OtherRevenueTextBlock_lbl0" xml:lang="en-US">The entire disclosure for other revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity&apos;s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure weighted average remaining lease terms and discount rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeasesMember_lbl0" xml:lang="en-US">Finance Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeasesMember" xlink:to="atnm_FinanceLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl1" xml:lang="en-US">License Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl1" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_VestedUnissuedSharesOfCommonStockMember_lbl0" xml:lang="en-US">Vested Unissued Shares Of Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestedUnissuedSharesOfCommonStockMember" xlink:to="atnm_VestedUnissuedSharesOfCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule Of Restricted Stock Unit Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_ScheduleOfRestrictedStockUnitActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl0" xml:lang="en-US">Finance Lease, Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetSalesPercentage_lbl1" xml:lang="en-US">Net Sales Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0" xml:lang="en-US">Government Assistance [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Nature Of Business Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonCashActivityAbstract_lbl0" xml:lang="en-US">Non Cash Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTextBlock_lbl1" xml:lang="en-US">Other Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RevenueMember_lbl0" xml:lang="en-US">Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueMember" xlink:to="atnm_RevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueMember_lbl0" xml:lang="en-US">Other Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueMember" xlink:to="atnm_OtherRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesTextBlock_lbl1" xml:lang="en-US">Leases Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms And Discount Rates Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl0" xml:lang="en-US">Equity, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1" xml:lang="en-US">Recently Issued Accounting Pronouncements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Net Proceed From Issuance Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrantRevenueMember_lbl0" xml:lang="en-US">Grant Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenueMember" xlink:to="atnm_GrantRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonRefundablePaymentReceived_lbl1" xml:lang="en-US">Non Refundable Payment Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl0" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="atnm_ScheduleOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl0" xml:lang="en-US">Finance Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US">Lessee Lease Liability Maturity Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingLeasesMember_lbl0" xml:lang="en-US">Operating Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeasesMember" xlink:to="atnm_OperatingLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0" xml:lang="en-US">Finance Lease, Interest Payment on Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWarrantActivityAbstract" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWarrantActivityAbstract" xlink:to="atnm_ScheduleOfWarrantActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<!-- [WMV6][yfChIItHyldCM9tsbOo0rLHb+D7XvHaR286HJJETV3LNGnliPqD1fIaqzJseIcjKojGXRc/4HvS3JCfSCApiFlpO6OywjZyGL4lsFj57X0rqcq2a+0PZSznG6kjHNLMcEKdihDnJWGvwaNzXtifofqux5Bo4/NPWgWdShgEUAHIb9dpAAQGkSwqah5fDWvsmLSpF9s1KhP9ELSMD7uiYM0IfXgFzpYdgghKp4GqSywejrlOpDTOzpcxW4Fwm7sjm6wETdcQHatMFjsZ+rXoPBdTUS59AwG0CHW6c830CFO6hjwKR3BrhWm8bCF9y+j0gaiVkRQhU2mVO0pcA4LPczdlOkjcxRaATyNxM8T/Nb/20LxrbkG6hLPV/] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>atnm-20250930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 14 19:35:07 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_Leases" roleURI="http://www.actiniumpharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_OtherRevenue" roleURI="http://www.actiniumpharma.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_Equity" roleURI="http://www.actiniumpharma.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_LeasesTables" roleURI="http://www.actiniumpharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_EquityTables" roleURI="http://www.actiniumpharma.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofStockOptionActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofRestrictedStockUnitActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_ScheduleofWarrantActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_LeasesDetails" roleURI="http://www.actiniumpharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_OtherRevenueDetails" roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250930.xsd#atnm_r_EquityDetails" roleURI="http://www.actiniumpharma.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RevenueMember" xlink:href="atnm-20250930.xsd#atnm_RevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="RevenueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueMember" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherRevenueMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTextBlock" xlink:href="atnm-20250930.xsd#atnm_LeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTextBlock" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="OtherRevenueTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureOfBusinessPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicenseRevenuePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250930.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20250930.xsd#atnm_LesseeLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LesseeLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestedUnissuedSharesOfCommonStockMember" xlink:href="atnm-20250930.xsd#atnm_VestedUnissuedSharesOfCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="VestedUnissuedSharesOfCommonStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:href="atnm-20250930.xsd#atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesMember" xlink:href="atnm-20250930.xsd#atnm_OperatingLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="OperatingLeasesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeasesMember" xlink:href="atnm-20250930.xsd#atnm_FinanceLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="FinanceLeasesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250930.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="EquityScheduleofRestrictedStockUnitActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivityAbstract" xlink:href="atnm-20250930.xsd#atnm_ScheduleOfWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_0" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_0" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250930.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="atnm-20250930.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GrantRevenueMember" xlink:href="atnm-20250930.xsd#atnm_GrantRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="GrantRevenueMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="atnm-20250930.xsd#atnm_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="MilestonePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetSalesPercentage" xlink:href="atnm-20250930.xsd#atnm_NetSalesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="NetSalesPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueDetailsTable" xlink:href="atnm-20250930.xsd#atnm_OtherRevenueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="OtherRevenueDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GrantRevenueMember" xlink:href="atnm-20250930.xsd#atnm_GrantRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="GrantRevenueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherRevenueDetailsTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundablePaymentReceived" xlink:href="atnm-20250930.xsd#atnm_NonRefundablePaymentReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="NonRefundablePaymentReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="atnm-20250930.xsd#atnm_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250930.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250930.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NetProceedFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
<!-- [WMV6][facQ+gK2ShUk3mmFEwy0VVE+g3bzhpF73cqkePd1fu/QHZktnqkgzwdZgv8nzpeTcRMdZ2SVt7prP9ciKscnijV9q8s4pVwqEos4Oj9jayhs9nsVlfM2zvqrcjLsrosI5jxsRZgKkZJkxdZ4hSMVHRiDOgFJGO8WcZ81EIXX7x6hf8KqB9/Vu7p/u+3Hw0CkJIafsqO7l8hbGoU6UvkPs7Ww/k2OfkP6QtnaFgPzkoKL0lzzFx3G+N3iwrANqxy6qoYN9EiGGq1d42UOgSpCMXPrRX/xaNm0583assQG2/n/qzKR5yBNpgdi00im6YNH9JcWRKgmEkqIhsISgQDfecBU4URp6bi4XuV+q5vb+1jF1zxHKIUL8nkU] CSR-->
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACTINIUM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Park Ave., 23rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,391<span></span>
</td>
<td class="nump">$ 72,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">54,366<span></span>
</td>
<td class="nump">74,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $1,030 and $891</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long term</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">56,151<span></span>
</td>
<td class="nump">76,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,224<span></span>
</td>
<td class="nump">7,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">6,834<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease obligations</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease obligations</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">42,367<span></span>
</td>
<td class="nump">44,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">417,526<span></span>
</td>
<td class="nump">408,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(403,773)<span></span>
</td>
<td class="num">(375,826)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">13,784<span></span>
</td>
<td class="nump">32,758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 56,151<span></span>
</td>
<td class="nump">$ 76,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation (in Dollars)</a></td>
<td class="nump">$ 1,030<span></span>
</td>
<td class="nump">$ 891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">4,248<span></span>
</td>
<td class="nump">9,774<span></span>
</td>
<td class="nump">16,827<span></span>
</td>
<td class="nump">25,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">2,827<span></span>
</td>
<td class="nump">13,096<span></span>
</td>
<td class="nump">9,382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,782<span></span>
</td>
<td class="nump">12,601<span></span>
</td>
<td class="nump">29,923<span></span>
</td>
<td class="nump">34,616<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,692)<span></span>
</td>
<td class="num">(12,601)<span></span>
</td>
<td class="num">(29,833)<span></span>
</td>
<td class="num">(34,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income - net</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,131)<span></span>
</td>
<td class="num">$ (11,568)<span></span>
</td>
<td class="num">$ (27,947)<span></span>
</td>
<td class="num">$ (31,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share &#8211; basic (in Dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.9)<span></span>
</td>
<td class="num">$ (1.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share &#8211; diluted (in Dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.9)<span></span>
</td>
<td class="num">$ (1.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8211; basic (in Shares)</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">31,071,297<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">29,692,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; diluted (in Shares)</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">31,071,297<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">29,692,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_RevenueMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_OtherRevenueMember', window );">Other Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_RevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_RevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 373,934<span></span>
</td>
<td class="num">$ (337,583)<span></span>
</td>
<td class="nump">$ 36,379<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">27,634,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,752,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="nump">10,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,670)<span></span>
</td>
<td class="num">(8,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">390,081<span></span>
</td>
<td class="num">(346,253)<span></span>
</td>
<td class="nump">43,857<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">29,396,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">373,934<span></span>
</td>
<td class="num">(337,583)<span></span>
</td>
<td class="nump">36,379<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">27,634,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,591)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">407,351<span></span>
</td>
<td class="num">(369,174)<span></span>
</td>
<td class="nump">38,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">390,081<span></span>
</td>
<td class="num">(346,253)<span></span>
</td>
<td class="nump">43,857<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">29,396,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,374<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">9,955<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,154,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,353)<span></span>
</td>
<td class="num">(11,353)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">401,410<span></span>
</td>
<td class="num">(357,606)<span></span>
</td>
<td class="nump">43,835<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">30,550,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,337<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in Shares)</a></td>
<td class="nump">13,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,604<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">631,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,568)<span></span>
</td>
<td class="num">(11,568)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">407,351<span></span>
</td>
<td class="num">(369,174)<span></span>
</td>
<td class="nump">38,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">408,553<span></span>
</td>
<td class="num">(375,826)<span></span>
</td>
<td class="nump">32,758<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,874<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,938)<span></span>
</td>
<td class="num">(15,938)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">417,427<span></span>
</td>
<td class="num">(391,764)<span></span>
</td>
<td class="nump">25,694<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">408,553<span></span>
</td>
<td class="num">(375,826)<span></span>
</td>
<td class="nump">32,758<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,947)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">417,526<span></span>
</td>
<td class="num">(403,773)<span></span>
</td>
<td class="nump">13,784<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">417,427<span></span>
</td>
<td class="num">(391,764)<span></span>
</td>
<td class="nump">25,694<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,878)<span></span>
</td>
<td class="num">(6,878)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">417,624<span></span>
</td>
<td class="num">(398,642)<span></span>
</td>
<td class="nump">19,013<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock units withheld to cover tax obligations</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,131)<span></span>
</td>
<td class="num">(5,131)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 417,526<span></span>
</td>
<td class="num">$ (403,773)<span></span>
</td>
<td class="nump">$ 13,784<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (27,947)<span></span>
</td>
<td class="num">$ (31,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,180<span></span>
</td>
<td class="nump">4,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,343)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(423)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(19,291)<span></span>
</td>
<td class="num">(27,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows used in/provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sales of shares of common stock, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock units withheld to cover tax obligations</a></td>
<td class="num">(207)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in/provided by financing activities</a></td>
<td class="num">(214)<span></span>
</td>
<td class="nump">29,324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(19,505)<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">73,228<span></span>
</td>
<td class="nump">76,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">53,723<span></span>
</td>
<td class="nump">78,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. is a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve
outcomes for patients with advanced cancers. The Company is focused on developing highly innovative, first-in-class product candidates.
To support its objective of achieving industry leading, cost-effective product development to maximize value creation from its innovative
pipeline, the Company is working to expand the scope of its capabilities to include radioisotope production of Ac-225 via collaborations
for its Ac-225 technology and in-house manufacturing of pipeline candidates to support clinical trials. The Company is deploying its technologies,
capabilities and intellectual property with approximately 250 issued and pending patents worldwide, to develop next-generation radiotherapies
focused on solid tumors, hematology and conditioning for cellular therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at September 30, 2025 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53,391</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">53,723</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers
</i>(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i> There was no revenue from collaborative arrangements for the nine months ended September 30, 2025 and
September 30, 2024, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>Grant
revenue for the three and nine months ended September 30, 2025 was $0.1 million. There was <span style="-sec-ix-hidden: hidden-fact-55"><span style="-sec-ix-hidden: hidden-fact-56">no</span></span> grant revenue recognized for the three and
nine months ended September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no license revenue for the three and nine months ended September
30, 2025 and September 30, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
September 30, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted
stock units, vested unissued shares of common stock and warrants, have not been included in the computation of diluted net loss per share
as the result would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,216</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vested unissued shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">348</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,525</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
December 2023, the Financial Accounting Standards Board, (the &#8220;FASB&#8221;), issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements
to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09
provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures.
The Company is required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount
computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required to disclose income
taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). <span style="background-color: white">The
amendments in ASU 2023-09 are effective January 1, 2025. The Company adopted this standard effective January 1, 2025 and will report on
it in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company will update all required disclosures
pursuant to ASU 2023-09 at that time.</span></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, the One Big
Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension
of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable
tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025
and others expected to be implemented through 2027. The Company has evaluated the impact of the OBBBA and determined that it does not
have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, the FASB
issued ASU 2025-07, <i>Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements
and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</i>, which excludes from derivative
accounting non-exchange-traded contracts with underlying terms that are based on operations or activities specific to one of the parties
to the contract. However, this scope exception does not apply to (1) variables based on a market rate, market price, or market index,
(2) variables based on the price or performance of a financial asset or financial liability of one of the parties to the contract, (3)
contracts (or features) involving the issuer&#8217;s own equity that are evaluated under the guidance in Subtopic 815-40, <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity,</i> and (4) call options and put options on debt instruments. The Company can
apply the amendments in AUS 2025-07 either (1) prospectively to new contracts entered into on or after the date of adoption or (2) on
a modified retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning
of the annual reporting period of adoption for contracts existing as of the beginning of the annual reporting period of adoption. The
amendments in ASU 2025-07 are effective January 1, 2027, for annual for annual reporting periods, including interim periods within annual
reporting periods. Early adoption is permitted. The Company is evaluating the impact of ASU 2025-07 on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, the FASB
issued ASU 2025-06, <i>Intangibles&#8212;Goodwill and Other&#8212; Internal-Use Software</i> (Subtopic 350-40): Targeted Improvements
to the Accounting for Internal-Use Software, which modernizes the accounting for software costs that are accounted for under Subtopic
350-40. The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages (referred to as
&#8220;project stages&#8221;) throughout Subtopic 350-40. Therefore, an entity is required to start capitalizing software costs when both
of the following occur: (a) the Company has authorized and committed to funding the software project and (b) it is probable that the project
will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition
threshold&#8221;). In evaluating the probable-to-complete recognition threshold, the Company is required to consider whether there is
significant uncertainty associated with the development activities of the software, such as determining whether (a) the software being
developed has technological innovations or novel, unique, or unproven functions or features, and the uncertainty related to those technological
innovations, functions, or features, if identified, has not been resolved through coding and testing and (b) the Company has determined
what it needs the software to do (for example, functions or features), including whether the entity has identified or continues to substantially
revise the software&#8217;s significant performance requirements. ASU 2025-06 specifies that disclosures in Subtopic 360- 10, <i>Property,
Plant, and Equipment&#8212;Overall</i>, are required for all capitalized internal-use software costs, regardless of how those costs are
presented in the financial statements and removes the requirement to disclose internal-use software information pursuant to paragraphs
350-30-50-1 through 50-3. ASU 2025-06 supersedes the website development costs guidance and incorporates the recognition requirements
for website-specific development costs from Subtopic 350-50, <i>Website Development Costs</i>, into Subtopic 350-40. The amendments in
ASU 2025-06 permit an entity to apply the new guidance using either (i) a prospective transition approach, (ii) a modified transition
approach that is based on the status of the project and whether software costs were capitalized before the date of adoption, or (iii)
a retrospective transition approach. The amendments in ASU 2025-06 are effective January 1, 2028 for annual reporting periods, including
interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The Company
is evaluating the impact of ASU 2025-06 on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, the FASB
issued ASU 2025-05, <i>Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets</i>, which permits a practical expedient whereby, when assessing credit losses on current accounts receivable
and current contract assets, the Company would assume that current conditions as of the balance sheet date do not change for the
remaining life of the asset and would not require the Company to consider adjustments to forecasts to also include anticipated
changes in the future to the underlying conditions as of the balance sheet date when measuring the credit losses for current
accounts receivable and current contract assets. The amendments in ASU 2025-05 are effective January 1, 2026 for annual reporting
periods, including interim periods within annual reporting periods and is required to be applied on a perspective basis. Early adoption is permitted in both interim and annual
reporting periods in which financial statements have not yet been issued or made available for issuance. The impact of ASU 2025-04
is not expected to be material to the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2025, FASB issued ASU
2025-04, <i>Compensation&#8212;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer</i>, which revises the Master Glossary definition of the term &#8220;performance condition&#8221;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#8217;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#8217;s goods or services from the grantor&#8217;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#8217;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#8217;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2025-04 are effective January 1, 2027 for annual reporting periods,
including interim periods within annual reporting periods. The Company is evaluating the impact of ASU 2025-04 on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028, either on a prospective or retrospective basis. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the United States District Court for the Southern District of New York. The Securities Complaint alleges that the
Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims
against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint
purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities
between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&#160; On June 24, 2025, the court in the
securities action appointed lead plaintiffs who filed an amended Securities Complaint on August 25, 2025. Defendants moved to dismiss
the amended Securities Complaint on October 24, 2025. Lead plaintiffs&#8217; opposition is due in late December 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On May 5, 2025, a derivative shareholder complaint (the &#8220;<i>Georges</i>
Complaint&#8221;) was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability
for the allegations made in the Securities Complaint.&#160; On May 13, 2025, a second derivative shareholder complaint (the &#8220;<i>Robinson
</i>Complaint&#8221; and, together with the <i>Georges </i>Complaint, the &#8220;Derivative Complaints&#8221;) was filed against the Company
and certain of the Company&#8217;s directors also alleging derivative liability for the allegations made in the Securities Complaint.
On June 24, 2025, the Court consolidated the Derivative Complaints (the &#8220;Derivative Action&#8221;). On July 29, 2025, the parties
to the Derivative Action filed a stipulation with the Court to stay the Derivative Action pending resolution of any motion to dismiss
the Securities Complaint. The Court entered the stipulation on July 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company and other Defendants intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At September 30, 2025, the
Company has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment.
The Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of 5 years 2 months, with an
expiration date of July 30, 2027 and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such
as insurance, utilities and maintenance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">519</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">519</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total finance lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">471</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">462</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance Leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8 years</span></td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding nine months ended September 30, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">159</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,130</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueTextBlock', window );">Other revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 - Other revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Grant revenue recognized
for the nine months ended September 30, 2025 was $0.1 million. There was no grant revenue recognized for the nine months ended September
30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#8220;EUMENA&#8221;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#8217;s contract liabilities consist of advanced payments from licensees. Long-term license revenue deferred was $35 million at
September 30, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#8217;s regulatory approval of
Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company entered into the Capital on Demand&#8482;
Sales Agreement with JonesTrading Institutional Services LLC, &#8220;JonesTrading&#8221;, pursuant to which the Company may sell, from
time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. On June 28, 2022, the Company entered
into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales Agreement&#8221;) with JonesTrading and
B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The A&amp;R Sales Agreement modifies the original Capital on Demand&#8482; Sales Agreement
to include B. Riley Securities as an additional sales agent thereunder. Shares of common stock are offered pursuant to a shelf registration
statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the &#8220;Prior Shelf Registration Statement&#8221;).
On August 11, 2023, the Company filed a new registration statement on Form S-3 (File No. 333-273911), which registration statement was
amended on February 2, 2024, and declared effective on February 5, 2024, to replace the Prior Shelf Registration Statement, including
a base prospectus which covers the offering, issuance and sale of up to $500 million of common stock, preferred stock, warrants, units
and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum aggregate offering
price of $200 million of common stock that may be issued and sold under the Amended Sales Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company did not sell any
shares of common stock during the nine months ended September 30, 2025. During the nine months ended September 30, 2024, the Company sold
3.5 million shares of common stock, resulting in gross proceeds of $29.9 million and net proceeds of $29.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,012</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">7.17</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">3.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, September 30, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.87</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.31</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended
September 30, 2025, the Company granted newly hired employees options to purchase 36 thousand shares of common stock with an exercise
price ranging from $1.06 to $1.55 per share, a term of 10 years, and a vesting period of 4 years. The stock options had an aggregated
fair value of $41 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 4.0% to 4.5% (2) expected life of 6 years, (3) expected volatility range from 90.1% to 90.7%,
and (4) <span style="-sec-ix-hidden: hidden-fact-81">zero</span> expected dividends. During the nine months ended September 30, 2024, the Company granted options to purchase 104 thousand
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, the Board
of Directors approved of the cancellation of stock options to purchase an aggregate of 4.9 million shares of common stock held by certain
current employees and directors that were initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated
Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options, which the Company received.
The cancellation of these stock options resulted in the recording of $8.8 million in stock option compensation expense for the nine months
ended September 30, 2025. During the nine months ended September 30, 2024, the Company recorded stock option compensation expense of $3.6
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30,
2025 was $0.1 million related to unvested stock options, which is expected to be expensed over a weighted average of 2.4 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vested on August
18, 2025. The fair value of the RSUs, $1.8 million, was determined based on the stock price on the dates of the grant and was recognized
over three years. During the nine months ended September 30, 2025 and 2024, the Company recorded compensation expense related to RSUs
of $0.4 million and $0.4 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">3.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">3.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (5,131)<span></span>
</td>
<td class="num">$ (6,878)<span></span>
</td>
<td class="num">$ (15,938)<span></span>
</td>
<td class="num">$ (11,568)<span></span>
</td>
<td class="num">$ (11,353)<span></span>
</td>
<td class="num">$ (8,670)<span></span>
</td>
<td class="num">$ (27,947)<span></span>
</td>
<td class="num">$ (31,591)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NatureOfBusinessPolicyPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. is a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve
outcomes for patients with advanced cancers. The Company is focused on developing highly innovative, first-in-class product candidates.
To support its objective of achieving industry leading, cost-effective product development to maximize value creation from its innovative
pipeline, the Company is working to expand the scope of its capabilities to include radioisotope production of Ac-225 via collaborations
for its Ac-225 technology and in-house manufacturing of pipeline candidates to support clinical trials. The Company is deploying its technologies,
capabilities and intellectual property with approximately 250 issued and pending patents worldwide, to develop next-generation radiotherapies
focused on solid tumors, hematology and conditioning for cellular therapies.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at September 30, 2025 and December 31, 2024:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53,391</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">53,723</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers
</i>(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i> There was no revenue from collaborative arrangements for the nine months ended September 30, 2025 and
September 30, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>Grant
revenue for the three and nine months ended September 30, 2025 was $0.1 million. There was <span style="-sec-ix-hidden: hidden-fact-55"><span style="-sec-ix-hidden: hidden-fact-56">no</span></span> grant revenue recognized for the three and
nine months ended September 30, 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LicenseRevenuePolicyTextBlock', window );">License Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no license revenue for the three and nine months ended September
30, 2025 and September 30, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
September 30, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted
stock units, vested unissued shares of common stock and warrants, have not been included in the computation of diluted net loss per share
as the result would have been anti-dilutive.</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,216</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vested unissued shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">348</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,525</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
December 2023, the Financial Accounting Standards Board, (the &#8220;FASB&#8221;), issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements
to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09
provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures.
The Company is required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount
computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required to disclose income
taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). <span style="background-color: white">The
amendments in ASU 2023-09 are effective January 1, 2025. The Company adopted this standard effective January 1, 2025 and will report on
it in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company will update all required disclosures
pursuant to ASU 2023-09 at that time.</span></span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, the One Big
Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension
of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable
tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025
and others expected to be implemented through 2027. The Company has evaluated the impact of the OBBBA and determined that it does not
have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, the FASB
issued ASU 2025-07, <i>Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements
and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</i>, which excludes from derivative
accounting non-exchange-traded contracts with underlying terms that are based on operations or activities specific to one of the parties
to the contract. However, this scope exception does not apply to (1) variables based on a market rate, market price, or market index,
(2) variables based on the price or performance of a financial asset or financial liability of one of the parties to the contract, (3)
contracts (or features) involving the issuer&#8217;s own equity that are evaluated under the guidance in Subtopic 815-40, <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity,</i> and (4) call options and put options on debt instruments. The Company can
apply the amendments in AUS 2025-07 either (1) prospectively to new contracts entered into on or after the date of adoption or (2) on
a modified retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning
of the annual reporting period of adoption for contracts existing as of the beginning of the annual reporting period of adoption. The
amendments in ASU 2025-07 are effective January 1, 2027, for annual for annual reporting periods, including interim periods within annual
reporting periods. Early adoption is permitted. The Company is evaluating the impact of ASU 2025-07 on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, the FASB
issued ASU 2025-06, <i>Intangibles&#8212;Goodwill and Other&#8212; Internal-Use Software</i> (Subtopic 350-40): Targeted Improvements
to the Accounting for Internal-Use Software, which modernizes the accounting for software costs that are accounted for under Subtopic
350-40. The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages (referred to as
&#8220;project stages&#8221;) throughout Subtopic 350-40. Therefore, an entity is required to start capitalizing software costs when both
of the following occur: (a) the Company has authorized and committed to funding the software project and (b) it is probable that the project
will be completed and the software will be used to perform the function intended (referred to as the &#8220;probable-to-complete recognition
threshold&#8221;). In evaluating the probable-to-complete recognition threshold, the Company is required to consider whether there is
significant uncertainty associated with the development activities of the software, such as determining whether (a) the software being
developed has technological innovations or novel, unique, or unproven functions or features, and the uncertainty related to those technological
innovations, functions, or features, if identified, has not been resolved through coding and testing and (b) the Company has determined
what it needs the software to do (for example, functions or features), including whether the entity has identified or continues to substantially
revise the software&#8217;s significant performance requirements. ASU 2025-06 specifies that disclosures in Subtopic 360- 10, <i>Property,
Plant, and Equipment&#8212;Overall</i>, are required for all capitalized internal-use software costs, regardless of how those costs are
presented in the financial statements and removes the requirement to disclose internal-use software information pursuant to paragraphs
350-30-50-1 through 50-3. ASU 2025-06 supersedes the website development costs guidance and incorporates the recognition requirements
for website-specific development costs from Subtopic 350-50, <i>Website Development Costs</i>, into Subtopic 350-40. The amendments in
ASU 2025-06 permit an entity to apply the new guidance using either (i) a prospective transition approach, (ii) a modified transition
approach that is based on the status of the project and whether software costs were capitalized before the date of adoption, or (iii)
a retrospective transition approach. The amendments in ASU 2025-06 are effective January 1, 2028 for annual reporting periods, including
interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The Company
is evaluating the impact of ASU 2025-06 on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, the FASB
issued ASU 2025-05, <i>Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets</i>, which permits a practical expedient whereby, when assessing credit losses on current accounts receivable
and current contract assets, the Company would assume that current conditions as of the balance sheet date do not change for the
remaining life of the asset and would not require the Company to consider adjustments to forecasts to also include anticipated
changes in the future to the underlying conditions as of the balance sheet date when measuring the credit losses for current
accounts receivable and current contract assets. The amendments in ASU 2025-05 are effective January 1, 2026 for annual reporting
periods, including interim periods within annual reporting periods and is required to be applied on a perspective basis. Early adoption is permitted in both interim and annual
reporting periods in which financial statements have not yet been issued or made available for issuance. The impact of ASU 2025-04
is not expected to be material to the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2025, FASB issued ASU
2025-04, <i>Compensation&#8212;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer</i>, which revises the Master Glossary definition of the term &#8220;performance condition&#8221;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#8217;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#8217;s goods or services from the grantor&#8217;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#8217;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#8217;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2025-04 are effective January 1, 2027 for annual reporting periods,
including interim periods within annual reporting periods. The Company is evaluating the impact of ASU 2025-04 on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028, either on a prospective or retrospective basis. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LicenseRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LicenseRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NatureOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NatureOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at September 30, 2025 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53,391</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">332</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">53,723</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss Per Share</a></td>
<td class="text">For the three and nine months ended
September 30, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted
stock units, vested unissued shares of common stock and warrants, have not been included in the computation of diluted net loss per share
as the result would have been anti-dilutive.<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,216</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Vested unissued shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">348</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,525</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 2.5pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">519</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">519</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total finance lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">471</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">462</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance Leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8 years</span></td><td style="text-align: left">&#160;</td></tr> </table>Below is information on the weighted average discount rates used at the time that the leases were evaluated:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LesseeLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding nine months ended September 30, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">159</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 9pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,130</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LesseeLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee lease liability maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LesseeLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure weighted average remaining lease terms and discount rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,012</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">7.17</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">3.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, September 30, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.87</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.31</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the nine months ended September 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">3.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">3.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_GrantRevenueMember', window );">Grant Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Grant revenue</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_GrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_GrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,391<span></span>
</td>
<td class="nump">$ 72,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long-term</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 53,723<span></span>
</td>
<td class="nump">$ 73,228<span></span>
</td>
<td class="nump">$ 78,982<span></span>
</td>
<td class="nump">$ 76,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">5,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atnm_VestedUnissuedSharesOfCommonStockMember', window );">Vested unissued shares of common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">179<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atnm_VestedUnissuedSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atnm_VestedUnissuedSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 15, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NetSalesPercentage', window );">Net sales percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term</a></td>
<td class="text">5 years 2 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Jul. 30,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Current annual rent</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Components of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Components of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term operating leases</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term finance Leases</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates operating leases</a></td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates finance Leases</a></td>
<td class="nump">6.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=atnm_OperatingLeasesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Schedule of Maturities of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Operating Leases, 2025</a></td>
<td class="nump">$ 159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Leases, 2026</a></td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Leases, 2027</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating Leases payments</a></td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Leases, Less imputed interest</a></td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">1,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=atnm_FinanceLeasesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Schedule of Maturities of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Finance Leases, 2025</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Leases, 2026</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Leases, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance Leases payments</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Leases, Less imputed interest</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of finance lease liabilities</a></td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=atnm_OperatingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=atnm_OperatingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=atnm_FinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=atnm_FinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Other Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NonRefundablePaymentReceived', window );">Non-refundable payment received</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term license revenue deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_GrantRevenueMember', window );">Grant Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Other Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of non-refundable payment received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_GrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_GrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Aggregated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Stock option grant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancellation of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember', window );">Capital on Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Aggregated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Cancellation of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Base prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NetProceedFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Exercise price minimum (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price maximum (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancellation of stock options (in Shares)</a></td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetProceedFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetProceedFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Schedule of Stock Option Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending balance (in Shares)</a></td>
<td class="nump">5,137<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">$ 6.48<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</a></td>
<td class="text">7 years 14 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Restricted Stock Unit Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs Outstanding, Beginning balance | shares</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance | $ / shares</a></td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs Outstanding, Ending balance | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs Outstanding, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs Outstanding, Vested | shares</a></td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs Outstanding, Cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Ending balance</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">$ 17.33<span></span>
</td>
<td class="nump">$ 17.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance</a></td>
<td class="text">4 years 5 months 15 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Exercisable</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable</a></td>
<td class="nump">$ 17.33<span></span>
</td>
<td class="nump">$ 17.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years) Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>103</ContextCount>
  <ElementCount>212</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Other Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/OtherRevenue</Role>
      <ShortName>Other Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Leases</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Equity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/LeasesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable</Role>
      <ShortName>Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/OtherRevenueDetails</Role>
      <ShortName>Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/OtherRevenue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/EquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable</Role>
      <ShortName>Equity - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0262047-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Equity - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable</Role>
      <ShortName>Equity - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnm-20250930.xsd</File>
    <File>atnm-20250930_cal.xml</File>
    <File>atnm-20250930_def.xml</File>
    <File>atnm-20250930_lab.xml</File>
    <File>atnm-20250930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ea0262047-10q_actinium.htm">ea0262047-10q_actinium.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="420">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0262047-10q_actinium.htm": {
   "nsprefix": "atnm",
   "nsuri": "http://www.actiniumpharma.com/20250930",
   "dts": {
    "schema": {
     "local": [
      "atnm-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "atnm-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atnm-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20250930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0262047-10q_actinium.htm"
     ]
    }
   },
   "keyStandard": 195,
   "keyCustom": 17,
   "axisStandard": 9,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 7,
   "hidden": {
    "total": 86,
    "http://fasb.org/us-gaap/2025": 77,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://www.actiniumpharma.com/20250930": 5
   },
   "contextCount": 103,
   "entityCount": 1,
   "segmentCount": 18,
   "elementCount": 518,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 420,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c40",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c45",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "longName": "995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.actiniumpharma.com/role/CommitmentsandContingencies",
     "longName": "995307 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.actiniumpharma.com/role/Leases",
     "longName": "995308 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:LeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:LeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.actiniumpharma.com/role/OtherRevenue",
     "longName": "995309 - Disclosure - Other Revenue",
     "shortName": "Other Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:OtherRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:OtherRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.actiniumpharma.com/role/Equity",
     "longName": "995310 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c12",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.actiniumpharma.com/role/LeasesTables",
     "longName": "996002 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.actiniumpharma.com/role/EquityTables",
     "longName": "996003 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:GovernmentAssistancePolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable",
     "longName": "996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
     "longName": "996006 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996007 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c79",
      "name": "atnm:MilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c79",
      "name": "atnm:MilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.actiniumpharma.com/role/LeasesDetails",
     "longName": "996008 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable",
     "longName": "996009 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable",
     "longName": "996010 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)",
     "shortName": "Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable",
     "longName": "996011 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c80",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "atnm:LesseeLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c80",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "atnm:LesseeLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.actiniumpharma.com/role/OtherRevenueDetails",
     "longName": "996012 - Disclosure - Other Revenue (Details)",
     "shortName": "Other Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c82",
      "name": "atnm:NonRefundablePaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c82",
      "name": "atnm:NonRefundablePaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.actiniumpharma.com/role/EquityDetails",
     "longName": "996013 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c14",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996014 - Disclosure - Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c96",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c96",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
     "longName": "996015 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "shortName": "Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c98",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c98",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable",
     "longName": "996016 - Disclosure - Equity - Schedule of Warrant Activity (Details)",
     "shortName": "Equity - Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c99",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c100",
      "name": "atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0262047-10q_actinium.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation (in Dollars)",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r70",
      "r355"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r498",
      "r817"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r705",
      "r706",
      "r707",
      "r708",
      "r760",
      "r819"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock units withheld to cover tax obligations",
        "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r727"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r727"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r537",
      "r548",
      "r564",
      "r599"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r540",
      "r551",
      "r567",
      "r602"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r552",
      "r568",
      "r594",
      "r603",
      "r607",
      "r615"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r242",
      "r251"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total anti-dilutive",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Diluted Net Loss Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r57",
      "r71",
      "r92",
      "r93",
      "r94",
      "r122",
      "r129",
      "r142",
      "r143",
      "r149",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r267",
      "r269",
      "r310",
      "r345",
      "r346",
      "r349",
      "r407",
      "r471",
      "r472",
      "r475",
      "r498",
      "r503",
      "r504",
      "r516",
      "r720",
      "r721",
      "r777"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r75",
      "r92",
      "r93",
      "r94",
      "r149",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r267",
      "r269",
      "r310",
      "r498",
      "r720",
      "r721",
      "r777"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r529",
      "r532",
      "r544"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r529",
      "r532",
      "r544"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r529",
      "r532",
      "r544"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation - Unaudited Interim Financial Information",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r532",
      "r544"
     ]
    },
    "atnm_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital on Demand Sales Agreement [Member]",
        "label": "Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r454"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r49"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r39",
      "r91"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r39"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r124",
      "r173",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r295",
      "r376",
      "r377",
      "r378",
      "r379",
      "r476",
      "r638",
      "r699",
      "r701"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r51",
      "r350",
      "r394"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r153",
      "r154",
      "r448",
      "r715",
      "r717"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r510",
      "r511",
      "r512",
      "r513",
      "r705",
      "r706",
      "r708",
      "r760",
      "r816",
      "r819"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r395"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29",
      "r395",
      "r413",
      "r819",
      "r820"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r171",
      "r177",
      "r352",
      "r498"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r464"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term license revenue deferred",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r202"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r571"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expenses",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r84",
      "r122",
      "r133",
      "r143",
      "r458",
      "r471",
      "r472"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r384",
      "r386",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427",
      "r428",
      "r438",
      "r439",
      "r440",
      "r441",
      "r455",
      "r456",
      "r457",
      "r491",
      "r492",
      "r506",
      "r508",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r756",
      "r757",
      "r758",
      "r759",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r384",
      "r386",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r426",
      "r427",
      "r428",
      "r438",
      "r439",
      "r440",
      "r441",
      "r455",
      "r456",
      "r457",
      "r491",
      "r492",
      "r506",
      "r508",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r756",
      "r757",
      "r758",
      "r759",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772"
     ]
    },
    "atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r571"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r532",
      "r544"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r532",
      "r544",
      "r595"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r532",
      "r544",
      "r595"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share \u2013 basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r82",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r112",
      "r114",
      "r116",
      "r117",
      "r118",
      "r121",
      "r169",
      "r241",
      "r262",
      "r265",
      "r307",
      "r308",
      "r344",
      "r359",
      "r465"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share \u2013 diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r82",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r114",
      "r116",
      "r117",
      "r118",
      "r121",
      "r169",
      "r241",
      "r262",
      "r265",
      "r307",
      "r308",
      "r344",
      "r359",
      "r465"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r120"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average term",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r63",
      "r64",
      "r65",
      "r78",
      "r79",
      "r80",
      "r96",
      "r97",
      "r98",
      "r100",
      "r107",
      "r109",
      "r111",
      "r123",
      "r150",
      "r151",
      "r152",
      "r168",
      "r187",
      "r241",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r339",
      "r358",
      "r369",
      "r370",
      "r371",
      "r381",
      "r431"
     ]
    },
    "atnm_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated fair value",
        "label": "Equity, Fair Value Disclosure",
        "documentation": "Fair value of the entity's equity."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r770"
     ]
    },
    "atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "EquityScheduleofRestrictedStockUnitActivityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Restricted Stock Unit Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r537",
      "r548",
      "r564",
      "r599"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r596"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r331",
      "r497"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow use from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r332"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of finance lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r336"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost",
        "label": "Finance Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases current liability",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease obligations",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance Leases payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r700",
      "r704",
      "r786"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2026",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r700",
      "r704",
      "r786"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2027",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r700",
      "r704",
      "r786"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2025",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance Leases, Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Financing cash flow use from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r332"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-to-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r331",
      "r497"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates finance Leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r497"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term finance Leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r497"
     ]
    },
    "atnm_FinanceLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "FinanceLeasesMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases [Member]",
        "label": "Finance Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r552",
      "r568",
      "r603"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r552",
      "r568",
      "r603"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r552",
      "r568",
      "r603"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r552",
      "r568",
      "r603"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r552",
      "r568",
      "r603"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r531",
      "r555"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r416"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Revenue",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "atnm_GrantRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "GrantRevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Revenue [Member]",
        "label": "Grant Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r529",
      "r532",
      "r544"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r90",
      "r255",
      "r256"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r695"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r552",
      "r568",
      "r594",
      "r603",
      "r607",
      "r615"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r619"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r619"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r619"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r89"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r560"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income - net",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r132",
      "r143",
      "r471",
      "r653"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r640"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r497"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Lease Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Remaining Lease Terms and Discount Rates",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases - Schedule of Maturities of Lease Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "LeasesTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for leases liability.",
        "label": "Leases Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Lease Liabilities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r338"
     ]
    },
    "atnm_LesseeLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "LesseeLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities",
        "documentation": "Tabular disclosure of lessee lease liability maturity.",
        "label": "Lessee Lease Liability Maturity Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Leases payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r700",
      "r704",
      "r786"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r700",
      "r704",
      "r786"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r700",
      "r704",
      "r786"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating Leases, Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r92",
      "r93",
      "r94",
      "r149",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r268",
      "r269",
      "r270",
      "r310",
      "r393",
      "r467",
      "r475",
      "r516",
      "r720",
      "r777",
      "r778"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r52",
      "r354",
      "r498",
      "r503",
      "r504",
      "r699",
      "r703",
      "r714",
      "r773"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r68",
      "r92",
      "r93",
      "r94",
      "r149",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r268",
      "r269",
      "r270",
      "r310",
      "r498",
      "r720",
      "r777",
      "r778"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LicenseRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "LicenseRevenuePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Revenue",
        "documentation": "Disclosure of accounting policy for license revenue.",
        "label": "License Revenue Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r155",
      "r156",
      "r157",
      "r158",
      "r204",
      "r234",
      "r235",
      "r236",
      "r252",
      "r309",
      "r342",
      "r367",
      "r368",
      "r374",
      "r385",
      "r386",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r474",
      "r476",
      "r485",
      "r487",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495",
      "r496",
      "r500",
      "r722",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "atnm_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "documentation": "The amount of milestone payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r155",
      "r156",
      "r157",
      "r158",
      "r204",
      "r234",
      "r235",
      "r236",
      "r252",
      "r309",
      "r342",
      "r367",
      "r368",
      "r374",
      "r385",
      "r386",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r474",
      "r476",
      "r485",
      "r487",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495",
      "r500",
      "r722",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "atnm_NatureOfBusinessPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "NatureOfBusinessPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "documentation": "Disclosure of accounting policy for nature of business.",
        "label": "Nature Of Business Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in/provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in/provided by financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r41",
      "r53",
      "r65",
      "r66",
      "r76",
      "r77",
      "r80",
      "r92",
      "r93",
      "r94",
      "r95",
      "r99",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r115",
      "r149",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r172",
      "r174",
      "r178",
      "r241",
      "r262",
      "r265",
      "r308",
      "r310",
      "r357",
      "r414",
      "r429",
      "r430",
      "r460",
      "r462",
      "r463",
      "r514",
      "r720"
     ]
    },
    "atnm_NetProceedFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "NetProceedFromIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock.",
        "documentation": "Net proceeds from issuance of common stock..",
        "label": "Net Proceed From Issuance Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_NetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "NetSalesPercentage",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales percentage",
        "documentation": "Net sales percentage.",
        "label": "Net Sales Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r560"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r552",
      "r568",
      "r594",
      "r603"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "atnm_NonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "NonRefundablePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable payment received",
        "documentation": "Represents the amount of non-refundable payment received",
        "label": "Non Refundable Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r460",
      "r463",
      "r468",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases current liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease obligations",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow use from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r332"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r497"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r497"
     ]
    },
    "atnm_OperatingLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "OperatingLeasesMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases [Member]",
        "label": "Operating Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "atnm_OtherRevenueDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "OtherRevenueDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Revenue (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_OtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "OtherRevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Revenue",
        "label": "Other Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_OtherRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "OtherRevenueTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "documentation": "The entire disclosure for other revenue.",
        "label": "Other Revenue Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r539",
      "r550",
      "r566",
      "r601"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r553",
      "r569",
      "r604"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r542",
      "r553",
      "r569",
      "r604"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current annual rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock units withheld to cover tax obligations",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r179"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r395"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r179"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r395",
      "r413",
      "r819",
      "r820"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r171",
      "r176",
      "r351",
      "r498"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of shares of common stock, net of costs",
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r343",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r453",
      "r459",
      "r462",
      "r463",
      "r477",
      "r478",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r639",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r718",
      "r719",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r343",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r453",
      "r459",
      "r462",
      "r463",
      "r477",
      "r478",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r639",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r718",
      "r719",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation of $1,030 and $891",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r337",
      "r348",
      "r356",
      "r498"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r155",
      "r156",
      "r157",
      "r158",
      "r203",
      "r204",
      "r234",
      "r235",
      "r236",
      "r240",
      "r252",
      "r309",
      "r340",
      "r341",
      "r342",
      "r367",
      "r368",
      "r374",
      "r385",
      "r386",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r474",
      "r476",
      "r485",
      "r487",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495",
      "r496",
      "r500",
      "r508",
      "r716",
      "r722",
      "r763",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r155",
      "r156",
      "r157",
      "r158",
      "r203",
      "r204",
      "r234",
      "r235",
      "r236",
      "r240",
      "r252",
      "r309",
      "r340",
      "r341",
      "r342",
      "r367",
      "r368",
      "r374",
      "r385",
      "r386",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r474",
      "r476",
      "r485",
      "r487",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495",
      "r496",
      "r500",
      "r508",
      "r716",
      "r722",
      "r763",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r534",
      "r545",
      "r561",
      "r596"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, net of reimbursements",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r451",
      "r460",
      "r461",
      "r471",
      "r785"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r535",
      "r546",
      "r562",
      "r597"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r536",
      "r547",
      "r563",
      "r598"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r543",
      "r554",
      "r570",
      "r605"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash \u2013 long term",
        "verboseLabel": "Restricted cash \u2013 long-term",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r642",
      "r696"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "netLabel": "RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r44",
      "r353",
      "r372",
      "r373",
      "r380",
      "r396",
      "r498"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r96",
      "r97",
      "r98",
      "r100",
      "r107",
      "r109",
      "r111",
      "r150",
      "r151",
      "r152",
      "r168",
      "r241",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r296",
      "r298",
      "r299",
      "r301",
      "r306",
      "r319",
      "r320",
      "r369",
      "r371",
      "r381",
      "r819"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r122",
      "r130",
      "r131",
      "r141",
      "r143",
      "r145",
      "r146",
      "r147",
      "r199",
      "r200",
      "r201",
      "r343",
      "r460",
      "r463"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r452"
     ]
    },
    "atnm_RevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "RevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r81",
      "r92",
      "r93",
      "r94",
      "r122",
      "r130",
      "r131",
      "r141",
      "r143",
      "r145",
      "r146",
      "r147",
      "r149",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r310",
      "r345",
      "r347",
      "r471",
      "r490",
      "r503",
      "r504",
      "r720"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r497"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r497"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of shares (in Shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ScheduleOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Lease Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfRestrictedStockUnitActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ScheduleOfRestrictedStockUnitActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Stock Unit Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrant Activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "atnm_ScheduleOfWarrantActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ScheduleOfWarrantActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Remaining Lease Terms and Discount Rates",
        "documentation": "Tabular disclosure weighted average remaining lease terms and discount rates.",
        "label": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rates Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r144",
      "r146",
      "r469",
      "r470",
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "RSUs Outstanding, Beginning balance",
        "periodEndLabel": "RSUs Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance",
        "periodEndLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RSUs Outstanding, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Unit Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Granted",
        "verboseLabel": "Stock option grant (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "terseLabel": "Aggregate Intrinsic Value Exercisable",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Warrants Outstanding, Ending balance",
        "terseLabel": "Number of Warrants Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance",
        "documentation": "Weighted average remaining contractual term for portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Exercisable (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Cancelled (in Shares)",
        "terseLabel": "Cancellation of stock options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted (in Shares)",
        "verboseLabel": "Issuance of stock options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Shares Outstanding, Ending balance (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r212",
      "r231",
      "r232",
      "r233",
      "r234",
      "r237",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250"
     ]
    },
    "atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "terseLabel": "Weighted Average Exercise Price Exercisable",
        "documentation": "The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r726"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29",
      "r32",
      "r33",
      "r63",
      "r64",
      "r65",
      "r78",
      "r79",
      "r80",
      "r96",
      "r97",
      "r98",
      "r100",
      "r107",
      "r109",
      "r111",
      "r123",
      "r150",
      "r151",
      "r152",
      "r168",
      "r187",
      "r241",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r339",
      "r358",
      "r369",
      "r370",
      "r371",
      "r381",
      "r431"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r123",
      "r170",
      "r171",
      "r173",
      "r175",
      "r320",
      "r343",
      "r375",
      "r382",
      "r383",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r462",
      "r463",
      "r509",
      "r818"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r123",
      "r148",
      "r170",
      "r171",
      "r173",
      "r175",
      "r320",
      "r343",
      "r375",
      "r382",
      "r383",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r462",
      "r463",
      "r509",
      "r818"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r538",
      "r549",
      "r565",
      "r600"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base prospectus",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of offering costs (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r29",
      "r44",
      "r376",
      "r431",
      "r443"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r29",
      "r44"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r29",
      "r44",
      "r218"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r29",
      "r44",
      "r381",
      "r431",
      "r443",
      "r515"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of stock options",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29",
      "r32",
      "r33",
      "r44"
     ]
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price minimum (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price maximum (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r755"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r32",
      "r33",
      "r42",
      "r397",
      "r413",
      "r432",
      "r433",
      "r498",
      "r516",
      "r699",
      "r702",
      "r703",
      "r714",
      "r773",
      "r819"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r125",
      "r126",
      "r127",
      "r128",
      "r345",
      "r347",
      "r466"
     ]
    },
    "atnm_VestedUnissuedSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250930",
     "localname": "VestedUnissuedSharesOfCommonStockMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested unissued shares of common stock [Member]",
        "label": "Vested Unissued Shares Of Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r118"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r118"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001213900-25-110979-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-110979-xbrl.zip
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MO[GX\"*B1>H,MB;,^X95O1%]#>%-Z?,N+GVO;PQ][^JW9."DX.?]=LQ65WW
M)WD\VQ6 >]52WC ^%A,_,FHP9(A87 #0:W528+8X_^FVLI"-3:TG^VF.[25!
M@G5=S%;\MIQ3RO.6(]Y>VZ9C^40P'WYI]I.:TU32+HHW[94R419E3L7OPLCC
MQ$Y8'V11ZC3LIH([-%W.HJQQ+ ;C=%# /I'WVY&6'8%665K.=D'VQ4&&.XBU
M*].N&Z)@3AM$U1U-7'KLC=$MMW.^3!$=LNRD.Y$B">66202-[!EO'&-)PG3$
M+DI[V*>H3BEBM#W@2TLB='4Y5>5]1:Y'J:;V0,<C]SYJ=D1^&?MQ 7KMUE9V
M%)">U93"!G;L,BMG-)=Q(GIG?]&4G>D\;_G2\+7(,?,?1HDSA#I])7G"+,6Q
MOKS7DBD!HAF+3RXM,6/B>=4_8>5>BG#_SY1@Z1A-BJE-K(I#"IYR,BAB,H,)
M,[@.XAV9/FM0ZG!?7)SLM4W"/ZKN7>@,2KP=XTMUD=B9[-I3$/6H4Q"94LX.
MI4FPG2;W)80",ZZ9MXR:94\G&W";& IDF$]W',*KZGO;#&^<<#5V/.8];=49
MH$94JMI"AKB<YNYRI-HERZI.MA4A:74LJB9G7)V:./C&X[,W617+T)%L>#9;
MM+F#,[EM\0QMC<_[W3U>EZL&X;S(;0C:=IBH?HM?0 RY]N64RX4INN-<HV6'
ML[SZS4;^YA;9V0M"T/]1^"3_C>;KE=B:AUMQR%AHW(&Z"+I!P_?-^*V31"8T
M$3^_?%W^&D2$&XK5!Z@[H4ADF(2[N#W;SF/<5P/W-[TX4&B =^Y'KZ2%C8/9
MB_BX%N4XI+UJ',NDFZ01/+;4O'MV?,+_0"32B?[&^<0C+E3T#\\G6V@B/I_L
MY(IKYN:M.Y0J=G%\BW4^&^9)T4-M!]ERH8+=ILL55N/B: NQ+N1M[[A6Q9&<
M43C"B:=O7:A:Y2DI]$2<VLZ<><;R&&ML/!ITT- AFFCFH2B*/7@B?CC]]0Q/
MM9'V$LM+Y#MYX9Q5\"*X2]Q&0^S.-E6$M"O;-$1A3FBV+:Z7<:CD,CK3 *9@
M/TG\<VAA!O4VN>"YB0=@X<GUD8UDFUMD#)"]'&(T4V2PM]Y)7<]BK&->82(4
MXA:/LB%/%$M)$,F)MQ>-LB%!!$?Q,QCO]X.]ZFU&,(AF*F$EN9P2,B+"*D?Q
M(&2*\[1,/_!)$=+Z!,O=$CD-IX'(E@UQTK+I^[C\"RU_/=X^'/[]5ZUYKIUA
MHW<_F92.,.Y.-/BUB?:^/8U1X^QR__H9CQ3\<SKX>MG;:]TH=>=HJ,&'WD7_
M\P7Z:%C-SZ4OU8L[]*WQU+F=M?%A]ZC\\=O!WF!LUJ:_QL\/^T/CD?ZJL<;7
M_9&U]T"=!KN;LK/QGJ+ 2?=K6^E<'!A/X_%CQ]%:9=@<_7ABI@Y_')#2@\I*
M_8GYT%?JL[[=O_FAGQ\<=HPN14II;P@)GFD#]5ZI5TGS7FD?*1\'3S>L4S-N
MK/OV(7L:M/1]J[YW]?P9T8/^^%I5O_1:]>O;7@-/K?[LOE*O#!RS_GAC?JD9
MAVCT^/B@/PV=S\/'T4^#*]O\LT6ZU?ONF7EC75W5;[J'NC6]O6_U:@VE=75(
M1H^=B7;X S5_';+6=>FN@LKEY]9-Z\?TOG/;:IK7#$TN9MK%?N4,73]V]BK&
MK^MGTORZ_^=S'4__!N?=COOW;R)770G'\;-S&"$5EV(2)X^^NZ=%I;/]#U!+
M P04    " !1AFY;EGUDY-()  ")90  %0   &%T;FTM,C R-3 Y,S!?8V%L
M+GAM;.U=67/B.!!^WU_A95]V:XHQ!,A5R6P12#+,0" <N;:VIHPM@P;;(I+,
MD5^_DH&$PQ=&CLGN/DP-XQ'=K>^36MU2RYS].3$-:00P@<@Z3V4_9U(2L%2D
M0:MWGNJTTL56J5))_?E%DGXY^S6=EJZ!!;!"@29UIU()F<.6"J4V5BRB(VQ*
MOU/S#RDM]2D=GLKR>#S^K+(V1(48$&1C%1#^0$JGF<"%R!(&7."I=(6A=(-&
M4C8O94].<X73S)'4:9>D@\Q!8?:57\X,: VZ"@$2L]LBYZDE39,N-CXCW),/
M,IF<O&B8FK4\G? '*^W'.:=U]N3D1';^][4I@6X-F=BL_%"KMM0^,)4TM A5
M+)4K(/"4. ^K2%6H@V2@79)G"_ZO]*)9FC]*9P_2N>SG"=%2,]PDZ0PC S2!
M+CF6G]+I$)RG"#2'!C?(>=;'0#]/*=0RTQS!S$DNPT7\QI_\P#]*R"+(@!K'
M_D(Q>%=:?0!H2N*B.\W*2B<4E4(+VN:PKV!3X23*O)GL*47^(M[,"AN9)FA1
M]MD$U@Z6K@N2O\0 :DDA_2L#C:.;^2J!VR?&0#YX-=L 2.?"^9_+9QN.%(/!
M0!1+:P)",53GRMM*ETO>QOXH"ISNB>\@\SS(XFJ17@5L+EU.AL B8+=.^0H5
M->C?]-44:F-((5CHJT*E"PWGR4X="18LO_H:53%4VW \6Y59/^\#%[B;CU@!
M"$PHL#0P=W%<+]-L('6ED<$=+,*+;QI*%QCG*9ND>XHR_%$D!%!2LC%VO,,R
MU-Q,PNQT7*VND*[C;^=?E#D',C H63QQ6'$8<9<M1S>2#_NBI:W-C"(M*1A/
MV;)[IQ@V$&Q\.)T++[/*>!&O]D[!ZL(Z]G%C$*RN9?,6,K%-TY&6ALSE+KZO
M8V0&L$?1UL@AK ',8IF4- :PUZ?\XVQB;LU5 X.A K7Y'&>ZZ[0/<)S#+(S&
MUXFYKT2%@FU.T\$:33M-_5CF_-O@20YL-Y3=\5P?]E$!;6 T!)A.&\Q?4T8A
MGW%#'BS= /%CWD?52A?VBP!_B+S'=R0^5N.F&V2IL?@?3S7S$'GO2/#&94Y
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MMB$&GA>:1%?*A%>\G[&C#_\KE35; +P9ZZ<C!_L>5L_JPQ(8M6Z*HX]:C%0
M-'+%B*H08O.2M[J^5$\CO*PK2-^^)IT^?*]=8PP"5.B5ZC=MCO3ZD/>.7$X
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M)/--S7*L@D_FF_H.6.I56H&#O"D[;=C_&)Q'PXFMW!4B/K;-^#0*H4N>O H
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M+=:"IJ+09\::9*DF-%BQYA#8&D77NG0,%VP:(PB*8,4$8@,<\Y1"3PRJC"U
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MS-967"/%<C+)Q)G'EBS)CF9LM5:2X\FFIJ:H)EIBADUV2+8LY==?'(!D\P&
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M7'Y=^ZW87ON=Y\HO6C9:!:NL:1!:J9'2%::(M.6MX%R?YP ACFAD7Z(</CU
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M)B(?Q#_BP'9-FA& ^,G>,05WT!W&3LT#!"3R[10;+Q[MO)Y11+.B$'@1;@,
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MJ)L5]&$>24/_-<<U[=(WK>YVGI6E1$SRCI^8JT*/L"A3W^+$AN3.&N[=$6T
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M6*P;U910E.R35&=$\4M [*%U_[$64L*-DF3';O#(N.RBVR@2U>W%SSK2<$E
MCYE-DE8G?4\+,[0OZ0=5/&.=&EM7]-5PB:<>(TN#I>\I\^<G8HN55_Q15XDM
MV,9#O[W6:PB_ =%%J%6?%^)WZE#4 AXF#OT9\BYGAA/%A>>NL^3/Q':K!$:8
M[[ZF<#:"$A"5%1=[T^+T"]_P?#WIFOJ3S>QX>"[WB.[93PSL=:I^$7)*/=TB
MZUX8-72E:6U[>LUTW#-\W>W?XNASV:1N_5]+73[HV:ST[:B*5R[V/FI_3=?P
M[!P4Z4N/*^0KD4@?@_=F;638[N<M$$W*GQ6YYK<+VYKHT]DSB,[K>>.@5&O
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MO6MWV\BQ*/KYX%?TU<[L+:]%RGP_;$=GT;(\46)+BB3O2<Z7+)!LBLB   .
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M"T\&/G/'_8D=T",W8RX*==8FG U32W-E<DG/-7(GEFI68JGEN:6_HV_) LZ
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MXZ#E)/\6*=WA#HS8#L1+X65C3I6<-D UPLW([/,S=@$JAXDM5B-UGWX[<-W
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M9GU'/*V(I\;V\=0X.:^56H5Z?7GE_YM#UI(DL^;&L+6T+J:.*2)-X(65Y0T
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ME'[!]K].9^+K+#[&F,,?ZBF:LR^)"X,GUYZ,B'YI*;J 1NP"SIH-4PI5'PU
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MV X"?1PBY$] F[IV8B_PKRX?FO8@G)#!/5\AC5PB,W$4<EV3L^ 9<Y+-GG1
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M HN)UW GX0-^.I@;J\$<@]$+8<W6@K61S+&$I([YR_'CQ.-.Z1OA$YV>EH0
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MBZ"4'W!M@1'A[]CER**T4OT;]C<X;]\=B<_^UT0SPV$7*$00;O]$ZCAC/T#
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M,WC&.29P932P&@<O^=HL#%4%]MW*!'C0Y8)Z@<;$KI6YQ%.Y>?ZR:X:^7,G
M-J9D&XK-['D*-^SD(5,A'G$G.XMWTK+2]_'L24LA:!RE$B=/.W^2,C-JFM<S
M3U7H;;,&:]KLH^1I4 0X>3 <\:DV>Y*=T<2PIHS,9O>9,S*?&[,Q.,)61I\M
M?ZY%G>;R)5M6PQ3NE758#5-8#5-XNF$*O/#51(751(67R.[LOD3#]?P&C_M"
MLV'P\]4/6-B]>R:.IJLUGU/^6 ?U:$@?&!GM;G?6Z_/;7OX@'W#S&FUW,.AN
M+)-=<'A/=';S\$*<4\+N90M(_=6/8-C>>$,C&&Y+DZ7")+_UJN\+$[,T>&%+
MLY#G0LD5\_3PSREBR]P]X_4])@CGET^\3O#F6Q-F?G7&ZR3,O7__MO?ZI%,>
MWC9L=W?M19 <']]AQ.ST]PKO7+-S'PD6N'*XK]'#7+^MA[F<)__@\H2%'FGW
M>_5(-[!;>_L[1?I^R&V^K>$TOS3PF;&RYZ 6+Z6+LUK(TB[D.2R\6R)IKRR\
M9;7P-E<6WANT\+96%MXR6GAWQRAW3G5[9>$M1A"\?5/!'2R\.=7$<Z%1'@T0
MXIDQ3^Z*;[*SPC>9BV^RM<(WN7=MJ_M6^I^ I&#P_];6UI%+@X]/OJ2CB\-C
M$!+^\=[7O5\/CP^_7B#,17?[EW/_X.A\__?S\Z.3K_[>UP/X?WM?_G5^=.Z=
M?/8_'WW=^[I_M/?%WS_Y>G!TH;YS=GC^^Y>+<Q^^<G)Z>+:'?VC>[D-WQ/^+
M5:0WPI\\U^GN[_V.^]T[^Y=_?K%W0<0$BORZ=W9P]/57__/)V1_PG^TO)R?_
M@'][YCM?3RZ.]@^?D$Y=3255M=I62$^+F?)9VSFBW/\_99"!Q(IG_EDX3;,"
M6Q@^@^SSNFOM_\.P<]C^Z6?TU]P?17%(")MVQP'A,Q>P*(*MQ/^?)B_@5\[#
M09E%123(FX=_#L8$Z0P_G41YKBQHL%!R/\U@+S/U;XWA"9(*;9]VG*;?L.R/
MT#3)Z*%'1@F;7!$U7P0%8^-1AT8YA<_Z81R%(VS':-6^+_"@L/O@*HABJB$N
M4J>=0BYG[@'E [;._ #!.N,8_W]$UYM0NP=-!# 8R+"588B$JCS'-\_I ,T#
M O'$)0^"$G^(PSY2PO^<@I9"J+YA25T;$79R>MQAP@"4<ZBBH.?PH6D">YMF
MX5!0R&F5^114 /\IT&TJA.L!)QVFHPYR 'P([#$MLVF:XU@&.&;S"D_.2(&#
M+F DGQA)'PSNS3I >#G\N$@SC"[X:&H1"_1A/2%\16'FS=]LQ^/;]$>$-=&%
M'T>3J%!--*CC+E-*(5V#!9#[.:*NPIX%8@A>U1*,(?71=13'U<\8P*_Z*?'5
M5:@^]N3C ,RV032%]=4>(ZRB/@8:RU_$UK/_@KT[0<8,26U':9Q>SHB$$9@8
M5(8/M$'T:KSA50IY%H5\IM"%0+QJVO,ECC+P3!"B%YY[E<97!$&+;B.BX8*9
MG']CIBD3N8]XEV7^!1?=,DYL3@<WC$:C$*\Q+)K0=+UA" X.H\8F.#$CR**P
MP(8#.NT4P=\GR%SP@6%;Y!(4(<!<:9F11,C2V-V)_%Q-5/#[I>$PX@*F4 @_
M3B?1 %EV&/$EN P3<(T0ZY<% C$+2,<2\:A"?*2LY3JD7<%)J$/]A;NJ"GJ2
ML\8QW)-$/676DG7AQJU?>"0J)\B&,8CM,--_A*V@F!Z,Z:3I.@3#*[SS3/\1
MR"<\)=@2<#%\FH]*W,$0>#!.I[#]'.YCGG.#%VYS'$WA\/=BO!B7M!=A6;J-
M'NZ9.3M0>+^CF($JA2*+!&^&,BG(TX3C=]<$*8RDOP0Y@%54\/.2V$K8HP5>
M$*R4 4ZEQ:2%+0LDC6&;+0_8/AB,<87"N(?<VT!M<^#P9JQY+!#D.+BV"4WM
M>$;AP%^U>$.4-,*#0UE-ZQVFQ"I\FPC(<XHRT!-FO($ \'U@*%R[QDZV_^9>
MC<[CZ_F7,+<.PGR015.%&?U)..[%#9EGI43S$A!Z+XG*B7\Z#H"=!V%)\?*\
MY1TE@P[W6DU1N\.-E]LE%W<B\-XL.5&:8Y,AF" H'I!ELV 8D0T63%DV&>D_
M"0,,[+ @B"8$*(\PP2!3X)O4$@1WFQ0VC\)B@3)D^&_L./TCI*L\2@>EM+3*
MLI#=Q]'E&!\,]_HJP&[$%IA_68Z;;P]BL'7 LDB')>CL 489J>NUXU^@@)JR
M"0!R,24\<T0B3D<>7V_J/A,Y"5(AX"*/00I/#H$(_&WU:)M,N&4<(A']%4I_
M,4ZA(GXDN8KO,ZL%@D]!X"4LGG";8 20<D2U\.=4 ;;G@W1*G<HDQH,I.-XQ
M"Q!4L*)=Z!2B/"WPN[(VN0=[@W:OM^E?10'WE?733"0JG@ ^5+ZAI3OI'0^H
MB&U<J&*2$K49=__"$]7"+;JRW&>R#N!OI" *U+'F%$'5QNF,G@$O-;H$^=O9
M%VN] G%!2$YYL"&0Q*"6F4UP-,&?9*O \?<VUWP+A5II<U2&*.R IO'P&NR0
M%BY1::,$[PBK62)3A8DM?J/XBU^4$S0%O'$(;]4D\K7.QC<B-;'!KP3-Z>MG
M/8%L75;10T+X!([V0LF&,T-6<#04L_BGPC_/*)F70@K+/6 QAQ==WQ30SI<A
M\V\65CYMDK0S^^KQN CD_TOT4PN4/?0G)4CE$7SA84WP<!8 X+TZ_.W?AK_I
M+WAW#).K.17:@AL'^#\@G\$NGX0%W+<0W!NT9X+A$*R.G$PEK]&_19')6H<]
M571#!_RM:1:E:#PA+#RZAL!K*)]1X%UFP:3E[UU\/6YOK*VU6*7=J"%X6 ^(
MVC91P%=ZDN2A0GIE\6C 7N/I.&B'8,$7FK1S3X<EEGVH\&F .A;63#:9QV?4
M NHD[7R"X/I$Y;A$TYS/3ZWDZ_G^EWVS$%@ZADOS0KY'DE8=@2(%G$5.>F2:
M%B%[36@ \C%X R0G+NLRF +%!CCU$NS_N(BFSEGD88%N*_D>(:A),Y1#$\!F
M+&*>@ R)C$*YZH7L5BB][TW3:2GN0(>(/PGZ[3T\/#S;"5#(,@J$@FV^%C7=
MKN(*)8YT^HO4B(]N8C\=@AJ/DF]LE"AEE\K*O?V#]76<ZTA4S\MLA&$->'H1
M1A*Q<18V#'.XZ?PL?D*+O\50^L+<93_"%!CH3^(_H&P)S#"9@?:!ZQ:'Y3=@
MH,#3+';\Q3E6^N)PED^!2>%\_'R6##.RFM0OC@_.G5^ JE)/'X*4PLD]J(]Q
M.7)OG=]J+NIX(I5"M%@"BDWH_>J@D,,[L)@0!.!?PMS19%*B+3 .!]^F*>AM
MV.\XZI/+J%]YM'^4Z_6J,(=<VTDX](CX0^"VL=_5/SH]:'??VT^+7'V,WA8:
M%2&M&G>E%X/[[?A'*6UC_T)Q5%7O*^;U'$D'[)44RBBS#$X=-20CE^P]9=4*
M0\,YH^M+03J9B<'&+OZTU6 >*%IX^WMG[0N2L1B" +[Q^^#6:0E>O5P5^8N_
M0_DQ(36$, E:D@/W#,$PS"B0IRB?1X-O@D> ?\51J9H7S_</-',LI?&R*#6W
MNTK-S4W-;:]2<TME2R\\XR;FP/*."8BGN/B?'W[P\VSP/S^ G+X,_]_:6K?S
M[^GE#Q\>TYR^Q_*6P,8^2M#4X/!GD7JVQ6B[ZN#(4[YH2#&C/MJ3_?2*7?$I
MCDOC !J%O=E>(BO$-@4P7*P<1=A @M-RT.ADJ4P1%I3+7AZB&VN;UJX)KJ*#
MXCXK_W@_19^7(P5G8&C1V#X4_0?6-O8NLY!S/DIZ[Y_M'>QI3:LTEO>57@=B
M:9_U"9;F1 7:)-JVW#_28M_:YB+KD<,3<";1"/8#BV!C?X+I'/@B&_WIR%-1
MGII]:2GSFH:CI:,!W\8@OZ,-;:J!Y41?!^UO!>C%\,_#)(^0@F3FYV6.\=J(
MLVADL-/[.$ 1YZD^>17),/8#GZPR=1NLA47>$:PK#KT\PGT'2<A&81Z&$K3%
MZ<JDIJV#Q9!^0O/S,BMJ@S:/P![EH3*?3( E$$PN_>S /-V3)]+O>5^?6LQH
M!QN;-VZMGR+(4I!EZ35X!4&"EJG%=9^.+S3/2?SP]\YYAP^2DQ2X)HQLR3I:
M.-PTS,%XSL&V:H.AU/(I'%6TXVA 4'!ZE9H;V:BRK+J$)J26E"L12BE@,EHV
M>E/D5QE&\RQ&LQVFEEJX'E[)>5;7<>-4,I&_ZBN[MMU,RP9U3&"#>NJ.4[@1
M8ZY,#*(U1K7 L]*3N496(J5%))RA*O0OT2D+%8*A7$^=ZJ:7YN@.1'#A['TW
MB3_VE?#UX9\1#V*#BPU<,7C<R-4==(E;C/:$*\@8-&;MMDOZ6_\C!R(\%;^R
M0EJ_H< A&+5'#FH]?-WS2+D0DNSVRW00RA8@F=UG_@OL?>YHC(V=Z9^WF9/0
MV\#O.;.8"31H%$RB>/;S3=NC[^9@/S UJ,R2IC0WOK,Y*OIH[SZ%RQG2\-<$
M?D,"*2ADJFMOTS^5D))2\I^Q\X$=W?-!1)EX4#-G(85UC)>]_UG+[F$X21/2
M&2I?R7J?Q]*6G/ 'X0&'-* TI(XR<4& Y+23OT V%;#)H0A1UDRB3T#._B_5
M??\-Q"&>X/8&G"#^M_]N+\>P?Y!_.!W!OK/W_'-)PN J0)B&"4V+G1:<0!I?
M!S,3)#!1N[/3(R="TMW>_M(^/3_>:V]UMYN7=1J75]&@2!L6]C6]PBQ[+BNB
M,"(:)8-O?3CG>8' CNP4XP((>0=_1K7TXV9GU^\+,*@D<W_LKG76](<(F^KG
M06PF;N)^+)L"=Z26*P4#-*A*_>3';F=;/TTT&P:3_.(ZQ"H* 4QL2*C +S?L
M7_(C5<Z=]FU#+L*[D/E^L:]%#8]XV65AW3^]8TTP,-PJ\# O\+#SF@,/%L>\
M-DU;T3]Z!:QZ'T^M*;K-UZOS5O(ZE;L1M&"R9[0,K6=5^HA204K[7V3D3E](
MFN\X#$5_P]_S<7K-R0"<AY)12D2R71I*=ZXBGX)ZP-+.F!9Q"=X?J NN;#,Z
M6&G<PU\_GVF-.RFQ1L]26,9E!Q\JP1HX[2/# L Y1HY,HK[_#I_C7_SCB-YY
ML??KV='Y^4E-)8-;B(;*_P75-PA *^=823=T'WL #EK[X'^'_KN++)VV>_[>
MP;Y_L'=Q=O+'WK\6/_'#01"!&Q;1(LZ#Y-LL93.B&$=9Y35PX%>PV0#<4EY]
M>W!\> $Z%&&RV>;ZUZ>SPW_N?;UH>.G?TW&2@ZK]KV R_47]"V,PZD0P-$'+
M,-89'BAG82@]I \RHL'K_2@)=/V?0UOZ $\X!E-% B_@[&(P1[0]2A<R2?!O
M(',#=DX3:AGL\)%@U,=Z^R3$HNDHG[ I$^7.&J)<A5.X/ [X '.6\ _)EEDV
MD-XR&U/$JVCN!2.TL)"RM  Q]IIVV/&M & +$Z]7$<=;IF4_CO*QE4CDNX3Y
M&[!3.5:2H@,LH;*08SJT%;I-*E>$2^ DL&( K*W1:Z<E$0_S+\225G:;I+UD
MXR.$U\_+[ HX*/;?G7X^?U\_M2#&Z L96MIN"W(AA:(F7-?U7J>GOM"?64NO
ML0!(LC##<" <\,1-7;\[_'1V\;XYE9QB#1C5BJEH8#RC9>0!EM52YA*3O:9,
M"FUSK!Z#)UUQG,/F'!V"TQ*MV8Q\F-YZ457UO"]_8A557\#JB);'@-A+DK2D
M4@F*6TKV8LBUA$K,JKML4ONZ^$5?:F]NT8I3;N)3AP[]";,$_1 E]0"- G%S
MIVS1\ T74P54J;^7%&D2I?XG?II$*\YGDRD(JG*B#8KSO4_[NLH!6TL.P.0@
M%(:NX"O_@C)GQ8\KD?$=']'+^AQLBHC,,)F5\_T#+M_%>[N?QB68$@%V*<!1
MY9&JQ#76ARKH IF1E1'7C)&UK"O(K!HIKE8$@X43&B!C*+$(=A%6.8]0=%%C
M14W\&,=H',0C"3UM=5Y'Z.E%,AKG&$KR+DC^GTJBZKO)8#QKY47_HU*=/WL'
ME6:(SZJH=)^*2OU3T*E,TSWR$W1!-/CX@XA4L5T:_?H)?H^.%>5S1&XA)_DJ
M("#^7=($"1/MM^IB,^S,1 'EV1D,IVR7JT#!6RRJ-9WBJJ@2 IRJA>6D<,KV
M@RS7!2M%V(+A*DO*]OL@D<C=X:"L5U"+0J?JX:(OI:0<O,P4;BO/5TE-',9F
MJDL7U%%(]P0ZFGDZ(/YD6:W*_"SOL^74JL"'$396#D).LT]3='^5"%:5C"^4
M%7ZR"J/'+,+J41%6)?^XA3'*7_RQS"CIK?>F?[Z^0JW[D/%.^97N*K\R-[^R
M^YKS*]_C;;B[NCNM.MM*Q(=%@#E];! /./3;5H*ZT#TDND]DLG]VNO^^Q;&T
M5KU#Q)^D0VQRMB+)\(4T&#H)?BM%H'/]G"CV1\%52E_R,.178$M.BI@;+;M\
MT42N*5;8W%VCFP@YV&"7%Z*R0V5CJ23JK53J3MJ&?$*/"[*A9[KM?&Z^I[I!
M+I"RZPJ+M$!5ANI]9VVMM09+Q$(*H"R<*;6U(!::6\&&L==;-M9X5FFDT<WA
M);==1PH:PUD1ZG><D0=J^L?>FIUW!U;Z%A;FZ<M9C/_P1G'+LJ:HT;%F>7]?
ML?R99OE*C<O3M! N!0S.^I9XZ,X5CYCGL#7*@SLR(9@4,$4ODS0/K781D!PX
M&+A>W@$J3L^D-<Q_&:=]C3A!%V2]NTX71/OK]JV($IFG_ >5ML*EB6?2ER5V
M)BUT-A7#ED%EQ!+-2T26F+6,#<V2RJIP@3^64^JPN@9:S!"'82"-Z+Q>9<62
M7$"AY[>] +P7N$^J;Y+>I9$VZEV%VBESTA_4-XB)3LI42GRB*FA;_C"=8(*+
M4UKZKRK?YTW"23\+DE#;\;K8ZOS85&>;_!!5(.6PVF_A_"*DCO];>HT9X5;E
M2$%"M3DM"?1A:NC&>D9D =%U277/U/*=*7 )'.2;,KJ$KB7"D[B*LH*+:K'R
M2)=O(_B,;J%V93-%>^5(T@6%5)Y DCA52,)&U1(GU:QDEY/Y[VY92@9..%60
M?5 599R]I?HOG<FKM'VK%\++X%C*B?^EQ*HQ(,<TNDH+?#W\(0O^! F5U%<R
M=].@CU7U&'?&2M>8"9LI[ZIE,:I%8$ZI K%>IPZX3UC ^,]8WXW'ZCD^\Q![
M('-)<>L$*[* 15>=N086Q K>6DH:A1BGH@=IQJ/)I68.66:HA9WM5'OY&)/=
MF48<$\.-< ::?&RUNB<_7.6)O-S9+EJ!;0>P;,9$$9ZHMV_5I.!1/WG [/MP
MH.?%(=9?9S/8D\<8>JL8P[P80V]M%6-8KMMPK]9(%UVD'!+VCJG,LRTM$V;P
MM.&4A:.,BO]F8F9R.*%EE2=:)6H_OR5L%RR*:XJ;I"//5(:!;:EB+.S>=*FB
M<Y8[59?8J%#J3@4_5=D*_9&51J!0"=S5ZH\L(Z?N WJ;[8*H$&.]&R]8, S)
M*NE9?\;!]U>$1FB5J8DS<W+N-/W1<ZH5@RL=-%=-;[Q.-7T/H[[AWJ"C6DX]
M^X[@]:$V7:<.UKXYY$#:0@S+076!)-N4EHG/I9"V=\F@1Z9XE8L59U[]FPR=
MR&&1A06U&VMV]&)U2>YX239?YR5Y<EMV?67+SK5ENRM;=KENP[UL64EE4;1G
M:NK8TH27YTAKUSIJ$88T'7OAF8 ;"7F3NV*HWZ&?I=CAV6 F81$]09TJPZC%
M12.8Z%?MLPQJ.9N7U;J,KD+JU/<2^'-LRCY4_\/09)@&&O=7(,S<BA8!_USI
MDOFZ9.MUZI)[.2NY1K[VK\,L5+7:X="30NT%S>3O3O<_OV]J*8>_G8![B!7:
MO0VNT&XI#!"5/E7]-B.*?#+.RLBN-+)P*CR[,2W(7]ZA7-C)Z?1G/C(C-?=T
MWEA"78=#8 [X\+'I+SUBCFY'3WL\3A.3&$/@QPS.,--1;PT*22A+*CC;UGBD
M=F*M9:IS;[/J!7,GJ_^4@M]E_3_-A<AO@9%ZAI'V+9]*,12KV[,ZA$/.&!)C
MTI",B9MRI,+.C4W!!91)#V^5M>K_Y^TRV[IA-C;HN9A(8S%E-;"RA*:)$IZY
M2G"/TCCFS#]%$K F'@0:RS%8H)AC_$29=T'^/C7>=RPV?.KF@Q<S,NKE.E1J
M]E1E.$M@*WVQ<)BMXAM)R MZLX&99[%&7;#@F6"93*W.3.;L#%4530TQC>IO
M>@NJ=#JJ_9]197*/L,Z<FI"=33OL%%0 I?EQIE,9N_6Y(&T8%KK<)W#N"U7W
M<6)<79B.OS>52@9=14%KH29X@0#@I:I!!;C18@:V)9;^?0.=0 5Q5?">BW\8
M[!X'&^!B[^Q6>  \0V9.'0LB%U#E1BYPX-S-K[6+<KL$-$#W'@RS$J?EJ-X#
M@RYP1T@!&TZ@$2Y O]%!%E@((D#H 7]_;R99$?8<PO<0+D(;WL4U0I7->LJ(
MZ_@'H%2C(M3]6!;Z-P/1:3C)W$(W; %_8OF72V*PX1,A?4/!D"X"2JG&:YR%
MH8>5E_ P<#+"+!^DF?*@L5@L801Y@3F&Q[4J\TAL*/IF3YNZ(@2L62<RGJ*I
M8>G*:LS;6%/>+8ZXL8HCSHTC]E9QQ-LRW1(H\GKI6&( 1BK-4EB719U2"6@?
M' ''-<GTWUIJ@Y)RBO0$PH(@2.Q$>UT9JK2YR;R?&"5GU??+][QG3J\OX>&=
M*_@BG2!TDH#]F;^.DE\EMA5&*@=M&;?(LV!C=-*0 7',&!)ESI!=T*HI3\;]
ML0_4*![+3FF);? G]U786CQ*/,GZZ2S@N 1".>;9U_VC]F_=W>U-!08["+)L
MYG_9V=PYHR=>;.^N'5=,MU7D=W[D=V<5^35E*G:"VPJP4IF/;6SSA!5,L8.C
M2_TK:.(U D/= "R%0-.%S%*D.J.(AO9RY32C&S% ]^5E2"C$7A.Z%37WF#BQ
MB]/DP$?9NZA@48W*C-[M8%)1O'N,KDB/&W?XQ#Q&0!"?Q"%-7&+-3D(62T!E
MX$X7 ?EC:G"-+2[F#_EI_>"_.P<C'D>@8.HGINUZ7_"/A1_NJVT?([HZ2"$Q
M]7GP,?8$$^XZ")+3S^=XK.N]SKJNKR>D%AF@R373'!/JPI?:]"5E'$]4,?MG
M!%17\/$:4A\>O @[2B'!?3HS>.#DS3)&;6=-7F8MM89V-3%!YQ;/UM0'Y?T1
M !6#?J@H1$XJR/JX30ZX80[Q:CJ+L:NJ:%5<DFW^S+!6&)RT&L,MUO2L+G!T
M]A>0AC-]E1@4O$)I*BO%)^D]!XC/?K!2"C2P%FX5#\_IHW6B%^D& S;:.Z(8
M:</]2,UPQ09W[IFI[ 3=*YS]%Z?7[9!J8'P\U(Z_K[O56UP?C\#DA B/Q?%8
MKX,Y4)K(S2%:O*<HN.!)R >PJ &-5J4,:H(C%J,$8>$-4EN9D.=)#"I-<+J)
M[GH,5+2Y1:/-*65.RS0R]C6(^<?4A+LK3<B:T+*XK4B'UGD(!PCW(2_DFMB1
M, 5[XTG@[O9 AN@C*-O.#<CQP"J2T]&"DK4I3B&U^9\E^<PS/ZHA?,%+07UF
MJ3^8%2E=0!%Y?)OT]:D^>W6+YMVB[MKKO$5/7I6VN8HFS8TFK:^B2<MU&^Y;
M5T/X#6Y1C4(_W-O;/VNC!C@\.;O8]X\2,NO4:*8TH9#V($2LP^,4C'4:**-@
MG=%BVE?(BQJW)W>J;C95U8T31Z^#/FJX!8)HL$QN2FC*BKQ!0]H>79N+?QQ9
M42J.>KTR43@WW_G;V7]_^.WPK-=VX2M?KB7QY2&[&*G 0>S",OU^2+X^SQ4-
M<:!X,QB)X23P V";6&D_3 =9)&$!HK8>KV%A?7Q50U!D*E.4FTG 153$\&T%
M#Z8[#+PFT',<_UH9'>]@E<Q!'^.14<$$3*I1F+0%\! V6/Y5(I"BV5C3OEOB
M(7O45M]OD!:WP4IM0D5]U>FLV\EA8(5R.D@IVF3#T#*QT:NTP"0)&IS&I [B
M-*>J#KONT )7=\ZQ)17 ^ X<MF4)U>DT%H@7]F['8'0@2H/A9]-=9\&V97!C
M0,8,]!,U=(X-U(80G$%!=<6KDV;W*^!3H#N*]0DF^^+9:$H*J*-%OM<"?"2)
M#N8.E-$@F%), NLI&.4'W_DMG-E9(*EFJ\TZ]%R,/HS43",;5X7C'?TP3J^M
MJ%46"O>BFAY68">KTXP-,J'6YK4IV1[*#?RV"2PA](J2=GU&<]4PE<[#*. X
M2,MX:&".@G]CHY8UY+V*39@F@]K4RY?Q+#7HZ9,@^]Q](<]27?P<<V)DM3_[
MFYT-XY1I;TSY8G,<R$<#,X:3%0A;_P.8UHK;^)SG0RPWKYZ/L[8#^:, JL[[
M<\4=?48"'.M9'#Q.A'V'-T4"&TJO.I;QC9" YU22>OM=64$'J =/+5.H1I+[
M K//(=U]J2-_1R%9^^NCCDM0.I:\XNXOM8X705.\!]?<M+=FTCSJYF[AOMCX
M8QI%R82J)VS#LH6B6CXX=<0P<7#)OJF^:\G?2EV=,H*>D73\^(=:GNK_=7I1
M4C$XV_0A&KV[6]N[O[ -8?_O@2 [-#6!.\ :!HC,*BRW' +<"=NA:"*\_,;J
MM3=7X'P?.D,^JPV6!"/1V]P;Z,^68R^?%7ZI[^*7<I3S>[KA]^G/4Y+N!#R"
M7J^M>O162L H@:\@!\^I0&,?L^I4_:_T 04ZWX8^F%,7V53W2%._='WDFQ+Y
MIS(10$6(Q/>U"WZ0.HW%G=^)F)="QH-J(>.2K)E']A5I'&:JU9XL$<9ML4)R
M#OOFWY^XOV7FR+]3YLC1!YLK95!5!F[0_=UO',7U/U (U]>@U&]:)=1S-3I5
M:)3$F](*(I2:!NW>,E^T=+KAD$+L>65># +F4WK#B:$OQXK/503?J !JAA/$
M F)=*VS]_2F$6PU2I F*[[4\.P@'.DEX\]"T56C^=D5-6ZNBIKE%31NKHJ8E
MO!"-Q2W'7&I]0G*S3%!=?6]M_;0ABMJ^XKD@>F)0;3!('V$I,D]#%,P9"Z+Q
M!A(:C7%>$*J]C(VC#@4$E,59\-T=3'9W=[ 9 :ORJ>KF!$N<4ZQSTX^7><'N
MC S/[4'8;&__Y(=_4@M>.+0&&^G8,DZZD]9S>;1JMP23B;K!\:WR"#1)]6R^
M^GP.%^^VM]9>7_N)YU<XDT-JB^CX>YS3E@HAZQO584LU. $I\M#FKQHGX<PU
M\8*\]B2>&YCQ* _<,"P1CDF>EU/9&?<P=N#0:$B(V;HLG&?YA=3Z;_H9D]3_
MEJ37B;1PX8.LB5+5=2@SP3R)ILOHZGBB61ZGUPQ*9XVQQQ'O0L"W7I'RA_1,
M22\IH@R,YH\&X06/L-LXT%-6L$&*I[A@17X1_!E87,4]2G"[;;82F"1!X7)_
MT?)5[5S;J>;@F=V$DQ#@84[ ATMHJ- T311<+8J2^5? ZIL(\-F7D\[\K?I2
MJ8* B4&,#;.C2IO2C]W.AIJ I7HKN$(K0?^2F]EDZN\FM5G_O4Q"*7A5(U:
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M^R@!0H35 JKI(-ATQ*5JN:5A7V?\3<:JE?DYW+MV%8%;I(#HKJ*KU$;8(W5
M_>/L4W,_"3U;5X/AD JBD:E(LM'9]!ER7EIUNG-3N)J]PU.<YIU:R[-&K_$/
MU7D6E5X5!"A#W 5*3!D6I+2OH6E8(LJ&>7D'+'1KQ516P,#=U@RF8NPY;:S5
MY\%1JM3&;X=GO9:_?["^SIT_!^L[<C-P?8GI<)B#DD9'(=C0-BWIZQ[#LKVV
MEO5[&3(V[(*R H+"GW=.D9D,)?@?7C]2H\M2L'3*&+^!7$US,N/H&XUDPI*B
M?()NO_X658L& ^KS&7 C,_RB%.C:)+Q,%9B]P2M(1A*9.M--FWN8EAIY6)EA
MBEA,KW)+H@\,J5Y9 95B8IT*CJCG.<RT$NOE.0^FYFDK?C#"!BI=16?W9R)(
M3)AX_#UJ!16Z:.QX?B9!+U)THPCHUDMJ#:=6V2_)0[(;L>CE,]?48KW?,"LI
M":L>;JQ$WB%UQ"!:S!0I3M]FS EI2#!8N>[(,%T^IV0-M>?AA6O19LB5QE*4
MC.!J(I!@>2B#L 1O616Q41T0%G'IZA(Y#FH9H;V[!)8R7TZ,EHC.R&( D_)<
M)EK;;$X;M7;&)*>Q.<1KU:5Z]E(I_PXF=17L/TBLI+FT+'*'&YY@I)@(#@V+
M4>7E=#_FT*0%VZ%KP&)-5SU[ULKQ!_1G>,!_2KBU(\)C53S&3(KO'V8!"#ZI
MG"7:[!^?ZURUH*OC@>-6-/?0ORQRNV"&GE7)TP\RT,/"O*1)X4Y+5$1NC#X)
ML?;G2 A:\@3WA/:)JNFE93D7D'\&<@HXT*"[,A0T@QXZHP0S?5HM/PDFA.M\
M&I=7T:!(_Y:74Y2HVQL@4?&_6_X7[%O#)37\#5G^?]-1=%G_8<?[5?:.N3'&
MF![I6BI:L:@WTEF$K$Z2D$18."TP3&7#^Z@Z8*S!=N5/JPE17^IQ/2PAOHH"
M+E?O]['OE)@-E< !'O/>=!HK7E6";^_K@4%ID"[7CG_!V/#?DO0Z#H>7<*7I
M.LO5RJ-)!,=LIOA->:\HH+TYYR](1Y5C1WQG-4YD?;/[[MM[N]N6:X<MAK.[
M< -[)5'.W$/7F8IKPS%/A?#LVE3]8V%6L00CEH)X;8FRQ#(*?5^_A)F4K,$!
M//,R)--.APZC!*PD7*867"XEC-9KM+OKD*$T) ,;U:[QOPA68&9#PHL=1D48
M(A"EI5%-WFRN#4+D)VMJ6T2FZY0C#OYDKP]$ =NG*/\J$1.#YU!JC(P6%TS.
MI$$8ZWRPOLB&,07JAT5$8P\.I'&7.CBPE%=OC#;%G<(RX9..3I4D*JQ[4SEH
M=AR,X 09WF0:34,:1P*VZY#,V%R5\V#Y>RCU^5AZPT>FT8@8R95A@0-L0G76
MP VYK"2=1].H,Q"[!+)24*5R7^IM^ 6OS4)\\L#OUBKP.S?PN[$*_"[7;;B7
MOZ2*.V6P#(4UJNC\A0IF1<XD2.7FHOL9J,@/"+QO:"$Y/[%"">+'*R!Q@K,N
M(U 25U$>J9$?,H/'1AV@D2TX^,,"LF9<[[*OS(8<40/_#5M( AZ;1-%D[N3O
M^':T*D0I7;#.'$B/@0I!"T25JJS'=YJ(!</L2&6G&"FC("^PY8^=<C%7/&5^
M2'G]%#2PBAO95J!^M,"+\CEPQPE7+UAC5MVYP+W--?A57NHO"T%"'C##G^$Z
M-'VXV!RQ1M^P)M"%8\@0IUD*'EQ88,7'WJ#=ZVUZ^]CPA(4!%<26)POI+@/]
M[B$[5&@1UCL$-V'<LH ]K" H]D4TQ4G3D<<$]RW;N^*)F,D?9B@/EF0GU&(;
MVJ)IAOJS-&AE9!\QPCZ]1$<3K)BQO!0Q'C1@#WV"J+K1$,ODX>AQF +NG.-M
MJ1Y)=9G&P[8> S$)P<\;YJI)E>Y>Z*Q/]=P27JH8PMB&IU9(@"$#Q7R><M<1
M'UBC;]KKD AX1OT\%%(*X.7PJ%U?XL8RTGX<Y(U)NL!'F(BLC=//6U:>#MMX
MX1W48L0.;YNB]=J-)ZEV-$'1%&"HC>$L9!NZU%JV1S:HF*SZJC&UJ$J=/+,D
M9>:):3/T\00KL5FD>11S(%<)$7"Z/^F^:'CCMG$6<0';9B#R[[EJ;=54;>M%
M*;8PYX/V,\-N( .Q>V0E+Y$D.$DJ58$ZT@4J!3BD&?(HHR]38 -DQJ$%>0,J
M-2ID5 W&4L"\EQIY54M.ODFNAF*KH(Q>.$86]3RL?NBIN'I!EYOHPY/NHZO0
M:GC,!,[$1$6#JR"BHZV>UVO3"/=+9\''0D2,+K0Q=X"H;SJ.P>@SB@4L[K'G
M8V)__V95-5=3S.OK]6]0*D>!Q)AD5/[S<I[-(Y4A.B5E-]6 T>3":0X>@_JO
M>>5A8/G?6'](SD&MZFMC!Q[07#ZF2('E5,T_[FW,_;$#E8GT:8] S,6SGV^B
M$'TWC_X*F:"XC-VM[=U?-)A?PW*>> 6'1@=KQ6OD'?7B,[XB-\^@("/S=^2?
M@88ER;UE\ >4$+(W1-5J]SC$NY[;8W__1=?]FECLU A:8!N>U8M%VI/]B =R
MD?X2<%+U362T<,5&*S;2*_B=LAF!XJ. 1F*5X*-PT;<VL59,LV(:H]X4L N9
M]=TUE#V]-65NH]O$5G:38;U29BN&JJW@S(XTJ+C"?UV"Q;V[^].*4U:<XG(*
M5R2:"-3N;F?G)RF\61@KT6#S%"7!@$@C<[V^)I '1#")3CH0J?/2% _<N_AZ
MW-[ 6G$5J)=IK3X6"0QI),X JT2ISHKPJBWCE)]H8OQ);:ZQ4Z4FZ6<J;&1D
MYY0&WEOCE1G>P\0=ZG%$3(%SK3PM$TL)*02E@K#V,%2G/'\8 G%?%(IF*=CB
M;AGB[56&>&Z&>'.5(5[&NT#)K_HT L3@ '&V/PZBY!4W+3B0JC;4HSUM8U*C
M3L[4&2!U.+U51#EW-^!7AB%!=2H ;$0GX.$\&,[O[E2'O6$R>V-3)1DX)8X0
MBY@D$)3QX"KT$I3Z/N*1T4@$?.*;%\]_5/J[3*K1FZJFVC)70_YR!F#CTJR,
M^\NPB=89@8G5F1$()[]^[$,<WA'U.;[I%/8*7*M3[]_Q#\I08;?F8YPK@#/E
MP%0;A?H'JMFD1;8'#J@@]J-25UT.3+A=XVB*&4]);XW30G);C-B$%0B8Q1M.
M\!%<PB!UO3B(I^/-Y?2!JD,,P0H86."$$K;%I;JD:.AL&*0I3O<(7+A6Q<0&
M4I\JZ<)@PK4><D_P-[(M/.PV2G3@#K4_NCIOE],1TYH'IR%TK@.LBRR37B<5
M 56KV.%)8#Q  EM?!E)XCI4V"*3%@3"34R3C4^K=K;8@%GHT\22BZ?46CZ)D
MH_87E0\GNU+ =6NS+?^H6+HB-N'<QVF95V\>+475B8;)F$?&R3"!EC^*PS]5
MK1"FASE;K=.C"+? _6"W6!I/B:N6!9GF(JMC2*HRL1058=B>B3>60N@>R9Q?
MT8(XR [<4BJ:4,C.[@DV24<-*D@5'6%R216J*I.=PX$-0C,_#&51F>DRK"">
MC@/_7=BY[+3$T^$Y./VP4)][/ 8//_U2MKLXIRVD(O2,.9!&#-'+=5M@Y&Y,
M0ZLS7W#_ B(Z7\%U2@D(!AEIH$<#$3&D>9#Z2LK,$Y3!A??A"*N+L!\/<>:Y
M[MB=+66P;_$RI\P#XN%5%\OB]W#P#8P2GUC9_[]1>!F'6<L+P'4,*"<GX(4(
ME!XE:M5ME=U&=0#.9B(5"#Q7.J-8^4"-A-'PY%+]-W,FZ-"%LXO;;5_7JNK6
M&7 GWUTCT9N5_DUVJN6E6RQ*QTY#Q(#E_ .KN K)ZUCXWDEV&222!K$&CAT<
MG^3N$$'+#*Z4<4WVN.">=0%=[S;(W3"N6B]<:]EHV7CT1NZG2WF24K4P@J6#
M\V8UY\YPBUP!5\PXC;%4K\,&1Q]K;!2TJ".G/$N5\)E31T%F]Q':34QFS@/O
M@P9M4H]?AK?,20,XRK)$G&=L@=&]=BJ,)(H+K<8,KB[F.55D"3ZBV8%/&J/Y
M/F-W=PO2[*R"-'.#-%NK(,UWHREX*C=P!&&P@%RB^F70^D^$,K&\!NE)I:#4
M1,2]J<+@L$ORL CUZ+1EJOH$QF!(DQ,S#1Q ]78<-]?8"RTW:"^5OE23DH>"
MGJQT"C>)20N=5VTC99$?J796R^ABE7ET*@5_NM>_\C+4PLITE0;=W!ZM:-I]
M6SS+A-TCT,)E3$ 35GESZ%\'&8XI:JF%:1P$6%<_DD;DE2%&U/^*PW<QN<,&
M.]KYM0Z-ZGSO>[1K^,WM&GJ&@W&CL0T7D;*+$,>?4-<T6AT&@3O/PT*SE8!L
MY/[&CGH3Y2<CEW^HV4461_>!W0,;.)-[;VO0&:81L>/1Y:P11ZV@UVLBPV9W
M(25JV/0X;UI']>1Y6/<OSZC4TO*<&D8F0,\$@U!ZQ$2]4)?*U=7*J;O>(0I6
MBM./#)*#>F]UT>Z30" DEVI$*IBXD>"(ZPDWP%Q;,N1F8^O-W[S/[%#;8 YN
MTZOI#QE1)TI3Q;5G_,W:G_>#)!@&+?^P1#5*7_I[, T2A_<EG$NRFE.RW/F-
M ] 'BEGMP2EYJ-]!9XQBV^NMK:N37=_N^&?B=C?Q>J"F(1L?Q+"UZRM5V;S6
MIHW8,@1]H7[BN7[4HCO70(32G896&>H@@^'4X"_L.Z#4!M]PG.<PH6/'#(O&
ME'@*!;,4W&ND8"['2;8%BE@-*^4.9!# "-=#Y9Y''9R9U__=LJ'[C$!O["TR
M3K).9.$W#.P#^:44<*/X&2Y#!<KT W5KBXK;5%QV9 /=,:258'?30MW3Z%3T
MKK;$Z@2+P<+GD6 %-EQYJN%*I0JJ_:;<-O$(W1=.VT<EO.F9"@^7L@UZNK'[
M2I5L")[(?W >%4?OS9,K]84"3V1UFATEG@O)@$R&%WY.A.VV5D?#O:\%=QVT
M'0_'WHMY.D\$O"EE-G^6;__C;R4\%#0/I<F>=9C14@\N<HWL[GK+1,9Q>B7<
MAU$9QY0E!*$TC=-9B*_M]O!WU^-TXI% .QUW#CJHEX[Q_Q^&&"S-U=A ^2:/
M,)/T TTLLS ]AY4H:F/OJN2 5+S1SFQYRB(1%!R-@XH3<_!&1684$0;EOT4T
M7Y#@1+4 Q?N9Y6F2A/A>@U*BT$O0A!U'&7?.(*"(91L 88'0V8S-<$TJ#=A"
M6H@=XL!"<T6X)!RI22+;#'R3C$T-2XW$ TJ+<30U<MR\C1+SV!D&3^EX?[CC
MTICVU&N7<>-C@L-UJ(011ZO"_\W;"4].1"N+XJQ%B VG[(10]#<4N,4H9TH6
MP6CT&J5,O7N]^O8I][.?\8@B9/,3/:+HA<>E/7$5TWF1#K[!;BDIM8^W(\DY
M0W5(W;#A*RYD.E$IQ/5NRT0E_$\I6$=HH!R Y\'CP30H',D0U,=QK/MA%!)8
M3J1,IV(#I%AY/* I37@?+T$D7!+,ZLC?Z.SJ29/Y.,C8:L$D1:H>,T9PU_Y,
M#X54B7A+'%%QC5JAI#S)58JDV?T2G.5"XV]1G2[<^*$(RS.LB2AHM&IWW6<^
M.,5R"9;UW5W[VY[^MOEBQS\G8"2+'#DO(2_[_R8$0^7X);G8,F07LZF$L98Q
M&*3HW<A?' J^K"2"JZ$X](6O_]T2-;NK1,W<1,WV*E'S.J[$N24G!+4A5&4O
M7C$&V\L'25J,<4XU"C!7RDMNW_IHHV5AY#$:1^T9?R^3T%]?LQ[A?.(^@;,&
M"U;IOH&".U@CXKSQ/)P6;,S#2_1;JY_6UDX "P3[A,8?6-S7CPE^\.ALLQ "
M80%DP3W'Z-P'Z8#O\N+&*XV.5^MB<GNCF!!6/]&BQTEOTW6(-;BXCGAX]S?H
M50/M\-/_^6'+@9AP'C\'\F_A*R]JE^5Y-[@BX7=.PD=YY=LFX:-PX=>J"GIF
M"M[<__IZ)?%-9G;# NYSQ&3VT#K6NV_I?CP3>=$D9.JNK:AK4_=1%J5-WQ6)
MGXJ!7YC$]]< =V-!C@'?><4_<HH@+7.<3_#2S-%[;N9 '_3UW[F7(.O&BJPK
M;OUNR+KBUL>W;5;<^E1D77'K2K9^/V1];FZ]K<7=5/R47?;?]=8V6KWUG59O
M<_-]W2J7D'X;[6U,"'1[FU%221.T]<<*_Q<C^E5K_::MG:D2).K>I758[9QS
MB*IR"#\]@%NJC[K[TG]<O+KMRB,S/.\;.:FUMCW/>7O 4A?>R]=+S?6-%2T?
MBY;=K14I'XLMU[=7M'PD6NZN*/E8JJ<[SS1<T?(>:GQW1<W'HN;.;N]9:/D0
MF_H/;BAXF"%]USW0?-L@%N2;/<%#P_KGJ[!"L0?SQ*/RZIU98*NUM3E/:3[*
MRKYS^NSLK*BSR.!:$6<!Z]PF)/16J7.KP,Y;)<[.[FV*4=XJ=;9:V]T5]RPR
MDK>VGE P/TV$]*9JQK2HC#]Y@6.:9X/?_7ZWMGNORZYX--)T6]4!$RO2R(,V
MYL5DWCA=D&7F.;)OG#2OS$!_1);IKLV+N[]QTNRT=M96@J;Y-K4V-Y_0IWO$
M,-EW<2Z/:_7>^FG?#^.N"+0BT(I *P*M"+0BT(I ST.@IQEGN3P@1W<#*F@$
M@"+TQ&[W%X];C(]3:I ]K&,T,#0$@B@%&>,>WN87&R\.I[$$M$<XV%$:QSQI
MDS$A\I!'J13CEIZ1@_ANB.8M,-WAL(68<($_A,\1GXEP@1'IB-"*])RQ5!_F
MSTNPV7E+>&50&&J;KLPBH>062JOB!HV9@X75SN\?W/I^&QRCSVG&KT1&^UL_
M^_"1[R]_R)>8_YMN,G_#N<[5O39NK+%NVZ;5_9L@&TAQ\[;?V3V-[Y_HN'J/
M?US<@_ 8!/].=KOQ4NP%:O$J3,KP9VU3W;#["G47_/.NOW[.=H5=/&?9^L*U
MS[7&?KR%^=>^V:B[!?F><PE/4-ZFJOJV&@KPYEQ!\[%U6B>(>>UG[IE57H)%
M?G>XU/4?W[W5?)ZXD8?NWOFA<G"[:W?=XYW7]HJH56/SAQ+K:8710^X!E0_,
MNP=W/\['.\-'8O,'\O9W1X$:ZSX[OU83+@_12<V$:=CVS5]\N()\TL4\KX0
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MCA^Z,.T/\&9P1*#9\1"!-W5YJ8$9DNG&A^LPE('&2K<*RQ+4=<CV7?0%!\]
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M^EXDXWTO'B&A!NB4-8+.:'F=%K^61&(-=\W>YY5?]/0FF-=T';C*Z<AU0.+
MV9.;.M,W+73 TH;TA$?U'<Y(G@7ROJ%ZA8O1SHE6#;.,"J3AJ@1X!^SOC-$Z
MF(3<PK,=WY&(:!@V#A=+,[$ZZ1GN'3<-(V0QMEK!QBG2&4UX7@EV;X@4^>8#
M9#'W%D&Z:0RIH;WD")L-KUDT\9514X3BV^X$<-LLU0^[+-7&+-7C79;JCHNZ
M/O4MP4*HI8#%]=_3OA^"J63 CT9 [1'N)ZN3P\!K9;0;,H5;C5HB TQ"W'(-
M:ZO5/Q5("[*FF88/H)?- ]VPE1EL,+@$)1?M+BRC]*86$KOD5T(LAOS@?V;<
M;-<4#04?FUQ"%]>V2L.'^QCTH";E?3Y^\IJP((88I2$"U3O#&ZRT>2@=<F[]
M3!;++*7*4#V0;75HM+A__>)-MCI"EDW 4EGB=%87__<O!W^Y_1"NBFDWQTL/
M_MV?*> \EMFR!5VJ?_FOVF4VP=>'(?_QTU]0)_YGU^A3P5BB=(>^ RC?OXC:
M[*9ZD3QPX*!UT\T7'K$7 X^N[/OMS;)%4:[^>MT;TK5M\:^<)P2?^>3['Y[
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M3CSNFWAHV CM)U 1S(#=26$T&6R21E""07*5VFQ&+GM,2TJ\C7".38)'OA9
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M^^Z?9 F2Y\V5?L3O;1W"2)[+,*Z1,10L OPYO1 9QVBO4]D@.C[\>S$UP3W
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M2:^=2&Z<EYOD*FOM6V?);W/DYSL:<K-0SFU15Z3#LJ7PW/G2I2NZR0K'75
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MF[82(<'C-XMP9J 0IO4"<7Q(V3+=Z^H]_._PN!G2WM.;GX,'/>/CA1HO;YP
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MA I2<C.S,5>!T;W5=<<>>A.9>,^]C['0UA#0Z4PUN>?\R:=8 (VTCH@"@+]
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MZ@)'0[$XSTI$5M-N&>MCI+!I*@4V  ;D,[M/H-/Q(7A^/<L3)YCDJ?,5*V.
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M9I3-6DLDV2Z^S!TQ!"LG\LB51Y,,&=L9F6^GG*BA>%K7XRQ&KH(X"'V-*M,
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M\?^B'41:/^[00#MT9D-I%H@(AIU,G^"7$J7R@R !;OG*57 R;XLEG**C<4V
MLY#*9PP,128Z^O6TRD>E85/HH^,%4RR!6 FX&.D@BL;PND>Z+([;"WZVQYJ4
M_.,G%+Q^W0_,3,751AA!]MP"KY_+W!,BKF Z1C-?WAG3^:4C:\4WE"$]^1,6
M^P$6N5X/?3RJ7;+O/7/\@U0WHMFH6%KF;\^_JE;/OOZN\IQ.8IXU*(GG YOV
M*?*$,W^5)$EO<*8[*^RSG$I:)"Y!%92 BA$S;-*YI%NXAD)0(QE9'JY3,B7
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MEB155KA) ZKB&"+&<?R3'V.Z9C+=/H_$^/SIFF9H?#:(:0^YR###IJ7<T14
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M(@$"/1\&JT96[,[4Z*JVGZ<%'B^-*JKDIU+?M<U=W*.[^JH?Z. :I?DX4!.
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MYGTU4AHCBE!]YJ')6/J,?2V_B0_>$E7;3+B6\?'854:>VKBE3FXE[ []-5B
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M<V?38XM0@IEW?:HELSWZ!8V-RZAFCX:Y )4$E9*4K6!^(#+6A:%A..?AIDF
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M;G*R[6YAU!CU<*I"RI$F_;B2,?D=, "_2A'R^0+*(>GK&80ZY+)_+NK^@V-
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M9VCI7D0>X[8Y#MWJ86V+_-@]._3_4DOM'\](MD4DVX=G)-MO?"],)-D2/BD
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M7=<9_CGCH5K!O3R*,IX!:3/B/PNL$RQ=8V[%G!1XJ03YE2?N1OK6T9CQ..F
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M.\:?@K"BL]Z=,K^ W*UKSI,,0XX(1N>O]G)Y&DIA>M"SQZI5C9P[74&Z2+3
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MD@C'5DA_TA>U4N2K=!.H&^/*Z%(]J$6',16'D(O$I8!W4B8?P6\QKZ3TC^;
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M91?[8T(]+ZCR(($);YXQC'^;E?P[+N_ J@!L@M%!H.\;:N6^<@S,0%O\0@2
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MS)N%VW@1LT*.+A5W*&0$NR+<-[A1+<#[V-:/1 _LU+N9$2*;/6E#!$!F@7'
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M,)T08C",-YN//@HM^!79_G++X.^BG"Y>Q[+TC6;%Z\OC]4:A>'UO#V5[O=9
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M$>KB84B^$M.[NG-SH'XG*W\K=3%EZZ5=SX.]A$F^GT>/\'EW[TS/XDKC61@
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M7:$'SKG!YQX1LEWBT5D-1-5>J;V?#Y#OV'9,9T >2;S2D:Z,W<"I)&H]^0[
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M+_[;=ZWY/OW;*)B,]_\?4$L#!!0    ( %&&;EMSIKEK@P<  "8G   >
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MQ$:]@]BO_<H^5H:51H4-6PVW9[7+JVKY(+YX0^8U>_U1J\FVMF7E6+%P6;U
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M<_K$F??,7F((^DU9]B,S^BW:OU!+ P04    " !1AFY;[3NV9!$$   8#P
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M1)6/1A%,ZL$?H1_B8NMK %:G>_FQN@,DV'MXA 52V.QC*6PR8!RM(%&->##
MY96(<<\^<%LD:089.%Y"H/62F 5AS#SIRUBXL#/0/0]A$C$5.O P\X4K.7.&
M/ @$#J7O'(,DP<:BIV!@A3! W\G@3J@XC&#_'J%192O76'<H &WI!_#;K2"4
M>8D*HP<8!.A1@$<]='V-MI-B"0%"2*()["K>%_$# 2'Z?<"3\X!;YLR-$GR"
MQVS(%>VT)P1,2?B'_0*B<?SGVDV-O0]#EZ8XQ4$=UP?$JEC3POJ:1?C[TTZ*
M:WQX/ QA1XX'#SOZ0/O2$^ER#\(L"4CA/4^JH7!K,+DK]7Z\API"4$#**$'T
MPG%X#X ;?\0CD=OE^AHL6P<$YW>:4@Z"=.4E=]*)PS> I$.VZ26QB)&2+A+6
MW-MC=W(D[P"=+LPJ8'_W(N;!%NMQ!0A1H2=@6:!^I--T6RZ/N=ZNC(<A$(U*
M>K"A( : U]?$'4IT$.X 53I$W(]@/_AQC=TDSA"^X=('OI#JEOE2>6#HX/D-
MR>9U<).(/*$4(09H;<0?1*29"[<_2@!_CB8UGS^P@;P3.)L@?A2#!.@-:&A]
M33D1,$N@Z6$4HI)!4A9!/XP<X9/.<1#]-> E0 ?('$1ARDD*3U>Q'LP'.V2N
M5)K:P#V-Z$ \R7&WB M-.AX?TV(&"A0>,..HP+EP;BYY:0IW3:!9LJX '\'8
M_R9 ))I:I4^,%R-S1)$ T&"O&F@@)Q8#VP0%*4$H\(&FX60R7/=A!3@((&-<
M,Z4P(B$]I ^"+-#/ 2^2N,B-QZ^2.(ERU+E*[?MMU,34P6M"8T#?,5$+X"N5
M2_IX++LA,1J))P?<2*@ @$.Y W)6$<]:N62.$:E(TS.PN=)_CX<2L"YC'-(3
M> S9K,+5,R7(3VB'P,%9%F=&%H0P831&7M!$I04&0@'"!E@(3EHE'MA<J:"
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M"&I>MQ&0D>!TG$#GQ*"X*3"XT+0 ,'$(_ B#'%L!I:(RPXE'=,+C,/%</*U
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M^@4I[Y5IL'DG4'_WZ?1W,JX^=#]>'/\_4$L#!!0    ( %&&;EL--(3CQG
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M;@&DI@]7!&:N9U[,VI(XA% <U^#L@)_M-%E!UUSJ%F,^I$;X+E.D7DWF#QM
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MC:'\TV(XT!<-\_&#7'N+Y36OET*;+T_2'O6Z1+-H70WDF55N#"BKK=4H(2\
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MWM]9XZC-\E);' Y@"$"NKTJ&X$"1OJEFG+C$IM<Z1EF0:#<*^3-WXGC$-FM
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MH.?C7X EZ0':#]$%#Y(U7V[]G!Y^E#QWU+D'OT X.HW9652VT<T3?FOF^AO
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MC9I%-TS+/_AVV-AI*V,Q,ZVTXPVE "07,T2CBV9BM0YGNSNA+1DV,K,!,9R
M1#4JNHLQT8M*#[@G80J+,C'E;6L2=GXK*S4NH)GJ-(F>M9#)1O5_EL_>>BAB
M.D*R&"6$8;"6)U+HA$L4;_>F,=F\!:BJ )R$4%JDK.%PD=7:KU'6#<H=42BU
M0TYJ42;7M- =I+^;ZD84DIBY!TO-NG3':5>I64V*9!=6>[!;;]%GFC.J,M=C
MCVES#H7.UZ*"VZ*$<'0-WQZ7[Y"5GZ^#N104-+SNXF>PJZKOV,Y'OS^"-0ZL
MM1L\RI#&&BB+C-?A*2!B"P4_67*D.,7</2[^Y.EA$*X>:_V8_)G)1D0*-5(C
MW@Z]YDJ[:^XR"_CM,7"'K'D/LFH%JBYK7LN^ZO<:S20^N*-%G#NFVT_-*[0'
M1)&<:Q!8(R\ 1"=-B=>)X?:LFTWP$3S%1:7U>4';@%9;^_(&L,/\DS#I/ZVD
MB%,!7[FQ4B:"](YVV#Q2]\?LIIJZ1$G,]4/B9*/WARI-6WY8A!)'\O4%UWEN
MB#0 9]42/OP9,?Z%'O$\?R#ZZ!7RO,O<<%&48D=G/,;'6EF.5]C^1X%20V=!
MYRIFY,.[-F K??"@^'G:+Z+5:>^(43W@E/)1-2,W?C6HZ#VRHA^4IM^;-:EI
M>/0-;A[S)X'JIVP@SH/QS"2LL96:I)(4/BXH_D/,ABK'^@W)6!?Y^KR_TY/D
M4*@](V,:LD#2AH9^_$BVY>EE()/E:K@I550[<4;G/!@#^SW<).FV-L3%A7W$
M;AF7W=R\&W5Z#*=V&CR(R'*:HG3K2(9+I2\5$-)]D1+^5'0RJ<.#3H+3:\.F
MZ9[R=N6;<6/R>*YX,LHQIF[2WM0O0 EOS2E[T!HBVI^3BOF-Q5&$>/Q'[]P#
MX:9"ZM)T::'.0?3WCO$$]] /'5'[R#)#JH!0TKY:CRAD!?)A/4FZF'?6ZCP-
M JH"E], #YP]M48?O%ZAR;6/U[5+<!_0];'EI1WTZ@1\N3Z>OC[+7Y^N)LMC
MD^ZCP.OUDH-$6;I6^,U!H>G<*DAGKQ7Y#K88"4I:%;W>T$RR_Q0B\A'.@E]P
M^_V)R/H+_G9PWV6RR#]!M%&Y=K5^M31T,A5SOGT#.!TJ.D8H<K#>= <"/$)D
M37NYTK\9+AY"J$)DY5]\ ^UN RQ$KN9'6BY)*/9_O*6%CS5-Z1XN3W<+B972
M:9=8PA')Y^NF$3CXPU5FP5_G[X_"84F,W;P#MHK4KM.J.Q>9KQ 9JE_!U0U
M]EP8N)\R"1X\SDH8SQK2]3- 91NWO@$8[J^]![<9WF;CP_Y*FCL_+#X'FP>N
M9/*NBY,>H3?G6;M804A$#?CX/:_],X_S0J.J68F[#6<GCGLCZH=,.LHX4T$<
M/WA0I\K ?U <$3)#T& 4V8F-H])=]*,KOF*]1Q$ACAF77^+XO/;O*OD%X1%^
M-[WG>%=NV>@&\/"XB, <"A>1OBPX5[72<DKX/(JUTV5ZFX V13'\;NN]0Z-_
M=>*_H_EK W_(VVWPI[Q';P V6=MB5^,#AUQU%^C9&N!52M!6-OQ9@HRUDK[$
MKV)#)UM9O]2B5DGT%P1_A?Q4F#US;TB26.H^PIF[_NAJA]>+U(QK$"1##4AJ
MWPWR(RPB)@PTRT-AV7_];DW$]VI78!D<S 6G:SX^.(_9+QOSA]*TC.^<O?V<
MF611/$EF,R$1]P,U6VT3QWJ%[LS.^HB9OM#U8R,C%6[N-])CP[/D&\ (=!74
M%O/[J51.WN@BRG\NK-\RDVRDFL#4AHQ[@/U(QAEZ=<]F;.\?:N35GHK](+UN
MQHTB\/E%2.[O!X/6G[#Q7VNY,(8WU;KOS%VC'[]6(;-Y(Y_ISA6,5#&W,BM<
MI4\?>@*"^*_USU1?+PKCU.A:VD* /][Y2=\ \/2.SMX--;*/F>*7%K;C8"@8
M%W[76Q]W$L.J9GD8OF&6$?O563WEW%.98[BT/V<F<2R2* [-C>2T(IGZ6><#
M*L7[ L1=5./ZR]_!(TI]X -N+U[#XY$CX)4"<]E7'_0"0CBP/OU9[7#F*FTX
MS#/R.<W*4N2=[!#O9)*2ND94;M@)NW5:FIZT945'(;+" \LD2*SB]J[YI$LF
MAT'<WW&R"*%^*G)ZO,"?TGJTCF(&%OA@ROW&$'-;T5%1%K!$>SGBAH.I-_M!
MN7099&YUU5MG0']]P8KLM/S@60"*M,MX^.[3=+8+J_,8.'T,?2\\S=_T!A!6
M4&!T0J!(9K _MA;VY$EN?5,TS!/-W=*4%G6ZCGF06%EZ%.;M"6BS\XT2980$
MQZ' D,BK8GN0;@"69I0--L.^?\>85V!<1) <FL$7X$36CIV](MH+,1(?Z97I
MWAH-N+J U&@W[EM,NCH50#UIE&J[7969D9F^([%C.R(1KWTLN^RNO 'D9[V]
M 2Q:'MHV;Q2L@L[2N+<I.RM6/3+1OG IT?(I*YP44DEI$P2VXIOA1=;J.DIB
M3:=I^][S/!3M+BFB9;HD,*8Q9?<-;KU,]7VU$W[<_)NRW+\@'_GD0PI-U_<%
M'=DM0R!?POG-IIMT._H^HE.CJ#3L!80F7"]ILC72\,"JZ*[X#L2"(T4E!.)9
MWO049\P7/I$E7@-H^OQ=0:3N.*9:1Q$X=_K-A[C37N,%)WVP7 X.9W4W>C_3
MCO5VL/ZCVL)VA:X7<Z$DKSE7?7U DU[N8V@?^_MZ(R'2X[G_F-!WLO.RY%U9
MDZ\[>ZM\'G%6$D@R]6>JW^._FVT[FNR/JJOOC''DT\28;Z4!()$P:V!'"XHT
M"G 9)U@744BYYKZ"(@Q=.@$15RB .&X '4,(G?/$<-7N2XY]Y]K4Y) Z4AP>
MQ!1-H.;.>1;=<M3VD7B=2ZT\8+R/6KXN[2%3[2#MJ@3N^5M_+QHDL75 N>1O
MQ?RVIR@AU(H2KY(F0+R-,7E:YDF/0P^[)D!$K'5PUMUX0Y\RM$"^8$J/^TK>
MB2,Q?V<*Y4[16GU;9):J3<'?<:55KC,\*]8PT4.$U=13UZMP\RI>-B#UOC/_
MNHV_>NTEIMSF5R1;E[WCHB;]T%.RGXF@:F0U^:<C!W%FZX/#<@K^]T49+]67
M"BB8-7L_P9? MPGATP:<7;Z?"6;1ZB'-9@UF$+XM^Y"4].<@I5(EUO;+*(0[
M!/_X>+@-JIO[F3-&.U!=E(JSAH_^ZU7,O\JM'N(4C7*N__]5]616MQQ[D[VM
MX</+F+O"_DYZ?%<T%UE7E^"EMB^JC#O^@^R2CA]8]]+G-EY<_=)6V3L+L@^1
M1?-T*OD7E(CPXCZ\X 8@,G>&&*D?7BO!_9H/%@Q2_]Y3K'ZDNG/ >\$C3P=_
ME]--HW_]Y,#%%:D.3K")=SNI&OH7F_V%@X>S_#&S5MW+,M85W>8&G,NLT3'K
M[W6!WVRQFH.7,K^+C.'\JQ*,28>"#4NEBC-\Y.]VEL7>5*S<5\P+.C@$S8!Z
M2G_3)F]'\#[E<3._,/1,U?F;#9:*4"K6:0PLOKJ/5S?F8O#?^! Q]M/(3I6T
M.O_U@O)?'8[]%O3;<?\%_XJ.7SI09 9:MP6M87A4PB-A.J3C_T\==625:,R:
M)%$CZQ_DP.V".F:-_^@&H)>ELU6,SF][&NF5>A&S7SK95OPE:GTXD:WO;U/0
M+U@<[-@@U_&;&%&A-EZ<J)-^V,PCTA^5)%EA:T%0 R:2,B,(E0*W4WQ>@/M=
M*C>06-QS-,N/'0=$ZKC9[K3W,#EE-D'H*3869(K^B8!$59J2Z/5(DF\!F]AR
M:_E^CZ<4N8+" >.W%S#%7(:>D^KNF'>V7=O9KSZH:CO:\W] '8NM5*;E)'M[
M. 5XBG/(8ZB]OY-?Y8/5=]A/_NVQ5AHGRL@7/3Z:>'3TY>*#=5-AJ.RB C9%
MDWFY6?HWP57CGHQY>.@A]]0>GN6%+V<WS_%SDZB7EDM&@Q5OD"JF?=NSO'.)
M EV[=)U[';6Z*BO,D:M>40TJPFV /45\[:6/,R"3>V(<]T/[FAF14,G!(SPG
M6UO:EQV;KFK6)^SK(]9M;FD]M!:<XD>[4.--ETYA&^$K[8+[)<LAS%-9-<\8
MT!SL]7-CA#SX@1Z9PLXX>6)\KXXCTAV8EG9PA7I>ICFP%_>FS(I-!2 Y/'?]
M$-3*JV$LE?71FE?4P7"ZOSLJW2OF"5J+;:QW9*;E* _KU%G\Y))FPXAD\OOX
M28;4)_%BM>QUM ^^K_'S+Q9990I^J^&?@2WLN+\V8AV5TN.G<S]T>5<0W:A1
MN>&8]^/'A,41VR,9,Y+Y>Y@HPG!3=98KAKSOWS=.8-_>:'1#BJ6*2FEL'Z=0
M.3MV1HE6 =]4>[R1F8RJ!M<3898S!<;%O8.B$J]FL3;DB?%4J\ZU1;G@*:"9
M!G3E/OF^\4HK: &>^ 3>O39SG4%_QYX86UG*,-_YA2A4;A3V5,BJM%K!A;9W
MI6-_D?>N<RU7EN,+I06I][(NY1LG%ZZ:W<SZDMR!C!ICOIU)@_L?*910-\*U
MW'8$)2!'K/=*(.CZ5)^O1^M(!M0/!4E+9DEJ[4#;B[L;]O>&OA"%M\@Q".LY
M00J(.SF4%>:WF)/5G'S\.!@C..)%GZ^@F3UQR@B$YJ.*2;TWB.F8Q,^.]/X:
M<4]U6Z(]^"[M-;M8@>0B"Z%9W.*8[8R)_JZ&LGOD$L/!8N7+??H4EHI7>763
M*LJQ4HZ/'F+/S0#?"6ZU3.I/UB7+PBWB1<7(N02;O%T"@X+VI+(+B^!40[DS
MS>K59 _-;'OX-2X+UGU4V=YPY_OEPV>XV.*#/^C)3"#;M:X]"EW3'O+D4JR%
M<.C*.]U%#9%9?E8?M8C\^"[QFE,7U+N<+X"[>Y?0_'/C-!W>PWJ9)[P^X!&.
MD=&AC]:&"5^]O;6^ZTMC[4"G3*V,0V:G&QN(]CA4OF&#!'UG&4>HFNLJW=,'
M(-5\,9>Y40%F >#F2(HOCM9$^WF?JCX%3EY<#.LRIA'OLDRC8=KU/NZBR<#V
MCG1ZD;]/F20\#8GBV9NBLV 3R(CO&3I_*?/4U,'7(KK:FC2-E"W,MN;,WJ"'
M^3VLI^R@^P&F^!U-8EKR)5A6C@WLXEBMV\'*[T[[H["H41$#+=S[Y!GST=:U
M6?/70(4$WGV[-[+DW??/5>A>3*T".+H!%K5>I<)"BA'/ [6R+5XF>S&80,_>
M08#MW&,7D1!)?#5 3CCCG>-VW@=(,^GGXRRH$:Y6*^I$8FC:^I%OD9#M'T)<
MH+2FL,^IT4^H1"+![QQ'?(6_K:HENL9!DN.>A;A;2:2:QJ1CHG!-9AM,HI$>
MGB6(OPKL+?Y.@X]]][G(!@GJX6I$\\/U6FK#ZDWW+A/T@8;#%@XD1503F:LM
M0;:[&\K!#ZM[B@" A]$TGM?"%#&P;$. 51AW?.G8ZFFD%-I+.D?E0&QA4P-!
MMX*/UC:]BRQ,C^,?^N!7<F_8:]!CJDSQSZSS/QV)>>/ZHI:(I5C[#48B+DG(
M3(M93&]:#_B.E7-7U!.(ZA/;YY9Z@/ ^[40CBWMO,[V*=+("&K>,:HEV(=A1
MF%73SL_I.8B5 5 D:=LL'1XLQ6@6'_DTB8B=3[250CE2AZQK3#+\K2<\Y/XT
MPP5U#Z;T65K9NWG7_5]BD""]$H[IXR]Z<,;:.;-B6;:'-X#)<+_%*_5)>ZT4
M1BV';)XG@^(P7;R,19U[/,DCNQ5O?F6EN^5=($0KTEJ>:V*C+P/YRVB5!+_-
MHB0+%\6%3!V1[W_?T4!8'M?LE\I9>MQ''!F5;\()9F*_K\6(:3^\XA]:T'BH
MY![9"W%T&ED^V;C\Y+1K%>\K,+)4"S*K2]]!PTEYF-2D+,6NB&J+;K!O[2J[
MB$4J^RB*1Y?7:X!:A;$W(PZZ>/\BW.8L1B*:-^Z'#YVD"PF],CM"8F4")3Y
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MTO536?CK[H7,LH7/?$N#Q[!7R=Y@M)P:'W<5-(=QJX=[81?82F!5/A>1,<W
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M9; D'B0F-V4 !7M7()!,9UC]HW01*$^ -:&FT.S1UX(*7^.G7M&UF\L'+',
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M&U^-!/^0%0ZM>IN<BYN&90R/_.P3,->[?\#X$>^G?NR3WTNW0O8@L S0,3\
MO47[D_G3('; 5!AB\]^4K6SL B?4]GNH=.@-[I,IF#9YB/C1T&SH#?V3?KD8
M([MW:7]&>8Q^CTI(>'1=.C"4URW_W6!&!B\^??PI9E5??(/G;2>L07SAV2:4
M\&?SS2&1N49YR#4Y^>#IET^-S8RVWD1^,1+P'R)-W,[5,/0;]F@Q)#TRD'XY
M*M['-3UC?*%[2!HD=J]15:8)RRW G!/XCKG#,(LAB8,\5Z441XW,,*=T,Y(K
MOB.=30A_]98N9?:.V:8[7WWI%5+BIK<[4N-S5_E8COE5X1FE/I^KQZ)<BY1T
M/<6[E+Y:M0B9O_?4:]?(GA6_S/O5-ON5AWA1T*R2MG"*DT_MR^7WS7XJO:K/
MI6VZULU5D]]U"YU&![_\8F]J*C7Y(_H&[UW(F3=OF]\/KYQL':I:45_VS3_A
M[/YCHC,8Y7_B\?NV0+3\B]X3 0+)BV1Q7W[< 1C@" 7U7#KW('6QL4:6.T:<
MSTV(YQPA]E%*\Z1Z%T(H,&34$GS--#03<)RY-K2LFGME&L'K[1=M^=G.Y@/S
M4,V]?M23,UFH0'^BTP;O'N30 F<D_#"XMJ\Y+$"LG5\#905C""ZWS+&UF?A8
MT8>3,I)K-L-UK8? 8G&WJ*3BI4R?GY1<;]]D8[CYL-KKAC?.+"86EOQI]MVW
M"Q=^/JX\\I@\GAF M%9/J42:UO$H/[\RMM.G:_TXP5LQ*;K_T<V)+LQ1HS13
M28U2R:U:Y>&HE!QEI<)?!5:-C?-%]]\4IK[<F6R03O[P:6EI2#X[\.3MY!:D
MN,XEQS8);@_].;W^ WHK/_PCG\&-\-<WMC=WSTYOR$7VX]R-FPA$;P#_,"Z,
M 1?_F2)H>T408'V1^-1Y+2I-XI/)TSG92-AUW.;VX/'AW!]RPUP+_1(+PP'L
MM/#Y[5"/C3<\_ZE;[6WW(#VP[27H[U)OI5"S/8B;!R> *]OP:& _-AG</I[[
M>BDYYX')GQGQ#2C!*)'Y:68H[_,*H?H#SRC>E;G]Z&BN>3_:=7-&SVAZVR^U
M7_BI_@*XG4S6_]*/_?FLVR2M#_Q(#@K7! CQ6)F2S\ "1Q68^DA/^)//5133
M@QBLJDUX[6'[R/VL[\\';2<U(;R0GP$7 [A94)O4_H5^HT"Y=V>OAF?G?NB'
M]Q#11+WB+"OM BNM':TA.&4!]J(BLV9$:VC%*V"TWXZ=@/-&C[4RX,OXG8ML
M^&XN1V5>S!W*]"+O,Y"W8U [YGYR3X>L6.XJLEF-,?G7KWL.PQN"QQ[T(\/N
ME%QT/Z.N*F#+X"V $W:3]7?-]&1;-(=:<!5K*TX[O.%?:/6L2"(8S'H-7J#C
MG_-<B\<8&3/T26-YX#CYPL3<"B]]37)>S #]/*#$<_+,#LK-W.=U#N'KE*73
MGZ'P$=AAV!WU$VPXN#"-^/$5BJ?Q81' W34&-R67&UPHQ?AWY@J!Q'SVA986
MN'C;-%H(62V8@)5@5!J:#FW"1)!-@LEW1T]2:OFAMI9)P684GW"R_S;%LN/1
MMX5U>_(HT3W) '>K_/!5C.>W$6V;KYH.2EV%E+[L8:G@E A;1/J<M+$1J:#4
M\OCE )0U<63!^G',J?52AX#\;!F#]U'J]\LN]9HZGRN8S9A=PT+=0W&P=96)
M/<C]ZK%^!F(%Q>RA]R]O AD7FYEBB:338 39<GWE3::+%=_%'?LK'>XJHU4>
M9G@+8"NVML ?5[+H=-_P0122*[4W5QC];@_BB8[:@[PEQH2?QAX!O%8RB)SO
M^^O!]F 6__[4(!9^ )0K ='MLA+@K3SVM>'I6B# 78NR><6/L0>1 *N=]AMD
M361J7E8@@0P\F)*A!-!J%K<IE2$R10W;ZIROA+?XY=<[Q^=#8Y[M:&+%@%9R
M,.5N!*W#1"'*'16NRU0-^K!C%'Z*6=7J7P)FV,>HE3A2EVQ1G@%.%\2D2OH^
M).?>$O2"\[L7A7XOW?2N2;P3DYH0,.M@U3M<*AFH8T,\:%/4<\ZL[QLAUNN?
M?JI]QXWH(W81'79114;70PHD7Q8RWI0.O9K>]"V<$,YAE)TSW?!ZRE;RF88=
MP*A_J@]6"T%.5_-B4.TZ&7CQ9ZLK;.W\L0=OW8R4^][6=3A::OY=P3@3]NP'
M?W?YVGCD^+P9S\FMF=&\ E@/<VWT3]B%!;-J&;!M7WYZAA80J3H_QWU7&L[L
MU(^C?XWC-#?E4\P5[J68!YG+9^2;GWX HZA;)RWL4G;AQD\$/C!J43I'_T16
M0; LCN@N9M>XW.)%>_S9-W_]-W5X=B=V'MR#M**'*#5P&0W_R,CDG'WUDTM^
M?:BVZ+^N<3 54Y/=!5[?F9_F#?P_<^^>Y_K3O>]/[NY6%>T^;[U-2T9(UJ(Z
M:\!G_OED8(E^12@?#MZ2A2$#K 2V:4^4M3@R-3YVG99\V:YGHEC3HFGV>Y#T
M@-\3$[W&([.]G;,KP[\GIR8G+14Z1V9GO^&-9R>'UVLLC4=&.E(F7.$J1C66
M*E]4Q.XK[NQGK\AW'#G$32QT]T7XB5N(KOK]#/9ZAB8-XBT]4[]EJA\&[W9;
M Y.,\W=$U=8V6VQUIBH6Y7?'7.O7&'\G$V6;A6#5QF%-S.S11:Q,5+1T*>-A
M2[%&B[F^"\+KJG6:WM1HW<@MEJ_3;]@%QK)]^7T4?_ R\.KV*S2QMJ*ETMP%
MM;ZCYSZN$OB \V8/,DVICL4)&@7OP#D#H^[Z@%B4$?()O36"JC874\5VH.]J
M(G""KC2P:>HK)TQ!VP55\K!*?<5E>4OW?%=-2],_1FW"*2J<?:/7=L=(:IH6
MNP<!;&E46KL[%U 5.TTXLD X3D9RI !*#KIP/EUH:GX[<(6=+NF9V8WTE%E9
MZ1A%HU'".LP>E;C;SP\[[U;N3XXU5KUR@NV[6\7V$TF<(SN;M=.X,(YK]DHG
MZR19'QE/=AW)UO'H37_7'-C?+8V-SR5R*:)U(9?5A@WW((JPZ8\FQT:-I/97
MUF&W;*5N24EUO"-S+AJ+RO],;\ZY0N8H LDO0XIISI;M<%E1%Y=(V3U(#<+%
M=>RKHTO(\8#VX5;17S=8*4C/'P%Y_8JR#\K..<;J*OO9PJ]-^NL6I/KZG4=%
M:_Q9-X6M')G:@YRVG?5MOCLQ')*9:JW6>&N]TVV]BY;3"C'1!8=8*' <J)E9
M(_=\J6B^ Z1V-4$3-_)$R.-F)9W%;J=&:J6^'+^YSU>85-,PL\O#+U,NL8RO
M.OVM*?^P=<D#(##@L>$:6#70CQG<KLL73$?$RQX$JO'-QH]:Y >-7/)O+:7+
M)\[>NMWL$*CX6"/-]Y((QT1\.D)/7UPNY<(/V;#'%_!9LH6X8A[V,3F&=G<'
M E2 +7_=&M6<7,P]%-F-$ZB>>^U@3XQI#F$<R&]#U^90*.Z2I(&'+UX4:@F=
M^_[&JW\&J^H9TS8CY#Z8@[Q3=*XJYZ;!"ZNUU6'BF8_^+2]I;?^\5@:_R:%3
M @KBXGVHVDJ]MEF6GKW6?J11/S?\#\8A0_SZA6W_;$CH?YG0GGX/6G9N=R*A
M(VAM_*7S\X%6&NX7ZG?DQO$-&U.(\'^JV+)=7%[1_TR%@E<V6)SF<*S-I7G<
MKCTDLL$]9S<LG*B8RR'EK8P32N>D Z53-\6EF>;]%PV3=W^GK@V-ENPZE<Z)
MRT[N0;;)4/SL1>G^)",/>FMLKB 3CL=ZE(T_"#\!.,76$40P6;>:[\A49>1A
M</ /(]INEX/V(+E!%)V:;Q=[SE\LD?CGR!Y$#08J9;"%-1FQ;&$S5B)3MZ-?
MV'N["-\^*6@W7(N+P/$[KU_)!U7:;KA^$8F>^='5/H@3Q<0?GADQLJQX;^YG
M/-SC@=8*]4S+:490^]FB7AS>W?U6%=YM=+("NI<'=BPQ9FTXB%3;_>YN*-?F
MQTE4NR8XU!GDM$5-<:-A(J\,JM]EGLDJZ\HTCI*$Q6U::9H-GJL('_UIW>!D
MI_CG!X9(EMR#1&"M&-!#8+7YQ^]8&[HQV@&@Q6U8@LY\*W(N ^KWA^JL#%9%
MN0IR^]:G'GA>YCH::W2;,*"G>S RT7O&N.7HU0OM%^SO%JV<M__YDV"0?;>E
M"&FJ:( =2-)Z0PSY GO*8-]7:[II>KGEJ*)65KDBU"NQ5(1708S7?,? PFK=
M?O85<6U=^W#- 3;^-R?D5ZO_/LM,MB;ODYSY/E0MT(:N=GIUB7,<ETQ53^"(
M@Z,6SVG+H_5,T-^1B8A9FXT\K4LP8\I&(^5U58_6LX)#L_W>NKQV:#UZ'M>/
MKOZELOUVGR0\]B"W6\7!F9G>M96!&:LCORU!-R#5:I2M"1!OM#:D3\$DV=>8
MYS+\\U &Z8EG$M4X"70HO[=D6@NEX+C.6I4WY0:U1YX:.)VPX+]8>W96?"O.
M[V>N;-'9JX[-2_:NM1[<FX]9V36.3O%11?E6!/V7MM5..I_*CK@"U4=J4EKR
MKF;YUA9NFP[Y"FR;]UT8J<6OTH@'@/XJD\9--E=!LA\>&[K+XVR\[7'2B^C[
MY,FS_M]%U9WX'U'&-;0#1 8N@TYY>AZRA/]-S?1/W>C79\V'?^@GNB8_HB?Z
M#37\82VL7.0S%;[!];^7C87 L>3!4T8G/AD!^AR<17H\I&=]&TO[(^#;NC7/
MW"SH,6+OGZ YVILRH)&_<]J?L?TYA^Z6LY_LG&'O-V\5&_81T'E9@K7?5T5Z
M:U1HP_/PDZ!=-TGO.UL]?\GD"'/K.9%R&L@@Z\TQTS^6\/7SCMURN874&17H
M"5%-N2JD>1IU.9$I<N=R6HY%4LGDF-M5_V"DY7*[BVG#O12? N61O-@B@Y%S
M>5:**BH?]2\?^<I$"#/JD"J3M:FPBSK2NS-@X;[L(G'6V3:S.YM[D&)_OS]_
MP])5UD_0Y]@B=G;?L5ST)_U4!"L,?#E-$U_8@T",D#MF6)>19O4W)@0ZXA!;
M!>C&-X=,PXYBFM#\F"6[ 2R..(&U)K0%A>)CC$X%%DZBTGD983K&GI5J>4W-
ML?E@]/XD8$!+H.PK8XC!TU:=F"O*[(N=\=%L(VD!]ZMY(A^NL,6QEX#%;@8Q
M.M *U?T8S,,>\!%+:)8K==Z#M!LC0QA\$JN!GP.-99D5"#CJ>5/NK>2Y1TD\
MND&I1 .[Q(J?U:)E*+'/*RIJTKX96O:-Z9X1/^T"9PY^S7*0LQ5*&G8KS#&6
M;TSQ7G.0SYK-4%_\?/G\E<<"9E]@/*.[#C@C6-T<^QB,#N]8H^(Z:?5>;8+"
MDQBYSBEE(+CK#^<T]D2J:?SO-II0\Q.FXO1<ASI$QO\R1?Y#':'-(#9.&RYV
MZ0E#SZJ^H-C=/:S</NKF!/Q135A:&:[-IM)(HI@S1%)E;K7Y(*P!V*>U9!:4
M!RM5B9PR!D,@S-U7K;P;L'BGS-\3F-2.3)DH SPKJ Q7H\7_UTR';FB^^SPP
M)E&<ONWBJ_[W/K&T@8Y[$ =F<4$@X-(EA.&QI>Q!O%IX6*'#*]IXOH5,6N>^
M""<3#FW"DOR(<:F=DE//WX G=A3;MAVFWL3:CWRUG.TF2D#M/S8T&-\TT"<)
M!"K3Y?3\KXS9S^;H'GE;*JD94)C]Y_ZP]V4?%>N,5NVS>E;9/YK&K,]I+=PM
MXEWOIP[]BG8PL"M>;->^.WPB_A=1S[2>;K-^J<O;#SZK_F.<<Y@/&*<35TX!
MOUG?P!W&$DT"7&K//0 >"*/#GP$+YZ],K\6VBH1+L$^ _L#V;V=*\R7I42<3
MG8R+HVP9OS+06WPEH->$[S>JI ]M57M<?</;0U^^WEP^];U_2HB^B5-UWK;3
M'*U+?=S)N1FTV9$#8UD! QO13*^5<B9?.^DPZ%_"]AJJR^$A<[C>C;"A#'5I
M,-*>24KRU*XJA<5M)"F2=:DZ>#H?:NG^:+.-<4L.J9!2XDGH#S^U[Z%,T7N0
M>X0#H/8>!%7)TV9RDAG^;J9?!#2T&]V?YVH)C+\]T(.DJB=M0'GFFU[)"C'Q
M<;7],KH):P7,<UEA#/Q?\Q39DR9"3\(L5[8'+]='(#NZ-;]Y61<%+3FX;IR]
M\R>_[+*PMT/BC'6*XXWHFWT:J25S^E?7YP9-;Z2[/4VZ9F.1IOO%O27<<:&O
MR#M@5L*^/&ABSJK=_.SCJP(#/RF*B^KIN)8ASNO>/4A7:S_=\NWOW^$FKOL4
M,Q"V#5U$_>;9]S,1-=@30%7US#]&G@"-08MA7Z KX1[DZ)HR"ZF(V.I:?)RL
MPNYK[!WZ&C?V"C :M;R,O72F2ELBL%]XOC[S:--(<II7:?]CIOSBVR]G6V?V
M(*"R^K-PH<5P2:"Z$_H,)L468_+8O!O=US@\%^T6>&[&&:@FKPAVFD@ SYF3
MJ>.8=Y7-?D3O3&)"0/U@ )K'I)3ADH R#D5N)-P;%)]8K_@H2;44U/E9+1(:
MOC[[RT<=6:V,RAS]^3C*JT>ITX2P<E3(JOEO-3&DH?W [\>%>Y#@@E1X^AY$
M,K%(X$&7+:+8IFK4]B8@#DVQ&;DF_<^GM8E=S<%:E=GJL2%6_A .J?9DQI@0
MS9'&+)%SA4%#IDH'[0B.;L*\^+VR5E 6+&_;GBK*QR1B#/JZ'5M&H?#!HG<1
M+EF]**M!ASU(;>6=.I?7<A]W8,-U/;;9"U9#I;*WBD095!__JYI.LX_-/_2I
M%:]6I9I/GLL,/.5XI$C?_U+]JQ2DR2T+@8FO:D5GORBB#'6R'!_FQROS_7?;
MZZ<S5F7]R'N0^88]R"9')&N\86EE#[+(_MW%[_U^5?R+3!L/]R,SGGDK;!I3
M<*8UWDANYW9X+ZV&0BA><)(5!KN!F9GN1*QI^:3V&&5C:0\2G3 M^GUE(S]%
MK6P<H1M?W5I+&A!.;N>[PXO?RJK*T7?P/5\W8UUD%I31:"%0N#6Y3O0<F?>R
M+42>_>I3I/QJH5QE9^1^WD&BV9DJEJ7=[QX.WZ4]"'?>:.LT$2=H<KP3&&>H
M1X>+LV^!A@QC[S6S$2RZ>'&4(\3DB6ZV0_KX5,XW=60>U94<*>I-ZDRJ*BJP
M].)^T3+DVHDQ:I2[!R)8^T0>N5^>>Q"N2\4H0EUP)UR*'<[4D#]!PUQI&^P!
MNNFO_&/X_>ZH=;[*,-$?5<VZ6Z&+K,"XS\NGJK[0L<E@)3!XV,)V=!YR3G"7
M@6@=O14Z83E=G=AZ+)QW,5A'-$BCS8\!B]G/$X6MM?6-N+N2V[I9U[/:7NID
MW+MF^5Q[\(6Y<-"R8K4,,,H60;635)OJ@9CG.T9LKP]@#P,NQ(;5@L% N)59
MVZ,ECCZ@V(&+"FWMECG!^-M@(A, IJ*+;K$-@%\MN,H'F:0\@1:/LK%+!45%
MW[8B;H8MFVC&G9TNB"+;5YKQ\2AUDG\,9299VJ>5ZS^Y-N0ZL=JGG)DVJU>,
M/W$\^C/*0R&^HSWIX?57MX=WZZ[I6@/XU5=A625_0N0"E:RZT\^G7M_)8(7O
M9I+^XGR=^BN!CE]F M7M"-[F8QGOO8,-=*-K]S%^*5L<[!1IWNYK*>T;E:QJ
MK8 ?/=9YKK3"?8IF9&-ZPNJ]ML,^7Q-9!W;QK3Y/5 QQ5,0T(BI<;C'3/4<G
M+0\DF;9\QX:\61BR\)7M-F,VQ/K6M@J-_4@HWD&P0KW5B'6?A2Q]SMS4C6=?
MWVW9= MFN>ZFFUP([^=(XRV99BMY3!R=T(:."8:)J%:AM6 QF;$=QE<0,;\[
MW8T'L<:EIF=*,@\1Z&%W5+50_-Z#:AX(PM5W/A92(;/^7]C[V3TB"D-D70#O
MY"/"ARFR7& K S0YA>EN#S_-5%Q>FQ'DFV_"NHL"17.Q=U/=6T'_&761'L8.
M0M;%&9-.01_#&@+33.4%/I3VY*^/'CZ!=\_I(>F_U7TDAQ<=;GZAE!\>/Z['
MF+5]-6DP^.O71YM2,6MKAS7%>P5Z8SEU%_1Q[].47Q0#+PLL'OM&R8IJ+78Z
M%,@Z\;G;_RPSO1IIX]QX.10:CZM39$OFT%L\;+)<=I-P#\:,3AR<''C)YF'N
M7&]F7L47DU5"4O;[&3/:1DG?_OFB,Y6_*+GHC6N/M#+AP8AOT=3<ML(^3O_P
MKGKH6[/E:*":A8SL>(D9<@9>29)J9A!BX]3^.QX,=4E,@?T'2F!/BT[[+_,S
MM8,/J1BM, 6%]=4S0[7CJ/(/'LT?/C@SC9TX1X8 ?W*N"ACIP:B.@8HUPX#?
MGQYQ!NN9;/NF^N^* T9.#.C8_2'K$9/3\^ZR VJ!K[59.^X9Y3]@L=IJ5RE=
MH[;#A5F6+WTR)ZLLPQ5Q;7;[B:D)]U25HQ3^;0\BS=9D0KN8F/(.//"U[W>;
MR1G*LHD8:#!^J9D2?AJYQ8$R#^XFMY[H9/B<'K4&.HECS5?"RI/@5BX/.&29
M3EJ0,@F'SS/CB0]4&4H<<?:V%"CKLTA%]N5G>]J-#?E\L73V]6,E63PR$Y5,
M-WU6[2(6;3]O_\K-(!EZ,V!&S%:I9.C1*Z4=\\*"'K8I[Q.M&5[M[:QNHO%N
M]QWV'L1@Q#J)L[,'T43(<?;5K\XM=D6304NDHJ-,I#!S?P."[>J2"*Q!+ ,?
MMZ9EZ"/6;7)A(%&=H:9.;CHJ&36E6!M[I;YEZ,R'EE&M20.)GZ0=X_<]:G5=
MM*JG!XB/S;=SK3 .2M:)DP8O9[/M7?,G7%P'$@>Q5>8FMTP_-& FE>0WW&<-
M7E0>M,UN?#.1DF)KOOZE;?RU:5VOA()\I8JN*"5_P%3D]9W_%!G^JZZ%RDZ<
M(,!G+:^GS23KRZ=%=$IJI6B&C?QMV]<]9B\4%@TYZ?MT[A</9$<@=#I[D[6P
M%,U3:B2K(7 (LO'SIU#HZ#?:?@!^B!L+GD$GQ#[E"+,? 8I);(1">ET9==[
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M/0@ QW.#_1UG:!TX\=;[?&J(3O?SW[5E-,GN4D-&/M.?H9TD'M +#8PODX2
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M'_?M80.7LMODR7#@F J>.S#2_K'E#ON>3)*=B)XZ1'P>O%'JN*ZV/TD=D=U
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M)_7:YK6?AIF)HG:87\FY$4=DY2>LGEP<,<V+PA_.^F8*LEI)I\2ZQ/]^\Y7
M=ID-+CPC2V<4=[<529C2 ?L9<S$%EC1)T53N5]P 89VXN(XDY^+>CLDS4!C
M[PIQYOT*?)E,K8;&)=-I"W0=R-R]>0 A/I#?O3)G%VLP5: [_RU93/-P<&AK
MSKY1(9"5_[A*%M51?CH$\).9X0U$7XFMRAF-29<A'$#G*,U>, !JUL)I&WB6
M07J&=>G16>YRV1[0[P7I<*(X$<69QX"&G<8'\GJ[G;?@0L_B@GY95\O,^_0?
MQ,5C]&0"'3K6,K=:CA'N)@3]ETF.Q@"]2_7K:FEG^7P4D-HW\EFH;1$CW!S)
M.@X:I6:\\:QC[8/T>KM'6\I.@MP'735?6V,?T&9>613CGL:=6A/E/3S>>K+5
MOKZR<HN_JUJ]^4_GS7_:_N+(KK/J>]1F_N^@4@-\%T3AL'1>)**XK:,E%5<K
M/G9*O5NS/GG@YK^T%IK?B-4._JQ!#'N,PSW$9NKN==%IT8V17:;Y[*GEU072
MW(_QJCUTZGWN)+CND75'/Z*X['7_)\#V%2TDS^"Q!U0\?&O!S.4C+7X1,UCI
ML=L_NLZ/X7%9UD5X-./R>^.X1U"3_P<V#('Y >B(DTI!]!4()27O)D8%9>))
M%T;CBY*9CHY:HM4; 36@::;<,4ABI/W!R771I.DU,)UL/<;0V@,5H=DO@:DG
MOPJJ:-KQIO?8$:ADBO8B71\*?\>R'R)Y2O+3!R\J'8'1,JN28. &\/ESH!&B
MRX!4"/951!9X8JT+ Z/*_PZ)M#WGY(M*F_4LTQC;_NB+1Y4,:6)_Y]'11Y5'
MJO6D)GW;O+2;"I#=_S<=#]OB2K-?J/.O^ESG1]W>]+?8/NKRC(N7]M_UVPF'
M^_:YNGN5G@GTGDH)^A+2YY)$)NFJ2#"'I E5BTK->R:MVEY!-A5$SK6A)G*Z
M7ID-B$XC:.V"NAAKL(M\:PUWA9.X9-[_,E"4M5BO^5O' GL#5#;)Z2HNO_OQ
M 37R1."U]_H#PKV(2/@?"#7Z0A]<LJ[&G=_X;GFEG49;JVZN-J;&@!C^RA=*
M6H.-TT59K+ZL N.O/,!N'FP@.(4U6,!M=&QH#.XKP83%SQ$)$R2C58^D/K:^
MLRTI%C*2M!M>A9#A %;<-U*4X8@NQ]J'9RZLJV793^<LM/M\)VM@!:9YCK8#
M?1@L\,WAO<)-1-ORC3SW&%0L*4U&:(U"EZ$'3NIN:V_7U6Z4)OW@&"05@+R.
MHKBR4SS*%8"[@7'!T/_E#\59+-9",[JF\P&+'BW&Q6MI!7UNLG,^4ORNY]GY
M.IN^_[Z9HBBW[UL]3,V G2V0?*3\% BAN<9F(XO9$S!N8-239R[B57KZ)2/8
M-?O"!Y@$*C$YH 6J%FMZ<EI_&?WM1Q"/L>DM3UH:UJPSZ]KP%27P_3+UY:G.
MH[L/?;.3,;:T(R5?"ALM)X[^]7PH->(.JJ2H6#ORY.VVE$</<:;$YB+K&!^/
MOJI;K7%SAJ8IB#!5 *&\IJ:R;!5^H(/B'%0CW(4G!8%N/<['^(L.1N:7(2D&
M].5.[N'1?V=HX/R1KT>;#C^'PB]34,R6@N!A&_.):)]M1ZOCMBL2""I+>@J]
MQ%>%0&0.I4D;8Z#'$.=GA,! XURK.E![7>TBOZ3+WK1'K@G%S,3:K<Q/M'_)
M3X^!9[$TAUP>@8RV,<A8]VK@A:9_#JW=@*)7W4B[H;:&'E7Z3F/O6L#OG=42
M!VD9M!<^V$D]+"#B?4=5WZ@5$#)STO/Z#H-@;NMT*LF]VO9Q;2^VOB.Q(O(2
MZKJ.X'_Z?<S-JW>4?Z%WQ1BA0GC.IK+ P(CBEB7;EAHH:]QGD)![])L$G1%^
MP4Z0./_4MVMG.Y5D#HZ^KOR@6RCW'(";?K"_ZU:SK]"JI"3W0HM]7L/G.I\B
M:\']J98C5X92<!%5-$)X;#3*JO/R)1_JD3K>Y6>5?@UW?WU*.;X\/O+1']<L
MORD8@'JY:, +G5WDM_SB*V5?C.E@-3\45&T>3KLW$T\EJO?\Q=9AD U[Q4*C
MLV):D->POUO;RV'KKE;6X 0A8!&NB=$K8 H.7PLR(H_U*+?Q092HJ!NQD70%
MA,]O5$72MP ]RUBRQG#R[!X*G@E1HXB.*^S6U5(3-?.JZ9$&OP0Z4\ -.&88
M=:W"O.0)KJG/.6'V_2+;^8NRX=4::UTM='PUUV](*&U)U?OADK7B.6M>C]KU
M*>2)]1C3!)]P_7IX8L7XM9D5KKZQ(W!9_?S0;^VCQGC=B-UNOWV/+,R&UREL
MURI96Q6_CL(XZVH[E >_*D^,'AQ(S[2:L_ZOC6N1UU!>]>W*;R.Y72F[90;W
M9_Q:;.D5,WA,0_? ^\.R6>TGQ^X66EUZ;'?ZSD>KDVM]1SZ'&?N]?8MO"1*Z
MQ [_5F'1MI5JD*4SE5)Y3+E2_:C2ZL8_=VF5LN;&]V?<>[\O2UH4.KY2>1[3
M!(SN#-3OAJ45!ZNH/B.>GQ4.%3W_I/!C0@\D2)TK[5!Z/<:V['!;,]ADKY[&
MR-\8:6P!+-+3Y K="@'R=B44Z:E1TG8!CY.\F'+\]TEFQEH5 >DFH:VESY^J
M=+DNE4-^K2F3AB-N7,N;O5V!+?<).(/E*R] K[>UV&5[9;(8E_21?[F%K8K%
M:58F@]\(9DVE/CSWP8.\JJ%&]H4#:VWL&PFEKNMJ'LG2_%03-L^FQ'+[MPG<
MXC?XXA;P89 GSFR0:R>X@-!RC(DBK.ZSLC;? Y2UFWRKQAN7WOI?(;DE?2X]
M47?X!2D6N)-]NFEL*DM&*-&HQ#7,LC2!T6P"/BRQ.BAX,A ;*.3"U,<BEF/_
M1.&>YT::EVR+LIC'?[.,.M-XTLSDN#N9G^7U+U#+UM7Z:P,_/[==OASS)3.,
M>,;AS4@[K3H^JW>Y.(*O6"N5__6%\-<7FC)N[;_K:M?[<] ;R!@->7;Q=,]I
M$E[4[B:VNB=R"G491>4HW"7LW<1T-Z#_WL(QAHQ!UH?2 [(Y#\X2Q [ULNL#
M7VP%_4M9[G$U 3.HNAG[_&E*)QDZ2IF_ F[D*DW(>XFO@R']<N@0STME@8J
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M^[6G55_,M(YW>!(OQT]."BJ0;]Y,5-]8B,>$563E7 XUQBZ90>K@*7$/5RC
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M@F<BN3-^+36W)RL&IC>S_%M"$-9AU:'$Z;!/\[9(4K:P)DE+<0+"KUHHK%Y
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M)90FMMM%\C[?2SY>!3OV\7S+H:#6KU!^9X?0SN9DW>OT.0^OVJ*S&JNW(',
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MS8!]JCR84P6_D:)$SM("6F232GA[%F8K-=OIT'Y<3DT\)HVO!W2T,XR@(Z'
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M*@);)@K;[\JG5FR:3J_:00=6SI$#H6;@JY*=<9WG#$A7.L8V >V5"N0&\B&
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M3Y0\')06_0;*Q8U&54R-R*-NO@G5<8VMP6EJS'7\_]/5N@NT!*S8\E"7 _7
M\V=8">2XY#=H\G9$81W*UH5BX3R1[C1^%]+,3 Q:)*^05+D1KNK#K-RHY'<C
M;'Z)OW-75_IH:CR]X[3+;O_/O>5$F@K44QC*WM=^AF9):%;L2O14:!!6_0I^
M:.#;,?9Y!K_Y/-9W\S4\96(K1Q,*)&N&ZF'M*U^'"A/RJVN35K*('^$[%-V.
MR@P@[Z.B /UDFL8T74UA07'M$GH.L_974ZZONK]E@F59Y?(]0U%QWTLL1^=O
MEV8$H$\!;S/^((9PF+?J^&:76]M&+>Y/%^Q2EL[+,Q?D\ $K^4G A^<S1HGW
MP^^8XTIV@-J4)!YM-Z#(!U5]LR3Z*0? +?\PDO7/\9'J15"]$)ZL+\B->LE6
M^SC%?VH/+#3>?:\U*P(N([X7S2J^Y[L84H^!S6E1"'VHWQ<(HK@&-#<"?JE8
M-%Q/;@Q(9NO83&H35N?*J/Q*PS!"[B!YUUBK^<&9A?VEJ<[:3A*S#P7XP._'
M1"?D^8 '((Y"FTA8G&1TKL'BH](6SJX=MY$[71-7>YRIO[ZJCPU^;(?:2_%P
M!58^W!XG.O:,?D%3JFW^B:\ ,N>#UG=01*XMT+?F.8H?P, <J>X(N9^'TH"*
M+XV$1>U9[$FZ76I?<*1.$(9X0K4OV I\>?&J8VM14D>E^)/MQ@%GZ^JI1_\Q
M.O.)BAV58#E7::ZXGD#_N28E\7)TY$>:F\ ,IOXCI%^EW )R PV[L?/"@N<E
MLZW_L-L(XG14MY["'.0DR(/(NMF%X>58KL3+<<-VPV8$]R.LE;9+C@.^]<%/
M6L/P4.J$ HN/5G:6^3X8ACN8^. UA<AS]*TH"O5S]"Z_&5LV>\1]85]T]E-F
M=G&(P""L^KI,F)T7'7$S:E??%(I9N[#-8KX'>, ^7)LX!5[U53A!)#&Z[\"@
MY7J>["W8D[Z,V3$Q06ARO-D^K"A_/2-;J\K)QMYLM#9;!DK?'=[WMF42MHMJ
M 1$G4VAF\@-X'0JW0R;:-1^YH.H!!'(JJ:?B>;FPQ!6\'J5(K7_'Z,1L3I\$
MH0>E^8 N5<T&_;)GJVP3RU(<^B[H/_;V/XL+&ZQ-E1NB](E];S^RS95Z/R9>
M@&.@(BN[<;BDN5,)M\X*^)RR6+C\"*%/-(&B=&3OVUQ$?&1F*O:O%'$:;'=U
MW\2+>Y(T]8M_Z;Z+/S-T\Y'J_]@'-E4ZSK,(I&\G14<!<^+VLKQR0L%/8$^2
MWQ4H"5B59E1(=BRP#('U28>T@$6Y*K"ITMF:DVI[B*RTA8X)+PT2:XE;L\++
MIN_J^WY%"M^XUU-0BIU!8&P7HY&3ZO(]A3Z9DT@EQ951_: *@.\U8$M<@E,P
MO)\(^%VL_4JI N&7P-HTZJ%-E9VM7T^T@CL^(A%OIAUOO5-*P!R%@1E:)(5)
MW@Z1!!\YH;R-3+D9^+4#B^KJ?R!JW ,RNDC7YRXT0&- I=NW=GVF<]CF1[>7
M19JC$*='\1WHG66?;YPY"7\88U,MH42I67QL1,&@:,_AFM)$W/U_?S7PZR9#
M%DE=L 2V:MVW1PXI!1I0!&@I@650@\7I]&Z%-AB=4!Z/%;"TWH2P#T,5T9(^
M!YZ#XV)"(87/Q8XPQ;'Y=[S<]5GOVCF-P_.W\P.5KHQ#O[F4[G+TVQ8XO3DV
M JA-M T2<^#$ HV/R,N3"*U0VD'ECYAX?7SUUL'E,&#>4#T=:#@<9:3=Z]\R
M)#_D4A+YP38=XP<LEL86AL8DYEO=VDH;A#,Q#SBW0J@')VR I0PDYIY4C6P8
MZG@K?S+=8,RW+>D,%"$606AJ\)O O'97[X?;(VLUS+KDFCL*EBZ]>Q#9Y[)W
M12TOQ$RTD4?3D!^$$$ #EPV'CHF5=='U?6Y93C$QQB$1B7X#E2G63[QM_3CO
MY_VQFR'IPUSD?#NS) ;GSTDJ(H;8?BA\JDK:5VE.14E7N^&?\@*'6.JE<B]P
M6[R+!92[*MFWJ:)"18@YVV??4GIXN>0T]M&9W/)'4>T[USV!B;)51Z^RTA*"
MXTA^S:S!4^[6W%;?XK#!KM?^?=^KW(G1E^]>E46 B8UKVQY4N9A!_//#S#HQ
M(\GC%&#S)G)3)=5@HSEY.7/GG&-THEW^B2O335Z%H;GCS[OFV>9#D;8M ^+A
MJ 4KI=[:E]LUO_QVI*<?[&$XY'=N6*X/?)604Y$>$LZC-1%OZ3L(XUL_2#5!
M)8=146(<QV"V0&-H:<E.W56AY8P5<==H15,71^:+![X,6Y5_K$;4D(=.QS"$
M3K*(C4RV >0K<F,/RQ'KCH'R&^!$?#DEHKOU-USMUFG%3\ -??SNKUN?2ZRC
M,8#@D8W=.B9I-2NT59"T*$?4S H?7_@C5QC:4,T-I^_DW"1#9APN?M>T\0_Q
M5R!K27L0U\!*U+!87 WE2>S3$<E1[23D'IH!,<:^[@>#E=)*RN#7#F%^\Z,:
MTXPAXMW60P.1KVO.XV:J3CB';JHH=GH"B$X]%QMZ<A#/T;QR<H/.L\<F/B\+
MB9AMCG;4>% I]^!'>45[U">*EU;F4+OZ ($_'XEQR2$>BK_T[F.N<+C:;L.:
M,8NXSS!&6JR?@FQ6NVDZ@RR_PIX22M9%()M93.GA"I.25@*<KO*M(Q=.79'@
M_I?-]^/7V([CT9SZD49TONN9UHSYL9X8,@E17<VFL(!5N4[]A'/@*FX$%1Q;
M!MB\ %6_@8T=7@M:XCJLNNRK@\15#LGL Q0/W! SX*Y_U13X5UU9 '[VB^P&
MZUYD>\!%R80SZO*9N$K9K2'V]_V3M3I0M"QF2#J,M% .JU^ZBQ%4<'F8N1 3
M2TYFZ[4V-8%W&;'54,;7\T,KZ#;+%-*K6&YL1"AHY1ELB3.EJ*P=9M_;*'9!
M4C6@'6(T7IM*8375 ;PG4-HE?DD[,"Y(N=XRA-PO;O?HTI<YDM*9Z?+F0#,Z
M[ K1H=7^>? /N4W5&HR*KK*3R-^\C.+4 SW I,E@+BS3T>_1,CXUT!"O35!L
M [\\ !%<+<,-#PSI6+>+0=(%YN#*?O/\J-#5\X9&^,M\\G(O-[QTMO56<6SY
MK&^T;XYVYWOXRXN*"51#<&<U75*BK(DLF 2>>GY.X31,]9#T&X3DEE5*<H:0
MKK .T1Y(2-<,C:E-K44LF0*/"]2@NU2S24/4-L\WA"8AZ=W'Y7Q#-+]*T6O!
ME =NU+!V*(,^NMI#;_S6;NMA;CD/KD-!=1\"^GGL/<-4LPAQ/KG#0,$(#][2
M70ZZX*RW\1P529.9VX7T(.+:8D7I3,QR[MW[(WZ_83,/8.HC<SWD.O$R;V U
M27Y(3(=1="X-V.)_(+!W?J0>"RZ&:GD&U)BP]$G$+DI;1XQ>5OW$BDD;G]$Y
M<1QT27\M#.P)5_^'7?JEOG2XNI1G7"G%C'J(,>E(-=#I?>:FR@YR8K6RW$Z=
MA_)JH/A.8ZL16]AN D,3L6 UOZDBMAB(POEOJ@R4-V5T#G6573T96_B7]AEE
M/'L)I0GO779OY+&MJ,:LC:)&2Y+))"U_<MQ'VL_%[Z0T7X+2)/34"2OHB1BO
M32F6:"14R7\95AA3=PEJEA>BQ7YID22] &]<=>#2>X7YP($A\^>%C8!\)'>W
M9L<"2A5UFZPB1T-2*>-AL)B1P-)]#1U&/2Y_/_+;' W. 5,&V;NHYUJ@".EQ
M)'Z2A/)*\X&"]5/M/@6!M0^V+#\=@]K>K_WU1++G"N;NM5H/P&]>:QTI=\[J
MP /),Q/V'^=I1E#8F!MP*P'&P^CWBSFPN1&VMLL6? KV;GSLFP "2/7*ZDQH
MK&!=_>@\U)51;(6IS'H-OP@XS \#'/&W362&\G,??P'-IE*I4=?B2D1>$ICN
M7.Y*=EH)T:"8$H\?9!V[61'0IY=Y4P+3_H!(MK-UM660GY#F;]8/6E<M]_X"
M2UQ&08>B.X_+X0 6H2ZW90$R)AC$96L*F/@$X_V#-DC#ZA#9MR,L--S*0W.C
MJG(=9"YMXK%\2\D?H=P+3W&6:6/6IK@/Y6/CXW;MG!**AVQE@T&6.X1'219V
M46*$7"_F""LXN BZ]967:\%%_9!OR5T+!_UX"[YC9YH&J<[B7D(4;^#B@I>$
MF9Y8;'6>?G,&^[(ISOO!ILH/8QO/J,<=XFNJ6&:2RMZE[UVO$<1]Z$ H28K2
M#K7/#<MP@7N\FE&/K24:/%XHH=!$XJ1')-N (\9.:$,BNO%,&GX<F:^F> ]O
MV/6D!#:Y$$6Z]5+];B>_AW;LV[KDD-YKP3>0)M+\8^B1^2IDT.32,>^Z(938
M2+!06^4ROFLJ>-3..9!_7J6NA#:RJ;)5&9)-%2VE8;#T;N<WBA)IWV=U_X9*
M15J^IAP=NP+8"K +3?D2:UUA)TX 9!=74_ \O2-_9E_X7+V8>?=?0FJB$!<_
MF;3@M^XH#Z9K$8VWU+<TMM4!?Y6#6]=Q;8"N[+E^:B-^%S$F,XEZ00)7%^7_
MC(>RX>J4HI%UC[9GG3G_3ESML,\GWR/%&?U9D*+$OW8@6J$91Q>/#I!QG1/F
M4/!-(.U* ^FZO"]BDJCNTV70U93;3",S=L_0I>IW?=GI";W5?X8W/'_X(U.Q
M5_$'8PM;:T:&Q3]$.M'+KWRB6'3!821)5N#PU!.DI12N#=<CRBPC9"6M&<3J
MD+SDVE>YEKVG>7<;3NN>O4^=II/AGRJ0SF+&[G$/]>9$>;3D9RJ"5.,Y:6B9
MOF-QQ9K>86S$O]4FJ/+]>FKXU8C=MPT#:O7,A@&F4;2_OL&SOK@2H;HJ#U%R
MQY<!7(1]RO RZ/&$TEY#:"[-M XP=;$'40]O#"[3M3S$1ECX5B$T^[5#\&3L
MU,UXGKVQYHC5"C<JJNS*-+IT]L+9M2%K4]!C1EN)N,=0-SP7EQ?<R5LH921O
M+L^ D1(6=4AA"LF^? T<BK*.54Z=E"=(]U5'^<<Y>VP8$Z@4]WUA!$<;GH)W
M.M+'W):$*YD+-E_/;230@[WT%$L7/K*<)/D&7JZ=\9W"]*8D4+\'NS6?-E?X
MB7*3ZA]='A*CR+^)R,CAYOJ^*(+I_6=9&1?O7>=Z*/NOB2OWG9/$T=]Z,-X
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MZCC-:6<SU )LQ(VCKY2&8)_B?2XCE:HF77J@5Z"5H[RI1TE=L!W^ 91U7JN
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ML,W.>O[W!QT_6DABI IY<#'N+MJMWX"!AI6219C]!(]]5Y&6 L:V%["8_,W
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MR7&61@FG.B8[5,</4:2)G5+44FIYF*QV)LPG+&P*]F?!P^'2O;*HJ]F=D4"
MSBI6E<\4;#:^:(-(F<-8S\5E>$5L!WNH3:=E%+H==&=<?)T6*@!#[OF25*-Q
MY(26Q/K\*$>!P*>NF<?OO>KFZU\V0,3O;+Q6OE1)@E>1=)Z+L#L1-">(N'"
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M_BVP=QG?5K"=5W3V]3=RV%'FB3O#P\HS!>UG7GT3#H:H<%)VMHW $G>WL;;
MO"A;R[!X>ZF:N@@S*A)\TM=*H[11C-H,FT,S96_5KCXC8%0&>FWGI0IE]+!E
M7_&=GIF9C'(>_\X_Z[<NZW1CJ!XSEOKZ%=-\H3BEI<")&+%VX GU[+?6?#SK
M[M>+$+L4LM>:*R?-58LPBQCO[)'4'_O=6=!A&CY_#W+DS@S*/"8Q+]OJ0'4$
MX?RRA//"=(;JOXPZ5,860!.#9^>@_C82&GUSS%O/.J\TGK(>BFHO$*9>VVE
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MH?D\AT9$P]^_/R+81BO7&:R&H*A3H-M38K)MI@?CGF%/=R1X=?[3Y^82_-#
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M.>V2NQGYU;P5V3(9TL=I SZRMO+]8A5.D["/$V;02R63T6:A7Y+>>2B'A"'
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M2]SY40&2PCDEX4R%9#Q2NWFW4ZYLMK[B0F'NHG<&&WQF$2;45- T"$I5D-=
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MPW92'I&3.#I<@L*T7#HF]IBTT,%K*1QE!+LN>N+\V.2,O:6@^9-.F[>WXL/
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M*S12PEGRE"[.$9V* OV'"*?_>?(*X_N08P2T?W_K2V I/+.I7WN*D3F&;>!
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M_0([:BC3:,E;RB&'?E9>/?"GW, ZX.$)X/R7HO]O7^,.@*7.OZH]2D0[0.>
MSRI,YX"-[A)8U:!@%;*V\DWK=:A;RK%NK[ LP4YC0_ 1.WY@XB2ZV*G,B.C]
MX48+$KYJ\6J]^<0]-,1@_06OI>*JHB/)";$/T^[TGLRD-Z/KP$*EJ8A0@-\.
M]:O(66@O*&8J[+80YD:*Z_(RO<$/M)O( 9\3<LO0^\H71+U5NT"[)]BJ>VE
MLTAF8_?^[MA.;&: -[>](.7X#301:#':P3H>",N#*]%YM$T)50XCJ+5UNI3R
MX4_BSU7P"A%^$X5Z6!D&!=<#+M.\A@3:AHT3&X#2.F7%H107^^40C5F"S-ZA
MN73N>"3C(SV794>/0:R/Q^\&6D6(0H)I"FEM=YOG;8$+1#XQ3$VHLPTE?-<V
MLL2R@L9Z(CC)#X-#\T>*VQ_/EFT+OM,%S&[97^QTOA1Y9]Y8[,7"YI9[#V?+
MR@,+T7ODO:EQ=H9?D$DII"2M+Y2#R.9.;L2(0W#JF%!^R'C /\-_:$Z-++H$
M_S4G:BNN;L075FQXAB,>RO#60 X?1,BMU. 1M!/E@Y(L1MA36L4 3U;<Q/>_
M.#793"D3 Q\%WPRF<"SE">5DQKP;V:+I3@/4%9(1;1LD@8>6VKE*O;DO/,L;
M)TV2"5L%*'KG07X@(/U(*5/"7G'RT&N&T8<<>^PN(;9  L36H <4E3*2F6KG
M>0:Z\R2HEA@3T3*\H,,IV<$^M.MQF?O^ZM%A^QN:?FF):)PA6#ZA3Y57H63J
M)2/I0353.;)\:AA0V&WOWBPS,FOL:X4:^UEAH2XNY% 8W=+TOXJ4I"^G)<&2
M>0,B(5W/RG-98!O;RS-W88EMK3E197%:_9!JI-U;"3IOT/!20=X^([3BTZ>8
MVRC(7B0(,ZX.HXZR-KR%!\+?"N!R7Q=IB1)FEIB>5+V>B]B4<DA9O&":6996
M<-G)NLI9EV6D_%O?Z-: %@-B)W6D$BYN9(<H>QF&/<P\K]I&Q7G7)4P^Q@KE
M#H:(JARAANHQ0;8<D[T4MVJ2TZ%4!YXTME2=K\+%51E/NN+6F.FMMBZYD;YJ
MPCRHST'!@8: WZBN/)#Y2I-GO_,%*.4H66OB6^4?1&K/5S0[0$7U$A@=NA 5
M9,^)7<.UWPUV+Y<&L)(;*;W=?F>DJ>86^Z-'5(+V$X1<@CTFAIYK?Q"ZIT1D
M39KJZ'$JPJX@S_S4#/H6"MKPX128=O-)*JN G*::W"QB4_+B:6;0&7B^P%YW
MMD/K(IY8*TG%;.N^^C@*2M=&@?7YR1R].]BX'%>A<N4!M_[YH!06\H\J.-GE
M-Z2]HKE,\U>&?4!DL<XOOL7L/M'P[;#NC*(?&_WO?[M^&"9.FO=:]/-RRYZ,
M5Z;-)R>VV$3W,_OAJR9 J,4W"Y(HB1H3/U HC_CUL2-#A]27Q-92O\W\DI"%
MMP%;Q<A\:\+ZU$8GH=F%@\(IK687];OV"D)'>_R2.EF4COY58:[V7SS*BW*W
M-"_S,AJZ,89M@IIKX\M;;_#]P?T$R&7J46HTO*?A @B_R0T)LZ!>&D:M5T9G
M=,JN"6S!#[FZ0&71?G%I>5H6HY"*5+(V&>&]Y-1@9.C(4)-Z\S9]F!+V]LAR
M,AC 4I <(Z%P18^$ND/)]NO![WPF89T=5',[XB)&[H\N$5,+_492WK<!4O8C
M;-1XHF"3 (ZV&*F5<#LS[O]53KJ% ^S-]<7_CN5F>GGV9FAL9[$+#0H2O-L(
MT6X[^;N N:X?9WZ"5"> GGO*@R.I&E-*C!\(S^>FM #=+P!-;JI6.VXK8L7[
MQIHWW;EOX31?8 (M?UY>I_^99TZVP@X N(#CNNAO@IYTE I5/AXS_V&>)UL>
M+'F GYDXP.,;4W! HX,12VY3+JD"@9E;G\,E?Y6FJ(,-4M4D&J';#Y&!QV';
M/46LC3.T+8P>;'>]4&F!\=.&UA<E-[[Y6!['(&F<N5][QZ\<MD$SZ^6A6_)C
M&G#C[H_'H_W<57U7'6O"CR%0NN_UO]#C!@HQEFZ( H2EP":!Y@"R&+G_=>$T
MN6,LW\ZDM\6GD1_&?PWU=<E_>!:K"$.(%-K/1 U,I&);B</C(QEJ;/#YO]9E
M'>DD/!N8'P+^^1P^8F2=FH!A,N]XJA-NK&%$%_CH#ZD7FYF_V-?AL6%TJ7'5
MY%G"X7K*0+=-$JOVK7FF9Y!DJ;#"Y4OI'V__4X"LC[\/NTNF7T2\W6=P.7U8
M8$;Y :F.=@P8DA/--5MGTM)]!+?D5F_Q4/#G$U(V$K55:9Y/12I>\SC;(:],
M<['@P(M!;@5S:Z*\=MEZ.'"!!1-8Z8Y"9TB/W^J\@.(["MO0GTC6'R):A_>5
M[B0GH7P4F;#.=-1PSS^_/\ A-U/(WP^?&]P?NB,[^=VNIK^KE(3O'MQ >2LG
MY\< /U53M<(H):TBO6=W&S-W'[]9XCHME"X^BAOB'68WN1/,B;V^HV[/E)SU
MQ"-OS_>S*8CNM5% ;K,+FU]>GW]ML">R" B<+S-:C-= ]\!V"B-X6)>@Y-QF
M60D5,5 -O@U8OJ-XN_QQP@QCKENCX&6)C-$O^@UDKBBFVM;-&OLP843#7D!J
M- OVL_/7$>%#QQ"6B70@#/8VYAST6A%69$7U*;:+Z\+O9HJ6#?:\T=1&PJ8Y
MQ*5"D376Y7,^-R,SV(ENY5I80PD+&2*EA%Y/15B,1]7K0P([^+GRZ2T"PAOB
M\NF[%K1Q]):/+0E*PC8YA7.VY(24&ED;[5H7>[UQUC(JP;,-+XR[KM!L<O^<
MA_)-39XBP ;JH(/+F?0+=S^))"W/'NH;YC8=6OO>)7+97O^+>X7ZR*D1]";H
MXO20&GG%>4_+2QE7_[4+DA>B3E"^&.+J\;+C JUKP^/$,J\395+/;S[2Y>F_
M>!UY@YL<[_9\!*5-A74AS1+E&]H5 U_$RT]R%)3_M )Z?>L82NUJ2UX73[>8
M*I[\L^V.1^\4V2(>;TOX^H(^ZT3KZR/_*\&PPX_9GP?#IEA=G*(6&X\R,++3
M*["(NVH"FX7;M!01&_6</LF2;8>'YOC+]JSY,H_^Z=#ZR>BW+<NI_S10#UWY
M:D[GK8!94([/%2GZ]\F"T [227'Z#.\371G;%%0WD^XT&VE_^2Z]UJ/L04)$
M8-^;JM!?, ?5\^,.VTTB=RF9C(FM8&DK\%F,/S"D'.&Q<F@N?%!V0U-%_&\L
ML&I2D I;!PD5H].-22[3^0?OJCJK4. /C .>(3[M."+<XOWUOLUWEE-.F?;;
M8_0_TTRH)V34<"7!FG(PI"BY%[XLJ_(8<9NTI!3ZL;J7I09[H#6'Y0N:QZ_4
ME2TS<\E<\CK*=Y.G =T+B;L9]6A=](6QU\E7GI=[:>8CM5]1[JK$G[$#70@+
M_#M*GQ)12'."RB/AC^6M8HPM9(-DH ^ H3UC]S?49"B.[^7F]6RSM?W8TQRS
MHZ4)NR2H>W #?9RUO%?/BAM!X W=(!6-++<X[$J]3@(=>UL,WNT=0TO(7;/7
MTOMEA?O 37-6<_Z"?=!"3^9W(27.*X$%2T7[CJ7\[\$M1&T*<@,E4F1O.<Q?
MH^@W/3FH@U=#-%E7FV?NXL/UQ??JH)]Z.MW:?>R[)M[UN%QAIT##PQL5AR[E
M;]^[;FVT^_8UP%NCVU\U_'[:-LC58-U4G4RFV^G[#=5*A.5$(K8/V__@PDR+
M?+G.HU8F[V^YA\E=-$L!Z5?=0(\[<=/O3CR<U9\Q=+&>*\ M#4H*>A=V9J6E
M>0LW-2BE,HXP'*$]*^-RML9[,?*3-E0\POYN.&3H!./RN#A2VI_:U*;*QZ&;
MM^WO)1W 1!M5]<AYP^^$-=P!AE>:R +>E49##*:P=LZQ+!?'SXBJ]LA0&*46
M9D^IXX4KA3O/4]H#!<]E5WB:[6/$M@66TGPLY/<MC^J)Z4VL'XN(&6X!T@[M
M0:J9C&9)T4Y=@HYR$0S6-K=H[^_!+2Q%44S48.K&ZB$J\@$%\YU@:*G":70D
MI3+2?XCJ65W/>HC]ZR <FQ*91D@HQY6R/JX<6CNM66=X+5RK6UM/13X;I!ZA
MRAF=VE63O)7)6_PSCRE9N%'41=," 5(^*UTUV8Z*:Z04+RPM69"[)[S*\-)4
MA"51_EL9/,VKOB:9;N5[9._)2&.H>+IJ\@JY\]]!6$C0GJ5BA^#!@\R,^L#K
M2..'B!R@J?KQ6'Q$N::0OSZI:D\4:JN*L%6DH&]QS-.%*GZ?=[>XFD*,6K)^
MD8O[?4'0;BRJ'T<PL;!;Y4P19AWU8(FOE$0]#'PZ.Y(ZN:FOGM+>;4/(FT_M
M_TDFOH8_*'4$?7(;R4V$1'LG(XX57@2=6\N:79NJ]H\*)+L\-\6HGJR:_(?Y
MUC%T-$Z:,I!E;S>L:6#,_T_2,'J%S59'!H/VC!UU]RH[=-=*(UI6P@I3M>8X
M8M2E7/F$KG9CU0G[R#?;3YGV6=.?D><5<<H.[QXBL.)=%"=:&?]+J%C7+EV:
MJW1\55:>L_SL\>P@Q<JO)-PK,)L[3CXO6R+%825N..\0ES/GVN%E/_8Y='!*
MW@YHW77;7PZC[3X>@:R[0AT5H8**A"GS(\D/UP%J ?/)QZH]DIJ6V';8H991
MG7<-_M'+A,*@&)N7EQ-VZ(<+3/['PNOO"$SG!' H<VIQT)T%^R@T1Y$:J?[
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MT:X"G:9R>E0RD#2OM3S^4FNCSMVR,U0W3O+.Y_NO:-\_AA;;0H#*J 0%7LZ
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M[!@!QWMN_.OO!8<(;IWR6/R8.?QX_2"^\#^WS_\*9T[7_@502P,$%     @
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MW-D@08 :C^:I\2 $"6K<[G#EQ58' "O9@2**%OIO)HX%Q&VQ-OH,O]V:8@$
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MSQ,OEC^)B2D G3K93K4)B>%X?KQFG01LT1Q&Y;?DDJ* Y(:<CQ>\@,RUL8#
MLQW9@E^3+.3OQ1A-5<<_UWVEA<GN7>!KFYONN076O0'*UL?D)(]JS4[VPY%N
M,(_V"*6J. 9-8:@<F5O47=0UE9[Y)91I2GXLC68K&F@YO]&05+6Y2$'A#4BH
MVD?7#'@;?O(I%G[/JA.T@#-5NC O11DD$N\P$CJD;K=O(K7()/V<5/KYA=)^
MA_[_*,ARP+9DC>#5S@/ >S@,]QN7!Z]'% ^<$ &8@IT76^^X$\0@.N\:\IX
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M\NP%2Z?YMR682KV,4ULB9_**>:T7=O1/@"\-@H4[GN#*#C#LZ()HK\=F!,B
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M7NU)'0AW5:_'RKK1;7Y1!Y@+% -["E@/_2!FL89JB=:2Z6Z>:HM\XNHQ1/"
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M,:2@?"LE6>?UNJJ&XTB19<^@!,N72KXUY.M*::O04*&]]6&72VVGQN!IJXL
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ML^XE'RYFN'V=_>7+5.BPH_U9[H:CO9>U1S5 7C40@^DEXY/*0XNA^64?[R?
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M,Y,11;LA?G' 99)'3Y!ZJ)N<+WFCPB;PRVVZ@]-ZA-F^?,(DI(\RF0QVVA*
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M1B(F5)_^38EJ;4V5>\<5WEFL%)[#N4\^>O "5*NR)*E+<51'$TU<^S5V'V-
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M'Y]H4KAZR-M1_6_,Z9)KZ9_6--O>LXH9@_F7)?Y3^A8N'[EFH+:.=RG?[K=
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MQ^3=EZW^L(8\+&,@[5E-]KEM>3^8%E[$D9N7\A4S74?K6]!YWV@*+=FM^7F
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M@!.&F5W^.'?1P"G.1KVK$KQL57VKC'OHB1H;:QZR9ZSINL( 1L;@5 YYB3#
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MHS; V63E&>#'WR<#=&AU,5UNXO1>?R6V0YX'X\\6%]G)]J@,.:X/HVU)QKT
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M<CND&,)^$BZ1O227&_7:D_^CH>8BG[X 0_1X>5>[?1SAR6NC,C"]LH(.?+M
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MK._SWM)9TU#F,^8.WN^?*1;H-3?;L,'-P<1+N<']@86B!C8U*[P?],V;G@D
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M [>:17I_1J](_9H]]Y2L-2CQ$MBVWQUR'7O?^&VO6MK1L8Z'F_]TJ*V4W#M
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MD#ENH:U!;P9*?9V@%0K #<Y\37?6=IM_XE# MB[](:/M)#H59(('?EAV7*8
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MAG5^'8?(VE5<PCGN_/+)L_S-/^O2OX))<$T MNT9BL,4NWU-O)M??(PWVI#
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MIJNGNZNJ9SX6/S8!:-+B4N( " @(@,'? _"Q A !P,/"PL'"P,/!P7WZ!(^
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M!WB#>X)X]#NEZ/:F&)I6S/E[I7J#S**MD-2CYO0Q$H (YY(/P&5-&[]3;/&
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MFC3NG,*]DR4A=6Q5X=Y![ U$IG;.!P#E5LM(,H\#&;^K"K01420AM%)!^)Y
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M,\MYAJZNOLZ<R,/*E[BK$M@Q#?+>J"HM;7H@Z"(=8 WH:CX>Y3K+"8_:=VE
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M-93W@)CF 85\I:DSAC)6((',2G2=G@A"7LW=:I>#U6DUQ52;,E)NL3K>,3+
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M+^M2?*TKK^,I1OWX/"WB)1,.?4C8S\^SAZ6,^$/E#[])B@J5Q "8_Q? .O@
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MK))NJ0P-+_D ]/#]@ @>'^[@A'O)=+SP^0TQ/:V[;=5!Z9!\>==R'CS.U2%
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MKI>Q<,:M--%)&YK^HB9;U#7IZ#]\5]'01$_2GX$]TW:%I($=S6X:JXNSC!6
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M,L.,.< 0>L3J]#(%#P)SW<9/"S/!S_4(G2@8,Y,NQ?<9REY+AW\P=&%(#%2
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M]@4#*5;FJVR2B]WRJJM'+[N])'[V*ST<M7K!VGXNYE4.1.WN#W2S2NVSC9Q
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MTG #]BTV6LQ_&*WXM6%F>2;M'(\RG87N?VXX%4N=?"X8%,'DN]F:%YBIW70
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MH/T[2^?LZ"CWM\+2A39HY +YNUW0L[JZ1@&J .?B_2]ECF->_@/+A(%@5KY
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M46OK70:HOKV[/6H#(,ZIT*?U?BY)T=;?L<P0.)@]H8O5*D_M.A:,;23:7>!
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MD"'IDC@R#4V"D?5T?R#;SH4QR=?/X?KD2@7\GM[O=-'?"9 Y-JCA28:&("(
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M$[9]JYV3]W!0<N7?'CGDDVK:-?>L;FYI608ELC+E^$V&:,"1/:&7%:8"&R+
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MOCI;;^W='&X&>//B$P<E.YO5MX:MLIZS$ ("E0DR3'(K",FO%DERF5H'C*5
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M<PPQ;G[W[M[W?U?WK?:M5MK3^J0J57=)7_?YZM2IJGY;>=L!8'^459 %P,#
M (S_7H"W=8 T !D1$0D1 1D)"0D%!1D5'0\#'0T-G1CW'18>.0DE!3D)&1D5
MD)V!BH:5EHR,48")E9.+EY>7DD%(3)!;E)V'E_N?3F"045#0T="),#"(N*G)
MJ+G_?]M;+P '&3 '8P('0P. Q8&!PX%Y&P!0 @ P"##_9H#_;C"P</ (B$C(
M**AH?V]HQ@; PL#!P<+#(2# P_]M]?_;#H#'0<"EYI)"?*=J@D3C@L<=G%B
M3/N^O@]?;?82R&/J&H*"2D!(1$Q"1\_ R,3,R\<O("@D+/U!1E9.7N&CNH:F
MUF=M'5TS<PM+*VL;6S=W#T\OL+=/Z)>P\*\1D5%)R=]24M/2,S(+BXI+2LO*
M*RH;&IN:6R"M;>T_^@<&AX9'1L?FYA<6EY975M=V]_8/#H^.?YY KZYO?M_>
MW3_\>?R'%PP #N9_V'_)"^<O+UAX>#AXI']XP<!Z_7,##CP"-1<BKI0JDHG+
M.QKN8&2\]XD%]7THM#QJE_BFKK.H!$#>7;JK?ZC]&[/_-6(A_UO,_H/8_\-K
M#8 .!_/WX\'A "0 ]X^,A4&H_XKP\_.MH3F[C@HM4K!*9Y)0KR:Y0D45W! )
MWQL@@E=SWM[1I$7'*F9#@>;\9:YE#W8?70G0U]O'"X 8\EZ>)382DE0SW:TL
MZ3D2_:G<1-UQTRJXHHAW#MY=,':Y*[*X;@D,X$E_[20YXNU!M%U2_<FI;ZBK
M2)!8/LG-'1*6[VZ<S\Z)S!%C1027.0UY< BTJ=:!$MRG7AUK)=T]8NO9C[=-
MV ON+@@AU9,_Y&/.<>!9N^FM35-4V,]N;KRD(F*\-M@G?O>]M#TJJ%@YT3H5
M>UGPO!*-QFWZ2NPIJ$EQL(QD=OE#A,6?>9<$IT+/8)!W@CQ&6P>-AVH8L]^:
M 4[$=CCR&:'J5*7O$!PT#<2DX.L*_ECE'348K,(I243F\SB#]&F+=097[R%+
MJQG+F,>]Y VPB+Z?-QPG<O7Y%Q^IF-*0R"E+^G%S@@6==(+OYQQ]/Z$EJU8K
M 4]2!PH=^_C)C$Q06'IDN""@5G!:?RGZ@4%=G#1\L;@Q<P>J!B74BJ4MZ>P8
MI^1P)OV.!HLI1%L"\&HCAA/-%. H?SZ=+KL4KZ>O,'-.TQJA!AD#=0XW;0ZY
MV.OA<G;[^EBE'A<1'TS\[W!IVX*=Q(=&Z)X^M#[)Y729/Q/2"CXSPLT,U9>1
M$E_(; 1:!J_2)8O2,JWUOF#ANW.*(?,='N\N08X-F[SXM<ZXVIV$A0XW!3)W
M4_3- .PH(]/T-1L/:)\)!0A3/Z>.>HAL.5FEOB>F \@6F]4CG:SSPFR/>]O!
MR39L?(AE]_L^!>.'GNVSXP9R\$ X;/I,<%V=,-8QNUR$I6KH4>8GNE!C.&87
MWI!QYH%B%<>?,1+'1+,:YM E[;?2B[26X[2#X<JR*?QY@8H-=MWR0)$A SD&
M^V=T#'>W-S"^8"](C K;!T?>0%.!%0 '/&K=1GG@WN^_9[X!O1NFSVVY9T[J
M\$Y&,C4Z.FO:%[-C #WXU^K:+B5O0&?';9-2,JEI<V8&DQT1Y;;@G[>7@D3B
M'^1YXQO]BY[>;PPVDU+_@5FWS?;H$T6%>/O:E:V.>WNYD!',LA^GRL)H^&;>
MQ#]H+0]M[B>LC+,-IC1WWO V(&Z2E621N1++$^]<Z5Z#Z7\]Z#XIQ!WA.YWQ
M^)O7ZNQKX"+);XONAR"3\TB2BZ?4GOAL-F[80&8V!DD=7+]^$_]"(;>O9=;5
MD@KU-<_X-./ 7>IMT$\KH6H86 FFU%M2U^AN3QTC?W\GSX70/!"-6_VQ%W<]
MP!3DSA(#$(.:["@J'4%7H ):\^M5Z\3["D"5/4$=(ICS 8K._4S ;XS^7#ER
M_TJA<ZJ6X.-<Z[U(0C>1[ZA%"\F&9F\ U'GMJ#ZJE@7J]PXFH"]_':4UD8[5
M55X0 5E_'_))L^S!R<.WE*_Y>>:3;!I;-75IXH!:8R/<%#> RFH]6)(B%..V
M9J!1!OVJHQ\R@1IP+BMW)%1NON3^TTGF6YI+S:A'C*RR2 8(YB%(>5??Y)+\
M;.(JNJ>!+2^#M+G:;40# 6)]*4A,.L(G]XI_WNI@GWKD2[H$\;4$E[5^8\W5
M_Q0C@# R:O+'39(B3\;\P0S4-NLG8%9FL(%R'")6NY,DG!RD#,0,%4^ID43
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M]@ 'ZH3$D9Y6G3;',82AS\-JZCG!Q:TC2N@O1L>C?FC':,FS8E]EJRUJCU/
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M&,['4-W14IV23OX]RLT?>_)]ILZ]!V3)FF^ 7<JYSA6+)Q*G+X>8RF3)I]/
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MV4(D=D;08_(W $H<A"];@/\1^?VG0GF&K0;VN0*NL.')5G^A\E]^+H%NU3*
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MJ_DS2]V2"/*#,%#(=R \VVV=/[2=6$ZG4<XEA+#1GSFD38/V!7(S.A]HYT/
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ML&0&DT0_,VL5?,"QN"&2<EUI>&?"'!8/=M"G39K_K-M,'Y<Q:D\M63X;4+Q
M@U[X";N:I)FL.DQO ,SA4V<ZT\$RSA(*3$6^_1TDQ>@6E96\&0>PL+"<\X>L
MB(DPV, >6NXHM13TE_T0$Z^*D \EB.R^TYV.0_U4<&YIX[O:IVD((W1<MAB/
M^<7M5MIU;^$K@0=O?3@PO0 '[KB+9/U$*KK?XR!- ,"]:X_R]9!#W.+-.$R<
MI.7RT1%!ZXFK[!N\D.L$GQ:&5=[(ZS[$L?;&% [0[Z?=K4!_EFJ6/OO;Y?R_
M7"K7C<0<_29FRP[#-US2/ PR_'5'E3"/EI;$DID5AFIHQIFFKJ:5[\W*NB]#
MA-T+Q=HY^[AH%FR,XN31#;W)NAUK6RUFFR(WJ:GFQC YT\Z*4O2RX"^6 <P7
M=JX(]*19/@_KO=<5/5!0$X[\A"J9^/9'X6R;(V<Z_;0'=@^#$!Q8"[?6A_94
MMAS1;FJXV-\BS2+L)$:0G/Z-A:PE 4E92#09SS9C@.CNZ WT;<WBIN2[WT2,
M=2(T#]>':8H3F7X\+:LTXWUNW!6**VC1R?&0M/7;J<Q\Z7>J@:I^SRS_:=K"
MU&U>S3+\SD'9ZT,,I 9/U44&OSQCCN7;]]R:DV^50R?#YZ(5V)ZJI_XDW%=I
MM5H6))07:^WIE,S^C.ZE\C@_;3!?=-9N^$?.M9I%=B'Y[.="/<[B%!>(T/[/
MU=P^(:*$.,-K@ .E]VF/%),U?TLY--YKR[=X"K ].,#67KQ, @=ZO92OM6XU
MB54H:<CA0-1FR_0=Q0F4%G'CL00Z/0\'7EU'8B.NG);W'W$\()$(OT'XR/XA
M'$CQS0/#@<8)! D_#'^4[=UF'_\$AO;NNL(!0P(HM^$'PZ0389C<Z]*[D]C;
MT'NJ<YA,50MB4%*)M 0<??\8+YN?5Y3_Y_&25L)1G+GH28IGSRJI*4W'Q5 V
MXCQ6<"-I4Q2),__:PX(W9K[Q#.M2U%%31+J\.M!Y:W[@E1]Z!(%4#'HW]S(_
M;9!M7N4?->&?;]1)W=]KEPL)];$4\('*_W-LY'-R^&@1'T1,E_TL?Q'/PM3]
MVJ?!KZ=%,785=KHR#^$KB'5)Z@]#<J]V/!2GF/N/T5)1:7]SA:"H4@0N3#7#
M 4^+<,@&R 9!>-.T=^0E! TM%-!>I&E82PGD@E>?R2?( G;^XL>&#[,C[!9Q
M=%U"8C2P_D* 7AZ+HL4W?1W,<*AN^GAN\ (QQ/5M#43'Y.PQHDJFJE62*2U-
MMUFI139XBLM+#W^<EF G"[(X$S,+D+#I%AE8#F21^'RHYL&G"W92FH$HM-5I
M[[-NM8IC7]X>;]ZE;HG/7_TX>Y3[(T-\G/:62%4)>FE[P0>B;C,/B4.*D@"S
M$..F!E$*FK1__0,8);&<EB8<ORA%/6PE5???$GBH%*L"SQ]#MH^@]S<V_9X!
M+1TW:=XT>+&1IUHP)#@P>%=24%*<UUA,UO#-ZQ*U/*)EQ5H4/?X$EJP=HU3I
MR=+2SQXUP71R/N)2,T5*YYGG*<>RM<#K)XIPE66-/197YU4+&H7:*UOJ=D,]
M!4A4;/?82DJ&OV#^<)Y9==#Q(?I[*CNJZYZW57V6+U:KID:MXJ\QN!0,&*.B
MFCX9CU@W<!Y^^40A8(_=1_9C0]MLP=T.PO-$E,=+G6Y'2[W<3(O4X= XZK4_
M'-C;ETZ,"^,F-VOT5P%>DZ,)E3Q=HZ:9VM.L'?]@F9;]S;%.#^0@WT.^T!(N
M@_? @#9V=3&C3S_SJU<_N0(),Z*#IA*T6%WT/@?4Z$=J^WF;VE>L,M:ZFDN_
MN+&&-:;: >\MFK(HJJ-;^8[[CQ-=SK _#VU?OCF.^!!P]ZULN)$5.1OMCALV
M55[%_AY&9I=C%49^PB-G)WZ9CMN^M$69_R5*_C<]C(F?T\*R>NI$FWW>_FP3
MLU5H P"0SY J+?^#<HN:J*1]LF M0#"[ERK-HTB-+*]@"!8'2XP,+(M:\0TA
M=[I-FRM4^;#$[]69,K?K,7QN.^Z[['(C4@%#5B[B16E<4HU>:337X=$9-$0F
M+JQ7N1"'K$)OP8L(MWX<@85;S_^-R/!$3^T?@LW@@"LTSECS^!MT0Y3EONBA
M"#,?Y__&%]X]0= -(?M+6% C;0^"G" V:9=7<&"X>?PS'%BRA@9^LGC)8.8<
MM]N"W++A4H_P;@S(SU*>4J4;:CC D+/\Z*'PT.4;X0D'GLXMKT(SAO!"2! #
MT%[6M7WU5VG,-P?3%D.Y* ULV7/%*X3J7BB>M_S[^3UVS>,<!#)X/YCW.$P+
M&0HD4C7TW_NW6MSY$S(<B%:<A]6_1O G1;WBU@."W9Z&USRZ_( #LOR U<[R
MZ2&"6XV<_V*%8HKA/RWK<]NPYFTX\"=<EP^TF<J'X$_4TD>H/G3'O%;QZ,$*
M#M!A&=W!:N' *")1GI&GW0\V&T6?)/3<;R".TQYX,#%7H[O3F#J&B6F]%<C-
M[21TOUMQ(U)=6P.&"KGW/I?C-[KV,KJZW@KA;%G?>G$=Z(M#>O<%#KAHC;Q<
M/CTGO6]O,M(YG:!@.BV+Z=N<"7V-!E#YV8SV[TN&63QKX(2H3_:5$^W(9N\)
M(\[+%T1E.#T'H02_QN2,<UH&G<2,>XAG/+SUE9]8Y9[26P:=)2F,*%[MK+-.
M_>!@<O/%P?;%/-O(8V])*/X7/MA#\%:1?49)19.=3Y$W'*"=IKV<;$F14%^"
M SV7/8^N]MLJ6OU-(\OT)Z52N\+:I=NC?/*_2G07=8G./[S3I/=I%K3W>1<L
M/:$G7#7[UFMKZCGT=*XJ\^4RCM5ALLD8;RQLIW"WZ,B,UOK+1N2M^=+D1;^"
M#.T7+357B_ZD2=C']W_XGRA0;/BEW;E^@P,A&7RBDOR8B1N%6>DDY>^AZU4-
M*DJ>]L@'\1JRW0Z^D%Y^VYRZSU;6@Z4'!J_)8(L_:-(^_/5:NF5]% J.FPJ>
MZI4V@I9[;,R?9:6\EE[]3F7F]8>CO#TI^WU1LMD?5YO R1)3'$)5S07^/F3D
MY&_:%7 @?9Q4O%F&K7[!CT:PZJ_.BG\>'6[Y1O?_ZK0 )B:84UL3O:D.[C[5
M?:#"L2CL<ZRV[) <E2TT74!V G;J2D(S8[;(#-04D"I<P"V"!9;U6+F(JIP[
M\.\^*&YO&W@\,[A[E9+T\.MAWM?:J[?^9"G%NU#TL9VWH6N3A^16?CVM%,GO
MZ4D#WL%]L]P#=.$:#N06Z[-TC834U_A=XO#@O,324=MC<>=%DJ?S[\9K<F=?
M:<%-IW?)?T>8BH4+?14*!6[4=CX[9LR]T?+[H#;S, 3XW$$MC<@(.U]YT*0B
MI"7%Z!\8Y";S7*.\(G&L]=<U!B67)"ZYW^5UJ2T<"+1?&;DCJ3R^/V,U"A;#
MT<1NIAKO0(Z2UG[JQ^VC-]S S/VW:L(+V8.EP\YI3J:!5K,/5O79V?8$-@9;
MZU9ZM; HWJ9+'/Z-0)P.M"P<*.ROU0$YHZJY0]0%AGCKQ[>T52-W]]!M0SB0
M;]6,#NNO?8K.02NFG-BOFNE41V7!C[F;AJL0PC16S)PPR_#\A*KA.[:0J!/Z
MP_Y"7\6'^,DX.5R;(GN[&IX"Y13MVX@F@17WAX@?B)0\\"5M4.N753/5#;1P
MX9NW/9[.;1 O,\VR_4#R)TB@K<P*+:9>\XT+N^#/,'/^.<<;K8K(M9\F9>/I
M!?R#Q=ZE9SSA6,(+IU:0*8&I)$-$H8A.&@C= 2-"W.?/OUZ@(@2)C]8&')@9
M@T%;;^' Y2>C\_,3.!#@W((E_V2/G.$O'A)MO7A:9GHB%Y0Y\B-;+]?KH'=D
MPWHH+\C%AC*[KKI<?NNM1H< ;;&WMK58=TR>]\P=-@WUZDYWK'MYL0R1EL3$
MWZ6<6I)F>4TSB;-^MC/9X$]G/R+W$<5M'[S"W3\>:K-F$YP:-0-M"1+WA\<&
MQ,/1>4L&E-^2M#>CNDV8NB74YXG#EG$?:(YT&H6-XX4@]>E8KV2+<XNKNEVQ
M))+J>A_/X,"(['4QWJ$O+RS@9=KU([2[;'[U^+-I>/*-6X=U@/)1$43RA,6_
MU*6JOG+LP/Y]HIQK5#</3^?A58]RNY_0,MGRK%C@QP)/N\$7=AA8;*D"M%ZK
ML'%[. #!ARZ;-)7"B$<^0W?TQ^' \:0%I&,$9:"T\[/"[PAM8Q-;GW24C/)S
M[W7J)IO>SLW0)BWUQ.DS$1%SE7+^%$-OH]X-'QQ?"^KNO"V#^=R/V<@NA3S0
M5YLX0\W*=]*0ZQ.M*FA[W8G](U8B]/&N4+>F PZ@2.0.FO_AL(WN'A$UH6T8
MH6PJWU?E*%#$#Q:;WEWH]WP:)]B1MMKR%@[P]A67%'<-FBU(70<_5!*WK"?-
M*XB\9F>:P&W6=?I=0.OB/9W%TI&&=J#OX:YL['_N*95H=*,EAH,0/L[*<*#E
M7;S:=RJA:ZO#.3BPA<6@F)0WTJ!L-WU^+J)^^!(.G)^2/EZQ3WVBWO/R$2-G
MYWPL%$A=X.O'L_<R8%_=#C"/N;*L3&+W.S^G[(0XB".;"[N,K.M"3DI\$.E/
M<C/X\:ZX+,&I8V)[JZ5W&36.@]/(:L27L[S,=9&.BEJME_;NQN@TQ];BM>4\
M15Q"+^1L$=I=9S,2W(S^*B>,,UM'@GG+-;(?4#Z+KEDF'Q8MDOIK$5IV],L0
M W?=HQFK.V_:[&2^6PG)HNM=[A2UQA.CO=U+NQXMS>"'(-_@*95[?QO">QOP
MHJ&EKP_E#C1$8=1ACYH;9UV4I6W(&B)>:]G&<WH=0E.U!;5XL?6 UZAORAAS
MQ7X,W? ,[H2&Z&XCI/XJ;=4H/[LC2J*9/:N&CIA=\IT6BAB?Q^0'*]0'RI\
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MHV<LK^+T>8ZCIUD-"=(4!@9/.;9'Q_O/$4* \[X!;II7S=6W5QE2M47/A-K
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M-O5L[ 6?9YN$<)U!<9WCA:A8''8SWGA>2E[BZ^"$;D:G%5*Q/"0_?O5WXQM
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M*QVB-/4 .X!/8193U9;I:)D<EOE^;/FMR&5Y_V13SG\&%#[[?P!02P,$%
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M$ 5.+Q@^>Z']PUN@GG"-,.XDHG]]XN/(1P\B%HPOLNVHD$VX(<J!.LMA!RA
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M3"V-NEKW8MV&R);XD49)Y8;(1'YR1NPSZ1K[,B1(_ZBMP"3J+-LN%I?O\>)
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M[Q*%,TPY7?F*75YSA(\DR\/K%0Z^W,KS'!M9F1@WIK2@C1 +H;3NK3'I(L)
M=B?3]^+-=V="K2VLB)BK43ME\; 7;H(<2*+@J\PACK&G0H&*>JUXG;WHCPO6
M/#M6K A\[*E/F;%N=0:V1$:@$M$D9)%;H&&2MF":X9WB3I-^"Y?L.DD*"RV.
MBF1*N&/8V)>)%$\1OI!TW[EKQG\YA'V -#F-?7^)CO3RLX)C%D5>''"$DG+P
M6?J48.*3$T4&/JU=%5U4MH;Y.DWQ=,=+SZ$0^DI.H,[\ SLJ9&7']6)450P1
M3^G'FR@NYBIH@G($?'VK;!-7&0J$QS^\Z(,"R6K3 )Z2Q(\WON+3FON>44ZN
MA=SI,X3O)6OU3.DITW0^>PF=;+8YE14*(@S2XWQALT5(;55)OV+HU7SK;N@E
MWL:?I==2%=?!7NP]_CGD@<:4]+E@_F-&)&3 !BQ;;K10*[+Y.&+_J!#_C:F)
MCI!"2SF0+)D:UAP>M!BI9G7U:(0WHLOCL[PUE7.4:JI_3BPE_&KO-_$EG^,5
M+T[1>8$A7)60EEPJ-K+/Q!]$^N\=3H"6EU:#*]N$;=NT3*YH)FK*U9[JR%F0
MUW:C4VM_U=2(M"<QL5V:UPX?3&HM-=E_K*1HE2$U;;LD_ T*2/N@?"J+("M#
M%6G;5"_@B7=V%\"JMDZ7<;"BNA03PZ'@[]RAQY#BAW\M1C94QS:T.CC/U8+!
MJ:/=9H^K78WY>N09J; T W;&LO;,G5%6!V>:P.6\=%-JW[I^\^7PKG39"+"_
M0=+I6UG#1(;B\E?E58.&@1#I\.VM)I#0Y#M?U<:VO0@WN(Z\8,:3F7VKZ EL
M&FV=&JP*@)"H@^CB&U+4ST3]2%8=%1303@6/28I>(^:8%[J+0\JEH<"7(/ %
MNMKPKWSA*6F2G'RYH(BE/2N,WF%X;?9((5O5PU.?Z^P),B5%,6U.FW/<T.!,
M69;04TWNQM%V31J$+7@&?!6R4(7SU-"V^\%-DAMEG5\4@JG;^I)(M;NHQ#N:
MC #R7BGX- <<B_L2.8]/P49?ZE0Q;7$YB7%MSYWP-Q01T.+(M<7,YDK]-MIK
M/E'0/*CGM5,)S<<2\?/B+"G UYDY[^>ITF77&-,Q6W57VE6V60Y%M.WE:B1#
M:Q@\]JAR_  %]B*FVEF/VN*?V-_OM)268*)J.%<X++=V7R13-_+(:4S1H1$=
M/[TU5>02@R/YF=N,TOP4,4#8T2?(VZR<)#H^W8(W[DFQJEM?;"+_>VH*1^M3
M?12*!2\!"T6\C?T)RFTD[U'5.+40T_R.$%(>C:Z[<ZN<6/:)E91-@5LU@K8L
MLWY'U;%+G'(LJ0H[X(! ;WF#@L"M]&"3(>X.RRUZ%U#(CF5(B,&,C1A-:$6S
MH6=I1IKYH/D=:IDT7<T6F@<:-)%F:L_X!64FIGQ*H,!#,5*57[F0 /1#S\D5
MKWW>0H+RLELH#[Z/ ]BP<4 %4)*P+Z>@O[U9M*ZD45. &B3DYYQ"*0J"^X![
MA@:LY8#TADDE!RBV'5WB![@/N<KMV942/#S$3O&?C39+GLR3D/.NYU*H!;#!
M*:,JBUM63N%2!8]="^0.[:?RN4K7>-Q+G#$. #VU1;?FY,5CGSZXN!J"DYQL
MK:K=8J*MS?,?+Z2=V3[DTBDAUC&!]YJ^%EY?;57GS1.>7JXB8FD(V>PTIN*+
MY39OSTA_QD,&!9Q=U1^FF)=5I1*^9)&HUNI:ELW[DDF%C, 9D?KB]69CCPH8
M?\T/"BB4E!M6Z3XP?B.'@N'?R8<)!90EA7N %S-G!Y#> SFGTE*GD'NJ_3K>
MQ304+\@.))WG/.G39, +'Y\J##E.U[Z7L3AYS9EL68R#84?'U0X"\_?:* X,
MG@TJQFT/8++WW*M(G'4/Q1._2HY]WBLI?@A0!NO%Z[S?*%-C2>ZZ6_604YK6
M]SV )W Y[?-Z=\*+7;V-)+>L7))4#I<E;JHF[6-957,A.WI) NZ*05:K*)IC
MSF+.-HL5=<1,QXZE9G=@FG<50[#?@*W/9;>3 +E GD4?KL9Z7'><V6" =)!2
M!S51J]# +:_8J:9T&^QU]4&M?KI7,CO,(^Z"YU:=S7!A"E+D>!#X"2].;FR<
M9SH6UAD]M+7-=CJZVQR5G V%'0?G/LD(9-A-^1;%N=+'4  [K5A/RL.PL!B!
M,P>N8I'*-5'@PEZQ8I\@%J%(C(UEYI6JP>TH\<8V.]MO/D?)F(%,\87[T;%.
M^"U-[2QY"W;O:'J3Z\@C?7M=&&U;K!\*J;/3[+4725#[23T,:SBB^H8P'+Q0
M?XY?RG:Q8&%<6*,)FV_*TJ" CCP@,2_W ?D-MYA)$,X+),E]*" T4B8R; T%
MA!>@0%V+'8E$Z-LC* "W[G1:I1NK^J6<6:*H6!#O"4#401,FDIZGG>$72^\V
M?6=4_D#S(?JFZ2(EWP/2*('&-;<GR'(G.>#S7<+K$X9+U?JKTW>02WQ?EOHW
M+,OWN+687^94Y.2*O?:R[WN)<S[8\M97OM%+:YW"//^0HOT4L=4^]+%]'##Q
MYT$\C^Q9B%L+%/ (;&0_XW]0_.&( _U.#AWUA/0&W/&2ZOL!(?Z=S"K/Z.[N
M3L";4^992H;2C!>/YU^14)J70X'$??"L?A;XJ\ G*/"- O8H 1?YXQMW]@]A
M;4[X+02>_NP)XFPI;);J<Z[?+92:R(,"JS5ZIV/9>GLAIN CY"^P\<?PQQ=K
MR6#=8@W[!13PZH#@P3EMJT&!PQFVRRVE/X-FC+D"Q5%>PVV)[A&+?@T]D^(6
MO8 ? \]Q@GV!IT/YST5H^U$2F>%%/&VO.\=_ =2]<1\IJ [4'_XJARIO=><6
M8N.YX+ZVZ,W;@>K_&UDY"$X/-L3KA/(,(VE>ZO>KO5BO?X'W6VJ5;\;]_6M>
M*V^A@)@;]A62XEXR>OTOP$)_ :)2?S/NOR$)'U>TYUM;]I'N(UV&Z4@/1<.^
M5NK36T2<A6$<'0CP[:OX(&?EB8T+N>F'RJ6)FAB"S8[K)-*@,-%>3B=<+ZXQ
MQ_RW_SH(SE)L]+7['_O=PLV?7X*T4M$R$5PL)X>@ +K)0+HE2:\NW<Z$Y</N
MJIK22^Y3B7-PC-5V[ 2V)Y #ZR;_-G61F6?V\D-6<>L%!(*%EG@$IVCJ[IBD
M7,A/-Z.77E$]/\XCIQN9E-,N/!E;MHB/KK"3)C*&I[(?#(SY_P'@MW9_,33E
M%P-5V7[G&N7?J)-1,-5@., A)$7RQF0W=*?TY5^^KI1.PTN%R-,;QQA6EZ(T
M-J-Q\I:3,QG\'J<8X?\'):5*KC\SJC[ 6G):+3TRSTNHAA"H]^]"[*[I9]FQ
MRJAY]U3#ZMD&4V826B,YZ."<^/PUPH5#;@X;&C/?*4Y7]MW!C\E10R]GA?Q[
M[@I0VEB_:-AN:'&@_/=>!;/Z$ V_S&=Q,(WH'402%(CL576/Z"6J<[IM@]HK
MZ,!=%>/'W:-PL'/AML!&ZYR(&OW8(ZFK\3&KC<VX%;C&PN!?DX:=>B^7#4US
M@^2KKMF^#'/X)+,%90\=1+-(IL&QE6-RH*0DY][62M#TYM<=AA<'^OZ,K1QM
MW6?T]L_A$I&?">34_Z\*E.X_"&_:3<*F_"_P0K2D$0J@QHJX:T#ZX 7;KH[R
MDGXQ1:?O!"D8]NG;F.LHH^)+4<?9XGRN%8?U?RV&3'%5WPQBFKDVOIGSHAVZ
M&$6X/8IZG]PPT?(:O_#?^4XDNA<XZ7+R[CH+>RR/5:3?FCA : QB.8E0V=M]
MTFK;:OYJKRXHCB7Z0Y$V@K<TA21.,A^%9CN6X.K%2/V_AM"@;3Z8F"7_9=#B
MEK)0* )'7:/U"@:_#MEM!6D$,L.33"LA]IBRC7+72Z%]R?U&3AI3?1JZ5@!\
MYSWRU 46D]N_)HI ASNY,9V?G+SD^*/'2[0]50H?#(.Q$4+ K[# $SRE^ FW
M3A6JHT]P::-JPA9X5-1GB\.X#A9-%%V+_RT(]S-\\WB$C1?.2QEP6(4BJ<]1
M!MAB!@W?+',=99=[8K]ACIC8Z%I!27OBQ4BL^>:#VG,7G?H'J(O>3)G_7M>P
ME*X($:=L%%UR0>;W2)H-43[=0A@O-P711]@G-9&IMNSEE3@>:(KGNKBZ574M
M(3QP\DH1K%I<6M\=)8-1]E_C^X(20SMMR"GZHB%P XD%MRB',>*@L',UD>[%
M9#)/OY:0VDBXV&D6%S4B)Q<#LX<T$?Q>YG\LIKE@O*F&&<(A5>.@2-0&+,;9
MW]TH$I+[9+KG;/TDFH6U4^ .M6HT(@+E$ULQ]/3UI(EZK*-W1A^:Z,?R#$.>
M5)?=9^1,<")6:J&9H"CT$.(KUPI.T=5NUR+R[)2O\O;5IBI;:'.T3^0(<LCQ
MQ*\ITT,Q#1QE]V:F0B!&OCK4&KUT*+BZ@E4(&!&P.Z% +B^4)NS5K(E]4YWZ
MAL#ZR)J><G0R[4G9GORYGYL,V]UR7QI,A"PK$JD7+PN1:!(L+V?O$2_F,Y7_
M9872JA0*)'T0W9U+QGHPV>!+$R>SB]-=9]L8'&\6@?<NAX.>E&NTCG'V[94P
MCU^M@Q.#+8(M#>_&V'F2>8 1@!L\B5L@Q)?W*NF7F93MD?K#0^3K*SPX_<""
MDTV]\W,?" 1-9-H""HBR@V<;Q0@8LJ' ?V,_\>^_A$@<*F )]3]ZP/JB@6OI
MW.<RJOC7$:!00OT? T/'4P67:\$TI)OR=$_IK_USL\U:>76%+MD?3"!=E8=Y
MEAB]0E[[/LME_=&DXX8(BV'*R2*L([0:5HMQM[OP]OWCX)>[J)P?A*FVOT0V
M.(C\=K1*X7LR^=A@^[N;,B==S' G_NSWW1>\^-_5$W=9Y$QI;KQ\JQ!L$K(@
MG6*:^I0$OM)FN<X@C)_\B_R3M\V$6CS>4YK/).QICPIH<GC&*P);5#G#K4PH
MN9P$EOP:A-132+M "5/B?7H)3UA?>C4D3F&;: &+K$+J!>*6+'M?O!^IFT;W
M@,!<-F5W5CU=2(LXRC-JI9"#> 0,E(0F/*J0(PES_:27&#._LN/T$D4+$^W5
M<K4X45J6_ (^VKEM@JHM?5^,+/_U0DZ/8G.? ;74B5J(R0,0PYI!&"L*LR+5
MZ@J:\YQ^L0.FG';]%[_9QY<Z<6_*"?F446A4.9B5\4*X*EZ7?'DBI0SO.NIR
MTB5F?_+==.;S2,4RSG,N[4]1W:$!R,RNB75#<"WB>>LSH'WR]]$7"2,B>C&T
M7TG;)*.5^5\;]+*+^B_F(^??[\/2Z;%--78R([FWXFMD5<0HW9EWYL6X7EDH
M%+M]N%EK+U\6HU!2%C(S8^&\$&2I>@<#[OP;X@1C_60>>'4%^_*,X;?RT/B<
M<UTU"O%\#@7JO4-_Y?\)DO6-?Y?*=WM64VK&':3SU3934G$7^52KS/,_X6JQ
MPVH$);:YW=?NHK34W*"/#Q'X03-Y'K]NC-PN2_JY=_7;9H:"QNJ  W$!E04#
M9,@X*A\4Z/A*53"V3ED\$F1#=LM6CC*(1R::-,5DI3O9A^SQG+3J#J$7*MFY
MN=OQ;HO3PD;[K<\+4_"3K@/798,_+_#B-Q,2S^GBU-$TYU5GLC:Q%_(3=$%0
MQM?X0,?G,1_!B=H@S!6NOE.*NG-%"1;4D3.<M7AUJ"+X4HEM_[838WCCB^#D
M"([ C;I)$UBPM[^/F&43X#\@0D[@>V=U%$RB9%0F&;P2KB43MT)\BYJ\4+9%
MAEB?XY!=H%4LQ[4^P*&UL-JT'\&.I]F&&:V#@8,S2K"CK2?B/MJNR+B)ET@_
M$K)B@JW4Y$N8@BY@7VX]0081!AY+1O3"F^'J/MM1\;]'\;BPD.O1U,$#.)\&
M^L0W*@1UC+5#&.Q=MBCJ&OE&<=/$(KW)7%WHA@E?4) -#NT0'8Q>C0S=.4][
M,T5CS&//-JUL9\,58B.PV:)U:93T(^\>@<!AIKN,0X;63-<"OP/*]C$W(:_I
M*"GV!^U;>(8ODR?TA1;/.G9U3=[H/^I'OI)'2F&2[J-Y)Q"+$RIXNY#>/ @N
MT>TT+]+%N G3%HYBAT&[BX=(VQ\XL14C,/UOJE8*1.HI%'@^#P52F,PK=\M@
M!/QJK+W-OG@IA ';[*K6]XNUMUKP]7X9_(M"7LQ*JI!?%J7^R^T"8!SG0$%=
M+126E=CE$BX9!TM <!RQ^GN[8?(9%'+ #Y@OP$^+#L\<-[^(%YZ2>M?'W0%/
M$!1UL"24L$6S"G!9DONZ$DXRGUI=/B(M''7NO2<R;%1LG61=/NBZX$7U;<)D
M#Q(W2ANT;8D35C_#\L5$Y#R/Y']%X@F82%N2#IC,]8Z;1T+_C),)U$+HV#<?
M+*&V<*<5UXO,7HS8E3?ILZ8SKDQMY4#N+ '!<GN9I#$MGJM]1T[9OK.5ZON.
MM+')#Q^8<D_V\U&)*:89!EXB9>Q=2I>PE0C[EFD3KV6Z>N(5.5M&"U"55FKD
MS>CQ=1U<&$F#J'Q"%@_6M0=5$CQ632[(5-/\@Q5MG_%>24UIGQE/SP>7; ND
M1@TKJ<UP>EJ]S5!TC1!DPVPO-%$<5%K6;0]%>.&?O7?VO/7;:T<TR?Y*"KUN
M35QKG3V4SVP81&H,+6,<OOXR[Y<^G).ZG-O/YCT-9C*CQM=1W9G+V^#%G9=9
M#B9H4V@.U-3-^W:OR;(-E&\^/UC#2R+!JZ7!@5'!WG9P[;R0'8H.F5^T".]6
MO$TMXE6W=;PY$:&(CHK9S@<RK.Y<EC&::@QQ:21S?6KS>2;"L#6?A>5Y_'&A
MT<L:SE5TDS3<X#,<J<%\5U?EMA?S'?X'N:_*.QAY6X@[X/G7UWM4A]R%>9H'
M=:3NUW?.Z&C;!K4^M;(/LD]8R-%Q]MS3F$?ALR-2U>)!*40DE1$Z;'S15DJK
M$"DW0UK@+S]#ZDDWI$7GRZTO?50K'.ZG&CV- CK($OW"K0-NI_YCA&*<NDU;
M6F/3RIMJCB^5#(_/9[[J6/<VN<#2B>O[_]?M!Z_A_!J]1#_#1J^?YY@D Q\*
MZ$H]'"!L=N7$9&UG<KGT*G],&5F/_WUDA;R##9/O?@R3V55_30=K\((0G&M"
MR&N"/V?D"[;K6\P_1K02TV2,OC.IHY>_7/O^Z &6A VI$C^&5)6X]^6\)XHL
MV4P=E'V%]?Y8R:YDKW*=A11+E3)>%_(?ZFNT,>'<54ETH<]'-A_A7J9U3CAL
M?I!0:;Q]3E(_1O+K(MA(>F1]@:#Q8R25RMCDF)V1MRKDMJ1PUH>C(GNU<2\N
M\4O8VJAZM+($T]<'QU/PAK>P1$IJWU=66N8G^7OH)X'B7)D@I)'@YZ:S1RA_
M/M+H;6'^BDLSNFI[H*K-UOP@UNA@WB&HI09QJCDGP4O@8B'179XP9L4CVC+W
ML\:^3RV?@1,Y1YC+MNH6O1O-@U9E\^W)I2XH,$;""U[Z$W>8[WQ_^E[<%@#_
M&,6+2*1K=6>FULF N)>1[4PVTMFQS*A<P]"))K@Q_.N<)_TQWK6OPE?G":9M
MDB28+5&8K23%8OHS99C/S;:I&I27CK#$#%KX7&)M7##(UC _-4CD,P3L[H>(
M]R K50Y^>C\C8VWSD$'\]E@3U3%"D@+'2,JXW&JA-:Z\P\!HI?4EO,2OM"A=
MOTX!?Z/[R:9 YVAB$LZR0Q<K4%>">YW)]*+ Q4 23BM+2H6%YB/EHEQF3;!+
MPN5^0Q_W=;#"UXMI@H*>\Q@8(W]EA.T$Z5WH^<^%A$$>[?5 $WY)LHL<D^!S
MA.F$6UP)>Q9:GY5L'<-+&"4_K[RK^B]Y&ODP:K2$Y2[-@*.9HUSUDR R[>3V
MB:E7>4DP(NC]>:W:/O+%- CRE0/VL,&BK0+W\2:+4W[GK18W;$B!N?GKTU1(
M0W_]+P>J:H=.U.@V\#&H!9>5!1A$3H3W^^8UOS@'^04*9FJ[5^N98Q^;KZ)@
M"R6NDC-)#[R/6K#OPT&S6XXO3/E^*>P!6BS^UZ6DQ)#V/SEF')LKE26475@B
M3\"9+VG;IS3T*M-!^+E42GS7/0/;E52W!E8D#?B&S9%0$U8K;7-L',7(CX)Y
M>M.5)M\-_>F]W,W(<KLL71?8 YS,NW<&\!STF(D&B?5S[>X?[0:Z.<?1OG/3
MZD65"!=OFWHY'T".3+:2,Z9P(MUCP##Q)U/Y]+9^>GL)+[EY'?D'"/B/G$-/
M!V"M=07?[QY^>;Z,G217@N/VFCG/OFRTF7PQNNVM"IK@R7=1D^>!PKX*#?LE
MZA-7/6Q;F# W>7^) XRYN#_M:7F8.(98Y2U.W@U[A/ 1+QH]<D.@KY977LN2
M=[QG/G"YZ<4C?LG6J0/4S:,L%<-K1Y8%LSSKM )/WWI8EJTFY']P51G6[TWK
M_RK:="$9N/=LX0RA=EGO%X'W,_R]KD^UFTVC][I/(C*3/KPONFJRVEH5LIW(
M&>O[4E<NI0[C*OA?<57J12[=)P<:#NU.?'S-U)< .L-SCH15Y*.\9Z7O/P\6
M\[U9Y'&N3A']-P*8JMD)!5Z84>Y]. >/JVF+%A^6;ZT'G7^T#1S_+H5_U9PJ
M#!10%A3X8@,%^J-*Q8CK]T+7?A,C45A!_.(C?DHB4U+=,%N> \BBB#-(:.B]
MCV\P>,30)(*_[?)K-KN=HZ0J8VM<S;OOV?QGE30.Q1>SK-DMEO=6SV>'OT<5
M^>U5VTAI?8GEHR<R-!U$2;>$NT7TI0#78=GWBU741(&J(@02WUD6A'WE_1)6
M4<_^*,L4!QB7+SQB8<_CQYCF$/)G%MJF_5>%Q!I7Z?J3H0+/;2HH2@7V[Q3"
MO4S7[]WPL0N^1)UR/2*ZLE?=,C&\C,W5934AV+;D9?MN"OSMG[N$FNW^(P5I
M/V2:KT9!94A0(-().#Y:B!*2Y9W,C>Y9Z0ZTR4U%,J+!JL$2O.C?8G2D'(49
MX' W_5UQR>$E*0]_@=E7M,]L3ZH:/3ZB&<%Y:?-@MW?63C3:7#OGLK6^RGM$
MVUEYA#M\PD;:<GPW$8#/HY>4&5_C>9?!,,,*!8:[DG[']+<>H9(O)(=8<]CZ
M3=!%NE=34]JRHGVS;6975D@L=P6_)#8?P5<HN2L1CT.@]S[[E>D)5^D6I7:*
MFSWAC=3BW4"",2B1OBQ$SO? B EP_P*?[25]LGFA5IO;)US502./R]XA215^
MKM*9\+F 5G]]U%?*M#KJIG3BARY8XLJ\;=)Z4VCF*$/=+%O4D.RS@<64E6M-
M /[CZR%/K RU4XNNN 8&\!W#QB9\41.2HH09G2UYY$6<G_O)9PGE[MPF5(%#
MPB-8CQ#5\HQ]L2#,)5O\1:8D0]OT#K!,@^#[A&MT(@_<(G.]34^YTP'AR66L
M:(N>((MB[T\XWQF<?'C7@<5TG#NH-XB8SP>UG5[PO7L%? :_Z#/S5T.E;VO]
MB69X.%(0G2$G*M'TP)S/)&B]QW1[G^VT)/1R17$_Q3K _K0D 0I4TY^-A)3H
MC4OJJ636+R]R(9X4DL'WF,D6/=BE>F,5Q.LT!]?++DAFG/;NR;#VT_+04S\"
MU.!O48=XJ_846 /\.R()P]MUM)"32"C@W@'A-FBNGQD [\:*MD9F)XU+,#,/
MUYY^F\138Q62O]X&0<XCKTS; NIK4\&SG.!@^X^MP_CO0G'!;M)0H Y&(1*.
M!>M=,\K3[J1%,5*5?SX$T*7!:IKW[7$23)GSJE:LN'?OZ)@3J/M9,O#D7S'(
ML$_Z"9NO_'42WCRPY:_31/M\/Q%(QG24"$=C[PSW%I9X8DG=\@:^';[]2>%<
MN"]1P]P!/QE)P7?'9'XZ]M@Y_G)"\?J0_FQ00<[XT2=B=]GE+EW.@9'YU4 J
MVN?B+R,;!:A,DOO2%&TM,(=8,-HI>#<RZ@5RNW^=&UALGOT)S=M[?(['B IH
M0EFFIET6&$4M3)]C_"."KZ>"* >R,;$5E:BTG\,O\ANT8CFOAK@LXB/-_N8)
M[UG,GYXH1XP'JGRBWY7@-/Y6,O(DR9#TP7N @PRW>G0TX;A'\))0<;)D\A[
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M IFV"]:Z]'^5]1\PT2K+&;>N/XW>U[.U?96#UZ#]"F!_,9JIFPS148$7'WR
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M9B@1FTDF.]%_V8>>EB=<XEQSO@N@^CP#OCX4=.A50D-7HV1BEE587FC\WLF
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M<F7BB-5@L/5+()W<ND20%!  U4S8FLP03HV6^_LJ?J%I;@YHGRMEH[:P%6=
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MU',_+CIV"+8=%[#Z3!NW;^<3/\E]Z+:VW^]W=U!>,3L_WT\?A/4+^)+\!$U
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M [AH( ($5400-8" "T+$!<': $H  "&#;E_ 'R\0 B(2,@HJ&CH&)KQ!Y5T
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MI5_1:;A4]PD,'8<P"&FY%^A^WJAVJ]E_IICO_TJSOQ3[AUY3 !8B".X\1%Q
M%#A=M.>TX"L^]<<9])8TFCL+;%7ZB1P0(B@Z5?R$VYB]^\O&EY-^-(HOW* <
MGK'*VH 4]R55>\P28M$09B6L"'158_/.3OMFO[-QRD#GGA#%?J0JS1YI^D6W
M;7N.L)A:'+ EA)O/5?].X'<=\6BQLFW#MV]>=1*M^@A 6L=#6L=+]XX%URO-
MG2]9^$T]'E@$R7.( 2\Y6I*.\XZ"SEU80$+AK*KH%'QBES[,WQ2Q'Y,IHX0N
M;$DM;,G&'E$F$]N)GP\B[%)4V%)4Q,.OAVYN FS_RP8^D?;NV1T- .E["/R?
MZ#23X@BPO:TQF@MK][ES*V_48V)5'/X<[&@@\3V$_ABZGT,1X[_(CJ=U9CD^
M9_4E.UR)*@3)R].?U>G+VR$%P%J66X5&*#0_D%,K%*#4-N9SG<#01E^*1O15
M>=NQHL:F:?6&V*Q"IK.^&@=OA@V%R-B6('FA0>14KJ+N10!]?+(6HFRL+<<A
M/]&%@Q@Y8P21B2;NYAU!^^,BRVF5FI%Z'OP-&[(X'$?#@]XORMJJ(B<"6!?J
M.Z*J]8G/OY0V5 02TWRDTP@T7/##$WSK]PVP^O_+5/_40 :=AAMOSN\PWVU\
MPHTCK:+)2@HI]A5>X\+&H7,:9OVERD"E$=C42O3H41<,\(F  ?Z4DPD#UUB<
MX!^TX 4Q4J%_T\)"1YI;HXOL,'X%<34Z3:]CG3\-_?PD,^E04\D$8A,=M!PQ
MQ83K_AT1C[>*X[NQ1FP\P2B)2_V+LH^VZD!$AX0YP@J^BACR_Z+<L0TZ)OCH
MMJ!' 0/4H2.U%7CZ 2&1AHKK5^4Q4UZ.B@X3/%6S]S>91D%/5(=97=PS R]F
MS4+Y\)BK'!(@>5-?S1:Z(#L9FNDAP%-]'V.-;Z9;30=(-3# &<PAAK9G 0/0
MR1B'..IXBS04O_*Q24_PY[[F@@$/NL!;NTLP0*I2P,+YK%[69DVA['QGEEJ#
M_X5>3Y)GTF+:?MM^EXD3GEP(JYO3GEAS&?1G;>@HJ$$27QGTMX)T[VEYVT^1
M'T79BN/,]MYHRQH&5]2U;E='33"@>:/I+'\T>3F4SSWST%B=[KD]:=AG);EL
M$Z\\)9:'X^$VRO1/2-^]3GV&LR9V%]SR, <\(+]WA1T' P(SH;@V@E!/ _ /
MYZ8K=7DS[_P!Y]*9]?8I/&P3/L:SHQ].LG=.\N@6O[$%#S5K^O%-*?_P_.%T
MIHR<>(=S7E%:WO73^\<BUGU45WSW HM%0LA.FZRX>FGQ: .)JYEC!L2_DQTP
MK]1/W),7&+!:SA"AL7O$]TG87L#[CEFRO#))5@G8K*0RU-A ^.UY=!YMF"X9
M!I H/1P0A52*^9'^T-1"GK^=Z[M&MLGZQ(3;29F\A[E-LJFQ^H.0;AS4A-$T
MQ$KCS0N"V#I\=(]5/\1X&O,LQFZY&*$P0TDKBNB@065D_&'K*&D]II<(7:\.
MD+3X)X.-A,U'*A+O4!,&MD\^D'I0HKA&U%5PI(S*=T^[(ZW9=M'BWLYWY9QP
MJ,,4&#&P&N<J]#[X>.4^-.!8WCOX#<7'8W1M?L)3P:_-=];(:X0#'!)B[&Q>
M_0R>LVGC.*]2\?!*N@,#!(^.T[ # AG3$/Y6D(290TYR4!+); 04OW8A=OEG
M79WX!=9[JB)($Z5AS>_4V6WO55O7'KAM=TRFO@'/MCOL!5*-[YB5IVRH;DNC
MSM^QH2Z]8"(6];=8^SZ4:B1&'.LY5KG_Z0GYX$&4ET=L?SS%)"+#=_4ZG:RZ
M"OD/K?X.X;02(6=^G06D8:<*5-8N^"!_G,#"G(K(%3P#)FH/>;*7VS99B*G:
M8R7U8<JEOKL/GCH]<+DS@9)DY/LL/9!W*5Q-+3==C=DG'P4@SP4=J4@"^/^+
MPE/+/OH\#S+T)B-9#/FW4:.MGE@$ SKQUJZ'KKX!TA#A+(XI>2?SJ-3*IQ'+
M6.V]S2BH4P626 YG<Z:AW!(7GK',:;8BKY8OQAI,(*ISW^>D=@-V[[X5%%FH
MN.92+KX*'09_?PP^,E)&&?LWHQ]-O%^*\;Q!\B$^D,J7F[EZC%^AC/!Z;A3^
M7Z&,:.^=-ZHB!MJ0:4 =CC[*TO?U(82["RN$C3OJJ7,\H4QOE*T4,9*=+8?6
M5+#&BS<8]YE,R"P?AK=EBW,$!P/>!4K2S4/3;DJ<UC!@WD:-77NV'JO/,CAV
M=?*9Y:S$S^!!5!D!%;&-?S4-%3&9RJ&7ZI 8^J'7WR[N?#U)<Q$55\RB=!]$
M&)+$!U3^*L3P-REI"#%%!?S3O/,8WK<X&?O@!".VX+?AGPF<PN9 1G"8]K]\
M,O[U$<@(NG6) CPLXF\"+'QZ,""<;N R\SS0M#0_F0W?I")A99E.Q9#XO,Z,
M'+7)LMC+B6X^@"[%RK4Z(F[U8PWS$Z.#-$S/F;M=GRM&4%DL6]:9DP@YKIK?
MQ,2.-%W1>4I.W<6#=BVY?S<NFN%_ (]0'R -3UMJ349TF<R1V(S5-U]8=%+Z
M&_8;"9P&/&/6H,&Z!&W>[]%51I7_-Z'O[P7P5&47E[MY.TI#SL@WF+T.Z-;)
M).VF(69,EAFP+,C<C-ITD*6MXIQF?-"Q:L::D_X5$774-0UY2$TD6NV(LUOT
MYTD^NJ4MQ 4'1PJJIE'RC>PY;DV-[G+H^VSS=8,#3,KC*8-KHM'8.-RNPDUE
M2&U6!%IUMT!7#/_ 2#8@?L)^%P8,FH[   !\*2#R;9'R FL*_ ,'!ICIJ"FC
ML'^O?P(#Q!.5KD P8'O]\OX'\#H7?(;P$;U.ME$1(VHR_(ESC6(CNH\* \HS
MM_6I8$!:7PX4@ $G+I62@%,<3I'%H5:72+J-$*=N%EN0I7)X!S&JPS=GEXAB
M&)!7 @.*S\!'S!/_$F 0PKV7Y&5$?L)M$GCKXUL_YV1[((\W%= M;];&-"-(
M :CK7/J-\\/U OLP($?W)PQXJ'.><.*8[Y 8Q]G8T>N +-O"?4ZJW9 <!-X/
MWZ(\PH./U\9U&/#NO29<T)B!ZU.M"HJ8W4L,<'?C"E2ZV]NR^K"I 0;$9\,G
M0>QRN.:"J9>[86<R+JD7Z+KP(>&\H]]'75<>.,6#8F6>: ZEM\WYR5V<D1NY
MBU8T+I_XE)W5D!.$N&=C?2 ]:%JJA&,\H]$HWU!'_G Q.DEMNCIQY\UU +CE
M22%X4&X->ID)Q2,W@OJ^$#T]**P.R)E^O<%9[UK*FO]5:8\@8%>8?V!%Z\(_
M[.3U!F8GR1,201^.DI+^*:ICC^XA^5VX#Q2D@S[7?%Z.*X !G&"XC&%_R/@/
M!H53+':OE,Y?S#1UKEV,V:V!O6  5T:B[M@+B8IH@W[RS^%<MLL^**B;5J)P
M4<QN19F]!P]E-48PP  /!E!I5<8P<V]?C]6MUUV03K2-*VC;F8R='',W+5"-
M@]?IG&" ]Q#<5BCEJ>?HNFO7%WT0\T*:U%8EQX]$27K;<P?(YZYF9$DN^7D8
M:CON$.=)< 1W_B(S;_3<QX9YI7C**UJ!CFND(O!>K>C"@W'17P3'@VMU6=QL
MR.R;T4=>;_"M1)=TT;X\7MI0?UA!)2!!L2W-.D@\AN35*#GP/*)KM33DF7#1
M8N/*VLJR,[_A2%D4F&]E;?7)C5"E< >RP!WHMWC'V&7TALM0G%QU?9A, %,D
MZ<>=LOO=ESL#K-+/ELBWDA[XBF_R\V3327T>,G#<G3!B'FX;]NR;'CM1:OI'
M;[@A5BGT&&+I1D%5'F!U/L?G2$Q<AM-M%0\)PX";;> 5]!P^G!0(UD?4LD8U
M!C)VUHET%<STT?MV:QNW>D^HA@,%50S(WL3^/I.0P8"/M"5O'YHV5<8N83_5
MP9[-"I4UE!*NR9]0Z?!:P/\B:SN$@*)N083'ATU*NUKK"]H$%5X[0<7B1'?#
M5AD1K-95=3 _+1]BV=UC05HI$>\7WDJHKZ\(W&KU?"=E-C+,I"97RA6. =0
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M/HL/W&RFX%?V;XJP5([P,!4:!\B2L)@F?>JD#><J8=?=6?418&8AW&K3T%#
MZ*73B*3[M,KEK\&__'9B*KW\IWZJ=VZK"<XG??=WI28>KR+1.UYR3.10^_#L
MLNX4]4HMHJUP\+OW%+E6YQ9P_T,B EMKR![H_EUI1N;G:[I7.;E7]LR:&3*&
MFIGJ3\4(U*4 BIB'^*#632CCJ#6/MV([!_&4(2]D9<T<]*RNP?U5&$1&R,R!
M!D00K!!M 9Z@C,#'4_^R -5/.?Y.%!XIQ\10C.^+%K MY>= NR!-'][/-OVM
M-GZ>N^KD4#(YG>"$P'#8AEC(63QI0CY]4_K%"-Y&A/HIIT >+0(VVFKQ.>[+
M,*9''J*,J\ED%GA((>KXSNI$" FXBDO2(T6[VHN+PTSTYE<9VYQRGM[,H\H=
M2++X<GDD0'[^(X \7_NO31V$F/XX(P_V1"<K_.*2CIH)4:9-9G=#F;N2>,Q2
M@;]4Y.'V/KEB!(W^+W^I],0!KP>Q;7)JR>+KUZ]+$-..A3XVTCJO#P_?<>KX
MHQD*2A,C/G#YD=)867@-.N+V"-H2(VLO-\D4(V'YP!:_+$M+3?W&I/^$>&.B
M4E221/)SM<NK'+&?SZBT3*C*"M$[&5+JET077O"8C&7%D7BUE!+IB+Q$.D]M
M]9&D3TF(W.(K=B+C^%Z6YL-(^G$O"3O50%O&&]-@ZB?8TMNGE3'*=7;Y3I.;
M6W&V^;BL/ S8">-Z;3H 5O!SY?4\OAS+6V6'<%.-/G_][3BSUT#[9G6-P]O\
M\/ZX#R/8\MMUE?/ PZNO.(E-9TK"(I69:KS/>.SXK2\?^UF<H^Q<-G@ND>?O
M?6JL #:9&@TOAN"T;E;.X#=N5,0/S4J=6E+\+O^I?K8Y&)3D*!#8I"6B-W]%
M*^(N>4D945$UUK]]M%%WH9'S7Y+ SB$:EXHOK6_%C7*5$DEI"C%GGR6(UCB$
MXH$8,4_8:2SXB6=3DKFN650T7SJ)81=:I6);Q!D^YRDQ2WC"TI4DXA#6,$&T
M1%#\Q7,851=G'YX\RPTH5%;=YY/G8J9U0)'X5I+#,C+?\&KZR<+E'8EV&0@;
MX8%.CC^MV7DKT^,!86Q/-TJYC6.NU^,^%M^$KK>@Y6^KA4[6 GO,*].]7TJ(
M#3UL"UB4R,>)N^(GZG?HP =EYUG^M B@HN6"QR;<%1^'"N-3R%U'4"%$BP?]
MF<'D'HE/<;T 8K^(?N/Q9[*7QH='::A#"G!KA\&-#OJ'%]+S-_<MF&Q'"DI2
M3/Q=+Q*&X 1LET.GMYDQ"]?[PK]@IGB&*2E:R7M>0*.!BW]GN$IA.6%>M*P(
MXG>1A09,Q,3\ SQO<@VRHJ3O1Y34]@:[I8DR"BT)8PN.S?\SY]_\;YF0Y:FK
M(LLLB$Z+AK 4]@8<8T#IW831,XYWHOF2D JSL'N@0;R9_)RR)U5N1%_KPX88
MSM]/N_X_7A!AD_\?4$L#!!0    ( %&&;EN&?G8U?2$  * L   -    :6UA
M9V5?,#$T+FIP9\UZ!5B46]?V0Z<2@H @@X!T2(? $-(BW2!*AW0) @,H!MU(
M"-)(B" I,0C2W4A*MW1/?(/GJ.>\Q_-_[_==Y_W__YEKS[5SK76OM?;>:\TS
MR#'D%X!824Y1#D!#0P/NH3X <@*0 7"QL7&PL7!Q<'#P\'#Q"<DN$!(0$%*1
M7B(BNWH%1'OU"@T-'2,7,QT]!P,-#8L0*\<-'GY^?A"SB+@PKQ@7'S_O.1$T
M7#P\0@)"R@L7*'FOT5SC_1\_R : !!>(0W?"0*,'T$G0,$C0D)\ $ "@8:%]
M>X#?'S1T#$PL;!Q</'P"U(1R8@ =#0,#'1,#"PL3$S7JBQH',$FP2*_Q2&%?
M4K^/0^],QAL0E8[+(%WRD5RC?YN1S]0E$ __,@4EU97K3,PLK&S\ H)"PB*B
M,K=DY>05%)4TM;1U=/7T#<S,+2RMK&UL7=W</3P?>GD_?A+T]-GS%\'1,;%Q
M\0DO$Y,R,K.R<W+SWN27OB\KKZBLJO[0V/2IN:6UK;UC8'!H>&1T[//X[-S\
MPN+2\LKJVL[NWO[!X='QR>DY+C0  ^W[\TM<)"A<Z)B8&)@XY[C0T#W/)Y!@
M8EWCP2:54L>Y[WR)GC< ETPZ*KWD(QX#G\8VN:E+/_YE1O[9ZSOGT+XA^_>
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M';#-'_="O#5!_Y]M:[^_M^H6XS,2.^:;?$,X\M'7R%+#SN4I#S7?2MJ'P&L
M(/0[?9'C@<U42V88]VV6.A!^7(H^GD-VUG+4;Q^/U!B#V"2R#>O\>-Z8&NF!
MM?WZV9ZMJ<>7"],3RC0@2^A)>CF"E=TO(QI]@W@[Y]9XH/5V*U&77<ZGA/"
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MN\_#E-7F[UN$CM\XR'FC>KZN['/]@$5]?*<:"PU+$,B]A%(W3D>S!9P64P_
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MO_A_2'2-;G8C/W?M5F3L<;_#5[C0Q.UYE%_[8JZ)_ 8L)U]$"P^T:R-6_?'
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M1?[NS:5"0ARUE '.%P_L7/S!4K=B5Y"[!R#J'L%PU^=++YGHA9@W9%92GE
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M[Y5X2*287J6KK@Z((C5_LYJV=Q)BLMVX(I5L-$R) 7[II_E4MXF!X.)?MS"
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MPX'LPWU1::@(R*R3.;X^^VY&E;^G?,@N7K+@0Z#$N2/E/YFI\J./FD1+66
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M/W]GO"W]0O''^N@_M3CJ2?^G"]X_9);O/1^6O6YNY;#8%BM+ZQISG ^R"KZ
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MZOJH[3K#79J3BXU#L\_ZGT]Q4 JCF!/90L;55M<I-4+V^2LN/1R72ZW3MM&
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M?$)!,M>HD]& #=G%8M2I/BFFD,1" [YZ:>%(L0+['P2#;L%#*2QQHE;N-+,
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M8GQCZ>T,==SI8G('2BY+'#>?:V.\Y#MW@)+9"06UK()D,-YH57%>2*-0?Z?
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MQH&]TLLTN!*>9&O"&&.]9_MF1U9MF UZ$/5JF70?QC8,!SQ=9@FT.7?<;D6
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M3QX19T8)[U]Q 3WQOP!02P$"% ,4    " !1AFY;7Y,ACAT,  "C:   $0
M            @ $     871N;2TR,#(U,#DS,"YX<V102P$"% ,4    " !1
MAFY;EGUDY-()  ")90  %0              @ %,#   871N;2TR,#(U,#DS
M,%]C86PN>&UL4$L! A0#%     @ 489N6[4D*+XQ(@  N2<" !4
M     ( !418  &%T;FTM,C R-3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( %&&
M;EL !-I]L5<  '^O!  5              "  ;4X  !A=&YM+3(P,C4P.3,P
M7VQA8BYX;6Q02P$"% ,4    " !1AFY;OB19S.HD  "2:P( %0
M    @ &9D   871N;2TR,#(U,#DS,%]P<F4N>&UL4$L! A0#%     @ 489N
M6^>P L3. P( Y7\. !H              ( !MK4  &5A,#(V,C T-RTQ,'%?
M86-T:6YI=6TN:'1M4$L! A0#%     @ 489N6W.FN6N#!P  )B<  !X
M         ( !O+D" &5A,#(V,C T-S Q97@S,2TQ7V%C=&EN:75M+FAT;5!+
M 0(4 Q0    ( %&&;EN2C/ *5 <  )(F   >              "  7O! @!E
M83 R-C(P-#<P,65X,S$M,E]A8W1I;FEU;2YH=&U02P$"% ,4    " !1AFY;
M[3NV9!$$   8#P  '@              @ $+R0( 96$P,C8R,#0W,#%E>#,R
M+3%?86-T:6YI=6TN:'1M4$L! A0#%     @ 489N6];,GAL !   Y0X  !X
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M P!I;6%G95\P,#(N:G!G4$L! A0#%     @ 489N6X7YCV\D8   @W,   T
M             ( !J-\$ &EM86=E7S P,RYJ<&=02P$"% ,4    " !1AFY;
M8IWK!B8V   Z.   #0              @ 'W/P4 :6UA9V5?,# T+FIP9U!+
M 0(4 Q0    ( %&&;EM%%QF]""T  ,HO   -              "  4AV!0!I
M;6%G95\P,#4N:G!G4$L! A0#%     @ 489N6XQ_?X051   H48   T
M         ( !>Z,% &EM86=E7S P-BYJ<&=02P$"% ,4    " !1AFY;+KD6
MO0 Y   A/@  #0              @ &[YP4 :6UA9V5?,# W+FIP9U!+ 0(4
M Q0    ( %&&;ENWK*9_Q#4  *4X   -              "  >8@!@!I;6%G
M95\P,#@N:G!G4$L! A0#%     @ 489N6Y(/E-B?-@  03D   T
M     ( !U58& &EM86=E7S P.2YJ<&=02P$"% ,4    " !1AFY;!ZY=@$TO
M  "#,@  #0              @ &?C08 :6UA9V5?,#$P+FIP9U!+ 0(4 Q0
M   ( %&&;EMOFR#%7$0  'U3   -              "  1>]!@!I;6%G95\P
M,3$N:G!G4$L! A0#%     @ 489N6X?X4GN'*0  WBH   T
M ( !G@$' &EM86=E7S Q,BYJ<&=02P$"% ,4    " !1AFY;DB!#OX X  !Z
M00  #0              @ %0*P< :6UA9V5?,#$S+FIP9U!+ 0(4 Q0    (
M %&&;EN&?G8U?2$  * L   -              "  ?MC!P!I;6%G95\P,30N
M:G!G4$L! A0#%     @ 489N6WK1B%5X(   RB@   T              ( !
MHX4' &EM86=E7S Q-2YJ<&=02P$"% ,4    " !1AFY;6"CV)/,F  !]+
M#0              @ %&I@< :6UA9V5?,#$V+FIP9U!+ 0(4 Q0    ( %&&
M;EM$J>&]\B   #LG   -              "  63-!P!I;6%G95\P,3<N:G!G
64$L%!@     < !P ^@8  ('N!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>ea0262047-10q_actinium_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnm="http://www.actiniumpharma.com/20250930"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnm-20250930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:GrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:GrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:GrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:GrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:VestedUnissuedSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atnm:VestedUnissuedSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2012-06-15</startDate>
            <endDate>2012-06-15</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">atnm:OperatingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">atnm:FinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-8932">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0" id="ixv-8933">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-8934">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-8935">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-8936">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-57">001-36374</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-63">ACTINIUM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-73">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-78">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-96">100 Park Ave., 23rd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-8937">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-8938">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-103">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-8939">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-8940">677-3870</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-142">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-147">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-152">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-8941">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-8942">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-182">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-189">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-8943">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0" id="ixv-8944">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-8945"
      unitRef="shares">31195891</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-8946" unitRef="usd">53391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-8947" unitRef="usd">72904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-8948" unitRef="usd">975000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-8949" unitRef="usd">1602000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-8950" unitRef="usd">54366000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-8951" unitRef="usd">74506000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-8952" unitRef="usd">1030000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-8953" unitRef="usd">891000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-8954" unitRef="usd">226000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-8955" unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" id="ixv-8956" unitRef="usd">332000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" id="ixv-8957" unitRef="usd">324000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-8958" unitRef="usd">1215000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-8959" unitRef="usd">1685000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-8960" unitRef="usd">12000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-8961" unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-8962" unitRef="usd">56151000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-8963" unitRef="usd">76899000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-8964" unitRef="usd">6224000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-8965" unitRef="usd">7568000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-8966" unitRef="usd">599000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-8967" unitRef="usd">569000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-8968" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-8969" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-8970" unitRef="usd">6834000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-8971" unitRef="usd">8148000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-8972" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-8973" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-8974" unitRef="usd">531000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-8975" unitRef="usd">984000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-8976" unitRef="usd">2000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-8977" unitRef="usd">9000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-8978" unitRef="usd">42367000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-8979" unitRef="usd">44141000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-8980"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-8981"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-8982" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-8983" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="0" id="ixv-8984" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" id="ixv-8985" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-8986" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-8987" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-8988"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-8989"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-8990" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-8991" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" id="ixv-8992" unitRef="shares">31195891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-8993" unitRef="shares">31195891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" id="ixv-8994" unitRef="shares">31195891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-8995" unitRef="shares">31195891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-8996" unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-8997" unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-8998" unitRef="usd">417526000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-8999" unitRef="usd">408553000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-9000" unitRef="usd">-403773000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-9001" unitRef="usd">-375826000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-9002" unitRef="usd">13784000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-9003" unitRef="usd">32758000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-9004" unitRef="usd">56151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-9005" unitRef="usd">76899000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c8" decimals="-3" id="ixv-9006" unitRef="usd">90000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c10" decimals="-3" id="ixv-9007" unitRef="usd">90000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c12" decimals="-3" id="ixv-9008" unitRef="usd">90000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-9009" unitRef="usd">90000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c12" decimals="-3" id="ixv-9010" unitRef="usd">4248000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c13" decimals="-3" id="ixv-9011" unitRef="usd">9774000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-9012" unitRef="usd">16827000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c14" decimals="-3" id="ixv-9013" unitRef="usd">25234000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c12" decimals="-3" id="ixv-9014" unitRef="usd">1534000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c13" decimals="-3" id="ixv-9015" unitRef="usd">2827000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-9016" unitRef="usd">13096000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c14" decimals="-3" id="ixv-9017" unitRef="usd">9382000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c12" decimals="-3" id="ixv-9018" unitRef="usd">5782000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c13" decimals="-3" id="ixv-9019" unitRef="usd">12601000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-9020" unitRef="usd">29923000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c14" decimals="-3" id="ixv-9021" unitRef="usd">34616000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c12" decimals="-3" id="ixv-9022" unitRef="usd">-5692000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c13" decimals="-3" id="ixv-9023" unitRef="usd">-12601000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-9024" unitRef="usd">-29833000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c14" decimals="-3" id="ixv-9025" unitRef="usd">-34616000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c12" decimals="-3" id="ixv-9026" unitRef="usd">561000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c13" decimals="-3" id="ixv-9027" unitRef="usd">1033000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-9028" unitRef="usd">1886000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c14" decimals="-3" id="ixv-9029" unitRef="usd">3025000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c12" decimals="-3" id="ixv-9030" unitRef="usd">561000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c13" decimals="-3" id="ixv-9031" unitRef="usd">1033000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-9032" unitRef="usd">1886000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c14" decimals="-3" id="ixv-9033" unitRef="usd">3025000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" id="ixv-9034" unitRef="usd">-5131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-9035" unitRef="usd">-11568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-9036" unitRef="usd">-27947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" id="ixv-9037" unitRef="usd">-31591000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c12"
      decimals="2"
      id="ixv-9038"
      unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c12"
      decimals="2"
      id="ixv-9039"
      unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c13"
      decimals="2"
      id="ixv-9040"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c13"
      decimals="2"
      id="ixv-9041"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-9042"
      unitRef="usdPershares">-0.9</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-9043"
      unitRef="usdPershares">-0.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c14"
      decimals="2"
      id="ixv-9044"
      unitRef="usdPershares">-1.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c14"
      decimals="2"
      id="ixv-9045"
      unitRef="usdPershares">-1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c12"
      decimals="0"
      id="ixv-9046"
      unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c12"
      decimals="0"
      id="ixv-9047"
      unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c13"
      decimals="0"
      id="ixv-9048"
      unitRef="shares">31071297</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c13"
      decimals="0"
      id="ixv-9049"
      unitRef="shares">31071297</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="0" id="ixv-9050" unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" id="ixv-9051" unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c14"
      decimals="0"
      id="ixv-9052"
      unitRef="shares">29692001</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c14"
      decimals="0"
      id="ixv-9053"
      unitRef="shares">29692001</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c15"
      decimals="0"
      id="ixv-9054"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-9055" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-9056" unitRef="usd">408553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-9057" unitRef="usd">-375826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-9058" unitRef="usd">32758000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c19" decimals="-3" id="ixv-9059" unitRef="usd">8874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c21" decimals="-3" id="ixv-9060" unitRef="usd">8874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c20" decimals="-3" id="ixv-9061" unitRef="usd">-15938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c21" decimals="-3" id="ixv-9062" unitRef="usd">-15938000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c22"
      decimals="0"
      id="ixv-9063"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-9064" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" id="ixv-9065" unitRef="usd">417427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" id="ixv-9066" unitRef="usd">-391764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-9067" unitRef="usd">25694000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c27" decimals="-3" id="ixv-9068" unitRef="usd">197000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c29" decimals="-3" id="ixv-9069" unitRef="usd">197000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c28" decimals="-3" id="ixv-9070" unitRef="usd">-6878000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c29" decimals="-3" id="ixv-9071" unitRef="usd">-6878000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c30"
      decimals="0"
      id="ixv-9072"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="-3" id="ixv-9073" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="-3" id="ixv-9074" unitRef="usd">417624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" id="ixv-9075" unitRef="usd">-398642000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" id="ixv-9076" unitRef="usd">19013000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c35" decimals="-3" id="ixv-9077" unitRef="usd">109000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c12" decimals="-3" id="ixv-9078" unitRef="usd">109000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c35" decimals="-3" id="ixv-9079" unitRef="usd">207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c12" decimals="-3" id="ixv-9080" unitRef="usd">207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c36" decimals="-3" id="ixv-9081" unitRef="usd">-5131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" id="ixv-9082" unitRef="usd">-5131000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c37"
      decimals="0"
      id="ixv-9083"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c37" decimals="-3" id="ixv-9084" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="-3" id="ixv-9085" unitRef="usd">417526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="-3" id="ixv-9086" unitRef="usd">-403773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-9087" unitRef="usd">13784000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c40"
      decimals="0"
      id="ixv-9088"
      unitRef="shares">27634213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" id="ixv-9089" unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" id="ixv-9090" unitRef="usd">373934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" id="ixv-9091" unitRef="usd">-337583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" id="ixv-9092" unitRef="usd">36379000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c45" decimals="-3" id="ixv-9093" unitRef="usd">1378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c47" decimals="-3" id="ixv-9094" unitRef="usd">1378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c44"
      decimals="0"
      id="ixv-9095"
      unitRef="shares">1752050</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c44" decimals="-3" id="ixv-9096" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c45" decimals="-3" id="ixv-9097" unitRef="usd">14694000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c47" decimals="-3" id="ixv-9098" unitRef="usd">14695000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c44"
      decimals="0"
      id="ixv-9099"
      unitRef="shares">10148</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c45" decimals="-3" id="ixv-9100" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c47" decimals="-3" id="ixv-9101" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c46" decimals="-3" id="ixv-9102" unitRef="usd">-8670000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c47" decimals="-3" id="ixv-9103" unitRef="usd">-8670000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c48"
      decimals="0"
      id="ixv-9104"
      unitRef="shares">29396411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c48" decimals="-3" id="ixv-9105" unitRef="usd">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-9106" unitRef="usd">390081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-9107" unitRef="usd">-346253000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-9108" unitRef="usd">43857000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c53" decimals="-3" id="ixv-9109" unitRef="usd">1374000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c55" decimals="-3" id="ixv-9110" unitRef="usd">1374000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c52"
      decimals="0"
      id="ixv-9111"
      unitRef="shares">1154191</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c52" decimals="-3" id="ixv-9112" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c53" decimals="-3" id="ixv-9113" unitRef="usd">9955000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c55" decimals="-3" id="ixv-9114" unitRef="usd">9957000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c54" decimals="-3" id="ixv-9115" unitRef="usd">-11353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c55" decimals="-3" id="ixv-9116" unitRef="usd">-11353000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c56"
      decimals="0"
      id="ixv-9117"
      unitRef="shares">30550602</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c56" decimals="-3" id="ixv-9118" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c57" decimals="-3" id="ixv-9119" unitRef="usd">401410000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c58" decimals="-3" id="ixv-9120" unitRef="usd">-357606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c59" decimals="-3" id="ixv-9121" unitRef="usd">43835000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c60"
      decimals="0"
      id="ixv-9122"
      unitRef="shares">13394</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c61" decimals="-3" id="ixv-9123" unitRef="usd">1337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c13" decimals="-3" id="ixv-9124" unitRef="usd">1337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c60"
      decimals="0"
      id="ixv-9125"
      unitRef="shares">631895</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c61" decimals="-3" id="ixv-9126" unitRef="usd">4604000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c13" decimals="-3" id="ixv-9127" unitRef="usd">4604000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c62" decimals="-3" id="ixv-9128" unitRef="usd">-11568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-9129" unitRef="usd">-11568000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c63"
      decimals="0"
      id="ixv-9130"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c63" decimals="-3" id="ixv-9131" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c64" decimals="-3" id="ixv-9132" unitRef="usd">407351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c65" decimals="-3" id="ixv-9133" unitRef="usd">-369174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c66" decimals="-3" id="ixv-9134" unitRef="usd">38208000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-9135" unitRef="usd">-27947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" id="ixv-9136" unitRef="usd">-31591000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-9137" unitRef="usd">9180000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c14" decimals="-3" id="ixv-9138" unitRef="usd">4089000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="-3" id="ixv-9139" unitRef="usd">615000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c14" decimals="-3" id="ixv-9140" unitRef="usd">607000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-9141" unitRef="usd">-627000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c14" decimals="-3" id="ixv-9142" unitRef="usd">-726000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-9143" unitRef="usd">-1343000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c14" decimals="-3" id="ixv-9144" unitRef="usd">-758000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-9145" unitRef="usd">-423000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c14" decimals="-3" id="ixv-9146" unitRef="usd">-394000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-9147" unitRef="usd">-19291000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c14" decimals="-3" id="ixv-9148" unitRef="usd">-27321000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c14" decimals="-3" id="ixv-9149" unitRef="usd">11000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c14" decimals="-3" id="ixv-9150" unitRef="usd">-11000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" id="ixv-9151" unitRef="usd">7000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c14" decimals="-3" id="ixv-9152" unitRef="usd">7000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c14" decimals="-3" id="ixv-9153" unitRef="usd">29256000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-9154" unitRef="usd">207000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c14" decimals="-3" id="ixv-9155" unitRef="usd">75000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-9156" unitRef="usd">-214000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c14" decimals="-3" id="ixv-9157" unitRef="usd">29324000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-9158" unitRef="usd">-19505000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c14" decimals="-3" id="ixv-9159" unitRef="usd">1992000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-9160" unitRef="usd">73228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c43" decimals="-3" id="ixv-9161" unitRef="usd">76990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-9162" unitRef="usd">53723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c66" decimals="-3" id="ixv-9163" unitRef="usd">78982000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-2435">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1 - Description of Business and Summary
of Significant Accounting Policies&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;
- Actinium Pharmaceuticals, Inc. is a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve
outcomes for patients with advanced cancers. The Company is focused on developing highly innovative, first-in-class product candidates.
To support its objective of achieving industry leading, cost-effective product development to maximize value creation from its innovative
pipeline, the Company is working to expand the scope of its capabilities to include radioisotope production of Ac-225 via collaborations
for its Ac-225 technology and in-house manufacturing of pipeline candidates to support clinical trials. The Company is deploying its technologies,
capabilities and intellectual property with approximately 250 issued and pending patents worldwide, to develop next-generation radiotherapies
focused on solid tumors, hematology and conditioning for cellular therapies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Segment Information - &lt;/b&gt;The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#x2019;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at September 30, 2025 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;53,723&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease of corporate office
space.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers
&lt;/i&gt;(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements
&lt;/b&gt;- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt; There was no revenue from collaborative arrangements for the nine months ended September 30, 2025 and
September 30, 2024, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue&lt;/b&gt; &lt;i&gt;&#x2013;
&lt;/i&gt;The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;b&gt;&#160;&lt;/b&gt;Grant
revenue for the three and nine months ended September 30, 2025 was $0.1 million. There was &lt;span style="-sec-ix-hidden: hidden-fact-55"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-56"&gt;no&lt;/span&gt;&lt;/span&gt; grant revenue recognized for the three and
nine months ended September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional. There was no license revenue for the three and nine months ended September
30, 2025 and September 30, 2024.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -
&lt;/b&gt;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share
&lt;/b&gt;- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
September 30, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted
stock units, vested unissued shares of common stock and warrants, have not been included in the computation of diluted net loss per share
as the result would have been anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt;
2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Vested unissued shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;348&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board, (the &#x201c;FASB&#x201d;), issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements
to Income Tax Disclosures&lt;/i&gt;, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09
provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures.
The Company is required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount
computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required to disclose income
taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). &lt;span style="background-color: white"&gt;The
amendments in ASU 2023-09 are effective January 1, 2025. The Company adopted this standard effective January 1, 2025 and will report on
it in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company will update all required disclosures
pursuant to ASU 2023-09 at that time.&lt;/span&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In July 2025, the One Big
Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension
of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable
tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025
and others expected to be implemented through 2027. The Company has evaluated the impact of the OBBBA and determined that it does not
have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2025, the FASB
issued ASU 2025-07, &lt;i&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements
and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract&lt;/i&gt;, which excludes from derivative
accounting non-exchange-traded contracts with underlying terms that are based on operations or activities specific to one of the parties
to the contract. However, this scope exception does not apply to (1) variables based on a market rate, market price, or market index,
(2) variables based on the price or performance of a financial asset or financial liability of one of the parties to the contract, (3)
contracts (or features) involving the issuer&#x2019;s own equity that are evaluated under the guidance in Subtopic 815-40, &lt;i&gt;Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity,&lt;/i&gt; and (4) call options and put options on debt instruments. The Company can
apply the amendments in AUS 2025-07 either (1) prospectively to new contracts entered into on or after the date of adoption or (2) on
a modified retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning
of the annual reporting period of adoption for contracts existing as of the beginning of the annual reporting period of adoption. The
amendments in ASU 2025-07 are effective January 1, 2027, for annual for annual reporting periods, including interim periods within annual
reporting periods. Early adoption is permitted. The Company is evaluating the impact of ASU 2025-07 on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2025, the FASB
issued ASU 2025-06, &lt;i&gt;Intangibles&#x2014;Goodwill and Other&#x2014; Internal-Use Software&lt;/i&gt; (Subtopic 350-40): Targeted Improvements
to the Accounting for Internal-Use Software, which modernizes the accounting for software costs that are accounted for under Subtopic
350-40. The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages (referred to as
&#x201c;project stages&#x201d;) throughout Subtopic 350-40. Therefore, an entity is required to start capitalizing software costs when both
of the following occur: (a) the Company has authorized and committed to funding the software project and (b) it is probable that the project
will be completed and the software will be used to perform the function intended (referred to as the &#x201c;probable-to-complete recognition
threshold&#x201d;). In evaluating the probable-to-complete recognition threshold, the Company is required to consider whether there is
significant uncertainty associated with the development activities of the software, such as determining whether (a) the software being
developed has technological innovations or novel, unique, or unproven functions or features, and the uncertainty related to those technological
innovations, functions, or features, if identified, has not been resolved through coding and testing and (b) the Company has determined
what it needs the software to do (for example, functions or features), including whether the entity has identified or continues to substantially
revise the software&#x2019;s significant performance requirements. ASU 2025-06 specifies that disclosures in Subtopic 360- 10, &lt;i&gt;Property,
Plant, and Equipment&#x2014;Overall&lt;/i&gt;, are required for all capitalized internal-use software costs, regardless of how those costs are
presented in the financial statements and removes the requirement to disclose internal-use software information pursuant to paragraphs
350-30-50-1 through 50-3. ASU 2025-06 supersedes the website development costs guidance and incorporates the recognition requirements
for website-specific development costs from Subtopic 350-50, &lt;i&gt;Website Development Costs&lt;/i&gt;, into Subtopic 350-40. The amendments in
ASU 2025-06 permit an entity to apply the new guidance using either (i) a prospective transition approach, (ii) a modified transition
approach that is based on the status of the project and whether software costs were capitalized before the date of adoption, or (iii)
a retrospective transition approach. The amendments in ASU 2025-06 are effective January 1, 2028 for annual reporting periods, including
interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The Company
is evaluating the impact of ASU 2025-06 on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In July 2025, the FASB
issued ASU 2025-05, &lt;i&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets&lt;/i&gt;, which permits a practical expedient whereby, when assessing credit losses on current accounts receivable
and current contract assets, the Company would assume that current conditions as of the balance sheet date do not change for the
remaining life of the asset and would not require the Company to consider adjustments to forecasts to also include anticipated
changes in the future to the underlying conditions as of the balance sheet date when measuring the credit losses for current
accounts receivable and current contract assets. The amendments in ASU 2025-05 are effective January 1, 2026 for annual reporting
periods, including interim periods within annual reporting periods and is required to be applied on a perspective basis. Early adoption is permitted in both interim and annual
reporting periods in which financial statements have not yet been issued or made available for issuance. The impact of ASU 2025-04
is not expected to be material to the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2025, FASB issued ASU
2025-04, &lt;i&gt;Compensation&#x2014;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer&lt;/i&gt;, which revises the Master Glossary definition of the term &#x201c;performance condition&#x201d;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#x2019;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#x2019;s goods or services from the grantor&#x2019;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#x2019;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#x2019;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2025-04 are effective January 1, 2027 for annual reporting periods,
including interim periods within annual reporting periods. The Company is evaluating the impact of ASU 2025-04 on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2024, FASB issued
ASU 2024-03,&#160;&lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/i&gt;&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028, either on a prospective or retrospective basis. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <atnm:NatureOfBusinessPolicyPolicyTextBlock contextRef="c0" id="ixv-2439">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;
- Actinium Pharmaceuticals, Inc. is a pioneer in the development of differentiated, targeted radiotherapies intended to meaningfully improve
outcomes for patients with advanced cancers. The Company is focused on developing highly innovative, first-in-class product candidates.
To support its objective of achieving industry leading, cost-effective product development to maximize value creation from its innovative
pipeline, the Company is working to expand the scope of its capabilities to include radioisotope production of Ac-225 via collaborations
for its Ac-225 technology and in-house manufacturing of pipeline candidates to support clinical trials. The Company is deploying its technologies,
capabilities and intellectual property with approximately 250 issued and pending patents worldwide, to develop next-generation radiotherapies
focused on solid tumors, hematology and conditioning for cellular therapies.&lt;/p&gt;</atnm:NatureOfBusinessPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-2444">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-2448">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-2452">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-2457">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Segment Information - &lt;/b&gt;The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#x2019;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0" id="ixv-2462">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at September 30, 2025 and December 31, 2024:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;53,723&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease of corporate office
space.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-2466">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at September 30, 2025 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;332&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;53,723&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-9164" unitRef="usd">53391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-9165" unitRef="usd">72904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" id="ixv-9166" unitRef="usd">332000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" id="ixv-9167" unitRef="usd">324000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-9168" unitRef="usd">53723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-9169" unitRef="usd">73228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-2531">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-2535">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-2539">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers
&lt;/i&gt;(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0" id="ixv-2554">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements
&lt;/b&gt;- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt; There was no revenue from collaborative arrangements for the nine months ended September 30, 2025 and
September 30, 2024, respectively.&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c0" id="ixv-2574">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue&lt;/b&gt; &lt;i&gt;&#x2013;
&lt;/i&gt;The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;b&gt;&#160;&lt;/b&gt;Grant
revenue for the three and nine months ended September 30, 2025 was $0.1 million. There was &lt;span style="-sec-ix-hidden: hidden-fact-55"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-56"&gt;no&lt;/span&gt;&lt;/span&gt; grant revenue recognized for the three and
nine months ended September 30, 2024.&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c67" decimals="-5" id="ixv-9170" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c68" decimals="-5" id="ixv-9171" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <atnm:LicenseRevenuePolicyTextBlock contextRef="c0" id="ixv-2582">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional. There was no license revenue for the three and nine months ended September
30, 2025 and September 30, 2024.&lt;/p&gt;</atnm:LicenseRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-2602">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-2607">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -
&lt;/b&gt;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-2626">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share
&lt;/b&gt;- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
September 30, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted
stock units, vested unissued shares of common stock and warrants, have not been included in the computation of diluted net loss per share
as the result would have been anti-dilutive.&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt;
2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Vested unissued shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;348&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-9172">For the three and nine months ended
September 30, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted
stock units, vested unissued shares of common stock and warrants, have not been included in the computation of diluted net loss per share
as the result would have been anti-dilutive.&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt;
2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Vested unissued shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;348&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c71"
      decimals="-3"
      id="ixv-9173"
      unitRef="shares">162000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c72"
      decimals="-3"
      id="ixv-9174"
      unitRef="shares">5216000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c74"
      decimals="-3"
      id="ixv-9175"
      unitRef="shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c75"
      decimals="-3"
      id="ixv-9176"
      unitRef="shares">179000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c77"
      decimals="-3"
      id="ixv-9177"
      unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c78"
      decimals="-3"
      id="ixv-9178"
      unitRef="shares">9000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="-3"
      id="ixv-9179"
      unitRef="shares">348000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c14"
      decimals="-3"
      id="ixv-9180"
      unitRef="shares">5525000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-2696">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board, (the &#x201c;FASB&#x201d;), issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements
to Income Tax Disclosures&lt;/i&gt;, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09
provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures.
The Company is required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount
computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required to disclose income
taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). &lt;span style="background-color: white"&gt;The
amendments in ASU 2023-09 are effective January 1, 2025. The Company adopted this standard effective January 1, 2025 and will report on
it in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company will update all required disclosures
pursuant to ASU 2023-09 at that time.&lt;/span&gt;&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In July 2025, the One Big
Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension
of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable
tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025
and others expected to be implemented through 2027. The Company has evaluated the impact of the OBBBA and determined that it does not
have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="c0" id="ixv-2709">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2025, the FASB
issued ASU 2025-07, &lt;i&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements
and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract&lt;/i&gt;, which excludes from derivative
accounting non-exchange-traded contracts with underlying terms that are based on operations or activities specific to one of the parties
to the contract. However, this scope exception does not apply to (1) variables based on a market rate, market price, or market index,
(2) variables based on the price or performance of a financial asset or financial liability of one of the parties to the contract, (3)
contracts (or features) involving the issuer&#x2019;s own equity that are evaluated under the guidance in Subtopic 815-40, &lt;i&gt;Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity,&lt;/i&gt; and (4) call options and put options on debt instruments. The Company can
apply the amendments in AUS 2025-07 either (1) prospectively to new contracts entered into on or after the date of adoption or (2) on
a modified retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning
of the annual reporting period of adoption for contracts existing as of the beginning of the annual reporting period of adoption. The
amendments in ASU 2025-07 are effective January 1, 2027, for annual for annual reporting periods, including interim periods within annual
reporting periods. Early adoption is permitted. The Company is evaluating the impact of ASU 2025-07 on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2025, the FASB
issued ASU 2025-06, &lt;i&gt;Intangibles&#x2014;Goodwill and Other&#x2014; Internal-Use Software&lt;/i&gt; (Subtopic 350-40): Targeted Improvements
to the Accounting for Internal-Use Software, which modernizes the accounting for software costs that are accounted for under Subtopic
350-40. The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages (referred to as
&#x201c;project stages&#x201d;) throughout Subtopic 350-40. Therefore, an entity is required to start capitalizing software costs when both
of the following occur: (a) the Company has authorized and committed to funding the software project and (b) it is probable that the project
will be completed and the software will be used to perform the function intended (referred to as the &#x201c;probable-to-complete recognition
threshold&#x201d;). In evaluating the probable-to-complete recognition threshold, the Company is required to consider whether there is
significant uncertainty associated with the development activities of the software, such as determining whether (a) the software being
developed has technological innovations or novel, unique, or unproven functions or features, and the uncertainty related to those technological
innovations, functions, or features, if identified, has not been resolved through coding and testing and (b) the Company has determined
what it needs the software to do (for example, functions or features), including whether the entity has identified or continues to substantially
revise the software&#x2019;s significant performance requirements. ASU 2025-06 specifies that disclosures in Subtopic 360- 10, &lt;i&gt;Property,
Plant, and Equipment&#x2014;Overall&lt;/i&gt;, are required for all capitalized internal-use software costs, regardless of how those costs are
presented in the financial statements and removes the requirement to disclose internal-use software information pursuant to paragraphs
350-30-50-1 through 50-3. ASU 2025-06 supersedes the website development costs guidance and incorporates the recognition requirements
for website-specific development costs from Subtopic 350-50, &lt;i&gt;Website Development Costs&lt;/i&gt;, into Subtopic 350-40. The amendments in
ASU 2025-06 permit an entity to apply the new guidance using either (i) a prospective transition approach, (ii) a modified transition
approach that is based on the status of the project and whether software costs were capitalized before the date of adoption, or (iii)
a retrospective transition approach. The amendments in ASU 2025-06 are effective January 1, 2028 for annual reporting periods, including
interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The Company
is evaluating the impact of ASU 2025-06 on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In July 2025, the FASB
issued ASU 2025-05, &lt;i&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable
and Contract Assets&lt;/i&gt;, which permits a practical expedient whereby, when assessing credit losses on current accounts receivable
and current contract assets, the Company would assume that current conditions as of the balance sheet date do not change for the
remaining life of the asset and would not require the Company to consider adjustments to forecasts to also include anticipated
changes in the future to the underlying conditions as of the balance sheet date when measuring the credit losses for current
accounts receivable and current contract assets. The amendments in ASU 2025-05 are effective January 1, 2026 for annual reporting
periods, including interim periods within annual reporting periods and is required to be applied on a perspective basis. Early adoption is permitted in both interim and annual
reporting periods in which financial statements have not yet been issued or made available for issuance. The impact of ASU 2025-04
is not expected to be material to the financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2025, FASB issued ASU
2025-04, &lt;i&gt;Compensation&#x2014;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer&lt;/i&gt;, which revises the Master Glossary definition of the term &#x201c;performance condition&#x201d;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#x2019;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#x2019;s goods or services from the grantor&#x2019;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#x2019;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#x2019;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2025-04 are effective January 1, 2027 for annual reporting periods,
including interim periods within annual reporting periods. The Company is evaluating the impact of ASU 2025-04 on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2024, FASB issued
ASU 2024-03,&#160;&lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/i&gt;&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028, either on a prospective or retrospective basis. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.&lt;/p&gt;</atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-2766">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On March 27, 2025, a putative class action complaint (the &#x201c;Securities
Complaint&#x201d;) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#x201c;Defendants&#x201d;), styled&#160;&lt;i&gt;Kohil v. Actinium Pharmaceuticals, Inc., et al&lt;/i&gt;., Case
No. 1:25-cv-02553 in the United States District Court for the Southern District of New York. The Securities Complaint alleges that the
Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims
against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the &#x201c;Exchange Act&#x201d;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint
purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities
between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&#160; On June 24, 2025, the court in the
securities action appointed lead plaintiffs who filed an amended Securities Complaint on August 25, 2025. Defendants moved to dismiss
the amended Securities Complaint on October 24, 2025. Lead plaintiffs&#x2019; opposition is due in late December 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On May 5, 2025, a derivative shareholder complaint (the &#x201c;&lt;i&gt;Georges&lt;/i&gt;
Complaint&#x201d;) was filed against the Company and certain of the Company&#x2019;s directors and officers alleging derivative liability
for the allegations made in the Securities Complaint.&#160; On May 13, 2025, a second derivative shareholder complaint (the &#x201c;&lt;i&gt;Robinson
&lt;/i&gt;Complaint&#x201d; and, together with the &lt;i&gt;Georges &lt;/i&gt;Complaint, the &#x201c;Derivative Complaints&#x201d;) was filed against the Company
and certain of the Company&#x2019;s directors also alleging derivative liability for the allegations made in the Securities Complaint.
On June 24, 2025, the Court consolidated the Derivative Complaints (the &#x201c;Derivative Action&#x201d;). On July 29, 2025, the parties
to the Derivative Action filed a stipulation with the Court to stay the Derivative Action pending resolution of any motion to dismiss
the Securities Complaint. The Court entered the stipulation on July 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
Company and other Defendants intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:MilestonePayment contextRef="c79" decimals="-6" id="ixv-9181" unitRef="usd">1000000</atnm:MilestonePayment>
    <atnm:NetSalesPercentage contextRef="c79" decimals="2" id="ixv-9182" unitRef="pure">0.02</atnm:NetSalesPercentage>
    <atnm:LeasesTextBlock contextRef="c0" id="ixv-2784">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 3 - Leases &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#x2019;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The lease term for all of
the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At September 30, 2025, the
Company has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment.
The Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of 5 years 2 months, with an
expiration date of July 30, 2027 and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such
as insurance, utilities and maintenance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;519&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;519&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Supplemental cash flow information related to leases
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;471&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;462&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#x2019;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands) &lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2025 (excluding nine months ended September 30, 2025)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,130&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:LeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c0" id="ixv-9183">5 years 2 months</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseExpirationDate1 contextRef="c0" id="ixv-9184">2027-07-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-5" id="ixv-9185" unitRef="usd">600000</us-gaap:PaymentsForRent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-2811">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;519&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;519&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nine months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;471&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;462&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c12" decimals="-3" id="ixv-9186" unitRef="usd">173000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c13" decimals="-3" id="ixv-9187" unitRef="usd">173000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-9188" unitRef="usd">519000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c14" decimals="-3" id="ixv-9189" unitRef="usd">519000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c12" decimals="-3" id="ixv-9190" unitRef="usd">2000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c13" decimals="-3" id="ixv-9191" unitRef="usd">3000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" id="ixv-9192" unitRef="usd">7000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c14" decimals="-3" id="ixv-9193" unitRef="usd">8000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" id="ixv-9194" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c14" decimals="-3" id="ixv-9195" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c12" decimals="-3" id="ixv-9196" unitRef="usd">2000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c13" decimals="-3" id="ixv-9197" unitRef="usd">3000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" id="ixv-9198" unitRef="usd">8000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c14" decimals="-3" id="ixv-9199" unitRef="usd">9000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-9200" unitRef="usd">471000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c14" decimals="-3" id="ixv-9201" unitRef="usd">462000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c0" decimals="-3" id="ixv-9202" unitRef="usd">8000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c14" decimals="-3" id="ixv-9203" unitRef="usd">8000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" id="ixv-9204" unitRef="usd">7000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c14" decimals="-3" id="ixv-9205" unitRef="usd">7000</us-gaap:FinanceLeasePrincipalPayments>
    <atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock contextRef="c0" id="ixv-3077">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-9206">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-9207">P1Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-9209" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-9210" unitRef="pure">0.062</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <atnm:LesseeLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-3138">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands) &lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2025 (excluding nine months ended September 30, 2025)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(52&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 9pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,130&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:LesseeLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c80" decimals="-3" id="ixv-9211" unitRef="usd">159000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c81" decimals="-3" id="ixv-9212" unitRef="usd">3000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c80" decimals="-3" id="ixv-9213" unitRef="usd">643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c81" decimals="-3" id="ixv-9214" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c80" decimals="-3" id="ixv-9215" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c80" decimals="-3" id="ixv-9216" unitRef="usd">1182000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c81" decimals="-3" id="ixv-9217" unitRef="usd">14000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c80" decimals="-3" id="ixv-9218" unitRef="usd">52000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c81" decimals="-3" id="ixv-9219" unitRef="usd">1000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c80" decimals="-3" id="ixv-9220" unitRef="usd">1130000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c81" decimals="-3" id="ixv-9221" unitRef="usd">13000</us-gaap:FinanceLeaseLiability>
    <atnm:OtherRevenueTextBlock contextRef="c0" id="ixv-3218">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 4 - Other revenue &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Grant revenue recognized
for the nine months ended September 30, 2025 was $0.1 million. There was no grant revenue recognized for the nine months ended September
30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 7, 2022, the Company
entered into a license and supply agreement (the &#x201c;License Agreement&#x201d;) with Immedica Pharma AB (&#x201c;Immedica&#x201d;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#x201c;EUMENA&#x201d;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s contract
liabilities are recorded within Other revenue deferred &#x2013; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#x2019;s contract liabilities consist of advanced payments from licensees. Long-term license revenue deferred was $35 million at
September 30, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#x2019;s regulatory approval of
Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.&lt;/p&gt;</atnm:OtherRevenueTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c68" decimals="-5" id="ixv-9222" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <atnm:NonRefundablePaymentReceived contextRef="c82" decimals="-6" id="ixv-9223" unitRef="usd">35000000</atnm:NonRefundablePaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c2" decimals="-6" id="ixv-9224" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-6" id="ixv-9225" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-3230">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5 - Equity&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the Company entered into the Capital on Demand&#x2122;
Sales Agreement with JonesTrading Institutional Services LLC, &#x201c;JonesTrading&#x201d;, pursuant to which the Company may sell, from
time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. On June 28, 2022, the Company entered
into an Amended and Restated Capital on Demand&#x2122; Sales Agreement (the &#x201c;A&amp;amp;R Sales Agreement&#x201d;) with JonesTrading and
B. Riley Securities, Inc. (&#x201c;B. Riley&#x201d;). The A&amp;amp;R Sales Agreement modifies the original Capital on Demand&#x2122; Sales Agreement
to include B. Riley Securities as an additional sales agent thereunder. Shares of common stock are offered pursuant to a shelf registration
statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the &#x201c;Prior Shelf Registration Statement&#x201d;).
On August 11, 2023, the Company filed a new registration statement on Form S-3 (File No. 333-273911), which registration statement was
amended on February 2, 2024, and declared effective on February 5, 2024, to replace the Prior Shelf Registration Statement, including
a base prospectus which covers the offering, issuance and sale of up to $500 million of common stock, preferred stock, warrants, units
and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum aggregate offering
price of $200 million of common stock that may be issued and sold under the Amended Sales Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company did not sell any
shares of common stock during the nine months ended September 30, 2025. During the nine months ended September 30, 2024, the Company sold
3.5 million shares of common stock, resulting in gross proceeds of $29.9 million and net proceeds of $29.3 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of stock option activity for the nine months ended September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;7.17&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;3.40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercisable, September 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the nine months ended
September 30, 2025, the Company granted newly hired employees options to purchase 36 thousand shares of common stock with an exercise
price ranging from $1.06 to $1.55 per share, a term of 10 years, and a vesting period of 4 years. The stock options had an aggregated
fair value of $41 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 4.0% to 4.5% (2) expected life of 6 years, (3) expected volatility range from 90.1% to 90.7%,
and (4) &lt;span style="-sec-ix-hidden: hidden-fact-81"&gt;zero&lt;/span&gt; expected dividends. During the nine months ended September 30, 2024, the Company granted options to purchase 104 thousand
shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 31, 2025, the Board
of Directors approved of the cancellation of stock options to purchase an aggregate of 4.9 million shares of common stock held by certain
current employees and directors that were initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated
Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options, which the Company received.
The cancellation of these stock options resulted in the recording of $8.8 million in stock option compensation expense for the nine months
ended September 30, 2025. During the nine months ended September 30, 2024, the Company recorded stock option compensation expense of $3.6
million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30,
2025 was $0.1 million related to unvested stock options, which is expected to be expensed over a weighted average of 2.4 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of restricted stock unit (&#x201c;RSU&#x201d;) activity for the nine months ended September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The RSUs vested on August
18, 2025. The fair value of the RSUs, $1.8 million, was determined based on the stock price on the dates of the grant and was recognized
over three years. During the nine months ended September 30, 2025 and 2024, the Company recorded compensation expense related to RSUs
of $0.4 million and $0.4 million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activity for the nine months ended September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;3.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;3.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c83" decimals="-6" id="ixv-9226" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c84" decimals="-6" id="ixv-9227" unitRef="usd">500000000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c84" decimals="-6" id="ixv-9228" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c85"
      decimals="-5"
      id="ixv-9229"
      unitRef="shares">3500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c85" decimals="-5" id="ixv-9230" unitRef="usd">29900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <atnm:NetProceedFromIssuanceOfCommonStock contextRef="c85" decimals="-5" id="ixv-9231" unitRef="usd">29300000</atnm:NetProceedFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-3256">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of stock option activity for the nine months ended September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;7.17&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;3.40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercisable, September 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c96"
      decimals="-3"
      id="ixv-9232"
      unitRef="shares">5137000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c96"
      decimals="2"
      id="ixv-9233"
      unitRef="usdPershares">6.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c97" id="ixv-9234">P7Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="-3"
      id="ixv-9235"
      unitRef="shares">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-9236"
      unitRef="usdPershares">1.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c0"
      decimals="-3"
      id="ixv-9237"
      unitRef="shares">5012000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-9238"
      unitRef="usdPershares">6.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c2"
      decimals="-3"
      id="ixv-9239"
      unitRef="shares">161000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-9240"
      unitRef="usdPershares">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-9241">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c2" decimals="-3" id="ixv-9242" unitRef="usd">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c2"
      decimals="-3"
      id="ixv-9243"
      unitRef="shares">134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-9244"
      unitRef="usdPershares">7.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-9245">P2Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c86"
      decimals="-3"
      id="ixv-9246"
      unitRef="shares">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="c86"
      decimals="2"
      id="ixv-9247"
      unitRef="usdPershares">1.06</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c86"
      decimals="2"
      id="ixv-9248"
      unitRef="usdPershares">1.55</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="c87" id="ixv-9249">10 years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c0" id="ixv-9250">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EquityFairValueDisclosure contextRef="c2" decimals="-3" id="ixv-9251" unitRef="usd">41000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c88" decimals="3" id="ixv-9252" unitRef="pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c89" decimals="3" id="ixv-9253" unitRef="pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-9254">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c0" decimals="3" id="ixv-9255" unitRef="pure">0.901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c0" decimals="3" id="ixv-9256" unitRef="pure">0.907</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c14"
      decimals="0"
      id="ixv-9257"
      unitRef="shares">104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c90"
      decimals="-5"
      id="ixv-9258"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c87" decimals="-5" id="ixv-9259" unitRef="usd">8800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c91" decimals="-5" id="ixv-9260" unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c92" decimals="-5" id="ixv-9261" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c87" id="ixv-9262">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-3439">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of restricted stock unit (&#x201c;RSU&#x201d;) activity for the nine months ended September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c98"
      decimals="INF"
      id="ixv-9263"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c98"
      decimals="2"
      id="ixv-9264"
      unitRef="usdPershares">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c94"
      decimals="INF"
      id="ixv-9265"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EquityFairValueDisclosure contextRef="c93" decimals="-5" id="ixv-9266" unitRef="usd">1800000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c94" decimals="-5" id="ixv-9267" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c95" decimals="-5" id="ixv-9268" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-3519">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activity for the nine months ended September 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;3.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;3.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c99"
      decimals="-3"
      id="ixv-9269"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c99"
      decimals="2"
      id="ixv-9270"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c100" id="ixv-9271">P4Y5M15D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c102"
      decimals="-3"
      id="ixv-9272"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c102"
      decimals="2"
      id="ixv-9273"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c101" id="ixv-9274">P3Y8M12D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c102"
      decimals="-3"
      id="ixv-9275"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c102"
      decimals="2"
      id="ixv-9276"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm contextRef="c101" id="ixv-9277">P3Y8M12D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c12" id="ixv-9278">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c12" id="ixv-9279">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c12" id="ixv-9280">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c12" id="ixv-9281">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c6"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c7"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c9"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c11"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c13"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c14"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c18"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c26"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c28"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c27"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c34"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c36"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c34"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c36"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c34"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c35"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c44"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c46"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c46"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c44"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c46"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c44"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c45"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c52"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c54"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c54"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c52"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c53"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c60"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c62"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c60"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c62"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c60"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c61"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c0"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c14"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c14"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c0"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c14"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c73"
      id="hidden-fact-53"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c76"
      id="hidden-fact-54"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c69"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c70"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="c12"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="c13"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c14"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c14"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="c81"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c96"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c2"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c94"
      id="hidden-fact-67"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c94"
      id="hidden-fact-68"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c94"
      id="hidden-fact-69"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c94"
      id="hidden-fact-70"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c94"
      id="hidden-fact-71"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c93"
      id="hidden-fact-72"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c93"
      id="hidden-fact-73"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c99"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c101"
      id="hidden-fact-75"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="c101"
      id="hidden-fact-76"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c101"
      id="hidden-fact-77"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="c101"
      id="hidden-fact-78"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c102"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c102"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-81"
      unitRef="pure"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-9366">0001388320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-9367">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-9368">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-9369">--12-31</dei:CurrentFiscalYearEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
